US20230372498A1 - Plk1 selective degradation inducing compound - Google Patents
Plk1 selective degradation inducing compound Download PDFInfo
- Publication number
- US20230372498A1 US20230372498A1 US18/229,353 US202318229353A US2023372498A1 US 20230372498 A1 US20230372498 A1 US 20230372498A1 US 202318229353 A US202318229353 A US 202318229353A US 2023372498 A1 US2023372498 A1 US 2023372498A1
- Authority
- US
- United States
- Prior art keywords
- mmol
- amino
- alkyl
- compound
- dioxopiperidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 386
- 108010056274 polo-like kinase 1 Proteins 0.000 title claims abstract description 65
- 230000001939 inductive effect Effects 0.000 title description 12
- 230000008684 selective degradation Effects 0.000 title description 2
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 claims abstract description 64
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims abstract description 17
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
- 201000010099 disease Diseases 0.000 claims abstract description 12
- 230000001588 bifunctional effect Effects 0.000 claims abstract description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 68
- -1 —OH Chemical group 0.000 claims description 52
- 229910052739 hydrogen Inorganic materials 0.000 claims description 34
- 239000001257 hydrogen Substances 0.000 claims description 34
- 150000003839 salts Chemical class 0.000 claims description 26
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 24
- 125000005647 linker group Chemical group 0.000 claims description 22
- 206010028980 Neoplasm Diseases 0.000 claims description 19
- 102000015367 CRBN Human genes 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 18
- 150000002367 halogens Chemical group 0.000 claims description 18
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 13
- 150000002431 hydrogen Chemical group 0.000 claims description 13
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 7
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 6
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 6
- 101000941994 Homo sapiens Protein cereblon Proteins 0.000 claims description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 6
- 229940125904 compound 1 Drugs 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 4
- 208000012902 Nervous system disease Diseases 0.000 claims description 4
- 208000025966 Neurological disease Diseases 0.000 claims description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 230000017854 proteolysis Effects 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 3
- 125000004434 sulfur atom Chemical group 0.000 claims description 3
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims description 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 2
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 claims description 2
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 claims description 2
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 2
- 125000003636 chemical group Chemical group 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 claims description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 150000003852 triazoles Chemical class 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 230000015556 catabolic process Effects 0.000 abstract description 17
- 238000006731 degradation reaction Methods 0.000 abstract description 17
- 239000000126 substance Substances 0.000 abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 601
- 239000000203 mixture Substances 0.000 description 421
- 230000015572 biosynthetic process Effects 0.000 description 344
- 238000003786 synthesis reaction Methods 0.000 description 338
- 235000019439 ethyl acetate Nutrition 0.000 description 239
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 219
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 216
- 239000007787 solid Substances 0.000 description 211
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 202
- 239000000243 solution Substances 0.000 description 201
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 201
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 196
- 239000011541 reaction mixture Substances 0.000 description 191
- 238000006243 chemical reaction Methods 0.000 description 154
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 152
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 144
- 238000005160 1H NMR spectroscopy Methods 0.000 description 115
- 239000007858 starting material Substances 0.000 description 108
- 239000000377 silicon dioxide Substances 0.000 description 103
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 100
- 239000007832 Na2SO4 Substances 0.000 description 96
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 96
- 239000003208 petroleum Substances 0.000 description 96
- 229910052938 sodium sulfate Inorganic materials 0.000 description 96
- 239000012044 organic layer Substances 0.000 description 92
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 91
- 239000003921 oil Substances 0.000 description 81
- 235000019198 oils Nutrition 0.000 description 81
- 229910052681 coesite Inorganic materials 0.000 description 78
- 229910052906 cristobalite Inorganic materials 0.000 description 78
- 229910052682 stishovite Inorganic materials 0.000 description 78
- 229910052905 tridymite Inorganic materials 0.000 description 78
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 77
- 239000012071 phase Substances 0.000 description 69
- 239000000706 filtrate Substances 0.000 description 66
- 238000002953 preparative HPLC Methods 0.000 description 64
- 239000012267 brine Substances 0.000 description 60
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 60
- 238000004440 column chromatography Methods 0.000 description 55
- 230000002829 reductive effect Effects 0.000 description 55
- 239000007821 HATU Substances 0.000 description 46
- 239000003480 eluent Substances 0.000 description 43
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 42
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 40
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 40
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 38
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 38
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 38
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
- 238000010898 silica gel chromatography Methods 0.000 description 32
- ULJAPBPDTJMCDX-JSWXEYCZSA-N (2S,4R)-N-[[2-[8-(4-aminopiperidin-1-yl)octoxy]-4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]-1-[(2S)-2-[(1-fluorocyclopropanecarbonyl)amino]-3,3-dimethylbutanoyl]-4-hydroxypyrrolidine-2-carboxamide Chemical compound NC1CCN(CC1)CCCCCCCCOC1=C(CNC(=O)[C@H]2N(C[C@@H](C2)O)C([C@H](C(C)(C)C)NC(=O)C2(CC2)F)=O)C=CC(=C1)C1=C(N=CS1)C ULJAPBPDTJMCDX-JSWXEYCZSA-N 0.000 description 30
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 30
- HWOIPTLSQRXGDK-OTNCWRBYSA-N FC1(CC1)C(=O)N[C@H](C(=O)N1[C@@H](C[C@H](C1)O)C(=O)NCC1=C(C=C(C=C1)C1=C(N=CS1)C)OCCOCCO)C(C)(C)C Chemical compound FC1(CC1)C(=O)N[C@H](C(=O)N1[C@@H](C[C@H](C1)O)C(=O)NCC1=C(C=C(C=C1)C1=C(N=CS1)C)OCCOCCO)C(C)(C)C HWOIPTLSQRXGDK-OTNCWRBYSA-N 0.000 description 30
- ORHHELHBRBIAFE-WYMKREKISA-N FC1(CC1)C(=O)N[C@H](C(=O)N1[C@@H](C[C@H](C1)O)C(=O)NCC1=C(OCCCCCCCCN2CCC(CC2)NC(OC(C)(C)C)=O)C=C(C=C1)C1=C(N=CS1)C)C(C)(C)C Chemical compound FC1(CC1)C(=O)N[C@H](C(=O)N1[C@@H](C[C@H](C1)O)C(=O)NCC1=C(OCCCCCCCCN2CCC(CC2)NC(OC(C)(C)C)=O)C=C(C=C1)C1=C(N=CS1)C)C(C)(C)C ORHHELHBRBIAFE-WYMKREKISA-N 0.000 description 30
- ZSJCKAGQFMQYPN-UHFFFAOYSA-N 4-[(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-2-fluoro-5-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=C(F)C=C1NC1=NC=C(N(C)C(=O)C(F)(F)CN2C3CCCC3)C2=N1 ZSJCKAGQFMQYPN-UHFFFAOYSA-N 0.000 description 28
- 150000003840 hydrochlorides Chemical class 0.000 description 28
- ZKCJTFMLVBIYLU-YLJHYDRVSA-N O[C@@H]1C[C@H](N(C1)C([C@H](C(C)(C)C)NC(COCCOCCN1CCC(CC1)NC(OC(C)(C)C)=O)=O)=O)C(NCC1=CC=C(C=C1)C1=C(N=CS1)C)=O Chemical compound O[C@@H]1C[C@H](N(C1)C([C@H](C(C)(C)C)NC(COCCOCCN1CCC(CC1)NC(OC(C)(C)C)=O)=O)=O)C(NCC1=CC=C(C=C1)C1=C(N=CS1)C)=O ZKCJTFMLVBIYLU-YLJHYDRVSA-N 0.000 description 27
- CKXZPVPIDOJLLM-UHFFFAOYSA-N tert-butyl n-piperidin-4-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCNCC1 CKXZPVPIDOJLLM-UHFFFAOYSA-N 0.000 description 25
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 23
- GHMJFBSQEKKFEJ-HRHHFINDSA-N NC1CCN(CC1)CCOCCOC1=C(CNC(=O)[C@H]2N(C[C@@H](C2)O)C([C@H](C(C)(C)C)NC(=O)C2(CC2)F)=O)C=CC(=C1)C1=C(N=CS1)C Chemical compound NC1CCN(CC1)CCOCCOC1=C(CNC(=O)[C@H]2N(C[C@@H](C2)O)C([C@H](C(C)(C)C)NC(=O)C2(CC2)F)=O)C=CC(=C1)C1=C(N=CS1)C GHMJFBSQEKKFEJ-HRHHFINDSA-N 0.000 description 21
- 239000000376 reactant Substances 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 229910000027 potassium carbonate Inorganic materials 0.000 description 19
- 230000000694 effects Effects 0.000 description 17
- 239000003643 water by type Substances 0.000 description 17
- 239000000725 suspension Substances 0.000 description 15
- HPLFLVWHYYTPPS-UHFFFAOYSA-N C1(CCCC1)N1C2=C(N(C(C(C1)(F)F)=O)C)C=NC(=N2)NC1=CC(=C(C(=O)NC2CCN(CC2)CC2=CC=C(OCCNC(OCC3=CC=CC=C3)=O)C=C2)C=C1OC)F Chemical compound C1(CCCC1)N1C2=C(N(C(C(C1)(F)F)=O)C)C=NC(=N2)NC1=CC(=C(C(=O)NC2CCN(CC2)CC2=CC=C(OCCNC(OCC3=CC=CC=C3)=O)C=C2)C=C1OC)F HPLFLVWHYYTPPS-UHFFFAOYSA-N 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 229940124823 proteolysis targeting chimeric molecule Drugs 0.000 description 14
- JDBKFTAEVIZHRZ-UHFFFAOYSA-N NC1CCN(CC1)CCOCCOCCNC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O Chemical compound NC1CCN(CC1)CCOCCOCCNC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O JDBKFTAEVIZHRZ-UHFFFAOYSA-N 0.000 description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 13
- CRAUTELYXAAAPW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindole-1,3-dione Chemical compound O=C1C=2C(F)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O CRAUTELYXAAAPW-UHFFFAOYSA-N 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- BPURBJUBPZRSFZ-UHFFFAOYSA-N C1(CCCC1)N1C2=C(N(C(C(C1)(F)F)=O)C)C=NC(=N2)NC1=CC(=C(C(=O)OC)C=C1OC(F)(F)F)F Chemical compound C1(CCCC1)N1C2=C(N(C(C(C1)(F)F)=O)C)C=NC(=N2)NC1=CC(=C(C(=O)OC)C=C1OC(F)(F)F)F BPURBJUBPZRSFZ-UHFFFAOYSA-N 0.000 description 12
- 239000012299 nitrogen atmosphere Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 239000012043 crude product Substances 0.000 description 11
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 10
- 239000000741 silica gel Substances 0.000 description 10
- 229910002027 silica gel Inorganic materials 0.000 description 10
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 108091005625 BRD4 Proteins 0.000 description 8
- 102100029895 Bromodomain-containing protein 4 Human genes 0.000 description 8
- TUXZTPCXKOZIOS-UHFFFAOYSA-N NCCOC1=CC=C(CN2CCC(CC2)NC(C2=C(C=C(C(=C2)OC)NC=2N=CC3=C(N(CC(C(N3C)=O)(F)F)C3CCCC3)N=2)F)=O)C=C1 Chemical compound NCCOC1=CC=C(CN2CCC(CC2)NC(C2=C(C=C(C(=C2)OC)NC=2N=CC3=C(N(CC(C(N3C)=O)(F)F)C3CCCC3)N=2)F)=O)C=C1 TUXZTPCXKOZIOS-UHFFFAOYSA-N 0.000 description 8
- 239000012230 colorless oil Substances 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 238000004007 reversed phase HPLC Methods 0.000 description 8
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 8
- ZVWIXIGBWIEDFO-UHFFFAOYSA-N 2-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]oxyacetic acid Chemical compound O=C1C=2C(OCC(=O)O)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O ZVWIXIGBWIEDFO-UHFFFAOYSA-N 0.000 description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 5
- GIAFURWZWWWBQT-UHFFFAOYSA-N 2-(2-aminoethoxy)ethanol Chemical compound NCCOCCO GIAFURWZWWWBQT-UHFFFAOYSA-N 0.000 description 5
- PDJTUNUXHWLYAY-UHFFFAOYSA-N 2-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]ethoxy]ethyl 4-methylbenzenesulfonate Chemical compound Cc1ccc(cc1)S(=O)(=O)OCCOCCNc1cccc2C(=O)N(C3CCC(=O)NC3=O)C(=O)c12 PDJTUNUXHWLYAY-UHFFFAOYSA-N 0.000 description 5
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 5
- LASZESHPAMXFPH-UHFFFAOYSA-N NCC=1C=C(C=NC=1)CN1CCC(CC1)NC(C1=C(C=C(C(=C1)OC)NC=1N=CC2=C(N(CC(C(N2C)=O)(F)F)C2CCCC2)N=1)F)=O Chemical compound NCC=1C=C(C=NC=1)CN1CCC(CC1)NC(C1=C(C=C(C(=C1)OC)NC=1N=CC2=C(N(CC(C(N2C)=O)(F)F)C2CCCC2)N=1)F)=O LASZESHPAMXFPH-UHFFFAOYSA-N 0.000 description 5
- CMMLTNSXEAVWTH-UHFFFAOYSA-N O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NCCN(CCOCCN1CCC(CC1)NC(OC(C)(C)C)=O)C)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NCCN(CCOCCN1CCC(CC1)NC(OC(C)(C)C)=O)C)=O)=O CMMLTNSXEAVWTH-UHFFFAOYSA-N 0.000 description 5
- 229910006124 SOCl2 Inorganic materials 0.000 description 5
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 5
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 235000012239 silicon dioxide Nutrition 0.000 description 5
- SXFVGSLYPJXDFE-UHFFFAOYSA-N tert-butyl 2-[2-(2-chloroethoxy)ethoxy]acetate Chemical compound CC(C)(C)OC(=O)COCCOCCCl SXFVGSLYPJXDFE-UHFFFAOYSA-N 0.000 description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 5
- CSRZQMIRAZTJOY-UHFFFAOYSA-N trimethylsilyl iodide Substances C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 5
- TWOVEQMWQFKDIL-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-4-[2-(2-hydroxyethoxy)ethylamino]isoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NCCOCCO)=O)=O TWOVEQMWQFKDIL-UHFFFAOYSA-N 0.000 description 4
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 4
- MYONBBJQCZKFNT-UHFFFAOYSA-N ethyl 2-[4-(2-hydroxyethyl)phenyl]acetate Chemical compound CCOC(=O)CC1=CC=C(CCO)C=C1 MYONBBJQCZKFNT-UHFFFAOYSA-N 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- WYCFAOQMGVSOAG-STHAYSLISA-N (1R,2S)-2-carbamoylcyclopropane-1-carboxylic acid Chemical compound NC(=O)[C@H]1C[C@H]1C(O)=O WYCFAOQMGVSOAG-STHAYSLISA-N 0.000 description 3
- PSZHOFGFZHHDLR-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-4-(7-hydroxyheptylamino)isoindole-1,3-dione Chemical compound OCCCCCCCNC1=CC=CC2=C1C(=O)N(C1CCC(=O)NC1=O)C2=O PSZHOFGFZHHDLR-UHFFFAOYSA-N 0.000 description 3
- KLDLLRZCWYKJBD-UHFFFAOYSA-N 2-(2-hydroxyethoxy)ethyl 4-methylbenzenesulfonate Chemical compound CC1=CC=C(S(=O)(=O)OCCOCCO)C=C1 KLDLLRZCWYKJBD-UHFFFAOYSA-N 0.000 description 3
- LIFWFWPWCDSXCH-UHFFFAOYSA-N 2-(7-hydroxyheptyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCCCCCCO)C(=O)C2=C1 LIFWFWPWCDSXCH-UHFFFAOYSA-N 0.000 description 3
- AHJZAWIFZSBGKJ-UHFFFAOYSA-N 2-chloro-9-cyclopentyl-7,7-difluoro-5-methyl-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound C1C(F)(F)C(=O)N(C)C2=CN=C(Cl)N=C2N1C1CCCC1 AHJZAWIFZSBGKJ-UHFFFAOYSA-N 0.000 description 3
- HZYDYUIQNFSPCW-UHFFFAOYSA-N 4-[7-(4-aminopiperidin-1-yl)heptylamino]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione Chemical compound NC1CCN(CC1)CCCCCCCNC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O HZYDYUIQNFSPCW-UHFFFAOYSA-N 0.000 description 3
- UDVUFBCKPVWGNL-UHFFFAOYSA-N 7-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]heptyl 4-methylbenzenesulfonate Chemical compound CC1=CC=C(C=C1)S(=O)(=O)OCCCCCCCNC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O UDVUFBCKPVWGNL-UHFFFAOYSA-N 0.000 description 3
- KYJSXYQQYWMITG-UHFFFAOYSA-N 7-aminoheptan-1-ol Chemical compound NCCCCCCCO KYJSXYQQYWMITG-UHFFFAOYSA-N 0.000 description 3
- KVLJNLRNOGFXRB-UHFFFAOYSA-N C(C)(C)(C)OC(=O)NC1CCN(CC1)CCCCCCCCOCC(=O)O Chemical compound C(C)(C)(C)OC(=O)NC1CCN(CC1)CCCCCCCCOCC(=O)O KVLJNLRNOGFXRB-UHFFFAOYSA-N 0.000 description 3
- JEHRESKYYMINPY-UHFFFAOYSA-N C(C)(C)(C)OC(=O)NC1CCN(CC1)CCCCCCCCOCC(=O)OCC Chemical compound C(C)(C)(C)OC(=O)NC1CCN(CC1)CCCCCCCCOCC(=O)OCC JEHRESKYYMINPY-UHFFFAOYSA-N 0.000 description 3
- GAXRZVZXSQHYDI-UHFFFAOYSA-N C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)OCC(=O)NCCOCCO Chemical compound C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)OCC(=O)NCCOCCO GAXRZVZXSQHYDI-UHFFFAOYSA-N 0.000 description 3
- FBRLBZDTAAIJNR-UHFFFAOYSA-N CCOC(=O)CC1=CC=C(CCOS(=O)(=O)C2=CC=C(C)C=C2)C=C1 Chemical compound CCOC(=O)CC1=CC=C(CCOS(=O)(=O)C2=CC=C(C)C=C2)C=C1 FBRLBZDTAAIJNR-UHFFFAOYSA-N 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 3
- 229910010084 LiAlH4 Inorganic materials 0.000 description 3
- WWBWAVSOUAJADJ-UHFFFAOYSA-N NC1=CC(=C(C(=O)OC)C=C1OCC)F Chemical compound NC1=CC(=C(C(=O)OC)C=C1OCC)F WWBWAVSOUAJADJ-UHFFFAOYSA-N 0.000 description 3
- JJLONHQHXDIKGT-UHFFFAOYSA-N NC1CCN(CC1)CCOCCNC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O Chemical compound NC1CCN(CC1)CCOCCNC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O JJLONHQHXDIKGT-UHFFFAOYSA-N 0.000 description 3
- ITZHKLGCQKTXCR-UHFFFAOYSA-N NC1CCN(CC1)CCOCCOCCOCCOCC#CC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O Chemical compound NC1CCN(CC1)CCOCCOCCOCCOCC#CC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O ITZHKLGCQKTXCR-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000012298 atmosphere Substances 0.000 description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 230000000593 degrading effect Effects 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- YVPJCJLMRRTDMQ-UHFFFAOYSA-N ethyl diazoacetate Chemical compound CCOC(=O)C=[N+]=[N-] YVPJCJLMRRTDMQ-UHFFFAOYSA-N 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- VUQUOGPMUUJORT-UHFFFAOYSA-N methyl 4-methylbenzenesulfonate Chemical compound COS(=O)(=O)C1=CC=C(C)C=C1 VUQUOGPMUUJORT-UHFFFAOYSA-N 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- GFQJINGCDIPEAV-UHFFFAOYSA-N tert-butyl N-[1-[7-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]heptyl]piperidin-4-yl]carbamate Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NCCCCCCCN1CCC(CC1)NC(OC(C)(C)C)=O)=O)=O GFQJINGCDIPEAV-UHFFFAOYSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- OQUHYNMITHDQLD-UHFFFAOYSA-N (5-bromopyridin-3-yl)methanamine Chemical compound NCC1=CN=CC(Br)=C1 OQUHYNMITHDQLD-UHFFFAOYSA-N 0.000 description 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- IBYHHJPAARCAIE-UHFFFAOYSA-N 1-bromo-2-chloroethane Chemical compound ClCCBr IBYHHJPAARCAIE-UHFFFAOYSA-N 0.000 description 2
- VXDTWULFGNROJV-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-4-iodoisoindole-1,3-dione Chemical compound O=C1C=2C(I)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O VXDTWULFGNROJV-UHFFFAOYSA-N 0.000 description 2
- LECMBPWEOVZHKN-UHFFFAOYSA-N 2-(2-chloroethoxy)ethanol Chemical compound OCCOCCCl LECMBPWEOVZHKN-UHFFFAOYSA-N 0.000 description 2
- LDEBJWHBKRIOEO-UHFFFAOYSA-N 2-[(5-bromopyridin-3-yl)methyl]isoindole-1,3-dione Chemical compound BrC1=CN=CC(CN2C(C3=CC=CC=C3C2=O)=O)=C1 LDEBJWHBKRIOEO-UHFFFAOYSA-N 0.000 description 2
- IPKWSCDDLHLVMC-UHFFFAOYSA-N 2-[2-(methylamino)ethoxy]ethanol Chemical compound CNCCOCCO IPKWSCDDLHLVMC-UHFFFAOYSA-N 0.000 description 2
- LRGLFYOYKPSPJQ-UHFFFAOYSA-N 2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]acetic acid Chemical compound O=C1C=2C(NCC(=O)O)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O LRGLFYOYKPSPJQ-UHFFFAOYSA-N 0.000 description 2
- JBVUERMJCKLQMU-UHFFFAOYSA-N 2-chloro-7,7-difluoro-9-propan-2-yl-5,8-dihydropyrimido[4,5-b][1,4]diazepin-6-one Chemical compound CC(C)N1CC(F)(F)C(=O)NC2=CN=C(Cl)N=C12 JBVUERMJCKLQMU-UHFFFAOYSA-N 0.000 description 2
- NOAQTIRLCGXAKA-UHFFFAOYSA-N 3-(4-phenylmethoxybutoxy)propan-1-ol Chemical compound OCCCOCCCCOCC1=CC=CC=C1 NOAQTIRLCGXAKA-UHFFFAOYSA-N 0.000 description 2
- QBIKCECAIKKIDQ-UHFFFAOYSA-N 3-[4-[(2-methylpropan-2-yl)oxycarbonylamino]piperidin-1-yl]propanoic acid Chemical compound CC(C)(C)OC(=O)NC1CCN(CCC(O)=O)CC1 QBIKCECAIKKIDQ-UHFFFAOYSA-N 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- DZLSXCCWIHLMAB-UHFFFAOYSA-N 4-[(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-8H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-5-ethoxy-2-fluorobenzoic acid Chemical compound CCOC1=CC(C(O)=O)=C(F)C=C1NC1=NC=C(N(C)C(=O)C(F)(F)CN2C3CCCC3)C2=N1 DZLSXCCWIHLMAB-UHFFFAOYSA-N 0.000 description 2
- DQJHTCZROXSXEZ-UHFFFAOYSA-N 4-[(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxybenzoic acid Chemical compound COC1=CC(C(O)=O)=CC=C1NC1=NC=C(N(C)C(=O)C(F)(F)CN2C3CCCC3)C2=N1 DQJHTCZROXSXEZ-UHFFFAOYSA-N 0.000 description 2
- CHTDHFJEJGLFIP-UHFFFAOYSA-N 4-[4-[(2-methylpropan-2-yl)oxycarbonylamino]piperidin-1-yl]butanoic acid Chemical compound CC(C)(C)OC(=O)NC1CCN(CCCC(O)=O)CC1 CHTDHFJEJGLFIP-UHFFFAOYSA-N 0.000 description 2
- GPVVHPCSOAWSDC-UHFFFAOYSA-N 4-amino-2-fluoro-5-(trifluoromethoxy)benzoic acid Chemical compound Nc1cc(F)c(cc1OC(F)(F)F)C(O)=O GPVVHPCSOAWSDC-UHFFFAOYSA-N 0.000 description 2
- SKHCDRLTAOLKHQ-UHFFFAOYSA-N 4-iodo-2-benzofuran-1,3-dione Chemical compound IC1=CC=CC2=C1C(=O)OC2=O SKHCDRLTAOLKHQ-UHFFFAOYSA-N 0.000 description 2
- CVDNOPQSKSZLNU-UHFFFAOYSA-N 5-(phenylmethoxycarbonylamino)pentyl 4-methylbenzenesulfonate Chemical compound S(=O)(=O)(OCCCCCNC(=O)OCC1=CC=CC=C1)C1=CC=C(C)C=C1 CVDNOPQSKSZLNU-UHFFFAOYSA-N 0.000 description 2
- GRXURBDZZQDUAH-UHFFFAOYSA-N 5-ethoxy-2-fluoro-4-nitrobenzoic acid Chemical compound CCOC1=CC(C(O)=O)=C(F)C=C1[N+]([O-])=O GRXURBDZZQDUAH-UHFFFAOYSA-N 0.000 description 2
- AUJAYNLPYRARLU-UHFFFAOYSA-N 5-fluoro-2-(trifluoromethoxy)aniline Chemical compound NC1=CC(F)=CC=C1OC(F)(F)F AUJAYNLPYRARLU-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- UIRFRNYHJIKNIK-UHFFFAOYSA-N BrC1=CC(=C(N)C=C1F)OC(F)(F)F Chemical compound BrC1=CC(=C(N)C=C1F)OC(F)(F)F UIRFRNYHJIKNIK-UHFFFAOYSA-N 0.000 description 2
- SJJMCHSBESACEZ-UHFFFAOYSA-N C(C)(C)(C)OC(=O)NC1CCN(CC1)CCC(=O)OCC1=CC=CC=C1 Chemical compound C(C)(C)(C)OC(=O)NC1CCN(CC1)CCC(=O)OCC1=CC=CC=C1 SJJMCHSBESACEZ-UHFFFAOYSA-N 0.000 description 2
- BNFIFMXPPKNQNQ-UHFFFAOYSA-N C(C)(C)(C)OC(=O)NC1CCN(CC1)CCC1=CC=C(C=C1)CC(=O)O Chemical compound C(C)(C)(C)OC(=O)NC1CCN(CC1)CCC1=CC=C(C=C1)CC(=O)O BNFIFMXPPKNQNQ-UHFFFAOYSA-N 0.000 description 2
- ROVHFALZLGHKTL-UHFFFAOYSA-N C(C)(C)(C)OC(=O)NC1CCN(CC1)CCC1=CC=C(C=C1)CC(=O)OCC Chemical compound C(C)(C)(C)OC(=O)NC1CCN(CC1)CCC1=CC=C(C=C1)CC(=O)OCC ROVHFALZLGHKTL-UHFFFAOYSA-N 0.000 description 2
- ZJLKFSIVJKJRKT-UHFFFAOYSA-N C(C)(C)(C)OC(=O)NC1CCN(CC1)CCCC(=O)OCC1=CC=CC=C1 Chemical compound C(C)(C)(C)OC(=O)NC1CCN(CC1)CCCC(=O)OCC1=CC=CC=C1 ZJLKFSIVJKJRKT-UHFFFAOYSA-N 0.000 description 2
- NQRMUQAYLVJSTE-UHFFFAOYSA-N C(C)(C)(C)OC(=O)NC1CCN(CC1)CCCN1C=NC(=C1)C(=O)OC Chemical compound C(C)(C)(C)OC(=O)NC1CCN(CC1)CCCN1C=NC(=C1)C(=O)OC NQRMUQAYLVJSTE-UHFFFAOYSA-N 0.000 description 2
- XHGSDKLCNZDNRB-UHFFFAOYSA-N C(C)(C)(C)OC(=O)NC1CCN(CC1)CCOCCN(C(OCC1=CC=CC=C1)=O)C Chemical compound C(C)(C)(C)OC(=O)NC1CCN(CC1)CCOCCN(C(OCC1=CC=CC=C1)=O)C XHGSDKLCNZDNRB-UHFFFAOYSA-N 0.000 description 2
- FJKZOLFTCORRMN-UHFFFAOYSA-N C(C)(C)(C)OC(=O)NC1CCN(CC1)CCOCCOCC(=O)O Chemical compound C(C)(C)(C)OC(=O)NC1CCN(CC1)CCOCCOCC(=O)O FJKZOLFTCORRMN-UHFFFAOYSA-N 0.000 description 2
- IDWBPIBZLVWMRC-UHFFFAOYSA-N C(C)(C)(C)OC(=O)NC1CCN(CC1)CCOCCOCC(=O)OCC Chemical compound C(C)(C)(C)OC(=O)NC1CCN(CC1)CCOCCOCC(=O)OCC IDWBPIBZLVWMRC-UHFFFAOYSA-N 0.000 description 2
- MDWRURZGZITUEM-UHFFFAOYSA-N C(C1=CC=CC=C1)N(CC(C(=O)OCC)(F)F)C(C)C Chemical compound C(C1=CC=CC=C1)N(CC(C(=O)OCC)(F)F)C(C)C MDWRURZGZITUEM-UHFFFAOYSA-N 0.000 description 2
- GCRRBQSOJCJFGI-UHFFFAOYSA-N C(C1=CC=CC=C1)OC(=O)NC1CCN(CC1)CCOCCOCC(=O)O Chemical compound C(C1=CC=CC=C1)OC(=O)NC1CCN(CC1)CCOCCOCC(=O)O GCRRBQSOJCJFGI-UHFFFAOYSA-N 0.000 description 2
- DELZLUJCYPKNNS-UHFFFAOYSA-N C(C1=CC=CC=C1)OC(=O)NC1CCN(CC1)CCOCCOCC(=O)OC(C)(C)C Chemical compound C(C1=CC=CC=C1)OC(=O)NC1CCN(CC1)CCOCCOCC(=O)OC(C)(C)C DELZLUJCYPKNNS-UHFFFAOYSA-N 0.000 description 2
- JLUDLIDWHVLTFL-UHFFFAOYSA-N C(C1=CC=CC=C1)OC(=O)NCC1C(C1)CN1CCC(CC1)NC(OC(C)(C)C)=O Chemical compound C(C1=CC=CC=C1)OC(=O)NCC1C(C1)CN1CCC(CC1)NC(OC(C)(C)C)=O JLUDLIDWHVLTFL-UHFFFAOYSA-N 0.000 description 2
- UCQBKLOHSWZPDV-UHFFFAOYSA-N C(C1=CC=CC=C1)OC(=O)NCC=1C=C(C=CC=1)C#CCCCCCN1CCC(CC1)NC(OC(C)(C)C)=O Chemical compound C(C1=CC=CC=C1)OC(=O)NCC=1C=C(C=CC=1)C#CCCCCCN1CCC(CC1)NC(OC(C)(C)C)=O UCQBKLOHSWZPDV-UHFFFAOYSA-N 0.000 description 2
- XEGJXECLOFOMBU-UHFFFAOYSA-N C(C1=CC=CC=C1)OC(=O)NCC=1C=C(C=CC=1)CN1CCC(CC1)NC(OC(C)(C)C)=O Chemical compound C(C1=CC=CC=C1)OC(=O)NCC=1C=C(C=CC=1)CN1CCC(CC1)NC(OC(C)(C)C)=O XEGJXECLOFOMBU-UHFFFAOYSA-N 0.000 description 2
- MFJKSCAUKJNTHR-UHFFFAOYSA-N C(C1=CC=CC=C1)OC(=O)NCC=1C=C(C=NC=1)CN1CCC(CC1)NC(OC(C)(C)C)=O Chemical compound C(C1=CC=CC=C1)OC(=O)NCC=1C=C(C=NC=1)CN1CCC(CC1)NC(OC(C)(C)C)=O MFJKSCAUKJNTHR-UHFFFAOYSA-N 0.000 description 2
- NVMAGTIWIIFNGM-UHFFFAOYSA-N C(C1=CC=CC=C1)OC(=O)NCC=1C=NC=C(C(=O)OC)C=1 Chemical compound C(C1=CC=CC=C1)OC(=O)NCC=1C=NC=C(C(=O)OC)C=1 NVMAGTIWIIFNGM-UHFFFAOYSA-N 0.000 description 2
- VSGZTLMYWLWNNV-UHFFFAOYSA-N C(C1=CC=CC=C1)OC(=O)NCCCCCN1CCC(CC1)NC(OC(C)(C)C)=O Chemical compound C(C1=CC=CC=C1)OC(=O)NCCCCCN1CCC(CC1)NC(OC(C)(C)C)=O VSGZTLMYWLWNNV-UHFFFAOYSA-N 0.000 description 2
- HOEGQTRAKQVFKU-UHFFFAOYSA-N C(C1=CC=CC=C1)OC(=O)NCCN(CCOCCN1CCC(CC1)NC(OC(C)(C)C)=O)C Chemical compound C(C1=CC=CC=C1)OC(=O)NCCN(CCOCCN1CCC(CC1)NC(OC(C)(C)C)=O)C HOEGQTRAKQVFKU-UHFFFAOYSA-N 0.000 description 2
- RBAODNIGQHPALQ-UHFFFAOYSA-N C(C1=CC=CC=C1)OC(=O)NCCOC1=CC=C(C(=O)OCC)C=C1 Chemical compound C(C1=CC=CC=C1)OC(=O)NCCOC1=CC=C(C(=O)OCC)C=C1 RBAODNIGQHPALQ-UHFFFAOYSA-N 0.000 description 2
- BVMKCGUGTCHOBK-UHFFFAOYSA-N C(C1=CC=CC=C1)OC(=O)NCCOC1=CC=C(C=C1)CN1CCC(CC1)NC(OC(C)(C)C)=O Chemical compound C(C1=CC=CC=C1)OC(=O)NCCOC1=CC=C(C=C1)CN1CCC(CC1)NC(OC(C)(C)C)=O BVMKCGUGTCHOBK-UHFFFAOYSA-N 0.000 description 2
- BYKVVNAKAGFDEN-UHFFFAOYSA-N C(C1=CC=CC=C1)OCCCCOCCCN1CCC(CC1)NC(OC(C)(C)C)=O Chemical compound C(C1=CC=CC=C1)OCCCCOCCCN1CCC(CC1)NC(OC(C)(C)C)=O BYKVVNAKAGFDEN-UHFFFAOYSA-N 0.000 description 2
- NWVMMPSGCHAUHT-UHFFFAOYSA-N C1(CCCC1)N1C2=C(N(C(C(C1)(F)F)=O)C)C=NC(=N2)NC1=CC(=C(C(=O)NC2CCN(CC2)CC=2C=C(CNC(OCC3=CC=CC=C3)=O)C=CC=2)C=C1OC)F Chemical compound C1(CCCC1)N1C2=C(N(C(C(C1)(F)F)=O)C)C=NC(=N2)NC1=CC(=C(C(=O)NC2CCN(CC2)CC=2C=C(CNC(OCC3=CC=CC=C3)=O)C=CC=2)C=C1OC)F NWVMMPSGCHAUHT-UHFFFAOYSA-N 0.000 description 2
- DVFCJOOTJPFDMK-UHFFFAOYSA-N C1(CCCC1)N1C2=C(N(C(C(C1)(F)F)=O)C)C=NC(=N2)NC1=CC(=C(C(=O)O)C=C1OC(F)(F)F)F Chemical compound C1(CCCC1)N1C2=C(N(C(C(C1)(F)F)=O)C)C=NC(=N2)NC1=CC(=C(C(=O)O)C=C1OC(F)(F)F)F DVFCJOOTJPFDMK-UHFFFAOYSA-N 0.000 description 2
- AWHDIMZRYUBMMC-UHFFFAOYSA-N C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC(=C3C2=O)C#CCOCCOCCOCCOCCO Chemical compound C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC(=C3C2=O)C#CCOCCOCCOCCOCCO AWHDIMZRYUBMMC-UHFFFAOYSA-N 0.000 description 2
- WZPUJNOBEUAQPN-UHFFFAOYSA-N CC(C)(C)OC(=O)CNc1cccc2C(=O)N(C3CCC(=O)NC3=O)C(=O)c12 Chemical compound CC(C)(C)OC(=O)CNc1cccc2C(=O)N(C3CCC(=O)NC3=O)C(=O)c12 WZPUJNOBEUAQPN-UHFFFAOYSA-N 0.000 description 2
- CLVLICGOFWJIIX-UHFFFAOYSA-N CC1=CC=C(C=C1)S(=O)(=O)OCCCCCC#CC1=CC(=CC=C1)CNC(=O)OCC1=CC=CC=C1 Chemical compound CC1=CC=C(C=C1)S(=O)(=O)OCCCCCC#CC1=CC(=CC=C1)CNC(=O)OCC1=CC=CC=C1 CLVLICGOFWJIIX-UHFFFAOYSA-N 0.000 description 2
- OMSINQLNBWWFOG-UHFFFAOYSA-N CC1=CC=C(C=C1)S(=O)(=O)OCCCCCCCCN1CCC(CC1)NC(=O)OC(C)(C)C Chemical compound CC1=CC=C(C=C1)S(=O)(=O)OCCCCCCCCN1CCC(CC1)NC(=O)OC(C)(C)C OMSINQLNBWWFOG-UHFFFAOYSA-N 0.000 description 2
- XMPUHQWOJKVRDA-UHFFFAOYSA-N CC1=CC=C(C=C1)S(=O)(=O)OCCCCOCCCN1CCC(CC1)NC(=O)OC(C)(C)C Chemical compound CC1=CC=C(C=C1)S(=O)(=O)OCCCCOCCCN1CCC(CC1)NC(=O)OC(C)(C)C XMPUHQWOJKVRDA-UHFFFAOYSA-N 0.000 description 2
- GZAYTTHOPFJQNA-UHFFFAOYSA-N CC1=CC=C(C=C1)S(=O)(=O)OCCOCCNC(CNC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O)=O Chemical compound CC1=CC=C(C=C1)S(=O)(=O)OCCOCCNC(CNC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O)=O GZAYTTHOPFJQNA-UHFFFAOYSA-N 0.000 description 2
- POWKVSFZSINFQV-UHFFFAOYSA-N CC1=CC=C(C=C1)S(=O)(=O)OCCOCCNC(COC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O)=O Chemical compound CC1=CC=C(C=C1)S(=O)(=O)OCCOCCNC(COC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O)=O POWKVSFZSINFQV-UHFFFAOYSA-N 0.000 description 2
- GNIIMASDXRVPIY-LFWISAHLSA-N CC1=CC=C(C=C1)S(=O)(=O)OCCOCCOC1=C(C=CC(=C1)C1=C(N=CS1)C)CNC(=O)[C@H]1N(C[C@@H](C1)O)C([C@H](C(C)(C)C)NC(=O)C1(CC1)F)=O Chemical compound CC1=CC=C(C=C1)S(=O)(=O)OCCOCCOC1=C(C=CC(=C1)C1=C(N=CS1)C)CNC(=O)[C@H]1N(C[C@@H](C1)O)C([C@H](C(C)(C)C)NC(=O)C1(CC1)F)=O GNIIMASDXRVPIY-LFWISAHLSA-N 0.000 description 2
- UGKUQVCGQYHWEP-UHFFFAOYSA-N CC1=CC=C(C=C1)S(=O)(=O)OCCOCCOCCN1CCC(CC1)NC(=O)OC(C)(C)C Chemical compound CC1=CC=C(C=C1)S(=O)(=O)OCCOCCOCCN1CCC(CC1)NC(=O)OC(C)(C)C UGKUQVCGQYHWEP-UHFFFAOYSA-N 0.000 description 2
- PDZVOBJGGIQQSD-UHFFFAOYSA-N CC1=CC=C(C=C1)S(=O)(=O)OCCOCCOCCNC1=C2C(N(C(C2=CC=C1)=O)C1C(N(C(CC1)=O)C)=O)=O Chemical compound CC1=CC=C(C=C1)S(=O)(=O)OCCOCCOCCNC1=C2C(N(C(C2=CC=C1)=O)C1C(N(C(CC1)=O)C)=O)=O PDZVOBJGGIQQSD-UHFFFAOYSA-N 0.000 description 2
- ZLOJSDPFBWOIPD-UHFFFAOYSA-N CC1=CC=C(C=C1)S(=O)(=O)OCCOCCOCCOCCNC(COC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O)=O Chemical compound CC1=CC=C(C=C1)S(=O)(=O)OCCOCCOCCOCCNC(COC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O)=O ZLOJSDPFBWOIPD-UHFFFAOYSA-N 0.000 description 2
- OCEBAZPXCUSLNI-UHFFFAOYSA-N CC1=CC=C(C=C1)S(=O)(=O)OCCOCCOCCOCCOCC#CC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O Chemical compound CC1=CC=C(C=C1)S(=O)(=O)OCCOCCOCCOCCOCC#CC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O OCEBAZPXCUSLNI-UHFFFAOYSA-N 0.000 description 2
- MRZRZENVBYRSQW-UHFFFAOYSA-N CN(C(OCC1=CC=CC=C1)=O)CCOCCOS(=O)(=O)C1=CC=C(C=C1)C Chemical compound CN(C(OCC1=CC=CC=C1)=O)CCOCCOS(=O)(=O)C1=CC=C(C=C1)C MRZRZENVBYRSQW-UHFFFAOYSA-N 0.000 description 2
- RMYTXVCGVFFXSD-UHFFFAOYSA-N CN1C(=O)CCC(N2C(=O)C3=C(C2=O)C(F)=CC=C3)C1=O Chemical compound CN1C(=O)CCC(N2C(=O)C3=C(C2=O)C(F)=CC=C3)C1=O RMYTXVCGVFFXSD-UHFFFAOYSA-N 0.000 description 2
- MORAUWDTHZFBEO-UHFFFAOYSA-N CN1C(C(CCC1=O)N1C(C2=CC=CC(=C2C1=O)NCCOCCOCCN1CCC(CC1)NC(OC(C)(C)C)=O)=O)=O Chemical compound CN1C(C(CCC1=O)N1C(C2=CC=CC(=C2C1=O)NCCOCCOCCN1CCC(CC1)NC(OC(C)(C)C)=O)=O)=O MORAUWDTHZFBEO-UHFFFAOYSA-N 0.000 description 2
- RBAQUPBQSGRTDO-UHFFFAOYSA-N CNCCOCCN1CCC(CC1)NC(OC(C)(C)C)=O Chemical compound CNCCOCCN1CCC(CC1)NC(OC(C)(C)C)=O RBAQUPBQSGRTDO-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- HSBLFAJJAQZKQH-UHFFFAOYSA-N ClCC1=CC=C(OCCNC(OCC2=CC=CC=C2)=O)C=C1 Chemical compound ClCC1=CC=C(OCCNC(OCC2=CC=CC=C2)=O)C=C1 HSBLFAJJAQZKQH-UHFFFAOYSA-N 0.000 description 2
- DUALIMLJHHKQSJ-UHFFFAOYSA-N ClCC=1C=C(C=NC=1)CNC(OCC1=CC=CC=C1)=O Chemical compound ClCC=1C=C(C=NC=1)CNC(OCC1=CC=CC=C1)=O DUALIMLJHHKQSJ-UHFFFAOYSA-N 0.000 description 2
- PNSQGHHEWBQNKW-UHFFFAOYSA-N ClCC=1C=C(CNC(OCC2=CC=CC=C2)=O)C=CC=1 Chemical compound ClCC=1C=C(CNC(OCC2=CC=CC=C2)=O)C=CC=1 PNSQGHHEWBQNKW-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 2
- 102100023877 E3 ubiquitin-protein ligase RBX1 Human genes 0.000 description 2
- 108010003751 Elongin Proteins 0.000 description 2
- XQSQNPAIURNSLX-UHFFFAOYSA-N FC1(C(N(C2=C(N(C1)C(C)C)N=C(N=C2)NC1=CC(=C(C(=O)O)C=C1OC)F)C)=O)F Chemical compound FC1(C(N(C2=C(N(C1)C(C)C)N=C(N=C2)NC1=CC(=C(C(=O)O)C=C1OC)F)C)=O)F XQSQNPAIURNSLX-UHFFFAOYSA-N 0.000 description 2
- CDDCFUBTWALJLE-UHFFFAOYSA-N FC1(C(N(C2=C(N(C1)C(C)C)N=C(N=C2)NC1=CC(=C(C(=O)OC)C=C1OC)F)C)=O)F Chemical compound FC1(C(N(C2=C(N(C1)C(C)C)N=C(N=C2)NC1=CC(=C(C(=O)OC)C=C1OC)F)C)=O)F CDDCFUBTWALJLE-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 230000004668 G2/M phase Effects 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- FIYMBLCYBPWBLW-UHFFFAOYSA-N N(=[N+]=[N-])CC=1N=CN(C=1)CCCN1CCC(CC1)NC(OC(C)(C)C)=O Chemical compound N(=[N+]=[N-])CC=1N=CN(C=1)CCCN1CCC(CC1)NC(OC(C)(C)C)=O FIYMBLCYBPWBLW-UHFFFAOYSA-N 0.000 description 2
- WBVBKADJSFHWPU-UHFFFAOYSA-N N-[2-[2-(4-aminopiperidin-1-yl)ethoxy]ethyl]-2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]acetamide Chemical compound NC1CCN(CC1)CCOCCNC(CNC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O)=O WBVBKADJSFHWPU-UHFFFAOYSA-N 0.000 description 2
- FBGGXXIIKCMRCB-UHFFFAOYSA-N NC1CCN(CC1)CC1=CC=C(OCCNC(OCC2=CC=CC=C2)=O)C=C1 Chemical compound NC1CCN(CC1)CC1=CC=C(OCCNC(OCC2=CC=CC=C2)=O)C=C1 FBGGXXIIKCMRCB-UHFFFAOYSA-N 0.000 description 2
- OXJVOEWRKJLUBO-UHFFFAOYSA-N NC1CCN(CC1)CC=1C=C(CNC(OCC2=CC=CC=C2)=O)C=CC=1 Chemical compound NC1CCN(CC1)CC=1C=C(CNC(OCC2=CC=CC=C2)=O)C=CC=1 OXJVOEWRKJLUBO-UHFFFAOYSA-N 0.000 description 2
- AWTKAMJTSLKPPH-UHFFFAOYSA-N NC1CCN(CC1)CC=1N=NN(C=1)CCOCCNC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O Chemical compound NC1CCN(CC1)CC=1N=NN(C=1)CCOCCNC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O AWTKAMJTSLKPPH-UHFFFAOYSA-N 0.000 description 2
- CKKZJKPRCXVBAC-UHFFFAOYSA-N NC1CCN(CC1)CCC(=O)NCCCCCCCNC(COC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O)=O Chemical compound NC1CCN(CC1)CCC(=O)NCCCCCCCNC(COC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O)=O CKKZJKPRCXVBAC-UHFFFAOYSA-N 0.000 description 2
- QUHWPDIGUAPODS-UHFFFAOYSA-N NC1CCN(CC1)CCCC(=O)NC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O Chemical compound NC1CCN(CC1)CCCC(=O)NC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O QUHWPDIGUAPODS-UHFFFAOYSA-N 0.000 description 2
- GZNRGAMVYAUBLD-UHFFFAOYSA-N NC1CCN(CC1)CCCCCCCC=1C=C(CNC(COC2=C3C(N(C(C3=CC=C2)=O)C2C(NC(CC2)=O)=O)=O)=O)C=CC=1 Chemical compound NC1CCN(CC1)CCCCCCCC=1C=C(CNC(COC2=C3C(N(C(C3=CC=C2)=O)C2C(NC(CC2)=O)=O)=O)=O)C=CC=1 GZNRGAMVYAUBLD-UHFFFAOYSA-N 0.000 description 2
- NUPBWHOMZXCQFC-UHFFFAOYSA-N NC1CCN(CC1)CCCCCNC(COC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O)=O Chemical compound NC1CCN(CC1)CCCCCNC(COC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O)=O NUPBWHOMZXCQFC-UHFFFAOYSA-N 0.000 description 2
- OPRURKKYMAGVDQ-UHFFFAOYSA-N NC1CCN(CC1)CCCOCCCCNC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O Chemical compound NC1CCN(CC1)CCCOCCCCNC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O OPRURKKYMAGVDQ-UHFFFAOYSA-N 0.000 description 2
- SRTAOLPZPVYSKZ-UHFFFAOYSA-N NC1CCN(CC1)CCN1CCN(CC1)C1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O Chemical compound NC1CCN(CC1)CCN1CCN(CC1)C1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O SRTAOLPZPVYSKZ-UHFFFAOYSA-N 0.000 description 2
- DCJPVGLTDZUNSL-UHFFFAOYSA-N NC1CCN(CC1)CCOCCN(CCNC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O)C Chemical compound NC1CCN(CC1)CCOCCN(CCNC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O)C DCJPVGLTDZUNSL-UHFFFAOYSA-N 0.000 description 2
- BGTUDSNDPIMOOA-UHFFFAOYSA-N NC1CCN(CC1)CCOCCNC(COC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O)=O Chemical compound NC1CCN(CC1)CCOCCNC(COC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O)=O BGTUDSNDPIMOOA-UHFFFAOYSA-N 0.000 description 2
- HNIAQHXCJSRFLU-UHFFFAOYSA-N NC1CCN(CC1)CCOCCOCC(=O)NC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O Chemical compound NC1CCN(CC1)CCOCCOCC(=O)NC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O HNIAQHXCJSRFLU-UHFFFAOYSA-N 0.000 description 2
- NLZRDCJKERZUBG-HRHHFINDSA-N NC1CCN(CC1)CCOCCOCC(=O)N[C@H](C(=O)N1[C@@H](C[C@H](C1)O)C(=O)NCC1=CC=C(C=C1)C1=C(N=CS1)C)C(C)(C)C Chemical compound NC1CCN(CC1)CCOCCOCC(=O)N[C@H](C(=O)N1[C@@H](C[C@H](C1)O)C(=O)NCC1=CC=C(C=C1)C1=C(N=CS1)C)C(C)(C)C NLZRDCJKERZUBG-HRHHFINDSA-N 0.000 description 2
- SIQWRAMXVXPTPH-UHFFFAOYSA-N NC1CCN(CC1)CCOCCOCCNC1=C2CN(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O Chemical compound NC1CCN(CC1)CCOCCOCCNC1=C2CN(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O SIQWRAMXVXPTPH-UHFFFAOYSA-N 0.000 description 2
- ILBJATDOLOMZQM-UHFFFAOYSA-N NC1CCN(CC1)CCOCCOCCOCCNC(COC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O)=O Chemical compound NC1CCN(CC1)CCOCCOCCOCCNC(COC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O)=O ILBJATDOLOMZQM-UHFFFAOYSA-N 0.000 description 2
- IGLRDSCZSGPLKO-RMAOKOMNSA-N NC1CCN(CC1)C[C@H]1[C@H](C1)CNC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O Chemical compound NC1CCN(CC1)C[C@H]1[C@H](C1)CNC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O IGLRDSCZSGPLKO-RMAOKOMNSA-N 0.000 description 2
- PIBLBTJMKOOVIK-UHFFFAOYSA-N NCC=1C=C(C=CC=1)CCCCCCCN1CCC(CC1)NC(OC(C)(C)C)=O Chemical compound NCC=1C=C(C=CC=1)CCCCCCCN1CCC(CC1)NC(OC(C)(C)C)=O PIBLBTJMKOOVIK-UHFFFAOYSA-N 0.000 description 2
- GUQVTHYXZJTUEM-UHFFFAOYSA-N NCC=1C=C(CN2CCC(CC2)NC(C2=C(C=C(C(=C2)OC)NC=2N=CC3=C(N(CC(C(N3C)=O)(F)F)C3CCCC3)N=2)F)=O)C=CC=1 Chemical compound NCC=1C=C(CN2CCC(CC2)NC(C2=C(C=C(C(=C2)OC)NC=2N=CC3=C(N(CC(C(N3C)=O)(F)F)C3CCCC3)N=2)F)=O)C=CC=1 GUQVTHYXZJTUEM-UHFFFAOYSA-N 0.000 description 2
- LHDMQAQEKFHJIX-UHFFFAOYSA-N NCC=1N=CN(C=1)CCCN1CCC(CC1)NC(OC(C)(C)C)=O Chemical compound NCC=1N=CN(C=1)CCCN1CCC(CC1)NC(OC(C)(C)C)=O LHDMQAQEKFHJIX-UHFFFAOYSA-N 0.000 description 2
- PBNKCHISTUFJBC-UHFFFAOYSA-N NCCCCCN1CCC(CC1)NC(OC(C)(C)C)=O Chemical compound NCCCCCN1CCC(CC1)NC(OC(C)(C)C)=O PBNKCHISTUFJBC-UHFFFAOYSA-N 0.000 description 2
- IDQFZFZGXQGLKN-UHFFFAOYSA-N NCCCCOCCCN1CCC(CC1)NC(OC(C)(C)C)=O Chemical compound NCCCCOCCCN1CCC(CC1)NC(OC(C)(C)C)=O IDQFZFZGXQGLKN-UHFFFAOYSA-N 0.000 description 2
- XTWOSQMCSPXLTK-UHFFFAOYSA-N NCCN(CCOCCN1CCC(CC1)NC(OC(C)(C)C)=O)C Chemical compound NCCN(CCOCCN1CCC(CC1)NC(OC(C)(C)C)=O)C XTWOSQMCSPXLTK-UHFFFAOYSA-N 0.000 description 2
- IRALAOUKVLWCOY-NEPJUHHUSA-N NC[C@@H]1[C@@H](C1)CN1CCC(CC1)NC(OC(C)(C)C)=O Chemical compound NC[C@@H]1[C@@H](C1)CN1CCC(CC1)NC(OC(C)(C)C)=O IRALAOUKVLWCOY-NEPJUHHUSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- HYIKWOFHPQPZBN-UHFFFAOYSA-N O=C1N(C(C2=CC=CC=C12)=O)CCCCOCCCN1CCC(CC1)NC(OC(C)(C)C)=O Chemical compound O=C1N(C(C2=CC=CC=C12)=O)CCCCOCCCN1CCC(CC1)NC(OC(C)(C)C)=O HYIKWOFHPQPZBN-UHFFFAOYSA-N 0.000 description 2
- NDOMOIVTVYDRES-UHFFFAOYSA-N O=C1NC(CCC1N1C(C2=CC=CC(=C2C1)NCCOCCOCCN1CCC(CC1)NC(OC(C)(C)C)=O)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1)NCCOCCOCCN1CCC(CC1)NC(OC(C)(C)C)=O)=O)=O NDOMOIVTVYDRES-UHFFFAOYSA-N 0.000 description 2
- AXQXXOUKDZLMQD-UHFFFAOYSA-N O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)C#CCOCCOCCOCCOCCN1CCC(CC1)NC(OC(C)(C)C)=O)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)C#CCOCCOCCOCCOCCN1CCC(CC1)NC(OC(C)(C)C)=O)=O)=O AXQXXOUKDZLMQD-UHFFFAOYSA-N 0.000 description 2
- UPRLAZKTOVTQFZ-UHFFFAOYSA-N O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)N1CCC(CC1)CN1CCC(CC1)NC(OC(C)(C)C)=O)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)N1CCC(CC1)CN1CCC(CC1)NC(OC(C)(C)C)=O)=O)=O UPRLAZKTOVTQFZ-UHFFFAOYSA-N 0.000 description 2
- KJCVCMOZGQEQPK-UHFFFAOYSA-N O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NC(CC1=CC=C(C=C1)CCN1CCC(CC1)NC(OC(C)(C)C)=O)=O)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NC(CC1=CC=C(C=C1)CCN1CCC(CC1)NC(OC(C)(C)C)=O)=O)=O)=O KJCVCMOZGQEQPK-UHFFFAOYSA-N 0.000 description 2
- DODNJSXPLAKVTQ-UHFFFAOYSA-N O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NC(CCCN1CCC(CC1)NC(OC(C)(C)C)=O)=O)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NC(CCCN1CCC(CC1)NC(OC(C)(C)C)=O)=O)=O)=O DODNJSXPLAKVTQ-UHFFFAOYSA-N 0.000 description 2
- DBFKEEAIZSFGEQ-UHFFFAOYSA-N O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NC(COCCOCCN1CCC(CC1)NC(OCC1=CC=CC=C1)=O)=O)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NC(COCCOCCN1CCC(CC1)NC(OCC1=CC=CC=C1)=O)=O)=O)=O DBFKEEAIZSFGEQ-UHFFFAOYSA-N 0.000 description 2
- AZPRKMMGNHJSEA-UHFFFAOYSA-N O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NCC(=O)NCCOCCN1CCC(CC1)NC(OC(C)(C)C)=O)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NCC(=O)NCCOCCN1CCC(CC1)NC(OC(C)(C)C)=O)=O)=O AZPRKMMGNHJSEA-UHFFFAOYSA-N 0.000 description 2
- XTWNETWIMFQOTR-UHFFFAOYSA-N O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NCC(=O)NCCOCCO)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NCC(=O)NCCOCCO)=O)=O XTWNETWIMFQOTR-UHFFFAOYSA-N 0.000 description 2
- QUKLHLWCAPDNBA-UHFFFAOYSA-N O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NCCCCOCCCN1CCC(CC1)NC(OC(C)(C)C)=O)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NCCCCOCCCN1CCC(CC1)NC(OC(C)(C)C)=O)=O)=O QUKLHLWCAPDNBA-UHFFFAOYSA-N 0.000 description 2
- MYOQBDOALQTIHR-UHFFFAOYSA-N O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NCCOCCN1N=NC(=C1)CN1CCC(CC1)NC(OC(C)(C)C)=O)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NCCOCCN1N=NC(=C1)CN1CCC(CC1)NC(OC(C)(C)C)=O)=O)=O MYOQBDOALQTIHR-UHFFFAOYSA-N 0.000 description 2
- NJPMWHWTBBYBDY-UHFFFAOYSA-N O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NCCOCCN=[N+]=[N-])=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NCCOCCN=[N+]=[N-])=O)=O NJPMWHWTBBYBDY-UHFFFAOYSA-N 0.000 description 2
- GLVHKDWDJDQLJV-UHFFFAOYSA-N O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NCCOCCOCCN1CCC(CC1)NC(OC(C)(C)C)=O)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NCCOCCOCCN1CCC(CC1)NC(OC(C)(C)C)=O)=O)=O GLVHKDWDJDQLJV-UHFFFAOYSA-N 0.000 description 2
- JKIVGAGYMHMHFI-LXMSXWCSSA-N O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NC[C@@H]1[C@@H](C1)CN1CCC(CC1)NC(OC(C)(C)C)=O)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NC[C@@H]1[C@@H](C1)CN1CCC(CC1)NC(OC(C)(C)C)=O)=O)=O JKIVGAGYMHMHFI-LXMSXWCSSA-N 0.000 description 2
- QZAUDHAQVUGLER-UHFFFAOYSA-N O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)OCC(=O)NCC=1C=C(C=CC=1)CCCCCCCN1CCC(CC1)NC(OC(C)(C)C)=O)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)OCC(=O)NCC=1C=C(C=CC=1)CCCCCCCN1CCC(CC1)NC(OC(C)(C)C)=O)=O)=O QZAUDHAQVUGLER-UHFFFAOYSA-N 0.000 description 2
- GVNCXNOCVNTPHJ-UHFFFAOYSA-N O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)OCC(=O)NCCCCCCCNC(CCN1CCC(CC1)NC(OC(C)(C)C)=O)=O)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)OCC(=O)NCCCCCCCNC(CCN1CCC(CC1)NC(OC(C)(C)C)=O)=O)=O)=O GVNCXNOCVNTPHJ-UHFFFAOYSA-N 0.000 description 2
- KZPFPSDQRZWZMB-UHFFFAOYSA-N O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)OCC(=O)NCCCCCCCNC(OCC1=CC=CC=C1)=O)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)OCC(=O)NCCCCCCCNC(OCC1=CC=CC=C1)=O)=O)=O KZPFPSDQRZWZMB-UHFFFAOYSA-N 0.000 description 2
- YPIXIWIDSMKXSY-UHFFFAOYSA-N O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)OCC(=O)NCCCCCN1CCC(CC1)NC(OC(C)(C)C)=O)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)OCC(=O)NCCCCCN1CCC(CC1)NC(OC(C)(C)C)=O)=O)=O YPIXIWIDSMKXSY-UHFFFAOYSA-N 0.000 description 2
- VIKBWDFZHKHUBG-UHFFFAOYSA-N O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)OCC(=O)NCCOCCN1CCC(CC1)NC(OC(C)(C)C)=O)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)OCC(=O)NCCOCCN1CCC(CC1)NC(OC(C)(C)C)=O)=O)=O VIKBWDFZHKHUBG-UHFFFAOYSA-N 0.000 description 2
- HTZASLGPSCZMRE-UHFFFAOYSA-N O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)OCC(NCCOCCOCCOCCN1CCC(CC1)NC(OC(C)(C)C)=O)=O)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)OCC(NCCOCCOCCOCCN1CCC(CC1)NC(OC(C)(C)C)=O)=O)=O)=O HTZASLGPSCZMRE-UHFFFAOYSA-N 0.000 description 2
- XEGLCPIJPHFLNW-UHFFFAOYSA-N OCC=1C=C(C=NC=1)CNC(OCC1=CC=CC=C1)=O Chemical compound OCC=1C=C(C=NC=1)CNC(OCC1=CC=CC=C1)=O XEGLCPIJPHFLNW-UHFFFAOYSA-N 0.000 description 2
- UMPAEBJCLHGAFF-UHFFFAOYSA-N OCC=1N=CN(C=1)CCCN1CCC(CC1)NC(OC(C)(C)C)=O Chemical compound OCC=1N=CN(C=1)CCCN1CCC(CC1)NC(OC(C)(C)C)=O UMPAEBJCLHGAFF-UHFFFAOYSA-N 0.000 description 2
- QRZFUSUJBLFVCP-UHFFFAOYSA-N OCCCCCC#CC=1C=C(CNC(OCC2=CC=CC=C2)=O)C=CC=1 Chemical compound OCCCCCC#CC=1C=C(CNC(OCC2=CC=CC=C2)=O)C=CC=1 QRZFUSUJBLFVCP-UHFFFAOYSA-N 0.000 description 2
- XSQVGEHRQDRUPU-UHFFFAOYSA-N OCCCCOCCCN1CCC(CC1)NC(OC(C)(C)C)=O Chemical compound OCCCCOCCCN1CCC(CC1)NC(OC(C)(C)C)=O XSQVGEHRQDRUPU-UHFFFAOYSA-N 0.000 description 2
- OOCRGMAXLQNTSV-UHFFFAOYSA-N OCCCN1C=NC(=C1)C(=O)OC Chemical compound OCCCN1C=NC(=C1)C(=O)OC OOCRGMAXLQNTSV-UHFFFAOYSA-N 0.000 description 2
- CCAWGCPAWRCEEJ-UHFFFAOYSA-N OCCOCCOCCN1CCC(CC1)NC(OC(C)(C)C)=O Chemical compound OCCOCCOCCN1CCC(CC1)NC(OC(C)(C)C)=O CCAWGCPAWRCEEJ-UHFFFAOYSA-N 0.000 description 2
- FRIDABJJJCXHGD-UHFFFAOYSA-N OCCOCCOCCNC1=C2C(N(C(C2=CC=C1)=O)C1C(N(C(CC1)=O)C)=O)=O Chemical compound OCCOCCOCCNC1=C2C(N(C(C2=CC=C1)=O)C1C(N(C(CC1)=O)C)=O)=O FRIDABJJJCXHGD-UHFFFAOYSA-N 0.000 description 2
- OZBLRLKNRQHSBY-NEPJUHHUSA-N OC[C@H]1[C@H](C1)CNC(OCC1=CC=CC=C1)=O Chemical compound OC[C@H]1[C@H](C1)CNC(OCC1=CC=CC=C1)=O OZBLRLKNRQHSBY-NEPJUHHUSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- IMWFWBPFMMSCHI-UHFFFAOYSA-N S(=O)(=O)(C1=CC=C(C)C=C1)OCCCN1C=NC(=C1)C(=O)OC Chemical compound S(=O)(=O)(C1=CC=C(C)C=C1)OCCCN1C=NC(=C1)C(=O)OC IMWFWBPFMMSCHI-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- KCTYUINIEPILPS-UHFFFAOYSA-N [3-(aminomethyl)phenyl]methanol Chemical compound NCC1=CC=CC(CO)=C1 KCTYUINIEPILPS-UHFFFAOYSA-N 0.000 description 2
- AAFSFCFTVGNWSY-UHFFFAOYSA-N [Si](C)(C)(C(C)(C)C)OCCCN1C=NC(=C1)C(=O)OC Chemical compound [Si](C)(C)(C(C)(C)C)OCCCN1C=NC(=C1)C(=O)OC AAFSFCFTVGNWSY-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- QJKVDFRAKMVERC-UHFFFAOYSA-N benzyl 3-bromopropanoate Chemical compound BrCCC(=O)OCC1=CC=CC=C1 QJKVDFRAKMVERC-UHFFFAOYSA-N 0.000 description 2
- FGPWOZTYXWEYIV-UHFFFAOYSA-N benzyl 4-[[4-[(2-methylpropan-2-yl)oxycarbonylamino]piperidin-1-yl]methyl]piperidine-1-carboxylate Chemical compound C1CC(NC(=O)OC(C)(C)C)CCN1CC1CCN(C(=O)OCC=2C=CC=CC=2)CC1 FGPWOZTYXWEYIV-UHFFFAOYSA-N 0.000 description 2
- JJUJDJNFXYNOKI-UHFFFAOYSA-N benzyl 4-bromobutanoate Chemical compound BrCCCC(=O)OCC1=CC=CC=C1 JJUJDJNFXYNOKI-UHFFFAOYSA-N 0.000 description 2
- CDDIGMBGUSFJKL-UHFFFAOYSA-N benzyl N-[(5-bromopyridin-3-yl)methyl]carbamate Chemical compound C(C1=CC=CC=C1)OC(NCC=1C=NC=C(C=1)Br)=O CDDIGMBGUSFJKL-UHFFFAOYSA-N 0.000 description 2
- BTZBVTLPHVTGNL-UHFFFAOYSA-N benzyl N-[2-(2-hydroxyethoxy)ethyl]-N-methylcarbamate Chemical compound CN(CCOCCO)C(=O)OCc1ccccc1 BTZBVTLPHVTGNL-UHFFFAOYSA-N 0.000 description 2
- SALIGUDCQGPNII-UHFFFAOYSA-N benzyl N-[2-[4-(hydroxymethyl)phenoxy]ethyl]carbamate Chemical compound OCC1=CC=C(OCCNC(OCC2=CC=CC=C2)=O)C=C1 SALIGUDCQGPNII-UHFFFAOYSA-N 0.000 description 2
- 229960004217 benzyl alcohol Drugs 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- HREXFDIZSAUXBO-UHFFFAOYSA-N benzyl n-(2-bromoethyl)carbamate Chemical compound BrCCNC(=O)OCC1=CC=CC=C1 HREXFDIZSAUXBO-UHFFFAOYSA-N 0.000 description 2
- TYIYHFWLYLHCHY-UHFFFAOYSA-N benzyl n-(5-hydroxypentyl)carbamate Chemical compound OCCCCCNC(=O)OCC1=CC=CC=C1 TYIYHFWLYLHCHY-UHFFFAOYSA-N 0.000 description 2
- ISUIGFYCBBIILY-UHFFFAOYSA-N benzyl n-(7-aminoheptyl)carbamate Chemical compound NCCCCCCCNC(=O)OCC1=CC=CC=C1 ISUIGFYCBBIILY-UHFFFAOYSA-N 0.000 description 2
- OYUCEOQQZUGXNK-UHFFFAOYSA-N benzyl n-[(3-bromophenyl)methyl]carbamate Chemical compound BrC1=CC=CC(CNC(=O)OCC=2C=CC=CC=2)=C1 OYUCEOQQZUGXNK-UHFFFAOYSA-N 0.000 description 2
- QBDBDTWXXVOFEW-UHFFFAOYSA-N benzyl n-[[3-(hydroxymethyl)phenyl]methyl]carbamate Chemical compound OCC1=CC=CC(CNC(=O)OCC=2C=CC=CC=2)=C1 QBDBDTWXXVOFEW-UHFFFAOYSA-N 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- LNKPHPQVHFEOFX-UHFFFAOYSA-N ethyl 2,2-difluoro-3-(propan-2-ylamino)propanoate Chemical compound CCOC(=O)C(F)(F)CNC(C)C LNKPHPQVHFEOFX-UHFFFAOYSA-N 0.000 description 2
- ZFDCWHPNBWPPHG-UHFFFAOYSA-N ethyl 2-(4-bromophenyl)acetate Chemical compound CCOC(=O)CC1=CC=C(Br)C=C1 ZFDCWHPNBWPPHG-UHFFFAOYSA-N 0.000 description 2
- UPKOVKMNWQZTFB-UHFFFAOYSA-N ethyl 2-(4-ethenylphenyl)acetate Chemical compound CCOC(=O)CC1=CC=C(C=C)C=C1 UPKOVKMNWQZTFB-UHFFFAOYSA-N 0.000 description 2
- XNMJBNFFMVWVMK-UHFFFAOYSA-N ethyl 2-[2-[2-(4-methylphenyl)sulfonyloxyethoxy]ethoxy]acetate Chemical compound S(=O)(=O)(C1=CC=C(C)C=C1)OCCOCCOCC(=O)OCC XNMJBNFFMVWVMK-UHFFFAOYSA-N 0.000 description 2
- PFCVBBXFUSBGTO-UHFFFAOYSA-N ethyl 3-[(2-chloro-5-nitropyrimidin-4-yl)-propan-2-ylamino]-2,2-difluoropropanoate Chemical compound CCOC(=O)C(F)(F)CN(C(C)C)C1=NC(Cl)=NC=C1[N+]([O-])=O PFCVBBXFUSBGTO-UHFFFAOYSA-N 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- LYBKPDDZTNUNNM-UHFFFAOYSA-N isopropylbenzylamine Chemical compound CC(C)NCC1=CC=CC=C1 LYBKPDDZTNUNNM-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 2
- OEGVADJWEKHZCC-UHFFFAOYSA-N methyl 4-[(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-8H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-3-methoxybenzoate Chemical compound CN1C2=CN=C(N=C2N(CC(C1=O)(F)F)C3CCCC3)NC4=C(C=C(C=C4)C(=O)OC)OC OEGVADJWEKHZCC-UHFFFAOYSA-N 0.000 description 2
- OAEFJPPUKFWJOR-UHFFFAOYSA-N methyl 4-[(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-8H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-5-ethoxy-2-fluorobenzoate Chemical compound CCOC1=CC(C(=O)OC)=C(F)C=C1NC1=NC=C(N(C)C(=O)C(F)(F)CN2C3CCCC3)C2=N1 OAEFJPPUKFWJOR-UHFFFAOYSA-N 0.000 description 2
- CNDSCIGLNFCBJS-UHFFFAOYSA-N methyl 4-amino-2-fluoro-5-(trifluoromethoxy)benzoate Chemical compound COC(=O)c1cc(OC(F)(F)F)c(N)cc1F CNDSCIGLNFCBJS-UHFFFAOYSA-N 0.000 description 2
- DJLFOMMCQBAMAA-UHFFFAOYSA-N methyl 4-amino-3-methoxybenzoate Chemical compound COC(=O)C1=CC=C(N)C(OC)=C1 DJLFOMMCQBAMAA-UHFFFAOYSA-N 0.000 description 2
- BQXFXCBTZKRDKC-UHFFFAOYSA-N methyl 5-ethoxy-2-fluoro-4-nitrobenzoate Chemical compound CCOc1cc(C(=O)OC)c(F)cc1[N+]([O-])=O BQXFXCBTZKRDKC-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- XSFKXJUCOOIVRH-UHFFFAOYSA-N n-[2-(2-hydroxyethoxy)ethyl]formamide Chemical compound OCCOCCNC=O XSFKXJUCOOIVRH-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 2
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 description 2
- FYRHIOVKTDQVFC-UHFFFAOYSA-M potassium phthalimide Chemical compound [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- KFMILLFSHLUMAN-UHFFFAOYSA-N tert-butyl N-[1-[2-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]ethoxy]ethyl]piperidin-4-yl]carbamate Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NCCOCCN1CCC(CC1)NC(OC(C)(C)C)=O)=O)=O KFMILLFSHLUMAN-UHFFFAOYSA-N 0.000 description 2
- GHJIPSJRPKMDAA-UHFFFAOYSA-N tert-butyl N-[1-[2-[4-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]piperazin-1-yl]ethyl]piperidin-4-yl]carbamate Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)N1CCN(CC1)CCN1CCC(CC1)NC(OC(C)(C)C)=O)=O)=O GHJIPSJRPKMDAA-UHFFFAOYSA-N 0.000 description 2
- ABIFKHRNNGLPMW-WYMKREKISA-N tert-butyl N-[1-[8-[2-[[(2S)-1-[(2S,4R)-4-hydroxy-2-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methylcarbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]amino]-2-oxoethoxy]octyl]piperidin-4-yl]carbamate Chemical compound O[C@@H]1C[C@H](N(C1)C([C@H](C(C)(C)C)NC(COCCCCCCCCN1CCC(CC1)NC(OC(C)(C)C)=O)=O)=O)C(NCC1=CC=C(C=C1)C1=C(N=CS1)C)=O ABIFKHRNNGLPMW-WYMKREKISA-N 0.000 description 2
- PSLWFSJZWCYJTI-UHFFFAOYSA-N tert-butyl n-[1-(2-chloroethyl)piperidin-4-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC1CCN(CCCl)CC1 PSLWFSJZWCYJTI-UHFFFAOYSA-N 0.000 description 2
- KAQZZWSBZVORPS-UHFFFAOYSA-N tert-butyl n-[1-(piperidin-4-ylmethyl)piperidin-4-yl]carbamate Chemical compound C1CC(NC(=O)OC(C)(C)C)CCN1CC1CCNCC1 KAQZZWSBZVORPS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- SXNJFOWDRLKDSF-STROYTFGSA-N volasertib Chemical compound C1CN([C@H]2CC[C@@H](CC2)NC(=O)C2=CC=C(C(=C2)OC)NC=2N=C3N(C(C)C)[C@@H](C(N(C)C3=CN=2)=O)CC)CCN1CC1CC1 SXNJFOWDRLKDSF-STROYTFGSA-N 0.000 description 2
- 229950003081 volasertib Drugs 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- OKBLHQUBMCCFKE-LVCYWYKZSA-N (2S,4R)-1-[(2S)-2-[(1-fluorocyclopropanecarbonyl)amino]-3,3-dimethylbutanoyl]-4-hydroxy-N-[[2-hydroxy-4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide Chemical compound FC1(CC1)C(=O)N[C@H](C(=O)N1[C@@H](C[C@H](C1)O)C(=O)NCC1=C(C=C(C=C1)C1=C(N=CS1)C)O)C(C)(C)C OKBLHQUBMCCFKE-LVCYWYKZSA-N 0.000 description 1
- GCTFTMWXZFLTRR-GFCCVEGCSA-N (2r)-2-amino-n-[3-(difluoromethoxy)-4-(1,3-oxazol-5-yl)phenyl]-4-methylpentanamide Chemical compound FC(F)OC1=CC(NC(=O)[C@H](N)CC(C)C)=CC=C1C1=CN=CO1 GCTFTMWXZFLTRR-GFCCVEGCSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 description 1
- ZLOXMSNKPDWMEF-ZIFCJYIRSA-N (2s,4r)-1-[(2s)-2-amino-3,3-dimethylbutanoyl]-4-hydroxy-n-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide Chemical compound N1=CSC(C=2C=CC(CNC(=O)[C@H]3N(C[C@H](O)C3)C(=O)[C@@H](N)C(C)(C)C)=CC=2)=C1C ZLOXMSNKPDWMEF-ZIFCJYIRSA-N 0.000 description 1
- SUYJXERPRICYRX-UHFFFAOYSA-N (3-bromophenyl)methanamine Chemical compound NCC1=CC=CC(Br)=C1 SUYJXERPRICYRX-UHFFFAOYSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- WDVDHJLKXYCOFS-UHFFFAOYSA-N (5-bromopyridin-3-yl)methanol Chemical compound OCC1=CN=CC(Br)=C1 WDVDHJLKXYCOFS-UHFFFAOYSA-N 0.000 description 1
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 1
- QXOGPTXQGKQSJT-UHFFFAOYSA-N 1-amino-4-[4-(3,4-dimethylphenyl)sulfanylanilino]-9,10-dioxoanthracene-2-sulfonic acid Chemical compound Cc1ccc(Sc2ccc(Nc3cc(c(N)c4C(=O)c5ccccc5C(=O)c34)S(O)(=O)=O)cc2)cc1C QXOGPTXQGKQSJT-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- INUSQTPGSHFGHM-UHFFFAOYSA-N 2,4-dichloro-5-nitropyrimidine Chemical compound [O-][N+](=O)C1=CN=C(Cl)N=C1Cl INUSQTPGSHFGHM-UHFFFAOYSA-N 0.000 description 1
- GPTNSBLYGCZJQV-UHFFFAOYSA-N 2,5-difluoro-4-nitrobenzoic acid Chemical compound OC(=O)C1=CC(F)=C([N+]([O-])=O)C=C1F GPTNSBLYGCZJQV-UHFFFAOYSA-N 0.000 description 1
- WGFNXGPBPIJYLI-UHFFFAOYSA-N 2,6-difluoro-3-[(3-fluorophenyl)sulfonylamino]-n-(3-methoxy-1h-pyrazolo[3,4-b]pyridin-5-yl)benzamide Chemical compound C1=C2C(OC)=NNC2=NC=C1NC(=O)C(C=1F)=C(F)C=CC=1NS(=O)(=O)C1=CC=CC(F)=C1 WGFNXGPBPIJYLI-UHFFFAOYSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- APURBVBIOACKLC-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-4-piperazin-1-ylisoindole-1,3-dione Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)N1CCNCC1)=O)=O APURBVBIOACKLC-UHFFFAOYSA-N 0.000 description 1
- ASDQMECUMYIVBG-UHFFFAOYSA-N 2-[2-(2-aminoethoxy)ethoxy]ethanol Chemical compound NCCOCCOCCO ASDQMECUMYIVBG-UHFFFAOYSA-N 0.000 description 1
- RSUCRUOTLCQWFX-UHFFFAOYSA-N 2-[2-(2-hydroxyethoxy)ethoxy]ethyl 4-methylbenzenesulfonate Chemical compound CC1=CC=C(S(=O)(=O)OCCOCCOCCO)C=C1 RSUCRUOTLCQWFX-UHFFFAOYSA-N 0.000 description 1
- ANOJXMUSDYSKET-UHFFFAOYSA-N 2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethanol Chemical compound NCCOCCOCCOCCO ANOJXMUSDYSKET-UHFFFAOYSA-N 0.000 description 1
- WQMJFCWQBPUZCK-UHFFFAOYSA-N 2-[2-[2-(2-prop-2-ynoxyethoxy)ethoxy]ethoxy]ethanol Chemical compound OCCOCCOCCOCCOCC#C WQMJFCWQBPUZCK-UHFFFAOYSA-N 0.000 description 1
- DEOUHEFHTMMUCM-UHFFFAOYSA-N 2-[2-[2-[2-(2-aminoethoxy)ethoxy]ethoxy]ethoxy]ethanol Chemical compound NCCOCCOCCOCCOCCO DEOUHEFHTMMUCM-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- VSWUXJWUEXNGLF-UHFFFAOYSA-N 2-chloro-7,7-difluoro-5-methyl-9-propan-2-yl-8h-pyrimido[4,5-b][1,4]diazepin-6-one Chemical compound CC(C)N1CC(F)(F)C(=O)N(C)C2=CN=C(Cl)N=C12 VSWUXJWUEXNGLF-UHFFFAOYSA-N 0.000 description 1
- DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 description 1
- SCLMDNYYDXZSJK-UHFFFAOYSA-N 3-(5-fluoro-4-oxo-1,2,3-benzotriazin-3-yl)piperidine-2,6-dione Chemical compound FC1=CC=CC=2N=NN(C(C=21)=O)C1C(NC(CC1)=O)=O SCLMDNYYDXZSJK-UHFFFAOYSA-N 0.000 description 1
- BGAJNPLDJJBRHK-UHFFFAOYSA-N 3-[2-[5-(3-chloro-4-propan-2-yloxyphenyl)-1,3,4-thiadiazol-2-yl]-3-methyl-6,7-dihydro-4h-pyrazolo[4,3-c]pyridin-5-yl]propanoic acid Chemical compound C1=C(Cl)C(OC(C)C)=CC=C1C1=NN=C(N2C(=C3CN(CCC(O)=O)CCC3=N2)C)S1 BGAJNPLDJJBRHK-UHFFFAOYSA-N 0.000 description 1
- DHXNZYCXMFBMHE-UHFFFAOYSA-N 3-bromopropanoic acid Chemical compound OC(=O)CCBr DHXNZYCXMFBMHE-UHFFFAOYSA-N 0.000 description 1
- QGMROEZDWJTIDW-UHFFFAOYSA-N 3-bromopropoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCCBr QGMROEZDWJTIDW-UHFFFAOYSA-N 0.000 description 1
- HNPVERUJGFNNRV-UHFFFAOYSA-N 3-iodophthalic acid Chemical compound OC(=O)C1=CC=CC(I)=C1C(O)=O HNPVERUJGFNNRV-UHFFFAOYSA-N 0.000 description 1
- ZRMYHUFDVLRYPN-UHFFFAOYSA-N 3-oxabicyclo[3.1.0]hexane-2,4-dione Chemical compound O=C1OC(=O)C2CC12 ZRMYHUFDVLRYPN-UHFFFAOYSA-N 0.000 description 1
- SUBIEWLFZOKEFV-UHFFFAOYSA-N 4-[(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]benzoic acid Chemical compound N1=C2N(C3CCCC3)CC(F)(F)C(=O)N(C)C2=CN=C1NC1=CC=C(C(O)=O)C=C1 SUBIEWLFZOKEFV-UHFFFAOYSA-N 0.000 description 1
- MPMKMQHJHDHPBE-RUZDIDTESA-N 4-[[(2r)-1-(1-benzothiophene-3-carbonyl)-2-methylazetidine-2-carbonyl]-[(3-chlorophenyl)methyl]amino]butanoic acid Chemical compound O=C([C@@]1(N(CC1)C(=O)C=1C2=CC=CC=C2SC=1)C)N(CCCC(O)=O)CC1=CC=CC(Cl)=C1 MPMKMQHJHDHPBE-RUZDIDTESA-N 0.000 description 1
- GRHQDJDRGZFIPO-UHFFFAOYSA-N 4-bromobutanoic acid Chemical compound OC(=O)CCCBr GRHQDJDRGZFIPO-UHFFFAOYSA-N 0.000 description 1
- PGISCPIWSHGJJJ-UHFFFAOYSA-N 4-fluoro-2-nitro-1-(trifluoromethoxy)benzene Chemical compound [O-][N+](=O)C1=CC(F)=CC=C1OC(F)(F)F PGISCPIWSHGJJJ-UHFFFAOYSA-N 0.000 description 1
- TYROJDFHUXSBHC-UHFFFAOYSA-N 4-phenylmethoxybutan-1-ol Chemical compound OCCCCOCC1=CC=CC=C1 TYROJDFHUXSBHC-UHFFFAOYSA-N 0.000 description 1
- LQGKDMHENBFVRC-UHFFFAOYSA-N 5-aminopentan-1-ol Chemical compound NCCCCCO LQGKDMHENBFVRC-UHFFFAOYSA-N 0.000 description 1
- HCCNBKFJYUWLEX-UHFFFAOYSA-N 7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)-3-(pyrazin-2-ylmethylamino)pyrido[3,4-b]pyrazin-2-one Chemical compound O=C1N(CCOCCC)C2=CC(C=3C=NC(OC)=CC=3)=NC=C2N=C1NCC1=CN=CC=N1 HCCNBKFJYUWLEX-UHFFFAOYSA-N 0.000 description 1
- MMXRRNUXCHUHOE-UHFFFAOYSA-N 7-bromoheptan-1-ol Chemical compound OCCCCCCCBr MMXRRNUXCHUHOE-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000023514 Barrett esophagus Diseases 0.000 description 1
- 208000023665 Barrett oesophagus Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WWGUAFRTAYMNHU-UHFFFAOYSA-N Benzyl 4-piperidinylcarbamate Chemical compound C=1C=CC=CC=1COC(=O)NC1CCNCC1 WWGUAFRTAYMNHU-UHFFFAOYSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 206010006220 Breast cyst Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- CEAPRSFGUCDTMD-UHFFFAOYSA-N C(C)(CC)OC=1C(=CC(=C(C(=O)O)C=1)F)NC=1N=CC2=C(N(CC(C(N2C)=O)(F)F)C2CCCC2)N=1 Chemical compound C(C)(CC)OC=1C(=CC(=C(C(=O)O)C=1)F)NC=1N=CC2=C(N(CC(C(N2C)=O)(F)F)C2CCCC2)N=1 CEAPRSFGUCDTMD-UHFFFAOYSA-N 0.000 description 1
- NZELEOJLZXYNEV-UHFFFAOYSA-N C(C1=CC=CC=C1)OCCCCOCCC(=O)OCC Chemical compound C(C1=CC=CC=C1)OCCCCOCCC(=O)OCC NZELEOJLZXYNEV-UHFFFAOYSA-N 0.000 description 1
- VGKWWQQCPUPATP-UHFFFAOYSA-N C1(=O)NC(=O)CCC1N1C(=O)C2=CC=CC(OCC(=O)NCCCCCCCN)=C2C1=O Chemical compound C1(=O)NC(=O)CCC1N1C(=O)C2=CC=CC(OCC(=O)NCCCCCCCN)=C2C1=O VGKWWQQCPUPATP-UHFFFAOYSA-N 0.000 description 1
- MKOOHRLLWNHLQI-UHFFFAOYSA-N C1(CCC1)OC=1C(=CC(=C(C(=O)O)C=1)F)NC=1N=CC2=C(N(CC(C(N2C)=O)(F)F)C2CCCC2)N=1 Chemical compound C1(CCC1)OC=1C(=CC(=C(C(=O)O)C=1)F)NC=1N=CC2=C(N(CC(C(N2C)=O)(F)F)C2CCCC2)N=1 MKOOHRLLWNHLQI-UHFFFAOYSA-N 0.000 description 1
- YMKFABYMCOSULQ-UHFFFAOYSA-N C1(CCCC1)N1C2=C(N(C(C(C1)(F)F)=O)C)C=NC(=N2)NC1=CC(=C(C(=O)O)C=C1OC(C)C)F Chemical compound C1(CCCC1)N1C2=C(N(C(C(C1)(F)F)=O)C)C=NC(=N2)NC1=CC(=C(C(=O)O)C=C1OC(C)C)F YMKFABYMCOSULQ-UHFFFAOYSA-N 0.000 description 1
- ZSLCJZRZLMNECX-UHFFFAOYSA-N C1(CCCC1)N1C2=C(N(C(C(C1)(F)F)=O)C)C=NC(=N2)NC1=CC(=C(C(=O)O)C=C1OC1CC1)F Chemical compound C1(CCCC1)N1C2=C(N(C(C(C1)(F)F)=O)C)C=NC(=N2)NC1=CC(=C(C(=O)O)C=C1OC1CC1)F ZSLCJZRZLMNECX-UHFFFAOYSA-N 0.000 description 1
- MOKHDCIXLQEDQM-UHFFFAOYSA-N C1(CCCC1)N1C2=C(N(C(C(C1)(F)F)=O)C)C=NC(=N2)NC1=CC(=C(C(=O)O)C=C1OC1CCCC1)F Chemical compound C1(CCCC1)N1C2=C(N(C(C(C1)(F)F)=O)C)C=NC(=N2)NC1=CC(=C(C(=O)O)C=C1OC1CCCC1)F MOKHDCIXLQEDQM-UHFFFAOYSA-N 0.000 description 1
- JJHKGKXTXSRQTO-UHFFFAOYSA-N C1(CCCC1)N1C2=C(N(C(C(C1)(F)F)=O)C)C=NC(=N2)NC1=CC(=C(C(=O)O)C=C1OCCO)F Chemical compound C1(CCCC1)N1C2=C(N(C(C(C1)(F)F)=O)C)C=NC(=N2)NC1=CC(=C(C(=O)O)C=C1OCCO)F JJHKGKXTXSRQTO-UHFFFAOYSA-N 0.000 description 1
- MODNLSWWWBVULV-UHFFFAOYSA-N CC1=CC=C(C=C1)S(=O)(=O)OCCCOCCCCOCC1=CC=CC=C1 Chemical compound CC1=CC=C(C=C1)S(=O)(=O)OCCCOCCCCOCC1=CC=CC=C1 MODNLSWWWBVULV-UHFFFAOYSA-N 0.000 description 1
- BNKBWIDQRILOOZ-UHFFFAOYSA-N CC1=CC=C(C=C1)S(=O)(=O)OCCOCCOCCNC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O Chemical compound CC1=CC=C(C=C1)S(=O)(=O)OCCOCCOCCNC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O BNKBWIDQRILOOZ-UHFFFAOYSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102100039193 Cullin-2 Human genes 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 102000012698 DDB1 Human genes 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101100170004 Dictyostelium discoideum repE gene Proteins 0.000 description 1
- 101100170005 Drosophila melanogaster pic gene Proteins 0.000 description 1
- 101710095156 E3 ubiquitin-protein ligase RBX1 Proteins 0.000 description 1
- 102000004662 Elongin Human genes 0.000 description 1
- 102100030209 Elongin-B Human genes 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 102100028043 Fibroblast growth factor 3 Human genes 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- 230000010190 G1 phase Effects 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- 101000746072 Homo sapiens Cullin-2 Proteins 0.000 description 1
- 101001111722 Homo sapiens E3 ubiquitin-protein ligase RBX1 Proteins 0.000 description 1
- 101000574654 Homo sapiens GTP-binding protein Rit1 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 101710092857 Integrator complex subunit 1 Proteins 0.000 description 1
- 102100024061 Integrator complex subunit 1 Human genes 0.000 description 1
- 108050002021 Integrator complex subunit 2 Proteins 0.000 description 1
- 206010061252 Intraocular melanoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 description 1
- 206010025280 Lymphocytosis Diseases 0.000 description 1
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 1
- 208000002231 Muscle Neoplasms Diseases 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- AVYVHIKSFXVDBG-UHFFFAOYSA-N N-benzyl-N-hydroxy-2,2-dimethylbutanamide Chemical compound C(C1=CC=CC=C1)N(C(C(CC)(C)C)=O)O AVYVHIKSFXVDBG-UHFFFAOYSA-N 0.000 description 1
- BADLMWGLLCZMNA-UHFFFAOYSA-N N1(N=NC2=C1C=CC=C2)CN(C(C)C)CC1=CC=CC=C1 Chemical compound N1(N=NC2=C1C=CC=C2)CN(C(C)C)CC1=CC=CC=C1 BADLMWGLLCZMNA-UHFFFAOYSA-N 0.000 description 1
- YASVYLKEHICNHZ-UHFFFAOYSA-N NC1CCN(CC1)C(CCCNC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O)=O Chemical compound NC1CCN(CC1)C(CCCNC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O)=O YASVYLKEHICNHZ-UHFFFAOYSA-N 0.000 description 1
- ZPLDXHRTTKQOTH-UHFFFAOYSA-N NC1CCN(CC1)CC1CCN(CC1)C1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O Chemical compound NC1CCN(CC1)CC1CCN(CC1)C1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O ZPLDXHRTTKQOTH-UHFFFAOYSA-N 0.000 description 1
- HJGNVAXFEDRGRY-UHFFFAOYSA-N NC1CCN(CC1)CCC1=CC=C(C=C1)CC(=O)NC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O Chemical compound NC1CCN(CC1)CCC1=CC=C(C=C1)CC(=O)NC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O HJGNVAXFEDRGRY-UHFFFAOYSA-N 0.000 description 1
- FAPZLLMTSVGUEQ-JSWXEYCZSA-N NC1CCN(CC1)CCCCCCCCOCC(=O)N[C@H](C(=O)N1[C@@H](C[C@H](C1)O)C(=O)NCC1=CC=C(C=C1)C1=C(N=CS1)C)C(C)(C)C Chemical compound NC1CCN(CC1)CCCCCCCCOCC(=O)N[C@H](C(=O)N1[C@@H](C[C@H](C1)O)C(=O)NCC1=CC=C(C=C1)C1=C(N=CS1)C)C(C)(C)C FAPZLLMTSVGUEQ-JSWXEYCZSA-N 0.000 description 1
- JVKVNPRZKHPXNU-UHFFFAOYSA-N NC1CCN(CC1)CCCN1C=NC(=C1)CNC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O Chemical compound NC1CCN(CC1)CCCN1C=NC(=C1)CNC1=C2C(N(C(C2=CC=C1)=O)C1C(NC(CC1)=O)=O)=O JVKVNPRZKHPXNU-UHFFFAOYSA-N 0.000 description 1
- ABAJAGBCILVIHD-UHFFFAOYSA-N NC1CCN(CC1)CCOCCOCCNC1=C2C(N(C(C2=CC=C1)=O)C1C(N(C(CC1)=O)C)=O)=O Chemical compound NC1CCN(CC1)CCOCCOCCNC1=C2C(N(C(C2=CC=C1)=O)C1C(N(C(CC1)=O)C)=O)=O ABAJAGBCILVIHD-UHFFFAOYSA-N 0.000 description 1
- 229910017852 NH2NH2 Inorganic materials 0.000 description 1
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- SGLJQWHWVVIOQV-UHFFFAOYSA-N O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NCC=1N=CN(C=1)CCCN1CCC(CC1)NC(OC(C)(C)C)=O)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)NCC=1N=CN(C=1)CCCN1CCC(CC1)NC(OC(C)(C)C)=O)=O)=O SGLJQWHWVVIOQV-UHFFFAOYSA-N 0.000 description 1
- ACEWXSQOQGCDKC-UHFFFAOYSA-N O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)OCC(=O)NCCOCCOCCOCCO)=O)=O Chemical compound O=C1NC(CCC1N1C(C2=CC=CC(=C2C1=O)OCC(=O)NCCOCCOCCOCCO)=O)=O ACEWXSQOQGCDKC-UHFFFAOYSA-N 0.000 description 1
- BHSSINPQJZLRIR-UHFFFAOYSA-N OCCCCCCCCN1CCC(CC1)NC(OC(C)(C)C)=O Chemical compound OCCCCCCCCN1CCC(CC1)NC(OC(C)(C)C)=O BHSSINPQJZLRIR-UHFFFAOYSA-N 0.000 description 1
- FSSARKIZJSTTTE-UHFFFAOYSA-N OCCOCCOCCOCCOCCNC1=CC=CC=2N=NN(C(C=21)=O)C1C(NC(CC1)=O)=O Chemical compound OCCOCCOCCOCCOCCNC1=CC=CC=2N=NN(C(C=21)=O)C1C(NC(CC1)=O)=O FSSARKIZJSTTTE-UHFFFAOYSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- BXHRXLMCYSZSIY-STECZYCISA-N Pro-Tyr-Ile Chemical compound CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H]1CCCN1)C(O)=O BXHRXLMCYSZSIY-STECZYCISA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102100032783 Protein cereblon Human genes 0.000 description 1
- 101710178916 RING-box protein 1 Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 206010046431 Urethral cancer Diseases 0.000 description 1
- 206010046458 Urethral neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 201000005969 Uveal melanoma Diseases 0.000 description 1
- 102000053200 Von Hippel-Lindau Tumor Suppressor Human genes 0.000 description 1
- 108700031765 Von Hippel-Lindau Tumor Suppressor Proteins 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- MXJIHEXYGRXHGP-UHFFFAOYSA-N benzotriazol-1-ylmethanol Chemical compound C1=CC=C2N(CO)N=NC2=C1 MXJIHEXYGRXHGP-UHFFFAOYSA-N 0.000 description 1
- ALNSORIFMQKXTJ-UHFFFAOYSA-N benzyl 4-[4-[(2-methylpropan-2-yl)oxycarbonylamino]cyclohexyl]piperazine-1-carboxylate Chemical compound C1CC(NC(=O)OC(C)(C)C)CCC1N1CCN(C(=O)OCC=2C=CC=CC=2)CC1 ALNSORIFMQKXTJ-UHFFFAOYSA-N 0.000 description 1
- ZJQMLJFHCKTCSF-UHFFFAOYSA-N benzyl 4-formylpiperidine-1-carboxylate Chemical compound C1CC(C=O)CCN1C(=O)OCC1=CC=CC=C1 ZJQMLJFHCKTCSF-UHFFFAOYSA-N 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- CTOUWUYDDUSBQE-UHFFFAOYSA-N benzyl piperazine-1-carboxylate Chemical compound C1CNCCN1C(=O)OCC1=CC=CC=C1 CTOUWUYDDUSBQE-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 201000003149 breast fibroadenoma Diseases 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 230000007681 cardiovascular toxicity Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940125936 compound 42 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 229940126545 compound 53 Drugs 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 101150077768 ddb1 gene Proteins 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- IRSJDVYTJUCXRV-UHFFFAOYSA-N ethyl 2-bromo-2,2-difluoroacetate Chemical compound CCOC(=O)C(F)(F)Br IRSJDVYTJUCXRV-UHFFFAOYSA-N 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- BVRCLEXKQNWTDK-UHFFFAOYSA-N hept-6-yn-1-ol Chemical compound OCCCCCC#C BVRCLEXKQNWTDK-UHFFFAOYSA-N 0.000 description 1
- PWSKHLMYTZNYKO-UHFFFAOYSA-N heptane-1,7-diamine Chemical compound NCCCCCCCN PWSKHLMYTZNYKO-UHFFFAOYSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 150000003949 imides Chemical class 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 208000029559 malignant endocrine neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- KCCSBYUQLFEETJ-UHFFFAOYSA-N methyl 1h-imidazole-4-carboxylate Chemical compound COC(=O)C1=CN[C]=N1 KCCSBYUQLFEETJ-UHFFFAOYSA-N 0.000 description 1
- FWSCIBSBSZSNGS-UHFFFAOYSA-N methyl 4-amino-2-fluoro-5-methoxybenzoate Chemical compound COC(=O)C1=CC(OC)=C(N)C=C1F FWSCIBSBSZSNGS-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000002077 muscle cancer Diseases 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000002575 ocular melanoma Diseases 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 201000002628 peritoneum cancer Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 208000014081 polyp of colon Diseases 0.000 description 1
- 229960000688 pomalidomide Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- XQSNXLDLKOJJOU-UHFFFAOYSA-N pyrimido[5,4-c]diazepin-3-one Chemical class N1=NC(=O)C=CC2=NC=NC=C21 XQSNXLDLKOJJOU-UHFFFAOYSA-N 0.000 description 1
- NPWMTBZSRRLQNJ-UHFFFAOYSA-N pyroglutamine Chemical compound NC1CCC(=O)NC1=O NPWMTBZSRRLQNJ-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical class [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 235000019187 sodium-L-ascorbate Nutrition 0.000 description 1
- 239000011755 sodium-L-ascorbate Substances 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- SJMDMGHPMLKLHQ-UHFFFAOYSA-N tert-butyl 2-aminoacetate Chemical compound CC(C)(C)OC(=O)CN SJMDMGHPMLKLHQ-UHFFFAOYSA-N 0.000 description 1
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
- LIFADCULPALWIZ-UHFFFAOYSA-N tert-butyl N-(1-prop-2-ynylpiperidin-4-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1CCN(CC#C)CC1 LIFADCULPALWIZ-UHFFFAOYSA-N 0.000 description 1
- WYVFPGFWUKBXPZ-UHFFFAOYSA-N tert-butyl n-(4-oxocyclohexyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1CCC(=O)CC1 WYVFPGFWUKBXPZ-UHFFFAOYSA-N 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 1
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
Definitions
- the present invention relates to a selective PLK1 degradation inducing compound, a method for preparing the same, and the use thereof.
- Polo-like kinase 1 is a serine/threonine kinase involved in the conversion of G2/M phase during cell growth and division. PLK1 is expressed and activated in a pulse form from the S phase to the G2/M phase, and rapidly degrades as mitosis ends.
- PLK1 is overexpressed in various carcinomas such as colon cancer, lung cancer, bladder cancer, and melanoma, etc., and cancer cells overexpressing PLK1 tend to show resistance to various types of anticancer drugs.
- PLK1 inhibitor compounds such as volasertib (also known as BI6727), etc.
- the conventional PLK1 inhibitors do not sufficiently inhibit PLK1 activity at concentrations that are clinically safe.
- the conventional PLK1 inhibitors do not sufficiently inhibit PLK1 activity at concentrations that are clinically safe.
- many pharmaceutical companies such as Boehringer Ingelheim, GlaxoSmithKline, etc., have attempted to develop small-molecular compound-based PLK1 inhibitors, but most of them have failed or stopped in the clinical trial stage, and thus there are no commercially available PLK1 inhibitors to date.
- proteolysis targeting chimera has been proposed as a small molecule-based platform technology capable of inducing proteolysis of a target protein in the body.
- the PROTAC is a bifunctional compound in which a ligand molecule that binds to disease-related target protein and an E3 ubiquitin ligase binding moiety are linked by a chemical linker. Theoretically, the PROTAC compound is capable of inducing degradation of the target protein by placing the disease-related target protein near the E3 ubiquitin ligase.
- the PROTAC compound described in the above-described document is characterized by a compound that simultaneously degrades PLK1 and BRD4, and degrade various proteins such as other PLK family proteins and BRD4, etc.), which may cause side effects due to off-target effects at the time of drug development.
- a compound that simultaneously degrades PLK1 and BRD4 and degrade various proteins such as other PLK family proteins and BRD4, etc.
- BRD4 activity inevitably accompanies on-target toxicity such as blood toxicity and gastrointestinal toxicity along with pharmacological effects. Therefore, the PROTAC compound described in the above document would expect to face greater clinical side effects as more BRD4 protein gets degraded (see Bolden et al. Cell Reports, 2014).
- the PROTAC compound which simultaneously degrades PLK1 and BRD4, has much stronger BRD4 degradation ability than PLK1 degradation ability at the cellular level, and the cell cycle thereof almost stops in the G1 phase, etc., that is, the PROTAC compound actually acts only as a BRD4 inhibitor regardless of the way that the conventional PLK1 inhibitors exert pharmacological effects.
- An object of the present invention is to provide selective PLK1 degradation inducing compounds.
- Another object of the present invention is to provide a method for preparing the compounds.
- Still another object of the present invention is to provide a use of the compounds.
- the present invention provides novel compounds that induce selective polo-like kinase 1 (PLK1) degradation.
- the present invention provides a bifunctional compound in which a PLK1 binding moiety and an E3 ubiquitin ligase-binding moiety are linked by a chemical linker.
- ULM is a CRBN E3 ubiquitin ligase binding moiety.
- CRBN means Cereblon E3 ubiquitin ligase.
- CRBN constitutes an E3 ubiquitin ligase complex together with DDB1, Cul4A and ROC1, wherein the CRBN is a substrate recognition subunit of the complex.
- Some compounds capable of binding to the CRBN E3 ubiquitin ligase are known in the art. For example, after it was known that thalidomide binds to the CRBN E3 ubiquitin ligase (see Ito et al. 2010), it has been reported that a number of immunomodulatory imide drugs (IMiD) including lenalidomide and pomalidomide have CRBN binding ability (see Chamberlain and Brian. 2019; Akuffo et al. 2018; and Burslem et al. 2018, etc.).
- IMD immunomodulatory imide drugs
- the CRBN E3 ubiquitin ligase binding moiety in Formula I is represented by the following Formula A-1:
- Formula A-1 is represented by the following Formula A-2:
- Formula A-2 is selected from the group consisting of:
- CRBN E3 ubiquitin ligase binding moieties of Formula A-1 or A-2 may be derived from the compounds having the following structures (Chamberlain and Brian. 2019; Akuffo et al. 2018; etc.):
- CRBN E3 ubiquitin ligase binding moieties of Formula A-1 or A-2 may be derived from the compounds having the following structures (Burslem et al. 2018; etc.):
- the CRBN E3 ubiquitin ligase binding moieties of the present invention have one of the following structures:
- ULM is a VHL E3 ubiquitin ligase ligand binding moiety.
- VHL means a von Hippel-Lindau tumor suppressor.
- VHL constitutes a VCB E3 ligation complex together with Elongin B, Elongin C, CUL2 and Rbx1, wherein VHL is a substrate recognition subunit of the complex.
- Some compounds capable of binding to the VHL E3 ubiquitin ligase are known in the art. For example, after it was known that peptide such as Ala-Leu-Ala-(Hy)Pro-Tyr-Ile-Pro heptapeptide (see Schneekloth et al. 2004) and Leu-Ala-(Hy)Pro-Tyr-Ile pentapeptide (see Rodriguez-Gonzalez et al.
- VHL E3 ubiquitin ligase binding moiety in Formula I is represented by the following Formula B-1:
- heterocycloalkyl is 5- to 6-membered cycloalkyl, phenyl, 5- to 6-membered heterocycloalkyl, or 5- to 6-membered heteroaryl, wherein the heterocycloalkyl or the heteroaryl contains one to three N, O or S atoms;
- VHL E3 ubiquitin ligase binding moiety in Formula B-1 is selected from the group consisting of the following Formula B-2-1 and B-2-2:
- 5-membered heteroaryl ring selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, pyrazole, triazole, oxadiazole, pyrrole, pyrrolidine, furan, dihydrofuran and tetrahydrofuran;
- Formula B-2-1 is represented by the moiety selected from the group consisting of:
- Formula B-2-2 is represented by the moiety selected from the group consisting of:
- CRBN E3 ubiquitin ligase binding moieties of Formula B-1, B-2-1 or B-2-2 may be derived from the compounds having the following structures (Galdeano et al. (2014); etc.):
- CRBN E3 ubiquitin ligase binding moieties of Formula B-1, B-2-1 or B-2-2 may be derived from the compounds having the following structures (Soares et al. 2017; etc.):
- ULM have a linker attached at a position necessary to exhibit the bifunctionality of PROTAC.
- the Linker may be covalently linked through represented in Formulas A-1, A-2, B-1, B-2-1, and B-2-2. If there is not indicated, one hydrogen in the moiety of E3 ubiquitin ligase binding compound may be substituted into a single bond to be connected to the Linker.
- the PTM a moiety that performs a target protein ligand function
- PLK1 polo-like kinase 1
- the compound represented by Formula II alone is a pyrimidodiazepinone derivative that may bind to the active site of PLK1 (see Nie, Zhe, et al. Bioorganic & medicinal). chemistry letters 23.12 (2013): 3662-3666.] and International Patent Publication No. WO2009/042711, etc.)
- Formula II is represented by the following Formula III:
- the PTM moiety is PTM moiety that is included in the compound selected from the group consisting of Compound 1 to 175.
- the Linker as defined in Formula I is represented by the following Formula L:
- p is 1 or more; 5 or more; 10 or more; 15 or more; 20 or more; or 25 or more. In another embodiment, p is 25 or less; 20 or less; 15 or less; 10 or less; 5 or less.
- L ULM may be any organic radical
- null is null or a ring selected from the group consisting of 3- to 10-membered cycloalkyl, 4- to 10-membered heterocycloalkyl, 6- to 10-membered aryl and 5- to 10-membered heteroaryl.
- —CH 2 — is selected from the group consisting of —CH 2 —, —CC—, —NH—, —NHCO—, —NHCO—CH 2 —O—, —NH—CH 2 —CONH—, —O—, —OCH 2 —CONH—,
- L ULM may be any organic radical
- null is null, amino substituted C 1-8 alkyl, or a ring selected from the group consisting of 3- to 10-membered cycloalkyl, 4- to 10-membered heterocycloalkyl, 6- to 10-membered aryl and 5- to 10-membered heteroaryl.
- X 1 is CH or N; X 2 and X 3 are each independently hydrogen, CH 3 or CH 2 CH 3 .
- null is null or a ring selected from the group consisting of 3- to 10-membered cycloalkyl, 4- to 10-membered heterocycloalkyl, 6- to 10-membered aryl and 5- to 10-membered heteroaryl.
- Linker is a linker that is included in the compound selected from the group consisting of Compound 1 to 175.
- the compound represented by Formula I is a compound that is selected from the group consisting of Compound 1 to 175.
- a pharmaceutically acceptable salt refers to any organic or inorganic acid addition salt with a concentration that is relatively non-toxic, is harmless, and has effective action to patients, wherein side effects caused by this salt does not deteriorate beneficial efficacy of the compound represented by Formula I.
- the pharmaceutically acceptable salt may be an inorganic acid such as hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, or the like, or an organic acid such as methanesulfonic acid, p-toluenesulfonic acid, acetic acid, trifluoroacetic acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, manderic acid, propionic acid, citric acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid, ascorbic acid, carbonic acid, vanillic acid or hydroiodic acid, but is not limited thereto.
- an inorganic acid such as hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, or the like
- an organic acid such as methanesulfonic acid, p-toluenesulf
- the compound represented by Formula I above, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof may be prepared through reactions such as the following Reaction Schemes 1 to 3 by a synthetic method known in the field of organic chemistry or a modification technique apparent to those skilled in the art.
- PTM, Linker and ULM are a group defined in the above, or a suitable derivative thereof.
- RG 1 , RG 2 , RG 2a , RG 2b , RG 3 , RG 3a , RG 3b and RG 4 are moieties including a suitable reactive group capable of linking together with an intermediate of the PROTAC compound represented by Formula I through formation of the covalent bond in the field of organic synthesis.
- the formation of the covalent bond may be achieved by synthetic reactions such as amide formation, ester formation, carbamate formation, urea formation, ether formation, amine formation, and single bonds, double bond formation between various carbons, click chemistry and the like, depending on specific reaction groups, but is not limited thereto.
- Variations of each step in the above Reaction Scheme may include one or multiple synthesis steps. Isolation and purification of the product may be accomplished by standard procedures known to those skilled in the art of organic chemistry.
- the compounds of the present invention can be prepared through Reaction Scheme 1 by one or multiple synthetic steps.
- Reaction Scheme 1 when ULM is Formula A-1, the compound of the present invention may be prepared through the following Reaction Scheme 1-A (see Example 40).
- Reaction Scheme 1 when ULM is Formula B-1, the compound of the present invention may be prepared through the following Reaction Scheme 1-B.
- the compound of the present invention may be prepared through the following Reaction Scheme 2-A (see Example 1-39, 41-60, 63-79, 90-122, 124-158, 162-175).
- the compound of the present invention may be prepared through the following Reaction Scheme 3-A (see Example 61, 62, 123, 159, 160, 161).
- Reaction Scheme 3 when ULM is Formula B-1, the compound of the present invention may be prepared through the following Reaction Scheme 3-B.
- RG 1 , RG 2 , and RG 2a are each independently L PTM or any reaction precursor thereof
- RG 3 , RG 4 and RG 3a are each independently L ULM or any reaction precursor thereof
- RG 1 , RG 2 , RG 2a , RG 3 , RG 3a and RG 4 may be appropriately selected according to the structure and linker position of the target compound.
- each compound represented by PTM and ULM may be synthesized by a person skilled in the art with reference to documents known in the field of organic chemistry, descriptions of Examples of the present invention, and the like.
- the present invention also provides the compounds represented by PTM-Linker-RG 3 or PTM-Linker 1-RG 2b that are the reaction intermediates of the compounds represented by Formula I.
- An embodiment of the present invention is a composition for inducing PLK1 degradation including a compound represented by Formula I or a pharmaceutically acceptable salt thereof.
- the Formula I is the same as defined above.
- the compounds of the present invention effectively induce the protein degradation of PLK1 (Table 3).
- the compounds of the present invention have significantly superior protein degradability of PLK1 compared to the compounds disclosed in CN 106543185 A, which is a prior art document ( FIGS. 1 & 2 ).
- the compounds of the present invention have little or no doorstepility to BRD4, a target protein other than PLK1. Therefore, there is an advantage of minimizing side effects due to off-target degradation occurring in the compounds disclosed in the prior art documents ( FIG. 2 ).
- the PLK1 degradation-inducing PROTAC compound of the present invention is capable of fundamentally degrading the target protein, PLK1 in view of the mechanism of action, thereby achieving an excellent PLK1 inhibitory effect as compared to the conventional PLK1 small molecule inhibitor that inhibits the simple activity of PLK1.
- composition including the compound represented by Formula I of the present invention or a pharmaceutically acceptable salt thereof may be effectively employed for selective degradation of PLK1.
- An embodiment of the present invention is a composition for preventing or treating PLK1-related diseases including the compound represented by Formula I or the pharmaceutically acceptable salt thereof.
- An another embodiment of the present invention is a method for the prevention or treatment of PLK-related diseases comprising administering the composition to a subject in need thereof.
- the Formula I is the same as defined above.
- the PLK1-related disease refers to any disease or condition capable of being treated, alleviated, delayed, inhibited or prevented from induction of degradation or inhibition of activity of PLK1.
- the PLK1-related disease may be a cancer (malignant tumor), a benign tumor, a neurological disease, or other genetic or non-genetic diseases caused by excessive cell division.
- the cancer includes all cancers capable of exhibiting prophylactic or therapeutic efficacy due to inhibition of PLK1 activity, and may be solid cancer or blood cancer.
- the cancer may be one or more selected from the group consisting of squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, peritoneal cancer, skin cancer, skin or intraocular melanoma, rectal cancer, anal muscle cancer, esophageal cancer, small intestine cancer, endocrine cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, chronic or acute leukemia, lymphocytic lymphoma, hepatocellular carcinoma, gastrointestinal cancer, gastric cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, liver tumor, breast cancer, colon cancer, colorectal cancer, endometrial or uterine cancer, salivary gland cancer, kidney cancer,
- the benign tumors include all benign tumors capable of exhibiting prophylactic or therapeutic efficacy due to the inhibition of PLK1 activity, such as benign tumors in pre-cancer stages, and may be solid tumors or blood tumors.
- the tumor may be one or more selected from the group consisting of Barrett's esophagus, colon adenoma and polyp, breast fibroadenoma and cyst, monoclonal gammopathy of undetermined significance (MGUS), monoclonal lymphocytosis, and the like, but is not limited thereto.
- the neurological diseases include all neurological diseases capable of exhibiting prophylactic or therapeutic efficacy due to the inhibition of PLK1 activity, and specifically, may be one or more selected from the group consisting of central nervous system disease, neurodegenerative disease, Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, senile dementia, epilepsy, Lou Gehrig, stroke, and nerve damage and axonal degeneration-related disorders following brain or spinal cord injury, but is not limited thereto.
- the pharmaceutical composition of the present invention may further include one or more active ingredients exhibiting the same or similar medicinal effects in addition to the compound represented by Formula I above, or the pharmaceutically acceptable salt thereof.
- An embodiment of the present invention is a method of degrading PLK1 by administering a compound represented by Formula I or a pharmaceutically acceptable salt thereof to mammals including humans.
- Another embodiment of the present invention is a method of degrading PLK1 by administering the compound represented by Formula I or the pharmaceutically acceptable salt thereof to a sample in vitro.
- the sample may be a cell, a cell culture, a body fluid or tissue of a mammal including a human, but is not limited thereto.
- the compound of the present invention exhibits an effect of inducing PLK1 degradation. Therefore, the pharmaceutical compound of the present invention may be effectively utilized for preventing or treating PLK1-related diseases.
- FIG. 1 shows the western blotting results from the measurement of the protein degradability of PLK1 according to the bifunctional compound of the present invention.
- FIG. 2 shows the results of western blotting results from the measurement of selective PLK1 protein degradability and off-target degradability other than PLK1.
- the present invention provides synthetic methods for Compound 1 to 175 shown in the table below.
- the compounds of the present invention were purified according to the following method and the structure was analyzed.
- Step 1 Synthesis of 2-(2,6-dioxopiperidin-3-yl)-4-((2-(2-hydroxyethoxy)ethyl)amino)isoindoline-1,3-dione (3)
- Step 2 Synthesis of 2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethyl 4-methylbenzenesulfonate (4)
- Step 3 Synthesis of tert-butyl (1-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino) ethoxy)ethyl)piperidin-4-yl)carbamate (6)
- Step 4 Synthesis of 4-((2-(2-(4-aminopiperidin-1-yl)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (7)
- Step 5 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide (Compound 1)
- Step 1 Synthesis of 4-fluoro-2-(1-methyl-2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (2)
- Step 2 Synthesis of 4-((2-(2-(2-hydroxyethoxy)ethoxy)ethyl)amino)-2-(1-methyl-2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (3)
- Step 3 Synthesis of 2-(2-(2-((2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (4)
- Step 4 Synthesis of tert-butyl (1-(2-(2-(2-((2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethyl)piperidin-4-yl)carbamate (6)
- Step 5 Synthesis of 4-((2-(2-(2-(4-aminopiperidin-1-yl)ethoxy)ethoxy)ethyl)amino)-2-0-methyl-2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (7)
- Step 6 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxy-N-(1-(2-(2-(2-((2-((2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethyl)piperidin-4-yl)benzamide (Compound 6)
- Step 3 Synthesis of 2-(2, 6-dioxopiperidin-3-yl)-4-((7-hydroxyheptyl)amino)isoindoline-1,3-dione (4)
- Step 4 Synthesis of 7-((2-(2, 6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)heptyl 4-methylbenzenesulfonate (5)
- Step 5 Synthesis of tert-butyl (1-(7-((2-(2, 6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)heptyl)piperidin-4-yl)carbamate (6)
- Step 6 Synthesis of 4-((7-(4-aminopiperidin-1-yl)heptyl)amino)-2-(2, 6-dioxopiperidin-3-yl)isoindoline-1,3-dione (7)
- Step 7 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6, 7, 8, 9-tetrahydro-5H-pyrimido[4, 5-b][1, 4]diazepin-2-yl)amino)-N-(1-(7-((2-(2, 6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)heptyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide (Compound 11)
- Step 4 Synthesis of tert-butyl (1-(3-(4-(benzyloxy)butoxy)propyl)piperidin-4-yl)carbamate (6)
- Step 5 Synthesis of tert-butyl (1-(3-(4-hydroxybutoxy)propyl)piperidin-4-yl)carbamate (7)
- Step 6 Synthesis of 4-(3-(4-((tert-butoxycarbonyl)amino)piperidin-1-yl)propoxy)butyl 4-methylbenzenesulfonate (8)
- Step 7 Synthesis of tert-butyl (1-(3-(4-(1,3-dioxoisoindolin-2-yl)butoxy)propyl)piperidin-4-yl)carbamate (9)
- Step 8 Synthesis of tert-butyl (1-(3-(4-aminobutoxy)propyl)piperidin-4-yl)carbamate (10)
- Step 9 Synthesis of tert-butyl (1-(3-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butoxy)propyl)piperidin-4-yl)carbamate (11)
- Step 10 Synthesis of 4-((4-(3-(4-aminopiperidin-1-yl)propoxy)butyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (12)
- Step 11 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(3-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butoxy)propyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide (Compound 20)
- Step 2 Synthesis of tert-butyl 2-(2-(2-(4-(((benzyloxy)carbonyl)amino)piperidin-1-yl)ethoxy)ethoxy)acetate (4)
- Step 3 Synthesis of 2-(2-(2-(4-(((benzyloxy)carbonyl)amino)piperidin-1-yl)ethoxy)ethoxy)acetic Acid (5)
- Step 4 Synthesis of benzyl (1-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-2-oxoethoxy)ethoxy)ethyl)piperidin-4-yl)carbamate (6)
- Step 5 Synthesis of 2-(2-(2-(4-aminopiperidin-1-yl)ethoxy)ethoxy)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)acetamide (7)
- Step 6 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-2-oxoethoxy)ethoxy)ethyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide (Compound 26)
- Step 1 Synthesis of tert-butyl 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)acetate (3)
- Step 2 Synthesis of 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)acetic Acid (4)
- Step 3 Synthesis of 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-N-(2-(2-hydroxyethoxy)ethyl)acetamide (5)
- Step 4 Synthesis of 2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)acetamido)ethoxy)ethyl 4-methylbenzenesulfonate (6)
- Step 5 Synthesis of tert-butyl (1-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)acetamido)ethoxy)ethyl)piperidin-4-yl)carbamate (8)
- Step 6 Synthesis of N-(2-(2-(4-aminopiperidin-1-yl)ethoxy)ethyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)acetamide (9)
- Step 7 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(2-(2 oxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)acetamido)ethoxy)ethyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide (Compound 29)
- Step 2 Synthesis of benzyl 4-(4-((tert-butoxycarbonyl)amino)piperidin-1-yl)butanoate (3)
- Step 4 Synthesis of tert-butyl (1-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-4-oxobutyl)piperidin-4-yl)carbamate (6)
- Step 5 Synthesis of 4-(4-aminopiperidin-1-yl)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)butanamide (7)
- Step 6 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-4-oxobutyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide (Compound 37)
- Step 1 Synthesis of ethyl 4-(2-(((benzyloxy)carbonyl)amino)ethoxy)benzoate (3)
- Step 2 Synthesis of benzyl (2-(4-(hydroxymethyl)phenoxy)ethyl)carbamate (4)
- Step 3 Synthesis of benzyl (2-(4-(chloromethyl)phenoxy)ethyl)carbamate (5)
- Step 4 Synthesis of tert-butyl N-[1-[[4-[2-(benzyloxycarbonylamino) ethoxy]phenyl]methyl]-4-piperidyl]carbamate (6)
- Step 5 Synthesis of benzyl (2-(4-((4-aminopiperidin-1-yl)methyl)phenoxy)ethyl)carbamate (7)
- Step 6 Synthesis of benzyl (2-(4-((4-(4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzamido)piperidin-1-yl)methyl)phenoxy)ethyl)carbamate (9)
- Step 7 Synthesis of N-(1-(4-(2-aminoethoxy)benzyl)piperidin-4-yl)-4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzamide (10)
- Step 8 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)benzyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide (Compound 40)
- H 2 O (8.28 g, 459.61 mmol, 8.28 mL), NaOH (3 M, 4.60 mL) and H 2 O 2 (9.77 g, 86.17 mmol, 8.28 mL, 30% purity) were added sequentially to this reaction at 0° C. and the resulting mixture was allowed to stir another 2 h at 20° C.
- the reaction mixture was quenched with saturated Na 2 SO 3 (50 mL) and extracted with EtOAc (50 mL ⁇ 3). The organic layer was dried over Na 2 SO 4 , filtered and concentrated.
- Step 3 Synthesis of ethyl 2-(4-(2-(tosyloxy)ethyl)phenyl)acetate (4)
- Step 4 Synthesis of ethyl 2-(4-(2-(4-((tert-butoxycarbonyl)amino)piperidin-1-yl)ethyl)phenyl)acetate (5)
- Step 5 Synthesis of 2-(4-(2-(4-((tert-butoxy carbonyl)amino)piperidin-1-yl)ethyl)phenyl)acetic Acid (6)
- Step 6 Synthesis of tert-butyl (1-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-2-oxoethyl)phenethyl)piperidin-4-yl)carbamate (7)
- Step 7 Synthesis of 2-(4-(2-(4-aminopiperidin-1-yl)ethyl)phenyl)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)acetamide (8)
- Step 8 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-2-oxoethyl)phenethyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide (Compound 42)
- Step 1 Synthesis of methyl 1-(3-((tert-butyldimethylsilyl)oxy)propyl)-1H-imidazole-4-carboxylate (2)
- Step 3 Synthesis of methyl 1-(3-(tosyloxy)propyl)-1H-imidazole-4-carboxylate (4)
- Step 4 Synthesis of methyl 1-(3-(4-((tert-butoxy carbonyl)amino)piperidin-1-yl)propyl)-1H-imidazole-4-carboxylate (5)
- Step 5 Synthesis of tert-butyl (1-(3-(4-(hydroxymethyl)-1H-imidazol-1-yl)propyl)piperidin-4-yl)carbamate (6)
- Step 6 Synthesis of tert-butyl (1-(3-(4-(azidomethyl)-1H-imidazol-1-yl)propyl)piperidin-4-yl)carbamate (7)
- Step 7 Synthesis of tert-butyl (1-(3-(4-(aminomethyl)-1H-imidazol-1-yl)propyl)piperidin-4-yl)carbamate (8)
- Step 8 Synthesis of tert-butyl (1-(3-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl) amino)methyl)-1H-imidazol-1-yl)propyl)piperidin-4-yl)carbamate (9)
- Step 9 Synthesis 4-(((1-(3-(4-aminopiperidin-1-yl)propyl)-1H-imidazol-4-yl)methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (10)
- Step 10 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(3-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)methyl)-1H-imidazol-1-yl)propyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide (Compound 43)
- Step 1 Synthesis of 4-((2-(2-azidoethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (2)
- Step 2 Synthesis of tert-butyl (1-((1-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl) amino)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methyl)piperidin-4-yl)carbamate (4)
- Step 3 Synthesis of 4-((2-(2-(4-((4-aminopiperidin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethyl) amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (5)
- Step 4 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-((1-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide (Compound 44)
- Step 2 Synthesis of benzyl (((1S, 2R)-2-(hydroxymethyl)cyclopropyl)methyl)carbamate (3)
- Step 3 Synthesis of ((1R, 2S)-2-((((benzyloxy)carbonyl)amino)methyl)cyclopropyl)methyl 4-methylbenzenesulfonate (4)
- Step 4 Synthesis of tert-butyl N-[1-[[2-(benzyloxycarbonylaminomethyl) cyclopropyl]methyl]-4-piperidyl]carbamate (5)
- Step 5 Synthesis of tert-butyl (1-(((1R,2S)-2-(aminomethyl)cyclopropyl)methyl)piperidin-4-yl)carbamate (6)
- Step 6 Synthesis of tert-butyl (1-(((1R,2S)-2-(((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)methyl)cyclopropyl)methyl)piperidin-4-yl)carbamate (8)
- Step 7 Synthesis of 4-((((1S,2R)-2-((4-aminopiperidin-1-yl)methyl)cyclopropyl)methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (9)
- Step 8 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(((1R,2S)-2-(((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)methyl)cyclopropyl)methyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide (Compound 48)
- Step 3 Synthesis of benzyl (2-(2-hydroxyethoxy)ethyl)(methyl)carbamate (4)
- Step 4 Synthesis of 2-(2-(((benzyloxy)carbonyl)(methyl)amino)ethoxy)ethyl 4-methylbenzenesulfonate (5)
- Step 5 Synthesis of benzyl (2-(2-(4-((tert-butoxycarbonyl)amino)piperidin-1-yl)ethoxy)ethyl)(methyl)carbamate (6)
- Step 6 Synthesis of tert-butyl (1-(2-(2-(methylamino)ethoxy)ethyl)piperidin-4-yl)carbamate (7)
- Step 7 Synthesis of tert-butyl N-[1-[2-[2-[2-(benzyloxycarbonylamino)ethyl-methylamino]ethoxy]ethyl]-4-piperidyl]carbamate (9)
- Step 8 Synthesis of tert-butyl (1-(2-(2-((2-aminoethyl)(methyl)amino)ethoxy)ethyl)piperidin-4-yl)carbamate (10)
- Step 9 Synthesis of tert-butyl (1-(2-(2-((2-((2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl) amino)ethyl)(methyl)amino)ethoxy)ethyl)piperidin-4-yl)carbamate (11)
- Step 10 Synthesis of 4-((2-((2-(2-(2-(4-aminopiperidin-1-yl)ethoxy)ethyl)(methyl)amino)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (12)
- Step 11 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(2-(2-((2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)(methyl)amino)ethoxy)ethyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide (Compound 49)
- Example 51 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(14-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)amino)-3,6,9,12-tetraoxatetradecyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide
- Step 3 Synthesis of 2-(2,6-dioxopiperidin-3-yl)-4-(1-hydroxy-3,6,9,12-tetraoxapentadec-14-yn-15-yl)isoindoline-1,3-dione (4)
- Step 4 Synthesis of 15-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-3,6,9,12-tetraoxapentadec-14-yn-1-yl 4-methylbenzenesulfonate (5)
- Step 5 Synthesis of tert-butyl (1-(15-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-3,6,9,12-tetraoxapentadec-14-yn-1-yl)piperidin-4-yl)carbamate (6)
- Step 6 Synthesis of 4-(1-(4-aminopiperidin-1-yl)-3,6,9,12-tetraoxapentadec-14-yn-15-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (7)
- Step 7 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(15-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-3,6,9,12-tetraoxapentadec-14-yn-1-yl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide (Compound 52)
- Step 8 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(15-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-3,6,9,12-tetraoxapentadecyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide (Compound 53)
- Example 54 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(2-(2-((3-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)prop-2-yn-1-yl)oxy)ethoxy)ethyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide
- Step 1 Synthesis of 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)-N-(2-(2-hydroxyethoxy)ethyl)acetamide (2)
- Step 2 Synthesis of 2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido) ethoxy)ethyl 4-methylbenzenesulfonate (3)
- Step 3 Synthesis of tert-butyl (1-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy) acetamido)ethoxy)ethyl)piperidin-4-yl)carbamate (4)
- Step 4 Synthesis of N-(2-(2-(4-aminopiperidin-1-yl)ethoxy)ethyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide (5)
- Step 5 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)ethoxy)ethyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide (Compound 56)
- Step 1 Synthesis of 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)-N-f2-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethyl)acetamide (2)
- Step 2 Synthesis of 1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)-2-oxo-6,9,12-trioxa-3-azatetradecan-14-yl 4-methylbenzenesulfonate (3)
- Step 3 Synthesis of tert-butyl (1-(1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)-2-oxo-6,9,12-trioxa-3-azatetradecan-14-yl)piperidin-4-yl)carbamate (4)
- Step 4 Synthesis of N-(2-(2-(2-(2-(4-aminopiperidin-1-yl)ethoxy)ethoxy)ethoxy)ethyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide (5)
- Step 5 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)-2-oxo-6,9,12-trioxa-3-azatetradecan-14-yl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide (Compound 57)
- Example 58 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)-2-oxo-6,9,12,15,18,21,24-heptaoxa-3-azahexacosan-26-yl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide
- Step 3 Synthesis of tert-butyl N-[1-[5-(benzyloxycarbonylamino)pentyl]-4-piperidyl]carbamate (5)
- Step 5 Synthesis of tert-butyl (1-(5-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)pentyl)piperidin-4-yl)carbamate (8)
- Step 6 Synthesis of N-(5-(4-aminopiperidin-1-yl)pentyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide (9)
- Step 7 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(5-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)pentyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide (Compound 59)
- Example 60 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(3-((7-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)heptyl)amino)-3-oxopropyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide
- Step 2 Synthesis of benzyl 3-(4-((tert-butoxy carbonyl)amino)piperidin-1-yl)propanoate
- Step 5 Synthesis of benzyl (7-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy) acetamido)heptyl)carbamate (6)
- Step 6 Synthesis of N-(7-aminoheptyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl) oxy)acetamide (7)
- Step 7 Synthesis of tert-butyl (1-(3-((7-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl) oxy)acetamido)heptyl)amino)-3-oxopropyl)piperidin-4-yl)carbamate (8)
- Step 8 Synthesis of 3-(4-aminopiperidin-1-yl)-N-(7-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)heptyl)propanamide (9)
- Step 9 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(3-((7-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)heptyl)amino)-3-oxopropyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide (Compound 60)
- Example 61 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(3-((2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)methyl)benzyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide
- Step 3 Synthesis of tert-butyl N-[1-[[3-(benzyloxycarbonylaminomethyl)phenyl]methyl]-4-piperidyl]carbamate (4)
- Step 4 Synthesis of benzyl 3-((4-aminopiperidin-1-yl)methyl)benzylcarbamate (5)
- Step 5 Synthesis of benzyl 3-((4-(4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzamido)piperidin-1-yl)methyl)benzylcarbamate (6)
- Step 6 Synthesis of N-(1-(3-(aminomethyl)benzyl)piperidin-4-yl)-4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzamide (7)
- Step 7 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(3-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)methyl)benzyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide (Compound 61)
- reaction mixture was diluted with H 2 O (12 mL) and extracted with EtOAc (12 mL ⁇ 3). The organic layer was dried over Na 2 SO 4 , filtered and concentrated. The residue was purified by prep-HPLC (column: 3-Phenomenex Luna C 18 75*30 mm*3 um; mobile phase: [water (0.1% TFA)-ACN]; B %: 32%-52%, 7 min) and then lyophilized to afford two batches of products with 59% and 42% purity.
- Example 62 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-((5-((2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)methyl)pyridin-3-yl)methyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide
- Step 3 Synthesis of benzyl ((5-bromopyridin-3-yl)methyl)carbamate (4)
- Step 4 Synthesis of methyl 5-((((benzyloxy)carbonyl)amino)methyl)nicotinate (5)
- Step 5 Synthesis of benzyl ((5-(hydroxymethyl)pyridin-3-yl)methyl)carbamate (6)
- Step 6 Synthesis of benzyl ((5-(chloromethyl)pyridin-3-yl)methyl)carbamate (7)
- Step 7 Synthesis of tert-butyl N-[1-[[5-(benzyloxycarbonylaminomethyl)-3-pyridyl]methyl]-4-piperidyl]carbamate (8)
- Step 8 Synthesis of benzyl 45-((4-aminopiperidin-1-yl)methyl)pyridin-3-yl)methyl)carbamate (9)
- Step 9 Synthesis of benzyl ((5-((4-(4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzamido)piperidin-1-yl)methyl)pyridin-3-yl)methyl)carbamate (11)
- Step 10 Synthesis of N-(1-((5-(aminomethyl)pyridin-3-yl)methyl)piperidin-4-yl)-4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzamide (12)
- Step 11 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1454242-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)methyl)pyridin-3-yl)methyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide (Compound 62)
- the product A was re-purified by prep-HPLC (column: 3_Phenomenex Luna C 18 75*30 mm*3 um; mobile phase: [water (0.1% TFA)-ACN]; B %: 28%-48%, 7 min).
- the product B was re-purified by prep-HPLC (column: 3_Phenomenex Luna C 18 75*30 mm*3 um; mobile phase: [water (0.1% TFA)-ACN]; B %: 30%-50%, 7 min).
- two batches of eluents were combined and lyophilized to afford the titled compound (64.4 mg, 64.27 ⁇ mol, 21.35% yield, 98% purity, TFA salt) as a white solid.
- Example 63 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(7-(3-((2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)methyl)phenyl)heptyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide
- Step 2 Synthesis of benzyl 3-(7-hydroxyhept-1-yn-1-yl)benzylcarbamate (4)
- Step 3 Synthesis of 7-(3-((((benzyloxy)carbonyl)amino)methyl)phenyl)hept-6-yn-1-yl 4-methylbenzenesulfonate (5)
- Step 4 Synthesis of tert-butyl N-[1-[7-[3-(benzyloxycarbonylaminomethyl) phenyl]hept-6-ynyl]-4-piperidyl]carbamate (6)
- Step 5 Synthesis of tert-butyl (1-(7-(3-(aminomethyl)phenyl)heptyl)piperidin-4-yl)carbamate (7)
- Step 6 Synthesis of tert-butyl (1-(7-(3-((2-((2-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)methyl)phenyl)heptyl)piperidin-4-yl)carbamate (9)
- Step 7 Synthesis of N-(3-(7-(4-aminopiperidin-1-yl)heptyl)benzyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide (10)
- Step 8 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(7-(34242-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)methyl)phenyl)heptyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide (Compound 63)
- Example 64 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(7-(5-((2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)methyl)pyridin-3-yl)heptyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide
- Example 65 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)methyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide
- Step 1 Synthesis of benzyl 4-((4-((tert-butoxycarbonyl)amino)piperidin-1-yl)methyl)piperidine-1-carboxylate (3)
- Step 2 Synthesis of tert-butyl (1-(piperidin-4-ylmethyl)piperidin-4-yl)carbamate (4)
- Step 3 Synthesis of tert-butyl (1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl) piperidin-4-yl)methyl)piperidin-4-yl)carbamate (5)
- Step 4 Synthesis of 4-(4-((4-aminopiperidin-1-yl)methyl)piperidin-1-yl)-2-(2,6-dioxopiperidin-3-yl) isoindoline-1,3-dione (6)
- Step 5 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)methyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide (Compound 65)
- Example 66 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6, 7, 8, 9-tetrahydro-5H-pyrimido[4, 5-b][1, 4]diazepin-2-yl)amino)-N-(1-(2-(4-(2-(2, 6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperazin-1-yl)ethyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide
- Step 2 Synthesis of tert-butyl (1-(2-(4-(2-(2, 6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl) piperazin-1-yl)ethyl)piperidin-4-yl)carbamate (4)
- Step 3 Synthesis of 4-(4-(2-(4-aminopiperidin-1-yl)ethyl)piperazin-1-yl)-2-(2, 6-dioxopiperidin-3-yl)isoindoline-1,3-dione (5)
- Step 4 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6, 7, 8, 9-tetrahydro-5H-pyrimido[4, 5-b][1, 4]diazepin-2-yl)amino)-N-(1-(2-(4-(2-(2, 6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperazin-1-yl)ethyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide (Compound 66)
- Example 70 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(2-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperazin-1-yl)acetyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide
- Example 72 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazine-1-carbonyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide
- Example 74 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(3-(4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)piperazin-1-yl)propanoyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide
- Example 75 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide
- Step 1 Synthesis of tert-butyl (1-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethyl)piperidin-4-yl)carbamate (2)
- Step 2 Synthesis of 2-(2-(2-(4-((tert-butoxy carbonyl)amino)piperidin-1-yl)ethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (3)
- Step 3 Synthesis of tert-butyl (1-(2-(2-(2-((2-(2,6-di oxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino) ethoxy)ethoxy)ethyl)piperidin-4-yl)carbamate (4)
- Step 4 Synthesis of 3-(4-((2-(2-(2-(4-aminopiperidin-1-yl)ethoxy)ethoxy)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (5)
- Step 5 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide (Compound 75)
- Example 76 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(14-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)-3,6,9,12-tetraoxatetradecyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide
- Example 77 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(8-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)octyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide
- Example 78 Synthesis of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(14-((3-(2,6-dioxopiperidin-3-yl)-4-oxo-3,4-dihydrobenzo[d][1,2,3]triazin-5-yl)amino)-3,6,9,12-tetraoxatetradecyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide
- Step 1 Synthesis of 3-(5-((14-hydroxy-3,6,9,12-tetraoxatetradecyl)amino)-4-oxobenzo[d][1,2,3]triazin-3 (4H)-yl)piperidine-2,6-dione (2)
- Step 2 Synthesis of ethyl 2-(2-(2-(4-((tert-butoxycarbonyl)amino)piperidin-1-yl) ethoxy)ethoxy)acetate (3)
- Step 3 Synthesis of 2-(2-(2-(4-((tert-butoxy carbonyl)amino)piperidin-1-yl)ethoxy)ethoxy)acetic Acid (4)
- Step 4 Synthesis of tert-butyl (1-(2-(2-(2-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)ethoxy)ethyl)piperidin-4-yl)carbamate (5)
- Step 5 Synthesis of (2S,4R)-1-((S)-2-(2-(2-(2-(2-(4-aminopiperidin-1-yl)ethoxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (6)
- Step 6 Synthesis of (2S,4R)-1-((S)-2-(2-(2-(2-(4-(4-(4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzamido)piperidin-1-yl)ethoxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (Compound 80)
- Step 1 Synthesis of ethyl 2-((8-(4-((tert-butoxycarbonyl)amino)piperidin-1-yl)octyl)oxy)acetate (2)
- Step 3 Synthesis of tert-butyl (1-(8-(2-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl) benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)octyl)piperidin-4-yl)carbamate (5)
- Step 4 Synthesis of (2S,4R)-1-(((S)-2-(2-((8-(4-aminopiperidin-1-yl)octyl)oxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (6)
- Step 5 Synthesis of (2S,4R)-1-(((S)-2-(2-((8-(4-(4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzamido)piperidin-1-yl)octyl)oxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (Compound 84)
- Step 2 Synthesis of (2S,4R)-1-((S)-2-(1-fluorocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(2-(2-(2-hydroxy ethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (4)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention provides novel compounds that induce selective polo-like kinase 1 (PLK1) degradation. Specifically, the present invention provides a bifunctional compound in which a PLK1 binding moiety and an E3 ubiquitin ligase-binding moiety are linked by a chemical linker. The present invention provides the compound, a method for preparing the same, and the use thereof. The compounds may be effectively utilized for preventing or treating PLK1 related diseases.
Description
- This is a continuation of U.S. patent application Ser. No. 17/428,467, filed on Aug. 4, 2021, which is the U.S. National Stage of International Application No. PCT/KR2021/003807, filed on Mar. 27, 2021, which claims the benefit of, and priority to, the earlier filing date of Korean Application No. 10-2020-0037875, filed on Mar. 27, 2020; each of these prior applications are incorporated herein by reference in its entirety.
- The present invention relates to a selective PLK1 degradation inducing compound, a method for preparing the same, and the use thereof.
- Polo-like kinase 1 (PLK1) is a serine/threonine kinase involved in the conversion of G2/M phase during cell growth and division. PLK1 is expressed and activated in a pulse form from the S phase to the G2/M phase, and rapidly degrades as mitosis ends.
- PLK1 is overexpressed in various carcinomas such as colon cancer, lung cancer, bladder cancer, and melanoma, etc., and cancer cells overexpressing PLK1 tend to show resistance to various types of anticancer drugs. As the PLK1 dependence in various carcinomas was revealed as described above, there have been attempts to develop PLK1 inhibitor compounds such as volasertib (also known as BI6727), etc.
- However, the conventional PLK1 inhibitors do not sufficiently inhibit PLK1 activity at concentrations that are clinically safe. Thus, there is a problem that even if the cell cycle of cancer cells is temporarily delayed, some cancer cells eventually restart the cell cycle, which may not obtain sufficient clinical effects (see Gheghiani et al., Cell Reports, 2017, etc.). In fact, many pharmaceutical companies such as Boehringer Ingelheim, GlaxoSmithKline, etc., have attempted to develop small-molecular compound-based PLK1 inhibitors, but most of them have failed or stopped in the clinical trial stage, and thus there are no commercially available PLK1 inhibitors to date. It shows that pharmacological mechanism that follows the method of inhibiting enzyme activity by binding to the active site of PLK1 like the small molecule compound inhibitors is not sufficiently effective in the development of new drugs intended to derive anticancer effects by inhibiting PLK1 activity of cancer cells.
- Recently, a proteolysis targeting chimera (PROTAC) has been proposed as a small molecule-based platform technology capable of inducing proteolysis of a target protein in the body. The PROTAC is a bifunctional compound in which a ligand molecule that binds to disease-related target protein and an E3 ubiquitin ligase binding moiety are linked by a chemical linker. Theoretically, the PROTAC compound is capable of inducing degradation of the target protein by placing the disease-related target protein near the E3 ubiquitin ligase.
- In the case of the PROTAC compound using PLK1 as a target protein, Chinese Patent Laid-Open No. 106543185 A discloses some bifunctional compounds in which a volasertib derivative compound and a binding moiety for the E3 ubiquitin ligase CRBN are linked by a chemical linker. However, the related art document merely describes some limited forms of synthesis examples of PROTAC compounds, wherein in general, the target degradation activity and selectivity of PROTAC may vary significantly depending on selection of the target protein moiety, the E3 ubiquitin ligase binding moiety, and the like (see Burslem and Crews, 2017, etc.).
- Further, the PROTAC compound described in the above-described document is characterized by a compound that simultaneously degrades PLK1 and BRD4, and degrade various proteins such as other PLK family proteins and BRD4, etc.), which may cause side effects due to off-target effects at the time of drug development. In particular, it is known that strong inhibition of BRD4 activity inevitably accompanies on-target toxicity such as blood toxicity and gastrointestinal toxicity along with pharmacological effects. Therefore, the PROTAC compound described in the above document would expect to face greater clinical side effects as more BRD4 protein gets degraded (see Bolden et al. Cell Reports, 2014).
- Moreover, according to the document published by the inventors of the above document (see Mu et al. BBRC, 2019), it can be confirmed that the PROTAC compound, which simultaneously degrades PLK1 and BRD4, has much stronger BRD4 degradation ability than PLK1 degradation ability at the cellular level, and the cell cycle thereof almost stops in the G1 phase, etc., that is, the PROTAC compound actually acts only as a BRD4 inhibitor regardless of the way that the conventional PLK1 inhibitors exert pharmacological effects.
- Therefore, there is an unsatisfied demand for effective and selective PLK1 degradation inducing compound, with no or minimal side effects.
- An object of the present invention is to provide selective PLK1 degradation inducing compounds.
- Another object of the present invention is to provide a method for preparing the compounds.
- Still another object of the present invention is to provide a use of the compounds.
- Selective PLK1 Degradation Inducing Compounds
- The present invention provides novel compounds that induce selective polo-like kinase 1 (PLK1) degradation. Specifically, the present invention provides a bifunctional compound in which a PLK1 binding moiety and an E3 ubiquitin ligase-binding moiety are linked by a chemical linker.
- In one general aspect, there is provided a compound represented by the following Formula I, a stereoisomer thereof or a pharmaceutically acceptable salt thereof:
-
ULM-Linker-PTM [Formula I] -
- in the Formula I above,
- ULM is CRBN or VHL E3 ubiquitin ligase binding moiety;
- PTM is PLK1 binding moiety represented by the following Formula II:
-
- {in the Formula II above,
- R1 is hydrogen, C1-5 alkyl, or C3-6 cycloalkyl;
- R1A is hydrogen or C1-3 alkyl;
- R2 is hydrogen, halogen, C1-6 alkyl or —OR2A;
- R2A is C1-4 alkyl or C3-6 cycloalkyl, optionally substituted by one or more halogen or hydroxy;
- R3 is hydrogen, halogen, —NO2, —CN, —OH, C1-4 alkyl or —OC1-4 alkyl;
- R4 is selected from the group consisting of a single bond,
-
- R5 is hydrogen or C1-4 alkyl}; and
- Linker is a chemical group that links ULM and PTM.
-
- (1) E3 Ubiquitin Ligase Binding Moiety (ULM)
- In one embodiment of the present invention, ULM is a CRBN E3 ubiquitin ligase binding moiety.
- In the present invention, CRBN means Cereblon E3 ubiquitin ligase. CRBN constitutes an E3 ubiquitin ligase complex together with DDB1, Cul4A and ROC1, wherein the CRBN is a substrate recognition subunit of the complex. Some compounds capable of binding to the CRBN E3 ubiquitin ligase are known in the art. For example, after it was known that thalidomide binds to the CRBN E3 ubiquitin ligase (see Ito et al. 2010), it has been reported that a number of immunomodulatory imide drugs (IMiD) including lenalidomide and pomalidomide have CRBN binding ability (see Chamberlain and Brian. 2019; Akuffo et al. 2018; and Burslem et al. 2018, etc.).
- In one embodiment, the CRBN E3 ubiquitin ligase binding moiety in Formula I is represented by the following Formula A-1:
-
- wherein:
- is a ring selected from the group consisting of
-
- X1 is a single bond, —CH2—, —NH—, —O—, —CH2CH2—, —CC— —CO—, —COO—, —NHCO— or —CONH—;
- X2 is —CH2—, —CH(C1-4 alkyl)-, —NH—, —N(C1-4 alkyl)-, —O—, —CO—, —CH2—CH2—, —NH—CH(C1-4 alkyl)-, —N═CH—, —N═C(C1-4 alkyl)- or —N═N—;
- X3 is hydrogen or C1-4 alkyl; and
- X4 is hydrogen, halogen, C1-6 alkyl, CN, NH2, NO2, OH, COH, COOH or CF3.
- In one embodiment, Formula A-1 is represented by the following Formula A-2:
-
- wherein:
- X2 is —CH2—, —CH(C1-4 alkyl)-, —CO— or —N═N—; and
- X3 is hydrogen or C1-3 alkyl.
- In certain embodiment, Formula A-2 is selected from the group consisting of:
- One example of CRBN E3 ubiquitin ligase binding moieties of Formula A-1 or A-2 may be derived from the compounds having the following structures (Chamberlain and Brian. 2019; Akuffo et al. 2018; etc.):
- Another example of CRBN E3 ubiquitin ligase binding moieties of Formula A-1 or A-2 may be derived from the compounds having the following structures (Burslem et al. 2018; etc.):
- In specific example, the CRBN E3 ubiquitin ligase binding moieties of the present invention have one of the following structures:
- In another embodiment of the present invention, ULM is a VHL E3 ubiquitin ligase ligand binding moiety.
- In the present invention, VHL means a von Hippel-Lindau tumor suppressor. VHL constitutes a VCB E3 ligation complex together with Elongin B, Elongin C, CUL2 and Rbx1, wherein VHL is a substrate recognition subunit of the complex. Some compounds capable of binding to the VHL E3 ubiquitin ligase are known in the art. For example, after it was known that peptide such as Ala-Leu-Ala-(Hy)Pro-Tyr-Ile-Pro heptapeptide (see Schneekloth et al. 2004) and Leu-Ala-(Hy)Pro-Tyr-Ile pentapeptide (see Rodriguez-Gonzalez et al. 2008), an improved low-molecular VHL E3 ubiquitin ligase binding compound has been reported (see Buckley et al. J. Am. Chem. Soc. 2012; Buckley et al. Ang. Chem. Int. Ed. 2012; Galdeano et al. 2014; Soares et al. 2017, etc.).
- In one embodiment, the VHL E3 ubiquitin ligase binding moiety in Formula I is represented by the following Formula B-1:
-
- wherein:
- n is an integer from 1 to 3;
- is 5- to 6-membered cycloalkyl, phenyl, 5- to 6-membered heterocycloalkyl, or 5- to 6-membered heteroaryl, wherein the heterocycloalkyl or the heteroaryl contains one to three N, O or S atoms;
-
- Y1 is hydrogen or C1-4 alkyl;
- Y2 is C1-4alkyl, hydroxy(C1-4alkyl), —(C0-2alkyl)-COH, C3-8cycloalkyl, or phenyl;
- Y3 is hydrogen, or
-
- Y4 is hydrogen, halogen, C1-4 alkyl, —O(C1-4alkyl), C3-6 cycloalkyl or 4- to 6-membered heterocycloalkyl, optionally substituted by halogen, —OH, —CN, —NHCOH, —NHCOCH3, —COH or —COCH3; and
- Y5 is hydrogen or C1-4 alkyl.
- In one embodiment, the VHL E3 ubiquitin ligase binding moiety in Formula B-1 is selected from the group consisting of the following Formula B-2-1 and B-2-2:
-
- wherein:
- is 5-membered heteroaryl ring selected from the group consisting of oxazole, isoxazole, thiazole, isothiazole, imidazole, pyrazole, triazole, oxadiazole, pyrrole, pyrrolidine, furan, dihydrofuran and tetrahydrofuran;
-
- Y1 is hydrogen or C1-3 alkyl; and
- Y4 is C1-4 alkyl or C3-5 cycloalkyl, optionally substituted by hydrogen or halogen.
- In certain example, Formula B-2-1 is represented by the moiety selected from the group consisting of:
- In certain example, Formula B-2-2 is represented by the moiety selected from the group consisting of:
- One example of CRBN E3 ubiquitin ligase binding moieties of Formula B-1, B-2-1 or B-2-2 may be derived from the compounds having the following structures (Galdeano et al. (2014); etc.):
- Another example of CRBN E3 ubiquitin ligase binding moieties of Formula B-1, B-2-1 or B-2-2 may be derived from the compounds having the following structures (Soares et al. 2017; etc.):
- In the present invention, ULM have a linker attached at a position necessary to exhibit the bifunctionality of PROTAC. In the present invention, the Linker may be covalently linked through represented in Formulas A-1, A-2, B-1, B-2-1, and B-2-2. If there is not indicated, one hydrogen in the moiety of E3 ubiquitin ligase binding compound may be substituted into a single bond to be connected to the Linker.
- (2) Protein Target Moiety (PTM)
- In the compound represented by Formula I, the PTM, a moiety that performs a target protein ligand function, is a polo-like kinase 1 (PLK1) binding moiety represented by Formula II above.
- The compound represented by Formula II alone is a pyrimidodiazepinone derivative that may bind to the active site of PLK1 (see Nie, Zhe, et al. Bioorganic & medicinal). chemistry letters 23.12 (2013): 3662-3666.] and International Patent Publication No. WO2009/042711, etc.)
- In one embodiment, Formula II is represented by the following Formula III:
-
- wherein:
- R1 is C1-5 alkyl or C3-7 cycloalkyl;
- R2 is hydrogen or —OR2A;
- R2A is C1-6 alkyl, C3-7 cycloalkyl, CF3 or —(C1-3alkylene)-OH;
- R3 is hydrogen or halogen.
- In one embodiment, the PTM moiety is PTM moiety that is included in the compound selected from the group consisting of
Compound 1 to 175. - (3) Linker
- In one embodiment of the present invention, the Linker as defined in Formula I is represented by the following Formula L:
-
- wherein:
- and are each independently bond;
- LULM is covalently bonded to ULM moiety through that is linked thereto,
- LPTM is covalently bonded to PTM moiety through that is linked thereto,
- LULM, LPTM and LINT are independently selected from the group consisting of null, a single bond, —CH2—, —NH—, —O—, —S—, —SO—, —SO2—, —CO—, —CH2CH2—, —CHCH—, —CC—, —CH2CH2O—, —OCH2CH2—, —CH2CH2S—, —SCH2CH2—, —COO—, —CONH—, —NHCO— and
- optionally substituted by one or more C1-6 alkyl, C3-8 cycloalkyl, halogen, hydroxy, amino, nitro, cyano or haloalkyl {wherein
- is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl}; and
-
- p is an integer from 1 to 30.
- In one embodiment, p is 1 or more; 5 or more; 10 or more; 15 or more; 20 or more; or 25 or more. In another embodiment, p is 25 or less; 20 or less; 15 or less; 10 or less; 5 or less.
- In Formula L above, LULM may be
-
- wherein:
- LU1 is selected from the group consisting of a single bond, —CH2—, —CH2CH2—, —CH═CH—, —C≡C—, —NH—, —NCH3—, —CO—, —NHCO— and —O—;
- LU2 is selected from the group consisting of a single bond, —CH2—, —NH—, —O—, —CO— and —CONH—; and
- is null or a ring selected from the group consisting of 3- to 10-membered cycloalkyl, 4- to 10-membered heterocycloalkyl, 6- to 10-membered aryl and 5- to 10-membered heteroaryl.
- In certain embodiment,
- is selected from the group consisting of —CH2—, —CC—, —NH—, —NHCO—, —NHCO—CH2—O—, —NH—CH2—CONH—, —O—, —OCH2—CONH—,
- In Formula L above, LULM may be
-
- wherein:
- LP1 is selected from the group consisting of a single bond, —O—, —S—, —NH—, —N(C1-4alkyl)-, —CH2—, —CH(C1-4 alkyl)-, —CH2NH—, and —CH2CH2—;
- LP2 selected from the group consisting of a single bond, —CO—, —COCH2—, —NHCO—, —NHCOCH2—, —HET- and —RET-CH2— {wherein HET is 5- to 6-membered heterocyclyl or heteroaryl containing one ore more N, S or O atoms}; and
- is null, amino substituted C1-8 alkyl, or a ring selected from the group consisting of 3- to 10-membered cycloalkyl, 4- to 10-membered heterocycloalkyl, 6- to 10-membered aryl and 5- to 10-membered heteroaryl.
- In certain embodiment,
- is selected from the group consisting of
- and for example, selected from the group consisting of
- In certain embodiment,
- wherein X1 is CH or N; X2 and X3 are each independently hydrogen, CH3 or CH2CH3.
- In certain embodiment,
- is selected from the group consisting of
- and for example,
- In Formula L above,
- may be
-
- wherein:
- is null or a ring selected from the group consisting of 3- to 10-membered cycloalkyl, 4- to 10-membered heterocycloalkyl, 6- to 10-membered aryl and 5- to 10-membered heteroaryl.
-
- LINT1 and LINT2 are each independently selected from the group consisting of CH2—, —NH—, —NCH3—, —O—, —S—, —SO—, —SO2—, —CO—, —CH2CH2O—, —OCH2CH2—, —CH2CH2S—, —SCH2CH2—, —COO—, —CONH— and —NHCO—; and
- q and r are each independently an integer from 1 to 10.
- In one embodiment, Linker is a linker that is included in the compound selected from the group consisting of
Compound 1 to 175. - In a certain embodiment of the present invention, the compound represented by Formula I is a compound that is selected from the group consisting of
Compound 1 to 175. - In the present invention, a pharmaceutically acceptable salt refers to any organic or inorganic acid addition salt with a concentration that is relatively non-toxic, is harmless, and has effective action to patients, wherein side effects caused by this salt does not deteriorate beneficial efficacy of the compound represented by Formula I. For example, the pharmaceutically acceptable salt may be an inorganic acid such as hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, or the like, or an organic acid such as methanesulfonic acid, p-toluenesulfonic acid, acetic acid, trifluoroacetic acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, manderic acid, propionic acid, citric acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid, ascorbic acid, carbonic acid, vanillic acid or hydroiodic acid, but is not limited thereto.
- Method for the Preparing the Selective PLK1 Degradation Inducing Compounds
- In the present invention, the compound represented by Formula I above, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof may be prepared through reactions such as the following
Reaction Schemes 1 to 3 by a synthetic method known in the field of organic chemistry or a modification technique apparent to those skilled in the art. - In the
Reaction Schemes 1 to 3 above, PTM, Linker and ULM are a group defined in the above, or a suitable derivative thereof. RG1, RG2, RG2a, RG2b, RG3, RG3a, RG3b and RG4 are moieties including a suitable reactive group capable of linking together with an intermediate of the PROTAC compound represented by Formula I through formation of the covalent bond in the field of organic synthesis. The formation of the covalent bond may be achieved by synthetic reactions such as amide formation, ester formation, carbamate formation, urea formation, ether formation, amine formation, and single bonds, double bond formation between various carbons, click chemistry and the like, depending on specific reaction groups, but is not limited thereto. - Variations of each step in the above Reaction Scheme may include one or multiple synthesis steps. Isolation and purification of the product may be accomplished by standard procedures known to those skilled in the art of organic chemistry.
- In one embodiment, the compounds of the present invention can be prepared through
Reaction Scheme 1 by one or multiple synthetic steps. - In one example of
Reaction Scheme 1, when ULM is Formula A-1, the compound of the present invention may be prepared through the following Reaction Scheme 1-A (see Example 40). - In one example of
Reaction Scheme 1, when ULM is Formula B-1, the compound of the present invention may be prepared through the following Reaction Scheme 1-B. - In one example of
Reaction Scheme 2, when ULM is Formula A-1, the compound of the present invention may be prepared through the following Reaction Scheme 2-A (see Example 1-39, 41-60, 63-79, 90-122, 124-158, 162-175). - In one example of
Reaction Scheme 2, when ULM is Formula B-1, the compound of the present invention may be prepared through the following Reaction Scheme 2-B (see Example 80-89) - In one example of
Reaction Scheme 3, when ULM is Formula A-1, the compound of the present invention may be prepared through the following Reaction Scheme 3-A (see Example 61, 62, 123, 159, 160, 161). - In one example of
Reaction Scheme 3, when ULM is Formula B-1, the compound of the present invention may be prepared through the following Reaction Scheme 3-B. - In the above schemes, RG1, RG2, and RG2a are each independently LPTM or any reaction precursor thereof, RG3, RG4 and RG3a are each independently LULM or any reaction precursor thereof, and RG1, RG2, RG2a, RG3, RG3a and RG4 may be appropriately selected according to the structure and linker position of the target compound.
- In the above Reaction Scheme, each compound represented by PTM and ULM may be synthesized by a person skilled in the art with reference to documents known in the field of organic chemistry, descriptions of Examples of the present invention, and the like.
- The present invention also provides the compounds represented by PTM-Linker-RG3 or PTM-Linker 1-RG2b that are the reaction intermediates of the compounds represented by Formula I.
- Use of the Selective PLK1 Degradation Inducing Compounds
- An embodiment of the present invention is a composition for inducing PLK1 degradation including a compound represented by Formula I or a pharmaceutically acceptable salt thereof. The Formula I is the same as defined above.
- In the experimental examples of the present invention, it was confirmed that the compounds of the present invention effectively induce the protein degradation of PLK1 (Table 3). Specifically, the compounds of the present invention have significantly superior protein degradability of PLK1 compared to the compounds disclosed in CN 106543185 A, which is a prior art document (
FIGS. 1 & 2 ). Further, the compounds of the present invention have little or no degrability to BRD4, a target protein other than PLK1. Therefore, there is an advantage of minimizing side effects due to off-target degradation occurring in the compounds disclosed in the prior art documents (FIG. 2 ). - The PLK1 degradation-inducing PROTAC compound of the present invention is capable of fundamentally degrading the target protein, PLK1 in view of the mechanism of action, thereby achieving an excellent PLK1 inhibitory effect as compared to the conventional PLK1 small molecule inhibitor that inhibits the simple activity of PLK1.
- Accordingly, the composition including the compound represented by Formula I of the present invention or a pharmaceutically acceptable salt thereof may be effectively employed for selective degradation of PLK1.
- An embodiment of the present invention is a composition for preventing or treating PLK1-related diseases including the compound represented by Formula I or the pharmaceutically acceptable salt thereof. An another embodiment of the present invention is a method for the prevention or treatment of PLK-related diseases comprising administering the composition to a subject in need thereof. The Formula I is the same as defined above.
- In the present invention, the PLK1-related disease refers to any disease or condition capable of being treated, alleviated, delayed, inhibited or prevented from induction of degradation or inhibition of activity of PLK1. In an embodiment, the PLK1-related disease may be a cancer (malignant tumor), a benign tumor, a neurological disease, or other genetic or non-genetic diseases caused by excessive cell division.
- The cancer includes all cancers capable of exhibiting prophylactic or therapeutic efficacy due to inhibition of PLK1 activity, and may be solid cancer or blood cancer. For example, the cancer may be one or more selected from the group consisting of squamous cell carcinoma, small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, lung squamous cell carcinoma, peritoneal cancer, skin cancer, skin or intraocular melanoma, rectal cancer, anal muscle cancer, esophageal cancer, small intestine cancer, endocrine cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, chronic or acute leukemia, lymphocytic lymphoma, hepatocellular carcinoma, gastrointestinal cancer, gastric cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, liver tumor, breast cancer, colon cancer, colorectal cancer, endometrial or uterine cancer, salivary gland cancer, kidney cancer, prostate cancer, vulvar cancer, thyroid cancer, head and neck cancer, brain cancer, osteosarcoma, and the like, but is not limited thereto. The cancer includes not only primary cancer but also metastatic cancer.
- The benign tumors include all benign tumors capable of exhibiting prophylactic or therapeutic efficacy due to the inhibition of PLK1 activity, such as benign tumors in pre-cancer stages, and may be solid tumors or blood tumors. For example, the tumor may be one or more selected from the group consisting of Barrett's esophagus, colon adenoma and polyp, breast fibroadenoma and cyst, monoclonal gammopathy of undetermined significance (MGUS), monoclonal lymphocytosis, and the like, but is not limited thereto.
- The neurological diseases include all neurological diseases capable of exhibiting prophylactic or therapeutic efficacy due to the inhibition of PLK1 activity, and specifically, may be one or more selected from the group consisting of central nervous system disease, neurodegenerative disease, Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, senile dementia, epilepsy, Lou Gehrig, stroke, and nerve damage and axonal degeneration-related disorders following brain or spinal cord injury, but is not limited thereto.
- The pharmaceutical composition of the present invention may further include one or more active ingredients exhibiting the same or similar medicinal effects in addition to the compound represented by Formula I above, or the pharmaceutically acceptable salt thereof.
- An embodiment of the present invention is a method of degrading PLK1 by administering a compound represented by Formula I or a pharmaceutically acceptable salt thereof to mammals including humans.
- Another embodiment of the present invention is a method of degrading PLK1 by administering the compound represented by Formula I or the pharmaceutically acceptable salt thereof to a sample in vitro. The sample may be a cell, a cell culture, a body fluid or tissue of a mammal including a human, but is not limited thereto.
- The compound of the present invention exhibits an effect of inducing PLK1 degradation. Therefore, the pharmaceutical compound of the present invention may be effectively utilized for preventing or treating PLK1-related diseases.
-
FIG. 1 shows the western blotting results from the measurement of the protein degradability of PLK1 according to the bifunctional compound of the present invention; and -
FIG. 2 shows the results of western blotting results from the measurement of selective PLK1 protein degradability and off-target degradability other than PLK1. - Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. The terminology used in the description is for describing particular embodiments only and is not intended to be limiting of the disclosure.
- The present invention provides synthetic methods for
Compound 1 to 175 shown in the table below. -
TABLE 1 Com- pound Structure 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 - The compounds of the present invention were purified according to the following method and the structure was analyzed.
- Instruments
-
- LCMS: Shimadzu LCMS-2020
- NMR: BRUKER AVANCE III/400 MHz
- HPLC: Shimadzu LC-20AB, Shimadzu LC-20AD, Agilent 1100 LC, Agilent 1200 LC, Agilent 1290 LC
- LC SM Analysis
- LCMS data were recorded with Shimadzu LCMS-2020 equipped with an electron spray ionization device. 0.0375% TFA in water (solvent A) and 0.01875% TFA in acetonitrile (solvent B) were used as mobile phases. As a column, Kinetex EVO C18 (2.1*30) mm, Sum was used.
- HPLC Analysis
- In HPLC analysis, Shimadzu LC-20AB, Shimadzu LC-20AD, Agilent 1100 LC, Agilent 1200 LC or Agilent 1290 LC was used. 0.0375% TFA in water (solvent A) and 0.01875% TFA in acetonitrile (solvent B) or 0.025% NH3·H2O in water (solvent A) and acetonitrile (Solvent B) was used as the mobile phase. As a column, XBridge C18 (2.1*50) mm, Sum or Kinetex C18 LC column (4.6*50) mm, Sum or Eclipse plus C18 (4.6*150) mm, 3.5 um or Waters)(Bridge® C18 (4.6*150) mm, 3.5 μm was used.
- NMR Analysis
- 1H NMR spectrum was recorded with Bruker AVANCE III 400 MHz/5 mm Probe (BBO).
-
- To a solution of 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (4 g, 14.48 mmol) and 2-(2-aminoethoxy)ethanol (2.10 g, 19.97 mmol, 2 mL) in DMSO (60 mL) was added TEA (4.40 g, 43.44 mmol, 6.05 mL). The reaction mixture was stirred at 90° C. for 16 hr. LCMS showed one main peak with desired mass. The reaction mixture was diluted with H2O (200 mL) and extracted with EtOAc (150 mL×3). The combined organic layer was dried over Na2SO4, filtered. The filtrate was concentrated in vacuo to afford the titled compound (3.5 g, 9.69 mmol, 66.89% yield) as a green oil, which was used for the next step directly. MS(M+H)+=362.1.
- To a solution of 2-(2,6-dioxopiperidin-3-yl)-4-((2-(2-hydroxyethoxy)ethyl)amino) isoindoline-1,3-dione (3.5 g, 9.69 mmol) and TosCl (2.22 g, 11.62 mmol) in DCM (100 mL) was added TEA (2.94 g, 29.06 mmol, 4.04 mL). The mixture was stirred at 20° C. for 16 hr. LCMS showed a peak (55%) with desired mass. The reaction was concentrated in vacuo. The residue was purified by reverse MPLC (FA, MeCN/H2O), the eluent was freeze-dried to afford the titled compound (1 g, 1.94 mmol, 20.03% yield) as a yellow solid. MS(M+H)+=516.1.
- To a solution of 2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethyl 4-methylbenzenesulfonate (1 g, 1.94 mmol) and tert-butyl piperidin-4-ylcarbamate (582.73 mg, 2.91 mmol) in dioxane (15 mL) were added DIPEA (752.09 mg, 5.82 mmol, 1.01 mL) and NaI (29.08 mg, 193.97 μmol), the reaction mixture was stirred at 65° C. for 3 hr. LCMS showed 50% of material remained, the reaction mixture was stirred at 65° C. for another 16 hr. LCMS showed one main peak with desired mass. The reaction mixture was diluted with H2O (50 mL) and extracted with EtOAc (60 mL×2). The combined organic layer was dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by column chromatography (SiO2, EA/MeOH=100%-8%), the eluent was concentrated in vacuo to afford the titled compound (600 mg, 1.09 mmol, 56.33% yield, 99% purity) as a yellow solid. MS(M+H)+=544.2.
- To a solution of tert-butyl (1-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino) ethoxy)ethyl)piperidin-4-yl)carbamate (600 mg, 1.10 mmol) in dioxane (5 mL) was added HCl/dioxane (4 M, 16.22 mL), the mixture was stirred at 20° C. for 3 hours. LCMS showed the starting material was consumed completely and one main peak (74%) with desired mass. The reaction mixture was concentrated in vacuo afford 4-((2-(2-(4-aminopiperidin-1-yl)ethoxy)ethyl) amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (810 mg, crude, HCl salt) as a yellow solid. MS(M+H)+=444.2.
- To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (174.55 mg, 375.03 μmol) in DMF (7 mL) were added HATU (356.50 mg, 937.59 μmol) and DIEA (403.92 mg, 3.13 mmol, 544.37 μL), the mixture was stirred at 20° C. for 2 hours. Then to this mixture was added 4-((2-(2-(4-aminopiperidin-1-yl)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (300 mg, crude, HCl salt), the resulting mixture was stirred at 20° C. for 12 hours. LCMS showed the reactant was consumed completely and one main peak (85%) with desired mass. The reaction mixture was filtered and the filtrate was purified by prep-HPLC (column: Phenomenex luna C18 150*40 mm*15 um; mobile phase: [water (0.1% TFA)-ACN]; B %: 22%-52%, 10 min), the eluent was freeze-dried to afford the titled compound (237.5 mg, 224.52 μmol, 35.92% yield, 95% purity, TFA salt) as a yellow solid. MS(M+H)+=891.6.
- 1H NMR (400 MHz, DMSO-d6) δ=11.09-11.08 (m, 1H), 9.53-9.36 (m, 1H), 8.34-8.22 (m, 2H), 8.22-8.08 (m, 2H), 7.61 (dd, J1=8.4 Hz, J2=7.2 Hz, 1H), 7.25-7.13 (m, 2H), 7.10-7.01 (m, 1H), 6.63 (s, 1H), 5.08 (dd, J1=12.8 Hz, J2=5.4 Hz, 1H), 4.84 (t, J=8.1 Hz, 1H), 4.15-4.05 (m, 3H), 3.95-3.92 (m, 3H), 3.80 (s, 2H), 3.71-3.66 (m, 2H), 3.57-3.48 (m, 4H), 3.33 (s, 3H), 3.32-3.27 (m, 2H), 3.20-3.08 (m, 1H), 2.94-2.80 (m, 1H), 2.58-2.51 (m, 1H), 2.16-1.83 (m, 6H), 1.82-1.47 (m, 8H).
-
- According to the reaction scheme, in a manner similar to the above-described example, the titled compound (126.5 mg, 133.95 umol, 31.17% yield, 99% purity) as was obtained as a yellow solid.
- MS (M+H)+=935.5
- 1H NMR (400 MHz, CDCl3) δ=9.15 (br s, 1H), 8.38 (d, J=14.6 Hz, 1H), 8.07 (s, 1H), 7.86 (s, 1H), 7.56-7.43 (m, 2H), 7.09 (d, J=7.0 Hz, 1H), 6.94 (d, J=8.8 Hz, 1H), 6.88-6.79 (m, 1H), 6.48-6.45 (m, 1H), 5.01-4.98 (m, 1H), 4.87 (t, J=8.6 Hz, 1H), 4.25 (br s, 1H), 4.04-3.87 (m, 7H), 3.77-3.69 (m, 6H), 3.49-3.46 (m, 2H), 3.42 (s, 3H), 3.40-325 (m, 2H), 3.09-3.06 (m, 2H), 2.93-2.71 (m, 3H), 2.30-2.02 (m, 6H), 1.85-1.77 (m, 3H), 1.70-1.56 (m, 6H).
- In a manner similar to the other examples, the titled compound (112.5 mg, 113.76 umol, 26.47% yield, 99% purity) was obtained as a yellow solid.
- MS (M+H)+=979.4
- 1H NMR (400 MHz, DMSO-d6) δ 11.11 (s, 1H), 8.30 (s, 1H), 8.24 (d, J=13.3 Hz, 1H), 8.03 (s, 1H), 7.87 (dd, J=7.6, 3.2 Hz, 1H), 7.61-7.55 (m, 1H), 7.17 (dd, J=21.8, 7.6 Hz, 2H), 7.04 (d, J=7.0 Hz, 1H), 6.61 (t, J=5.8 Hz, 1H), 5.06 (dd, J=12.9, 5.5 Hz, 1H), 4.81 (q, J=8.5 Hz, 1H), 4.08 (t, J=13.8 Hz, 2H), 3.91 (s, 3H), 3.75-3.68 (m, 1H), 3.63 (t, J=5.5 Hz, 2H), 3.59-3.56 (m, 2H), 3.55-3.53 (m, 2H), 3.52-3.50 (m, 2H), 3.49-3.46 (m, 6H), 3.31-3.26 (m, 2H), 2.94-2.79 (m, 3H), 2.66-2.51 (m, 3H), 2.43 (t, J=6.1 Hz, 2H), 2.07-2.00 (m, 3H), 2.00-1.93 (m, 2H), 1.81-1.69 (m, 4H), 1.67-1.57 (m, 4H), 1.56-1.46 (m, 2H).
- In a manner similar to the other examples, the titled compound (97.2 mg, 95.01 umol, 27.64% yield, 100% purity) was obtained as a yellow solid.
- MS (M+H)+=1023.5
- 1H NMR (400 MHz, Chloroform-d) δ 9.08 (s, 1H), 8.33 (d, J=14.9 Hz, 1H), 8.05 (s, 1H), 7.84 (s, 1H), 7.55-7.37 (m, 2H), 7.06 (d, J=7.1 Hz, 1H), 6.96-6.77 (m, 2H), 6.51-6.40 (m, 1H), 5.02-4.78 (m, 2H), 4.34-4.09 (m, 1H), 3.98-3.85 (m, 5H), 3.82 (t, J=4.9 Hz, 2H), 3.78-3.59 (m, 17H), 3.53-3.42 (m, 3H), 3.40 (s, 3H), 3.37-3.17 (m, 2H), 3.12-3.01 (m, 1H), 2.90-2.65 (m, 3H), 2.26 (d, J=13.7 Hz, 1H), 2.18-2.01 (m, 5H), 1.79-1.69 (m, 4H), 1.65-1.50 (m, 2H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (36.5 mg, 31.81 μmol, 13.77% yield, 93% purity) as yellow solid. MS(M+H)+=1067.9
- 1H NMR (400 MHz, DMSO-d6) δ=11.07 (br s, 1H), 8.30 (s, 1H), 8.24 (d, J=13.3 Hz, 1H), 8.02 (s, 1H), 7.90-7.81 (m, 1H), 7.62-7.54 (m, 1H), 7.23-7.11 (m, 2H), 7.03 (d, J=7.1 Hz, 1H), 6.60 (br t, J=5.5 Hz, 1H), 5.10-4.99 (m, 1H), 4.88-4.75 (m, 1H), 4.07 (br t, J=13.8 Hz, 2H), 3.91 (s, 3H), 3.75-3.69 (m, 1H), 3.65-3.59 (m, 2H), 3.56-3.48 (m, 18H), 3.47-3.44 (m, 2H), 3.33-3.21 (m, 3H), 2.88-2.79 (m, 2H), 2.62-2.54 (m, 2H), 2.48-2.42 (m, 2H), 2.10-1.92 (m, 6H), 1.81-1.68 (m, 5H), 1.67-1.47 (m, 5H).
-
- To a mixture of 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (5 g, 18.10 mmol) and MeI (3.08 g, 21.72 mmol, 1.35 mL) in DMF (50 mL) was added K2CO3 (2.75 g, 19.91 mmol) and the resulting mixture was stirred at 25° C. for 14 h. LCMS showed the starting material was consumed and one main peak (89%) with desired mass. EtOAc (100 mL) and water (100 mL) were added and layers were separated. The aqueous phase was extracted with EtOAc (100 mL×2). Combined extracts were washed with brine (100 mL), dried over Na2SO4, filtered. The filtrate was concentrated under vacuum. The residue was purified by silica gel chromatography (Petroleum ether/Ethyl acetate=2/1 to 1/1) to afford the titled compound (2.5 g, 8.53 mmol, 47.11% yield, 99% purity) as a white solid. MS(M+H)+=291.1
- To a solution of 4-fluoro-2-(1-methyl-2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (1 g, 3.42 mmol) in DMF (25 mL) were added 2-(2-(2-aminoethoxy)ethoxy)ethanol (510.46 mg, 3.42 mmol) and DIPEA (884.43 mg, 6.84 mmol, 1.19 mL) and the resulting mixture was heated to 90° C. for 16 hr. LCMS showed reactant was consumed completely and 37% of desired mass was detected. The mixture was combined with another batch (1 g scale). The combined mixture was diluted with H2O (80 mL) and extracted with EtOAc (80 mL×2). The combined organic layer was dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by column chromatography (SiO2, PE/EtOAc 50%-100%) to afford the titled compound (1.45 g, 3.34 mmol, 97.54% yield, 97% purity) as a yellow oil. MS(M+H)+=420.1
- To a solution of 4-((2-(2-(2-hydroxyethoxy)ethoxy)ethyl)amino)-2-(1-methyl-2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (1.45 g, 3.46 mmol, and TosCl (3.30 g, 17.29 mmol) in DCM (20 mL) was added Py (2.19 g, 27.66 mmol, 2.23 mL) and the resulting mixture was stirred at 15° C. for 16 hr. LCMS showed one peak (30%) with desired mass. The mixture was diluted with H2O (60 mL) and extracted with DCM (80 mL×2). The combined organic layer was dried over Na2SO4, filtered. The filtrate was concentrated in vacuo. The residue was purified by column chromatography (SiO2, PE/EtOAc, 50%-100%) to afford the titled compound (1.64 g, 2.77 mmol, 80.22% yield, 97% purity) as a green oil.
- MS(M+H)+=574.1
- To a solution of 2-(2-(2-((2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (1.64 g, 2.86 mmol) and tert-butyl piperidin-4-ylcarbamate (1.15 g, 5.72 mmol) in dioxane (20 mL) were added DIPEA (1.11 g, 8.58 mmol, 1.49 mL) and NaI (42.86 mg, 285.91 umol) and the resulting mixture was heated to 80° C. for 16 hr. LCMS showed one main peak with desired mass. The mixture was diluted with H2O (50 mL) and extracted with EtOAc (50 mL×2). The combined organic layer was dried over Na2SO4 and filtered. The filtrate was concentrated in vacuo. The residue was purified by column chromatography (SiO2, EtOAc (100%)˜DCM/MeOH (10%) to afford the titled compound (1.46 g, 2.38 mmol, 83.17% yield, 98% purity) as a green oil. MS(M+H)+=602.3
- tert-butyl (1-(2-(2-(2-((2-(1-methyl-2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino) ethoxy)ethoxy)ethyl)piperidin-4-yl)carbamate (1.46 g, 2.43 mmol, was dissolved in dioxane (10 mL), and HCl/dioxane (4 M, 10 mL) was added. The mixture was stirred at 15° C. for 16 hr. LCMS showed one main peak with desired mass. The mixture was concentrated in vacuo to afford the titled compound (1.4 g, crude, HCl salt) as a brown oil. Ms(M+H)+=502.1
- To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (300 mg, 644.57 umol, in DMF (6 mL) was added HATU (367.63 mg, 966.86 umol) and DIPEA (249.92 mg, 1.93 mmol, 336.82 uL), after stirring for 10 min, 4-((2-(2-(2-(4-aminopiperidin-1-yl)ethoxy)ethoxy)ethyl)amino)-2-(1-methyl-2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (416.16 mg, 773.49 umol, HCl salt) was added and the resulting mixture was stirred at 15° C. for 2 hr. LCMS showed one main peak with desired mass. The mixture was diluted with H2O (30 mL) and extracted with EtOAc (30 mL×2). The combined organic layer was dried over Na2SO4, filtered. The filtrate was concentrated in vacuo. The residue was diluted with MeCN and purified by prep-HPLC (column: Phenomenex Luna C18 150*25 mm*10 um; mobile phase: [water (0.225% FA)-ACN]; B %: 25%-55%, 10 min) to afford two batches and the eluent was lyophilized to afford the titled compound (1st batch: 108 mg, 110.16 umol, 17.09% yield, 96.8% purity) as a yellow solid and the titled compound (2nd batch: 72 mg, 75.87 umol, 11.77% yield, FA salt, 100% purity) as a yellow solid. MS(M+H)+=949.2
- 1H NMR (400 MHz, CDCl3) δ=8.51 (s, 1H), 8.39 (d, J=15.1 Hz, 1H), 8.09 (s, 1H), 7.84 (s, 1H), 7.58-7.47 (m, 2H), 7.12 (d, J=6.9 Hz, 1H), 6.95 (d, J=8.5 Hz, 1H), 6.73 (br dd, J=7.7, 14.9 Hz, 1H), 6.50 (t, J=5.5 Hz, 1H), 5.01-4.82 (m, 2H), 4.15-4.05 (m, 1H), 4.02-3.88 (m, 5H), 3.78-3.73 (m, 4H), 3.71-3.65 (m, 4H), 3.50 (q, J=5.4 Hz, 2H), 3.44 (s, 3H), 3.25-3.15 (m, 5H), 3.02-2.96 (m, 1H), 2.88-2.76 (m, 4H), 2.55-2.47 (m, 2H), 2.19-2.05 (m, 5H), 1.87-1.72 (m, 6H), 1.69-1.56 (m, 2H).
-
- According to the above reaction scheme, in a manner similar to the other examples afforded two batches and lyophilized. As the first batch, the titled compound (103 mg, 92.36 umol, 14.33% yield, 93% purity) was obtained as a yellow solid. As the second batch, the titled compound (99 mg, 95.46 umol, 14.81% yield, 100% purity) was obtained as a yellow solid.
- Ms (M+H)+=1037.4
- 1H NMR (400 MHz, Chloroform-d) δ 8.37 (d, J=15.0 Hz, 1H), 8.05 (s, 1H), 7.87-7.80 (m, 1H), 7.51-7.44 (m, 2H), 7.08 (d, J=7.0 Hz, 1H), 6.91 (d, J=8.5 Hz, 1H), 6.79 (dd, J=14.7, 7.7 Hz, 1H), 6.46 (t, J=5.7 Hz, 1H), 5.00-4.80 (m, 2H), 4.29-4.16 (m, 1H), 4.00-3.87 (m, 7H), 3.71 (t, J=5.4 Hz, 2H), 3.67-3.53 (m, 14H), 3.46 (q, J=5.5 Hz, 2H), 3.41 (s, 3H), 3.19 (s, 3H), 3.18-3.12 (m, 2H), 3.00-2.88 (m, 3H), 2.82-2.70 (m, 2H), 2.28-2.16 (m, 4H), 2.16-2.04 (m, 3H), 1.84-1.71 (m, 4H), 1.67-1.51 (m, 2H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (234.1 mg, 244.03 μmol, 37.74% yield, 96% purity, FA salt) as a yellow solid. MS(M+H)+=875.7.
- 1H NMR (400 MHz, DMSO-d6) δ=11.10 (s, 1H), 8.36-8.20 (m, 2H), 8.14 (s, 1H), 8.10-7.97 (m, 2H), 7.60 (dd, J1=8.3 Hz, J2=7.4 Hz, 1H), 7.23-7.08 (m, 2H), 7.04 (d, J=7.0 Hz, 1H), 6.61 (t, J=5.8 Hz, 1H), 5.05 (dd, J1=12.8 Hz, J2=5.3 Hz, 1H), 4.86-4.82 (m, 1H), 4.08 (t, J=13.9 Hz, 2H), 3.96-3.87 (m, 4H), 3.23-3.02 (m, 6H), 2.90-2.83 (m, 1H), 2.78-2.70 (m, 2H), 2.69-2.41 (m, 4H), 2.06-1.88 (m, 5H), 1.86-1.39 (m, 13H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (224.8 mg, 230.13 μmol, 42.84% yield, 91% purity, FA salt) as a yellow solid. MS(M+H)+=889.3
- 1H NMR (400 MHz, DMSO-d6) δ=11.09 (s, 1H), 8.29 (s, 1H), 8.26 (s, 1H), 8.21 (d, J=10.4 Hz, 1H), 8.03 (s, 1H), 7.88 (dd, J=3.2, 7.2 Hz, 1H), 7.58 (dd, J=7.2, 8.4 Hz, 1H), 7.19 (d, J=6.6 Hz, 1H), 7.10 (d, J=8.8 Hz, 1H), 7.02 (d, J=7.0 Hz, 1H), 6.53 (t, J=5.8 Hz, 1H), 5.04 (dd, J=5.4, 12.8 Hz, 1H), 4.86-4.76 (m, 1H), 4.12-4.02 (m, 2H), 3.91 (s, 3H), 3.81-3.67 (m, 2H), 3.33 (s, 3H), 2.93-2.82 (m, 3H), 2.63-2.52 (m, 3H), 2.34-2.27 (m, 2H), 2.07-1.91 (m, 5H), 1.83-1.68 (m, 4H), 1.66-1.43 (m, 10H), 1.40-1.29 (m, 2H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (23.2 mg, 23.89 umol, 28.13% yield, 93% purity) as a yellow solid. MS(M+H)+=903.7
- 1H NMR (400 MHz, CDCl3) δ=9.21-8.79 (m, 1H), 8.38 (d, J=15.2 Hz, 1H), 8.07 (s, 1H), 7.86 (s, 1H), 7.55-7.47 (m, 2H), 7.11 (d, J=7.1 Hz, 1H), 6.94-6.81 (m, 2H), 6.20 (br t, J=5.5 Hz, 1H), 4.97-4.90 (m, 1H), 4.89-4.82 (m, 1H), 4.40-4.18 (m, 1H), 3.97 (s, 3H), 3.92 (m, 2H), 3.63-3.49 (m, 2H), 3.42 (s, 3H), 3.30 (q, J=5.6 Hz, 2H), 3.04-2.68 (m, 8H), 2.16-2.11 (m, 5H), 1.88-1.72 (m, 7H), 1.71-1.64 (m, 2H), 1.60 (m, 2H), 1.51-1.40 (m, 4H).
-
- A mixture of 7-bromoheptane-1-ol (5 g, 25.63 mmol) and
potassium 1, 3-dioxoisoindolin-2-ide (7.12 g, 38.44 mmol) in DMF (20 mL) was stirred at 85° C. for 16 hours. LCMS showed no reactant and 64% of desired mass was detected. The reaction mixture was diluted with H2O (150 mL) and extracted with EtOAc (100 mL×3). The combined organic layers were washed with brine (200 mL×5), dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by silica gel chromatography (SiO2, Petroleum ether/Ethyl acetate=10/1 to 5/1) to afford 2-(7-hydroxyheptyl)isoindoline-1,3-dione (6.4 g, 24.49 mmol, 95.56% yield) as a white solid. MS(M+H)+=262.0. - Step 2: Synthesis of 7-aminoheptan-1-ol (3)
- To a solution of 2-(7-hydroxyheptyl)isoindoline-1,3-dione (6.4 g, 24.49 mmol) in EtOH (120 mL) was added N2H4·H2O (14.42 g, 244.91 mmol, 14.00 mL, 85% purity in H2O), the mixture was stirred at 80° C. for 4 hours. TLC (EtOAc:MeOH=10:1) indicated the starting material was consumed completely, and one major new spot with larger polarity was detected. The reaction mixture was concentrated in vacuo to remove most of the solvent, the residue was diluted with DCM (50 mL) and filtered, the filtrate was concentrated in vacuo. The residue was purified by flash silica gel chromatography (20 g SepaFlash® Silica Flash Column, Eluent of 0-14% MeOH/Ethyl acetate gradient @ 100 mL/min) to afford 7-aminoheptan-1-ol (1.3 g, 9.91 mmol, 40.45% yield) as a light yellow oil.
- 1H NMR (400 MHz, DMSO-d6) δ=3.43-3.30 (m, 4H), 1.54-1.37 (m, 2H), 1.37-1.30 (m, 2H), 1.30-1.18 (m, 6H).
- A mixture of 2-(2, 6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (2.3 g, 8.33 mmol), 7-aminoheptan-1-ol (1.20 g, 9.16 mmol) and TEA (2.53 g, 24.98 mmol, 3.48 mL) in DMSO (20 mL) was stirred at 85° C. for 16 hours under N2 atmosphere. LCMS showed reactant was consumed completely and 61% of desired mass was detected. The reaction mixture was diluted with H2O (200 mL) and extracted with EtOAc (200 mL×3). The combined organic layers were washed with brine (400 mL×5), dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash silica gel chromatography (40 g SepaFlash® Silica Flash Column, Eluent of 50˜65% Ethyl acetate/Petroleum ether gradient @ 80 mL/min) to afford 2-(2, 6-dioxopiperidin-3-yl)-4-((7-hydroxyheptyl)amino)isoindoline-1,3-dione (1.74 g, 4.49 mmol, 53.94% yield) as a green oil. MS(M+H)+=388.2.
- To a solution of 2-(2, 6-dioxopiperidin-3-yl)-4-((7-hydroxyheptyl)amino)isoindoline-1,3-dione (1.74 g, 4.49 mmol) in DCM (25 mL) were added TEA (1.82 g, 17.96 mmol, 2.50 mL) and TosCl (1.71 g, 8.98 mmol), the mixture was stirred at 20° C. for 16 hours. LCMS showed trace of the starting material remained and 69% of desired mass was detected. The reaction mixture was concentrated in vacuo. The residue was purified by flash silica gel chromatography (40 g SepaFlash® Silica Flash Column, Eluent of 50˜70% Ethyl acetate/Petroleum ether gradient @ 100 mL/min) to afford 7-((2-(2, 6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)heptyl 4-methylbenzenesulfonate (1.64 g, 3.03 mmol, 67.42% yield) as a yellow oil. MS(M+H)+=542.2.
- 1H NMR (400 MHz, DMSO-d6) δ=11.09 (s, 1H), 7.77 (d, J=8.3 Hz, 2H), 7.58 (dd, J=7.2 Hz, J=8.5 Hz, 1H), 7.47 (d, J=8.1 Hz, 2H), 7.07 (d, J=8.6 Hz, 1H), 7.02 (d, J=7.0 Hz, 1H), 6.51 (t, J=5.9 Hz, 1H), 5.05 (dd, J=5.4 Hz, J=12.8 Hz, 1H), 4.02-3.96 (m, 2H), 3.25 (q, J=6.7 Hz, 2H), 2.94-2.82 (m, 1H), 2.68-2.51 (m, 2H), 2.40 (s, 3H), 2.07-1.99 (m, 1H), 1.60-1.44 (m, 4H), 1.32-1.19 (m, 6H).
- To a solution of 7-((2-(2, 6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)heptyl 4-methylbenzenesulfonate (1.64 g, 3.03 mmol), tert-butyl piperidin-4-ylcarbamate (909.66 mg, 4.54 mmol) and DMA (978.36 mg, 7.57 mmol, 1.32 mL) in dioxane (20 mL) was added NaI (45.39 mg, 302.80 μmol), the mixture was stirred at 60° C. for 16 hours. LCMS showed the starting material was consumed completely and 96% of desired mass was detected. The reaction mixture was concentrated in vacuo. The residue was purified by flash silica gel chromatography (40 g SepaFlash® Silica Flash Column, Eluent of 60˜100% Ethyl acetate/Petroleum ether gradient @ 100 mL/min) to afford tert-butyl (1-(7-((2-(2, 6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)heptyl)piperidin-4-yl)carbamate (1.21 g, 2.12 mmol, 70.14% yield) as a yellow solid. MS(M+H)+=570.6.
- To solution of tert-butyl (1-(7-((2-(2, 6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)heptyl)piperidin-4-yl)carbamate (1.21 g, 2.12 mmol) in dioxane (10 mL) was added HCl/dioxane (4 M, 20 mL), the mixture was stirred at 20° C. for 3 hours. LCMS showed the starting material was consumed completely. The reaction mixture was concentrated in vacuo to afford 4-((7-(4-aminopiperidin-1-yl)heptyl)amino)-2-(2, 6-dioxopiperidin-3-yl)isoindoline-1,3-dione (1.52 g, HCl salt, crude) as a yellow solid, which was used for the next step directly. MS(M+H)+=470.4.
- To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6, 7, 8, 9-tetrahydro-5H-pyrimido[4, 5-b][1, 4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (252.93 mg, 543.44 μmol) in DMF (8 mL) were added HATU (563.54 mg, 1.48 mmol) and DIEA (766.21 mg, 5.93 mmol, 1.03 mL), the mixture was stirred at 20° C. for 15 minutes, to this mixture was added 4-((7-(4-aminopiperidin-1-yl)heptyl)amino)-2-(2, 6-dioxopiperidin-3-yl)isoindoline-1,3-dione (500 mg, 988.07 μmol, HCl salt), the resulting mixture was stirred at 20° C. for 2 hours. LCMS showed trace of reactant remained and 68% of desired mass was detected. The reaction mixture was filtered and the filtrate was purified by prep-HPLC (column: Phenomenex luna C18 150*40 mm*15 um; mobile phase: [water (0.1% TFA)-ACN]; B %: 26%-56%, 10 min) followed by prep-HPLC (column: Phenomenex luna C18 150*40 mm*15 um; mobile phase: [water (0.1% TFA)-ACN]; B %: 27%-57%, 10 min), the eluent was freeze-dried to afford the titled compound (181.6 mg, 169.09 μmol, 17.11% yield, 96% purity, TFA salt) as a yellow solid. MS(M+H)+=917.2.
- 1H NMR (400 MHz, DMSO-d6) δ=11.11 (s, 1H), 9.47-9.34 (m, 1H), 8.43-8.08 (m, 4H), 7.59 (t, J=7.7 Hz, 1H), 7.19-7.17 (m, 1H), 7.09 (d, J=8.5 Hz, 1H), 7.03 (d, J=6.9 Hz, 1H), 6.54 (s, 1H), 5.05 (dd, J=5.1 Hz, J=12.6 Hz, 1H), 4.86-4.79 (m, 1H), 4.10 (t, J=13.7 Hz, 2H), 3.91 (s, 3H), 3.52 (d, J=10.3 Hz, 2H), 3.40-3.27 (m, 5H), 3.12-2.97 (m, 4H), 2.93-2.83 (m, 1H), 2.62-2.56 (m, 1H), 2.23-1.84 (m, 6H), 1.84-1.48 (m, 12H), 1.46-1.21 (m, 6H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (191.9 mg, 176.77 μmol, 22.98% yield, 90% purity, FA salt) as a yellow solid. MS(M+H)+=931.8.
- 1H NMR (400 MHz, DMSO-d6) δ=11.09 (br s, 1H), 8.28 (s, 1H), 8.25 (d, J=13.4 Hz, 1H), 8.05 (s, 1H), 8.09-8.01 (m, 2H), 7.58 (dd, J=7.2, 8.4 Hz, 1H), 7.21-7.15 (m, 1H), 7.09 (d, J=8.5 Hz, 1H), 7.02 (d, J=6.9 Hz, 1H), 6.51 (t, J=5.8 Hz, 1H), 5.04 (dd, J=5.4, 12.7 Hz, 1H), 4.86-4.77 (m, 1H), 4.06 (br t, J=13.9 Hz, 3H), 3.96-3.83 (m, 5H), 3.32 (s, 3H), 3.15 (br d, J=11.0 Hz, 2H), 2.91-2.84 (m, 1H), 2.71-2.55 (m, 5H), 2.04-1.87 (m, 5H), 1.80-1.45 (m, 13H), 1.30 (br d, J=12.1 Hz, 8H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (312.6 mg, 283.36 μmol, 30.27% yield, 96% purity, TFA salt) as a yellow solid. MS(M+H)+=945.6.
- 1H NMR (400 MHz, DMSO-d6) δ=11.10 (s, 1H), 9.56-9.24 (m, 1H), 8.31 (s, 1H), 8.19-8.27 (m, 2H), 8.17 (s, 1H), 7.66-7.55 (m, 1H), 7.26-7.16 (m, 1H), 7.13-7.07 (m, 1H), 7.06-7.00 (m, 1H), 6.53 (s, 1H), 5.06 (dd, J1=12.8 Hz, J2=5.3 Hz, 1H), 4.82-4.86 (m, 1H), 4.21-4.02 (m, 3H), 3.92 (s, 3H), 3.52 (d, J=10.8 Hz, 2H), 3.37-3.27 (m, 5H), 3.09-2.99 (m, 3H), 2.94-2.84 (m, 1H), 2.63-2.57 (m, 1H), 2.29-1.87 (m, 6H), 1.86-1.50 (m, 12H), 1.39-1.22 (m, 10H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (144.2 mg, 124.97 μmol, 19.57% yield, 93% purity, TFA salt) as a yellow solid. MS(M+H)+=959.7.
- 1H NMR (400 MHz, DMSO-d6) δ=11.09 (s, 1H), 9.39-9.08 (m, 1H), 8.30 (s, 1H), 8.29-8.17 (m, 2H), 8.13 (s, 1H), 7.62-7.54 (m, 1H), 7.25-7.15 (m, 1H), 7.12-7.06 (m, 1H), 7.05-7.00 (m, 1H), 6.52 (s, 1H), 5.05 (dd, J1=12.7 Hz, J2=5.4 Hz, 1H), 4.83 (t, J=8.3 Hz, 1H), 4.13-4.06 (m, 2H), 3.91 (s, 3H), 3.52 (d, J=10.9 Hz, 2H), 3.33 (s, 3H), 3.31-2.26 (m, 2H), 3.13-2.95 (m, 4H), 2.93-2.84 (m, 1H), 2.62-2.56 (m, 1H), 2.17-1.85 (m, 6H), 1.84-1.68 (m, 4H), 1.66-1.54 (m, 8H), 1.36-1.25 (m, 12H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (215.1 mg, 210.00 μmol, 39.35% yield, 95% purity) as a yellow solid. MS(M+H)+=973.3.
- 1H NMR (400 MHz, DMSO-d6) δ=11.09 (s, 1H), 8.29 (s, 1H), 8.24 (d, J=13.3 Hz, 1H), 8.03 (s, 1H), 7.86 (dd, =7.4 Hz, J2=3.4 Hz, 1H), 7.57 (dd, =8.4 Hz, J2=7.3 Hz, 1H), 7.19 (d, J=6.6 Hz, 1H), 7.08 (d, J=8.6 Hz, 1H), 7.01 (d, J=7.0 Hz, 1H), 6.52 (t, J=5.6 Hz, 1H), 5.04 (dd, J1=12.5 Hz, J2=5.4 Hz, 1H), 4.88-4.76 (m, 1H), 4.07 (t, J=13.9 Hz, 2H), 3.91 (s, 3H), 3.78-3.65 (m, 1H), 3.30-3.24 (m, 3H), 2.94-2.85 (m, 1H), 2.80 (d, J=11.4 Hz, 2H), 2.64-2.55 (m, 2H), 2.22 (t, J=7.3 Hz, 2H), 2.04-1.90 (m, 5H), 1.82-1.69 (m, 4H), 1.66-1.50 (m, 8H), 1.49-1.13 (m, 18H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (142.5 mg, 142.34 μmol, 17.87% yield) as a yellow solid. MS(M+H)+=1001.4.
- 1H NMR (400 MHz, DMSO-d6) δ=11.09 (s, 1H), 8.34-8.20 (m, 2H), 8.03 (s, 1H), 7.87 (dd, J1=7.7 Hz, J2=3.5 Hz, 1H), 7.57 (dd, =8.4 Hz, J2=7.2 Hz, 1H), 7.18 (d, J=6.7 Hz, 1H), 7.08 (d, J=8.5 Hz, 1H), 7.01 (d, J=6.9 Hz, 1H), 6.52 (t, J=5.8 Hz, 1H), 5.04 (dd, J1=12.9 Hz, J2=5.4 Hz, 1H), 4.89-4.73 (m, 1H), 4.07 (t, J=13.9 Hz, 2H), 3.91 (s, 3H), 3.76-3.67 (m, 1H), 3.31-3.26 (m, 3H), 2.94-2.85 (m, 1H), 2.84-2.76 (m, 2H), 2.85-2.75 (m, 2H), 2.23 (t, J=7.3 Hz, 2H), 2.05-1.90 (m, 5H), 1.81-1.68 (m, 4H), 1.66-1.49 (m, 8H), 1.43-1.17 (m, 22H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (80.7 mg, 75.52 μmol, 22.82% yield, 95% purity) as a yellow solid. MS(M+H)+=1015.5.
- 1H NMR (400 MHz, CDCl3) δ=8.37 (d, J=15.2 Hz, 1H), 8.07 (s, 1H), 7.83 (s, 1H), 7.57 (d, J=7.1 Hz, 1H), 7.49 (dd, J=7.3, 8.4 Hz, 1H), 7.09 (d, J=7.1 Hz, 1H), 6.89 (d, J=8.6 Hz, 1H), 6.70 (dd, J=7.5, 15.2 Hz, 1H), 6.23 (t, J=5.4 Hz, 1H), 4.97-4.80 (m, 2H), 4.13-4.00 (m, 1H), 3.99-3.87 (m, 5H), 3.42 (s, 3H), 3.31-3.23 (m, 2H), 3.00-2.68 (m, 5H), 2.48-2.31 (m, 2H), 2.26-2.04 (m, 7H), 1.86-1.69 (m, 6H), 1.53-1.49 (m, 2H), 1.45-1.39 (m, 2H), 1.36-1.22 (m, 22H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (58.7 mg, 58.13 umol, 85.97% yield, 91% purity) as a yellow solid. MS(M+H)+=919.7
- 1H NMR (400 MHz, CDCl3) δ=8.39 (d, J=15.2 Hz, 1H), 8.07 (s, 1H), 7.85 (s, 1H), 7.57-7.48 (m, 2H), 7.11 (d, J=6.8 Hz, 1H), 6.94-6.82 (m, 2H), 6.59 (t, J=5.2 Hz, 1H), 5.00-4.93 (m, 1H), 4.90-4.82 (m, 1H), 4.45-4.25 (m, 1H), 3.97 (s, 3H), 3.92 (t, J=13.4 Hz, 2H), 3.64-3.46 (m, 6H), 3.42 (s, 3H), 3.09-3.02 (m, 2H), 2.92-2.72 (m, 6H), 2.19-2.12 (m, 8H), 2.01-1.92 (m, 3H), 1.84-1.75 (m, 5H), 1.67-1.54 (m, 3H)
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (37.2 mg, 35.88 μmol, 6.68% yield, 90% purity) as a yellow solid. MS(M+H)+=933.4
- 1H NMR (400 MHz, CDCl3) δ=8.39 (d, J=15.2 Hz, 1H), 8.07 (s, 1H), 7.84 (s, 1H), 7.55-7.47 (m, 2H), 7.10 (d, J=7.1 Hz, 1H), 6.91 (d, J=8.6 Hz, 1H), 6.82 (dd, J=7.9, 14.7 Hz, 1H), 6.72-6.65 (m, 1H), 4.98-4.90 (m, 1H), 4.90-4.82 (m, 1H), 4.33-4.12 (m, 1H), 3.97 (s, 3H), 3.96-3.88 (m, 2H), 3.63-3.43 (m, 6H), 3.42 (s, 3H), 3.03-2.56 (m, 8H), 2.17-2.07 (m, 6H), 1.97-1.86 (m, 6H), 1.75-1.52 (m, 8H)
-
- A solution of 4-benzyloxybutane-1-ol (8.0 g, 44.38 mmol, 7.77 mL), Cs2CO3 (28.92 g, 88.77 mmol), ethyl prop-2-enoate (44.44 g, 443.85 mmol, 48.25 mL) in CH3CN (100 mL) was stirred at 25° C. for 12 h. LCMS showed that the reaction was completed. The mixture was filtered; the filter liquor was concentrated in vacuo. The crude product was purified by reversed-phase HPLC (0.1% FA condition, MeCN/water) to afford the titled compound (9.04 g, crude) as colorless oil. MS(M+H)+=281.0
- To a solution of ethyl 3-(4-benzyloxybutoxy) propanoate (9.04 g, 32.24 mmol) in THF (100 mL) was added LAH (1.47 g, 38.69 mmol) at 0° C., the mixture was stirred at 25° C. for 2 h. TLC (Petroleum ether/EtOAc=3/1) showed that the reaction was completed. The mixture was quenched with water (1.5 mL), 1.5 mL 15% NaOH (aq) and water (4.5 mL) sequently. The mixture was stirred at 25° C. for 30 min, the mixture was filtered and the filtrate was concentrated under vacuum to afford the titled compound (8.41 g, crude) as colorless oil.
- To a solution of 3-(4-benzyloxybutoxy) propan-1-ol (8.41 g, 35.29 mmol) in DCM (100 mL) were added TEA (4.28 g, 42.35 mmol, 5.89 mL) followed by TosCl (8.07 g, 42.35 mmol). The reaction mixture was stirred at 20° C. for 3 h. LCMS showed the desired mass was detected. The reaction mixture was diluted with H2O (250 mL) and extracted with DCM (200 mL×3), the combined organic layers were washed with brine (50 mL×1), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (20 g SepaFlash® Silica Flash Column, Eluent of 10˜30% Ethyl acetate/Petroleum ether gradient @ 60 mL/min) to afford the titled compound (6.8 g, 17.32 mmol, 49.09% yield) as colorless oil. MS(M+H)+=393.0
- To a solution of 3-(4-benzyloxybutoxy) propyl 4-methylbenzenesulfonate (3.4 g, 8.66 mmol) and tert-butyl piperidin-4-ylcarbamate (2.60 g, 12.99 mmol) in dioxane (20 mL) were added NaI (129.84 mg, 866.22 μmol) and DIEA (2.24 g, 17.32 mmol, 3.02 mL), the mixture was heated at 60° C. for 12 h. LCMS showed the desired mass was detected. The mixture was concentrated in vacuo. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=2/1 to EtOAc/MeOH=10/1) to afford the titled compound (3.05 g, 7.25 mmol, 83.72% yield) as yellow oil. MS(M+H)+=421.2
- To a solution of tert-butyl (1-(3-(4-(benzyloxy)butoxy)propyl)piperidin-4-yl)carbamate (2.4 g, 5.71 mmol) in EtOAc (20 mL) was added Pd/C (400 mg, 10% purity) and Pd(OH)2/C (400 mg, 10% purity) under N2. The suspension was degassed under vacuum and purged with H2 several times. The mixture was stirred under H2 (50 psi) at 60° C. for 24 h. TLC (EtOAc/MeOH=10/1) showed the reactant was remained and the desired product was detected. The mixture was filtered, the filtrate was concentrated in vacuo to afford the titled compound (1.9 g, 4.52 mmol, 79.17% yield) as colorless oil.
- To a solution of tert-butyl (1-(3-(4-hydroxybutoxy)propyl)piperidin-4-yl)carbamate (1.69 g, 5.11 mmol) in DCM (20 mL) were added TEA (1.55 g, 15.34 mmol, 2.14 mL) and TosCl (1.46 g, 7.67 mmol), the mixture was stirred at 25° C. for 12 h. LCMS showed the desired mass was detected. The mixture was concentrated in vacuo. The residue was purified by flash silica gel chromatography (Biotage, 25 g SepaFlash® Silica Flash Column, Eluent of 30˜100% Ethyl acetate/Petroleum ether gradient @ 80 mL/min) to afford the titled compound (1.23 g, 2.09 mmol, 40.84% yield, 82.3% purity) as yellow oil. MS(M+H)+=485.3.
- A solution of 4-(3-(4-((tert-butoxycarbonyl)amino)piperidin-1-yl)propoxy)butyl 4-methylbenzenesulfonate (1.23 g, 2.54 mmol) and (1, 3-dioxoisoindolin-2-yl) potassium (940.15 mg, 5.08 mmol) in DMF (15 mL), the mixture was heated at 80° C. for 12 h. LCMS showed the desired mass was detected. The reaction mixture was diluted with brine (10 mL) and extracted with EtOAc (30 mL×2). The combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (Biotage, 25 g SepaFlash® Silica Flash Column, Eluent of 30-100% Ethyl acetate/Petroleum ether gradient @ 80 mL/min) to afford the titled compound (600 mg, 1.30 mmol, 51.34% yield, 99.8% purity) as colorless oil. MS (M+H)+=460.2.
- tert-butyl (1-(3-(4-(1,3-dioxoisoindolin-2-yl)butoxy)propyl)piperidin-4-yl)carbamate (0.78 g, 1.70 mmol) and NH2NH2·H2O (999.56 mg, 16.97 mmol, 970.45 μL, 85% purity) were placed in a 50 mL round bottom flask, and EtOH (10 mL) was added. The mixture was stirred at 75° C. for 2 h. TLC (Ethyl acetate/Methanol=10/1) showed that the reaction was completed. Stop heating, remove insoluble solids by filtration, the filtrate was concentrated to the titled compound (0.5 g, 1.52 mmol, 89.41% yield) as yellow oil.
- 1H NMR (400 MHz, MeOD) δ=3.51-3.41 (m, 4H), 3.40-3.35 (m, 1H), 2.92 (d, J=11.6 Hz, 2H), 2.73 (t, J=7.0 Hz, 2H), 2.51-2.38 (m, 2H), 2.17-2.06 (m, 2H), 1.90-1.81 (m, 2H), 1.82-1.73 (m, 2H), 1.65-1.55 (m, 4H), 1.48-1.40 (m, 11H).
- To the solution of tert-butyl (1-(3-(4-aminobutoxy)propyl)piperidin-4-yl)carbamate (440 mg, 1.34 mmol) and 2-(2, 6-dioxo-3-piperidyl)-4-fluoro-isoindoline-1,3-dione (400 mg, 1.45 mmol) in DMSO (5 mL) was added TEA (439.60 mg, 4.34 mmol, 604.68 μL) and the mixture was stirred at 60° C. for 12 h. TLC (Ethyl acetate/Methanol=10/1) showed that the reaction was completed, the mixture was poured into water (30 mL) and extracted with EtOAc (20 mL×3), the combined organic layer was dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column (Ethyl acetate/Methanol=10/1) to the titled compound (160 mg, 264.99 μmol, 18.30% yield, 97% purity) as yellow oil. MS(M+H)+=586.2
- to the solution of tert-butyl (1-(3-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)butoxy)propyl)piperidin-4-yl)carbamate (160 mg, 273.18 μmol) in dioxane (5 mL) was added HCl/dioxane (4 M, 5 mL) and the mixture was stirred at 20° C. for 1 h. LCMS showed that the reaction was completed. The mixture was concentrated to afford the titled compound (140 mg, 268.18 μmol, 98.17% yield, HCl) as yellow oil. MS(M+H)+=486.5.
- To the solution of 4-((4-(3-(4-aminopiperidin-1-yl)propoxy)butyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (140 mg, 268.18 μmol, HCl) and 4-[(9-cyclopentyl-7, 7-difluoro-5-methyl-6-oxo-8H-pyrimido[4, 5-b][1, 4]diazepin-2-yl) amino]-2-fluoro-5-methoxy-benzoic acid (124.82 mg, 268.18 μmol) in DMF (3 mL) were added HATU (203.94 mg, 536.36 μmol) and DIPEA (103.98 mg, 804.54 μmol, 140.14 μL) and the resulting mixture was stirred at 20° C. for 1 h. LCMS showed that the reaction was completed, the mixture was poured into water (20 mL) and extracted with EtOAc (20 mL×3), the combined organic layers were washed with brine (50 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (column: Unisil 3-100 C18 μLtra 150*50 mm*3 um; mobile phase: [water (0.225% FA)-ACN]; B %: 33%-53%, 10 min) and the eluant was lyophilized to afford the titled compound (14.8 mg, 15.55 μmol, 5.80% yield, 98% purity, FA) as yellow solid. MS(M+H)+=933.3
- 1H NMR (400 MHz, DMSO-d6) δ=11.10 (s, 1H), 8.30 (s, 1H), 8.26 (d, J=13.2 Hz, 1H), 8.14 (s, 1H), 8.08-7.99 (m, 2H), 7.65-7.54 (m, 1H), 7.19 (d, J=6.8 Hz, 1H), 7.11 (d, J=8.6 Hz, 1H), 7.04 (d, J=6.8 Hz, 1H), 6.61-6.54 (m, 1H), 5.12-5.00 (m, 1H), 4.89-4.77 (m, 1H), 4.08 (t, J=13.6 Hz, 2H), 3.95-4.83 (m, 5H), 3.42-3.41 (m, 8H), 3.18-3.07 (m, 1H), 2.95-2.82 (m, 2H), 2.70-2.56 (m, 5H), 1.97-1.95 (m, 2H), 1.89-1.88 (m, 2H), 1.76-1.72 (m, 4H), 1.71-1.55 (m, 12H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (199.8 mg, 200.01 μmol, 46.55% yield, 95% purity) as yellow solid. MS(M+H)+=949.2.
- 1H NMR (400 MHz, DMSO-d6) δ=11.10 (s, 1H), 8.30 (s, 1H), 8.26 (d, J=13.2 Hz, 1H), 8.16-8.15 (m, 1H), 8.06 (s, 1H), 7.61-7.57 (m, 1H), 7.25-7.14 (m, 2H), 7.05 (d, J=6.8 Hz, 1H), 6.66-6.65 (m, 1H), 5.13-5.05 (m, 1H), 4.81-4.73 (m, 1H), 4.13-4.06 (m, 2H), 4.12-3.95 (m, 4H), 3.69-3.64 (m, 2H), 3.60-3.56 (m, 2H), 3.53-3.46 (m, 8H), 3.33 (s, 3H), 3.27-3.18 (m, 2H), 3.15-3.05 (m, 2H), 2.78-2.69 (m, 1H), 2.58-2.50 (m, 2H), 2.05-1.94 (m, 5H), 1.87-1.73 (m, 6H), 1.67-1.56 (m, 4H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (172.4 mg, 164.09 μmol, 55.14% yield, 97% purity) as yellow solid. MS(M+H)+=1019.3.
- 1H NMR (400 MHz, CDCl3) δ=9.09 (s, 1H), 8.36 (d, J=15.2 Hz, 1H), 8.06 (s, 1H), 7.87 (s, 1H), 7.49-7.45 (m, 2H), 7.07 (d, J=6.8 Hz, 1H), 6.92-6.87 (m, 2H), 6.54-6.51 (m, 1H), 4.97-4.94 (m, 1H), 4.89-4.83 (m, 1H), 4.34-4.16 (m, 1H), 3.94-3.91 (m, 5H), 3.78-3.77 (m, 3H), 3.70-3.65 (m, 2H), 3.49-3.41 (m, 11H), 3.19-3.11 (m, 2H), 2.81-2.78 (m, 3H), 2.31-2.25 (m, 2H), 2.19-2.07 (m, 5H), 1.78-1.71 (m, 6H), 1.62-1.49 (m, 6H), 1.42-4.33 (m, 2H), 1.32-1.21 (m, 6H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (6.3 mg, 5.80 μmol, 8.85% yield, 94% purity, FA salt) as yellow solid. MS(M+H)+=1021.8.
- 1H NMR (400 MHz, DMSO-d6) δ=11.10 (br s, 1H), 8.31 (s, 1H), 8.25 (d, J=13.2 Hz, 1H), 8.18 (s, 1H), 8.04 (s, 1H), 7.94-7.86 (m, 1H), 7.62-7.55 (m, 1H), 7.19 (d, J=6.6 Hz, 1H), 7.15 (d, J=8.6 Hz, 1H), 7.05 (d, J=7.0 Hz, 1H), 6.61 (t, J=5.6 Hz, 1H), 5.11-5.02 (m, 1H), 4.87-4.79 (m, 1H), 4.08 (t, J=14.0 Hz, 2H), 3.92 (s, 3H), 3.83-3.72 (m, 2H), 3.63 (t, J=5.3 Hz, 2H), 3.59-3.55 (m, 2H), 3.51-3.40 (m, 13H), 2.95-2.82 (m, 2H), 2.63-2.56 (m, 4H), 2.53 (s, 3H), 2.37-2.31 (m, 2H), 2.12-1.96 (m, 4H), 1.87-1.78 (m, 2H), 1.75-1.68 (m, 4H), 1.64-1.55 (m, 4H), 1.50-1.42 (m, 2H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (134.7 mg, 120.05 μmol, 35.21% yield, 91% purity) as yellow solid. MS(M+H)+=1021.7.
- 1H NMR (400 MHz, CD3OD) δ=8.41 (d, J=14.8 Hz, 1H), 8.21 (s, 1H), 7.56-7.52 (m, 1H), 7.33 (d, J=6.4 Hz, 1H), 7.09-7.04 (m, 2H), 5.08-5.06 (m, 1H), 4.94-4.92 (m, 1H), 4.62-4.55 (m, 2H), 4.24-4.12 (m, 1H), 4.07-3.98 (m, 5H), 3.70-3.66 (m, 2H), 3.57-3.48 (m, 14H), 3.04 (s, 3H), 3.26-3.25 (m, 2H), 3.15-3.10 (m, 1H), 2.76-2.72 (m, 1H), 2.70-2.65 (m, 2H), 2.21-2.28 (m, 2H), 2.11-2.18 (m, 3H), 2.03-1.97 (m, 2H), 1.80-1.75 (m, 4H), 1.69-1.62 (m, 4H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (21.3 mg, 17.21 μmol, 11.44% yield, 93% purity, TFA) as a yellow solid. MS(M+H)+=1037.5
- 1H NMR (400 MHz, CD3OD) δ=8.36-8.29 (m, 1H), 8.21 (s, 1H), 7.53 (dd, J=7.2, 8.6 Hz, 1H), 7.37-7.32 (m, 1H), 7.08-7.03 (m, 2H), 5.06 (dd, J=5.6, 12.6 Hz, 1H), 4.99-4.94 (m, 1H), 4.08 (t, J=13.0 Hz, 2H), 3.98 (s, 3H), 3.77-3.70 (m, 6H), 3.67-3.63 (m, 6H), 3.60-3.56 (m, 6H), 3.49 (t, J=5.4 Hz, 3H), 3.41 (s, 3H), 3.37-3.30 (m, 2H), 3.21-3.13 (m, 2H), 2.93-2.80 (m, 1H), 2.78-2.67 (m, 2H), 2.32-2.26 (m, 2H), 2.15-2.07 (m, 4H), 1.93-1.83 (m, 5H), 1.77-1.70 (m, 4H).
-
- To a mixture of 2-(2-chloroethoxy)ethanol (10 g, 80.28 mmol, 8.47 mL) and tert-butyl 2-bromoacetate (31.32 g, 160.56 mmol, 23.73 mL) in THF (100 mL) were added TBAB (25.88 g, 80.28 mmol) and t-BuOK (9.01 g, 80.28 mmol) in one portion at 20° C. and the resulting mixture was stirred at 20° C. for 16 h. TLC (SiO2, Petroleum ether:Ethyl acetate=5:1) indicated 2-(2-chloroethoxy)ethanol remained and three new spots were detected. The reaction mixture was concentrated in vacuum. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=10/1 to 5/1) to afford the titled compound (3 g, 12.57 mmol, 15.66% yield) as a yellow oil.
- To a mixture of tert-butyl 2-(2-(2-chloroethoxy)ethoxy)acetate (1.5 g, 6.28 mmol) and benzyl piperidin-4-ylcarbamate (1.77 g, 7.54 mmol) in ACN (20 mL) was added K2CO3 (2.61 g, 18.85 mmol) in one portion at 20° C. and the resulting mixture was stirred at 60° C. for 16 h. LCMS showed 64% of tert-butyl 2-(2-(2-chloroethoxy)ethoxy)acetate remained and 14% peak with desired mass was detected. NaI (188.38 mg, 1.26 mmol) was added to this reaction mixture at 20° C. and the resulting mixture was stirred at 80° C. for 12 h. LCMS showed 51% of tert-butyl 2-(2-(2-chloroethoxy)ethoxy)acetate remained and 36% desired mass was detected and the reaction mixture was concentrated in vacuum. The residue was diluted with dioxane (20 mL) at 20° C. and the resulting mixture was stirred at 90° C. for 16 h. LCMS showed 46% of tert-butyl 2-(2-(2-chloroethoxy)ethoxy)acetate remained and 38% desired mass was detected. The reaction mixture was concentrated in vacuum. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=3/1 to 0/1) to afford the titled compound (860 mg, 1.77 mmol, 28.22% yield, 90% purity) as a yellow oil. MS(M+H)+=437.2
- To a mixture of tert-butyl 2-(2-(2-(4-(((benzyloxy)carbonyl)amino)piperidin-1-yl)ethoxy)ethoxy)acetate (750 mg, 1.72 mmol) in dioxane (5 mL) was added HCl/dioxane (4 M, 10 mL) in one portion at 20° C. and the resulting mixture was stirred at 20° C. for 2 h. LCMS showed starting material was consumed completely and one peak with desired mass was detected. The reaction mixture was concentrated in vacuum to afford the titled compound (680 mg, crude) as a yellow oil. MS(M+H)+=381.2
- To a mixture of 2-(2-(2-(4-(((benzyloxy)carbonyl)amino)piperidin-1-yl)ethoxy)ethoxy)acetic acid (650 mg, 1.71 mmol) and 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (560.23 mg, 2.05 mmol) in DMF (4 mL) were added T3P (6.52 g, 10.25 mmol, 6.10 mL, 50% purity in EtOAc solution) and Py (1.35 g, 17.09 mmol, 1.38 mL) in one portion at 20° C. and the resulting mixture was stirred at 80° C. for 16 h. LCMS showed all starting material was consumed completely and one peak with desired mass was detected. The reaction mixture was diluted with H2O (15 mL) and extracted with EtOAc (15 mL×3). The organic layer was washed with brine (15 mL×3), dried over Na2SO4, filtered and concentrated. The crude product was purified by prep-HPLC (column: Phenomenex luna C18 150*40 mm*15 um; mobile phase: [water (0.1% TFA)-ACN]; B %: 17%-47%, 10 min) and then lyophilized to afford the titled compound (910 mg, 1.40 mmol, 82.11% yield, 98% purity) as a yellow solid. MS(M+H)+=636.1
- 1H NMR (400 MHz, CD3OD) δ=8.79 (d, J=8.6 Hz, 1H), 7.84-7.76 (m, 1H), 7.61 (d, J=7.4 Hz, 1H), 7.34-7.26 (m, 5H), 5.15 (dd, J=5.6, 12.8 Hz, 1H), 5.04 (s, 2H), 4.22 (s, 2H), 3.90 (t, J=5.0 Hz, 2H), 3.85-3.83 (m, 3H), 3.75-3.54 (m, 3H), 3.50-3.33 (m, 2H), 3.29-3.05 (m, 2H), 2.94-2.65 (m, 3H), 2.24-1.91 (m, 4H), 1.86-1.56 (m, 2H)
- To a solution of benzyl (1-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-2-oxoethoxy)ethoxy)ethyl)piperidin-4-yl)carbamate (810 mg, 1.27 mmol) in THF (10 mL) was added Pd/C (0.1 g, 10% purity) under N2. The suspension was degassed under vacuum and purged with H2 several times. The mixture was stirred under H2 (15 psi) at 20° C. for 16 h. LCMS showed 72% of starting material remained and 18% peak with desired mass was detected. Pd/C (0.4 g, 127.43 μmol, 10% purity) was added to this reaction mixture under N2. The reaction mixture was stirred under H2 (15 psi) at 20° C. for 16 h. LCMS showed starting material was consumed completely and one peak with desired mass was detected. The reaction mixture was diluted with THF (20 mL) and filtered. The filtrate was concentrated in vacuum to afford the titled compound (563 mg, 1.04 mmol, 81.93% yield, 93% purity) as a yellow solid. MS(M+H)+=502.1
- To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (120 mg, 257.83 μmol) in DMF (2 mL) were added HATU (98.03 mg, 257.83 μmol) and DIPEA (99.97 mg, 773.49 μmol, 134.73 μL). The mixture was stirred at 20° C. for 10 min and a solution of 2-(2-(2-(4-aminopiperidin-1-yl)ethoxy)ethoxy)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)acetamide (168.10 mg, crude) in DMF (2 mL) were added drop-wise at 20° C. and the resulting mixture was stirred at 20° C. for 1 h. LCMS showed all starting material was consumed completely and one peak with desired mass was detected. The reaction mixture was diluted with H2O (10 mL×3) and extracted with EtOAc (10 mL×3). The organic layer was dried over Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (column: 3_Phenomenex Luna C18 75*30 mm*3 um; mobile phase: [water (0.1% TFA)-ACN]; B %: 34%-54%, 7 min) and then lyophilized to afford the titled compound (105.3 mg, 95.10 μmol, 36.88% yield, 96% purity, TFA) as a white solid. MS(M+H)+=949.0
- 1H NMR (400 MHz, CD3OD) δ=8.85-8.74 (m, 1H), 8.38-8.29 (m, 1H), 8.23-8.20 (m, 1H), 7.83-7.76 (m, 1H), 7.62-7.53 (m, 1H), 7.31 (d, J=6.8 Hz, 1H), 5.17 (dd, J=5.4, 12.8 Hz, 1H), 4.99-4.94 (m, 1H), 4.26-4.21 (m, 2H), 4.08 (t, J=13.2 Hz, 2H), 3.99 (s, 3H), 3.93 (t, J=4.8 Hz, 2H), 3.90-3.84 (m, 4H), 3.73-3.69 (m, 1H), 3.50-3.44 (m, 1H), 3.40 (s, 3H), 3.39-3.35 (m, 2H), 3.25-3.11 (m, 2H), 2.96-2.69 (m, 3H), 2.26-2.03 (m, 6H), 1.93-1.78 (m, 4H), 1.76-1.66 (m, 4H)
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (22.6 mg, 20.70 μmol, 9.64% yield, 95% purity) as white solid. MS(M+H)+=1037.3
- 1H NMR (400 MHz, DMSO-d6) δ=11.20 (br s, 1H), 10.36 (s, 1H), 8.72 (d, J=8.4 Hz, 1H), 8.29 (s, 1H), 8.23 (d, J=13.4 Hz, 1H), 8.04 (s, 1H), 7.94-7.81 (m, 2H), 7.62 (d, J=7.6 Hz, 1H), 7.17 (d, J=6.8 Hz, 1H), 5.16 (dd, J=5.6, 12.8 Hz, 1H), 4.88-4.73 (m, 1H), 4.20 (s, 2H), 4.08 (t, J=13.6 Hz, 2H), 3.90 (s, 3H), 3.80-3.73 (m, 2H), 3.72-3.63 (m, 3H), 3.58-3.35 (m, 12H), 2.95-2.79 (m, 3H), 2.69-2.53 (m, 2H), 2.43 (t, J=5.9 Hz, 2H), 2.14-1.99 (m, 3H), 1.97-1.87 (m, 2H), 1.79-1.69 (m, 4H), 1.69-1.44 (m, 7H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (14.1 mg, 12.15 μmol, 6.30% yield, 89% purity) as white solid. MS (M+H)+=1033.4
- 1H NMR (400 MHz, DMSO-d6) δ=11.17 (s, 1H), 10.35 (s, 1H), 8.74 (d, J=8.4 Hz, 1H), 8.30 (s, 1H), 8.24 (d, J=13.6 Hz, 1H), 8.03 (s, 1H), 7.89-7.84 (m, 2H), 7.63 (d, J=7.2 Hz, 1H), 7.18 (d, J=6.4 Hz, 1H), 5.18-5.14 (m, 1H), 4.86-4.77 (m, 1H), 4.14-4.08 (m, 5H), 3.91 (s, 4H), 3.76-3.69 (m, 1H), 3.61-3.57 (m, 3H), 3.46-3.43 (m, 1H), 2.88-2.86 (m, 2H), 2.63-2.54 (m, 2H), 2.15-2.10 (m, 2H), 2.05-1.95 (m, 2H), 1.76-1.73 (m, 5H), 1.65-1.61 (m, 10H), 1.47-1.39 (m, 5H), 1.28-1.19 (m, 9H).
-
- To a solution of 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (5 g, 18.10 mmol) and tert-butyl 2-aminoacetate (2.37 g, 18.10 mmol) in DMSO (50 mL) was added DIPEA (4.68 g, 36.20 mmol, 6.31 mL). The reaction mixture was stirred at 90° C. for 24 h. LCMS showed 51% of desired mass was detected. The mixture was poured into H2O (100 mL) and extracted with ethyl acetate (50 mL×3). The combined organic phase was washed with brine (30 mL×3), dried over Na2SO4, filtered. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (1000 mesh silica gel, eluted with petroleum ether:ethyl acetate=10:1 to 1:1) to afford the titled compound (4.4 g, crude) as green solid. MS(M-56+H)+=332.0
- To a solution of tert-butyl 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)acetate (4 g, 10.33 mmol) in dioxane (5 mL) was added HCl/dioxane (4 M, 40 mL) and the resulting mixture was stirred at 25° C. for 2 h. LCMS showed one peak (72%) with desired mass. The mixture was concentrated under reduced pressure. The residue was triturated with petroleum ether:ethyl acetate (10:1, 40 mL) and stirred for 20 min. Then the suspension was filtrated. The filter cake was collected and dried in vacuo to the titled compound (3.3 g, crude) as yellow solid. MS(M+H)+=332.0
- To a mixture of 2-((2-(2, 6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)acetic acid (3.15 g, 9.51 mmol) and 2-(2-aminoethoxy)ethanol (1.40 g, 13.31 mmol, 1.33 mL) in DCM (40 mL) were added HOBt (1.54 g, 11.41 mmol), EDCI (2.19 g, 11.41 mmol) and TEA (2.89 g, 28.53 mmol, 3.97 mL) and the resulting mixture was stirred at 25° C. for 12 h. LCMS showed one peak (83%) with desired mass. The mixture was concentrated under reduced pressure. The residue was purified by reversed-phase HPLC (0.1% FA condition) to the titled compound (1.79 g, 4.28 mmol, 44.99% yield, 100% purity) as green solid. MS(M+H)+=419.2
- To a solution of 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-N-(2-(2-hydroxyethoxy)ethyl)acetamide (1.69 g, 4.04 mmol) and TEA (1.63 g, 16.16 mmol, 2.25 mL) in DCM (20 mL) was added TosCl (3.08 g, 16.16 mmol) at 25° C. The solution was stirred at 25° C. for 12 h. LCMS showed the starting material was consumed completely, and a peak (15%) with desired mass. The mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (1000 mesh silica gel, eluted with petroleum ether:ethyl acetate=3:1 to 0:1) to afford the titled compound (1.7 g, 2.67 mmol, 66.15% yield, 90% purity) as brown oil. MS(M+H)+=573.1
- To a solution of 2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)acetamido)ethoxy)ethyl 4-methylbenzenesulfonate (787.00 mg, 3.93 mmol) tert-butyl N-(4-piperidyl)carbamate (787.00 mg, 3.93 mmol) in dioxane (20 mL) were added DIPEA (1.02 g, 7.86 mmol, 1.37 mL) and NaI (196.34 mg, 1.31 mmol). The reaction mixture was stirred at 100° C. for 16 h. LCMS showed one peak (72) with desired mass. The mixture was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (1000 mesh silica gel, eluted with petroleum ether:ethyl acetate=5:1 to 0:1; ethyl acetate:methanol=10:1) to afford the titled compound (0.8 g, 1.31 mmol, 49.82% yield, 98% purity) as green solid. MS(M+H)+=601.2
- A solution of tert-butyl (1-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)acetamido)ethoxy)ethyl)piperidin-4-yl)carbamate (1.2 g, 2.00 mmol) in HCl/dioxane (4 M, 40 mL) was stirred at 25° C. for 2 h. LCMS showed one peak (41%) with desired mass. The mixture was concentrated under reduced pressure. The residue was purified by reversed-phase HPLC (0.1% HCl condition) to afford the titled compound (500 mg, crude, HCl salt) as yellow solid. MS (M+H)+=501.3
- To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (150 mg, 322.29 μmol) in DMF (2 mL) were added HATU (134.80 mg, 354.51 μmol) and DIPEA (83.31 mg, 644.57 μmol, 112.27 μL). The mixture was stirred at 25° C. for 10 min and a solution of N-(2-(2-(4-aminopiperidin-1-yl)ethoxy)ethyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)acetamide (224.99 mg, 418.97 μmol, HCl salt), DIPEA (83.31 mg, 644.57 μmol, 112.27 μL) in DMF (2 mL) was added and the resulting mixture was stirred at 25° C. for 1 h. LCMS showed the starting material remained. Additional HATU (110.29 mg, 290.06 μmol) was added and the resulting mixture was stirred at 25° C. for another 12 hrs. LCMS showed the starting material was consumed completely, and a main peak with desired mass. The mixture was concentrated under reduced pressure. The crude product was purified prep-HPLC (column: Phenomenex luna C18 150*40 mm*15 um; mobile phase: [water (0.1% TFA)-ACN]; B %: 19%-49%, 10 min) and the eluent was lyophilized to afford the titled compound (94.1 mg, 82.41 μmol, 25.57% yield, 95% purity, TFA salt) as yellow solid. MS (M+H)+=948.2.
- 1H NMR (400 MHz, CD3OD) δ=8.36 (d, J=13.9 Hz, 1H), 8.21 (s, 1H), 7.64-7.55 (m, 1H), 7.40-7.31 (m, 1H), 7.17-7.10 (m, 1H), 6.97-6.90 (m, 1H), 4.97 (br dd, J=7.0, 11.6 Hz, 2H), 4.11-4.03 (m, 4H), 4.00 (s, 3H), 3.84-3.75 (m, 2H), 3.69-3.56 (m, 4H), 3.54-3.42 (m, 3H), 3.41 (s, 3H), 3.31-3.41 (m, 1H), 3.22-3.06 (m, 2H), 2.65-2.83 (m, 3H), 2.29-1.84 (m, 8H), 1.84-1.64 (m, 6H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (99.4 mg, 83.84 μmol, 26.01% yield, 97% purity, TFA salt) as yellow solid. MS(M+H)+=1036.8
- 1H NMR (400 MHz, CD3OD) δ=8.30 (d, J=13.8 Hz, 1H), 8.19 (s, 1H), 7.51 (dd, J=7.2, 8.4 Hz, 1H), 7.32 (d, J=6.8 Hz, 1H), 7.07 (d, J=7.0 Hz, 1H), 6.83 (d, J=8.4 Hz, 1H), 5.06 (dd, J=5.4, 12.4 Hz, 2H), 4.07 (m, 2H), 3.99-3.95 (m, 5H), 3.85-3.79 (m, 2H), 3.72 (m, 2H), 3.68-3.63 (m, 4H), 3.60 (s, 3H), 3.55 (m, 2H), 3.50-3.42 (m, 3H), 3.41 (s, 3H), 3.36 (m, 2H), 3.25-3.10 (m, 2H), 2.93-2.81 (m, 1H), 2.79-2.67 (m, 2H), 2.35-1.86 (m, 8H), 1.84-1.63 (m, 6H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (35.3 mg, 36.80 μmol, 83.25% yield, 94.330% purity) as a yellow solid. MS(M+H)+=905.4
- 1H NMR (400 MHz, CDCl3) δ=9.91-9.22 (m, 1H), 8.44-8.31 (m, 1H), 8.08 (s, 1H), 7.84 (br d, J=7.5 Hz, 1H), 7.72-7.48 (m, 2H), 7.13 (t, J=6.7 Hz, 1H), 6.95-6.85 (m, 1H), 6.81-6.66 (m, 1H), 6.58-6.48 (m, 1H), 4.98-4.78 (m, 2H), 4.60-4.47 (m, 1H), 4.45-4.21 (m, 2H), 4.19-4.08 (m, 1H), 4.06-3.87 (m, 6H), 3.82-3.70 (m, 2H), 3.60-3.46 (m, 2H), 3.42 (s, 3H), 3.36-3.22 (m, 1H), 2.99-2.66 (m, 4H), 2.26-2.03 (m, 5H), 1.85-1.70 (m, 4H), 1.61-1.55 (m, 2H), 1.53-1.34 (m, 2H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (82.1 mg, 86.66 μmol, 33.61% yield, 97% purity) as a yellow solid. Ms (M+H)+=918.8
- 1H NMR (400 MHz, DMSO-d6) δ=11.29-10.79 (m, 1H), 8.32-8.22 (m, 2H), 8.03 (s, 1H), 7.94 (dd, J=3.1, 7.6 Hz, 1H), 7.62-7.55 (m, 1H), 7.20 (d, J=6.7 Hz, 1H), 7.14 (d, J=8.7 Hz, 1H), 7.04 (d, J=7.1 Hz, 1H), 6.59 (t, J=5.6 Hz, 1H), 5.06 (dd, J=5.3, 13.2 Hz, 1H), 4.84-4.80 (m, 1H), 4.29 (d, J=12.1 Hz, 1H), 4.07 (t, J=13.9 Hz, 2H), 4.03-3.96 (m, 1H), 3.91 (s, 3H), 3.89-3.86 (m, 1H), 3.68 (t, J=6.5 Hz, 2H), 3.63-3.58 (m, 2H), 3.47 (q, J=5.2 Hz, 2H), 3.33 (s, 3H), 3.12 (t, J=12.3 Hz, 1H), 2.93-2.83 (m, 1H), 2.77-2.69 (m, 1H), 2.63-2.55 (m, 4H), 2.06-1.94 (m, 3H), 1.87-1.78 (m, 2H), 1.71-1.67 (m, 2H), 1.67-1.57 (m, 4H), 1.49-1.34 (m, 2H)
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (20.5 mg, 21.39 μmol, 11.06% yield, 99% purity) as yellow solid. MS(M+H)+=949.4
- 1H NMR (400 MHz, DMSO-d6) δ=11.20-10.96 (m, 1H), 8.30 (s, 1H), 8.24 (d, J=13.3 Hz, 1H), 8.03 (s, 1H), 7.95 (dd, J=3.2, 7.7 Hz, 1H), 7.62-7.53 (m, 1H), 7.23-7.11 (m, 2H), 7.03 (d, J=7.0 Hz, 1H), 6.61 (t, J=5.8 Hz, 1H), 5.04 (dd, J=5.2, 12.9 Hz, 1H), 4.82 (br t, J=7.8 Hz, 1H), 4.30-4.20 (m, 1H), 4.19-4.14 (m, 2H), 4.12-3.98 (m, 3H), 3.91 (s, 3H), 3.83-3.72 (m, 1H), 3.66-3.55 (m, 6H), 3.51-3.44 (m, 2H), 3.17-3.00 (m, 1H), 2.93-2.81 (m, 1H), 2.80-2.69 (m, 1H), 2.64-2.51 (m, 5H), 2.09-1.89 (m, 3H), 1.88-1.77 (m, 2H), 1.76-1.54 (m, 6H), 1.54-1.29 (m, 2H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (75.6 mg, 69.98 μmol, 32.57% yield, 96% purity) as a yellow solid. MS(M+H)+=1037.4.
- 1H NMR (400 MHz, DMSO-d6) δ=11.09 (s, 1H), 8.30 (s, 1H), 8.24 (d, J=13.3 Hz, 1H), 8.06 (s, 1H), 7.96 (dd, J1=3.0, J2=7.5 Hz, 1H), 7.57 (dd, J1=7.2, J2=8.5 Hz, 1H), 7.20 (d, J=6.7 Hz, 1H), 7.13 (d, J=8.5 Hz, 1H), 7.03 (d, J=7.0 Hz, 1H), 6.64-6.54 (m, 1H), 5.05 (dd, J1=5.3, J2=12.9 Hz, 1H), 4.82 (br t, J=7.5 Hz, 1H), 4.24 (br d, J=11.9 Hz, 1H), 4.13 (br d, J=12.5 Hz, 2H), 4.10-3.95 (m, 3H), 3.91 (s, 3H), 3.79 (br d, J=12.8 Hz, 1H), 3.63-3.59 (m, 2H), 3.58-3.50 (m, 12H), 3.46 (br d, J=6.0 Hz, 2H), 3.33 (s, 3H), 3.09 (br t, J=11.9 Hz, 1H), 2.93-2.83 (m, 1H), 2.80-2.71 (m, 1H), 2.62-2.55 (m, 2H), 2.06-1.91 (m, 3H), 1.89-1.78 (m, 2H), 1.77-1.65 (m, 2H), 1.68-1.56 (m, 4H), 1.55-1.45 (m, 1H), 1.44-1.33 (m, 1H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (170 μmol, 0.2 mg, 163.19 μmol, 49.11% yield, 91% purity) as a light yellow solid. MS(M+H)+=948.3
- 1H NMR (400 MHz, DMSO-d6) δ 11.10 (s, 1H), 8.31 (s, 1H), 8.25 (d, J=13.4 Hz, 1H), 8.04 (s, 1H), 7.87 (dd, J=3.4, 7.5 Hz, 1H), 7.69 (br t, J=5.9 Hz, 1H), 7.62-7.54 (m, 1H), 7.21-7.11 (m, 2H), 7.04 (d, J=7.0 Hz, 1H), 6.61 (t, J=5.6 Hz, 1H), 5.09-5.03 (m, 1H), 4.87-4.77 (m, 1H), 4.08 (br t, J=13.7 Hz, 2H), 3.92 (s, 3H), 3.80-3.68 (m, 1H), 3.64-3.58 (m, 2H), 3.53-3.46 (m, 4H), 3.31-3.28 (m, 2H), 2.96-2.85 (m, 3H), 2.81-2.75 (m, 2H), 2.61-2.53 (m, 4H), 2.17 (t, J=10.6 Hz, 2H), 2.06-1.92 (m, 3H), 1.83-1.50 (m, 11H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (53.8 mg, 50.89 μmol, 15.79% yield, 98% purity) as a light yellow solid. MS(M+H)+=1036.6
- 1H NMR (400 MHz, DMSO-d6) δ 11.08 (br s, 1H), 8.30 (s, 1H), 8.25 (d, J=13.3 Hz, 1H), 8.03 (s, 1H), 7.88 (dd, J=3.5, 7.5 Hz, 1H), 7.65 (t, J=5.7 Hz, 1H), 7.60-7.54 (m, 1H), 7.19 (d, J=6.7 Hz, 1H), 7.13 (d, J=8.7 Hz, 1H), 7.03 (d, J=7.0 Hz, 1H), 6.59 (t, J=5.6 Hz, 1H), 5.10-5.02 (m, 1H), 4.87-4.77 (m, 1H), 4.08 (t, J=13.9 Hz, 2H), 3.91 (s, 3H), 3.80-3.69 (m, 1H), 3.65-3.59 (m, 2H), 3.58-3.53 (m, 4H), 3.53-3.48 (m, 4H), 3.47-3.40 (m, 4H), 3.34 (s, 3H), 3.28-3.22 (m, 2H), 2.93-2.84 (m, 3H), 2.82-2.75 (m, 2H), 2.62-2.55 (m, 2H), 2.17 (t, J=10.9 Hz, 2H), 2.06-1.93 (m, 3H), 1.85-1.58 (m, 10H).
-
- To a mixture of 4-bromobutanoic acid (5 g, 29.94 mmol) and phenylmethanol (4.21 g, 38.92 mmol, 4.05 mL) in cyclohexane (50 mL) was added TsOH (257.79 mg, 1.50 mmol) in one portion at 20° C. and the resulting mixture was stirred at 90° C. for 16 h. LCMS showed starting material was consumed completely and no peak with desired mass was detected. TLC (SiO2, Petroleum ether:Ethyl acetate=5:1) indicated starting material was consumed completely and two new spots were detected. The reaction mixture was concentrated in vacuum. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=1/0 to 10/1) to afford the titled compound (6.5 g, 25.28 mmol, 84.43% yield) as a yellow oil.
- 1H NMR (400 MHz, CDCl3) δ=7.46-7.32 (m, 5H), 5.17 (s, 2H), 3.49 (t, J=6.5 Hz, 2H), 2.59 (t, J=7.2 Hz, 2H), 2.18-2.25 (m, 2H).
- To a mixture of benzyl 4-bromobutanoate (6.5 g, 25.28 mmol) and tert-butyl piperidin-4-ylcarbamate (7.59 g, 37.92 mmol) in dioxane (60 mL) were added NaI (378.93 mg, 2.53 mmol) and DIPEA (9.80 g, 75.84 mmol, 13.21 mL) in one portion at 20° C. and the resulting mixture was stirred at 80° C. for 16 h. LCMS showed all starting material was consumed completely and one peak with desired mass was detected. The reaction mixture was concentrated in vacuum. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=1/1 to 0/1 to Dichloromethane:Methanol=1/0 to 10/1) to afford the titled compound (6.8 g, 16.26 mmol, 64.30% yield, 90% purity) as a yellow solid. MS(M+H)+=377.4
- To a solution of benzyl 4-(4-((tert-butoxycarbonyl)amino)piperidin-1-yl)butanoate (3.4 g, 9.03 mmol) in MeOH (40 mL) was added Pd/C (340 mg, 10% purity) under N2. The suspension was degassed under vacuum and purged with H2 several times. The mixture was stirred under H2 (15 psi) at 20° C. for 16 h. LCMS showed starting material was consumed completely and one peak with desired mass was detected. The reaction mixture was diluted with MeOH (40 mL) and filtered. The filtrate was concentrated in vacuum to afford the titled compound (2.7 g, crude) as a white oil. MS(M+H)+=287.2
- To a mixture of 4-amino-2-(2, 6-dioxo-3-piperidyl) isoindoline-1,3-dione (1.5 g, 5.49 mmol) and 4-(4-((tert-butoxycarbonyl)amino)piperidin-1-yl)butanoic acid (2.04 g, 7.14 mmol) in DMF (15 mL) were added T3P (20.96 g, 32.94 mmol, 19.59 mL, 50% purity in EtOAc solution) and Py (4.34 g, 54.90 mmol, 4.43 mL) in one portion at 20° C. and the resulting mixture was stirred at 80° C. for 16 h. LCMS showed 4-amino-2-(2, 6-dioxo-3-piperidyl) isoindoline-1,3-dione was consumed completely and one peak with desired mass was detected. The reaction mixture was diluted with H2O (30 mL) and extracted with EtOAc (30 mL×3). The organic layer was washed with brine (30 mL×3), dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=1/1 to 0/1 to Dichloromethane/Methanol=1/0 to 10/1) to afford the titled compound (825 mg, 1.49 mmol, 27.19% yield, 98% purity) as a yellow solid. MS(M+H)+=542.2
- To a mixture of t tert-butyl (1-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-4-oxobutyl)piperidin-4-yl)carbamate (825 mg, 1.52 mmol) in dioxane (5 mL) was added HCl/dioxane (4 M, 10 mL) in one portion at 20° C. and the resulting mixture was stirred at 20° C. for 1 h. TLC (SiO2, Dichloromethane:Methanol=10:1) indicated starting material was consumed completely and one new spot was detected. The reaction mixture was concentrated in vacuum to afford the titled compound (730 mg, crude, HCl) as an off-white solid.
- To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (200 mg, 429.71 μmol) in DMF (3 mL) were added HATU (179.73 mg, 472.69 μmol) and DIPEA (111.08 mg, 859.43 μmol, 149.70 μL). The mixture was stirred at 20° C. for 10 min and a solution of 4-(4-aminopiperidin-1-yl)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)butanamide (246.62 mg, crude, HCl) in DMF (3 mL) and DIPEA (111.08 mg, 859.43 μmol, 149.70 μL) were added and the resulting mixture was stirred at 20° C. for 1 h. LCMS showed all starting material was consumed completely and one peak with desired mass was detected. The reaction mixture was diluted with H2O (10 mL) and extracted with EtOAc (10 mL×3). The organic layer was dried over Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (column: Phenomenex luna C18 150*40 mm*15 um; mobile phase: [water (0.225% FA)-ACN]; B %: 17%-47%, 10 min) and then lyophilized to afford the titled compound (116.9 mg, 124.94 μmol, 29.07% yield, 95% purity) as a white solid. MS(M+H)+=888.7
- 1H NMR (400 MHz, DMSO-d6) δ=11.16 (s, 1H), 9.71 (s, 1H), 8.48 (d, J=8.3 Hz, 1H), 8.30-8.25 (m, 1H), 8.22 (d, J=5.5 Hz, 1H), 8.04 (s, 1H), 7.91-7.77 (m, 2H), 7.61 (d, J=7.2 Hz, 1H), 7.18 (d, J=6.7 Hz, 1H), 5.19-5.10 (m, 1H), 4.89-4.75 (m, 1H), 4.13-4.02 (m, 2H), 3.91 (s, 3H), 3.81-3.63 (m, 2H), 3.33 (s, 3H), 2.94-2.81 (m, 3H), 2.69-2.54 (m, 3H), 2.38-2.32 (m, 2H), 2.09-1.93 (m, 5H), 1.81-1.46 (m, 12H)
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (230.9 mg, 239.45 umol, 46.44% yield, 98% purity) as a light yellow solid. MS (M+H)+=945.6
- 1H NMR (400 MHz, CD3OD) δ 8.69-8.63 (m, 1H), 8.35-8.28 (m, 1H), 8.23 (s, 1H), 7.81 (dd, J=7.4, 8.4 Hz, 1H), 7.63-7.58 (m, 1H), 7.37 (d, J=6.5 Hz, 1H), 5.20-5.12 (m, 1H), 5.07-5.00 (m, 1H), 4.13 (t, J=12.9 Hz, 2H), 4.01 (s, 3H), 3.72-3.63 (m, 2H), 3.42 (s, 3H), 3.23-3.08 (m, 4H), 2.96-2.85 (m, 1H), 2.83-2.71 (m, 2H), 2.55 (t, J=7.3 Hz, 2H), 2.30 (d, J=14.6 Hz, 2H), 2.22-2.05 (m, 4H), 1.94-1.71 (m, 12H), 1.55-1.42 (m, 6H)
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (202.8 mg, 221.31 μmol, 51.50% yield, 97% purity) as a yellow solid. MS(M+H)+=889.0
- 1H NMR (400 MHz, CD3OD) δ=8.39 (d, J=14.0 Hz, 1H), 8.20 (s, 1H), 7.56 (dd, J=7.2, 8.6 Hz, 1H), 7.32 (d, J=6.6 Hz, 1H), 7.12 (d, J=8.4 Hz, 1H), 7.04 (d, J=7.0 Hz, 1H), 5.04 (dd, J=5.0, 12.2 Hz, 1H), 4.49 (d, J=11.8 Hz, 1H), 4.18-4.10 (m, 1H), 4.07-4.00 (m, 2H), 3.98 (s, 3H), 3.52-3.41 (m, 2H), 3.40 (s, 3H), 3.25-3.17 (m, 1H), 2.89-2.79 (m, 2H), 2.78-2.68 (m, 2H), 2.54 (t, J=6.7 Hz, 2H), 2.15-1.92 (m, 8H), 1.87-1.62 (m, 7H), 1.58-1.44 (m, 2H)
-
- To a solution of ethyl 4-hydroxybenzoate (3 g, 18.05 mmol) and benzyl (2-bromoethyl)carbamate (4.19 g, 16.25 mmol) in MeCN (70 mL) was added K2CO3 (4.99 g, 36.11 mmol). The reaction mixture was heated to 85° C. for 4 hr. LCMS showed one peak (69%) with desired mass. The reaction mixture was diluted with H2O (150 mL) and extracted with EtOAc (150 Ml×2). The combined organic layer was washed with NaOH (100 mL, 3M), dried over Na2SO4, filtered. The filtrate was concentrated in vacuo to afford the titled compound (5 g, 14.56 mmol, 80.66% yield) as a white solid. MS(M+H)+=344.1
- To a solution of ethyl 4-(2-(((benzyloxy)carbonyl)amino)ethoxy)benzoate (5 g, 14.56 mmol) in THF (80 mL) was added LiAlH4 (718.47 mg, 18.93 mmol) at 0° C. portion-wise. The reaction mixture was stirred at 20° C. for 2 hr. One main peak showed on LCMS. The reaction mixture was quenched with H2O (0.8 mL), NaOH (0.8 mL, 15% solution) and H2O (2.4 mL). The suspension was diluted with THF (120 mL), dried over Na2SO4, filtered. The filtrate was concentrated in vacuo. The residue was purified by column chromatography (SiO2, PE/EtOAc=30%˜50%) to afford the titled compound (2.2 g, 7.15 mmol, 49.14% yield, 98% purity) as a white solid. MS(M-OH+H)+=284.1
- To a mixture of benzyl (2-(4-(hydroxymethyl)phenoxy)ethyl)carbamate (1.5 g, 4.98 mmol) in DCM (15 mL) was added SOCl2 (710.65 mg, 5.97 mmol, 433.33 μL) in one portion at 20° C. and the resulting mixture was stirred at 20° C. for 2 h. LCMS showed 75% of starting material remained and a peak (21%) with desired mass. Additional SOCl2 (710.65 mg, 5.97 mmol, 433.33 μL) was added and the resulting mixture was stirred at 20° C. for another 2 h. LCMS showed 70% of starting material remained. Additional SOCl2 (710.65 mg, 5.97 mmol, 433.33 μL) was added and the resulting mixture was continue to stir at 20° C. for 16 h. TLC (SiO2, Petroleum ether:Ethyl acetate=1:1) indicated starting material was consumed completely and one new spot was detected. The reaction mixture was concentrated in vacuum to afford the titled compound (1.6 g, crude) as a white solid. MS(M+Na)+=342.3
- To a mixture of benzyl (2-(4-(chloromethyl)phenoxy)ethyl)carbamate (1.6 g, 5.00 mmol) and tert-butyl piperidin-4-ylcarbamate (1.20 g, 6.00 mmol) in ACN (20 mL) was added K2CO3 (2.07 g, 15.01 mmol) in one portion at 20° C. and the resulting mixture was stirred at 60° C. for 2 h. LCMS showed all starting material was consumed completely and one peak with desired mass was detected. The reaction mixture was concentrated in vacuum. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=5/1 to 0/1) to afford the titled compound (2.3 g, 4.71 mmol, 94.10% yield, 99% purity) as a white solid. MS(M+H)+=484.4
- To a mixture of tert-butyl N-[1-[[4-[2-(benzyloxycarbonylamino) ethoxy]phenyl]methyl]-4-piperidyl]carbamate (1 g, 2.07 mmol) in dioxane (5 mL) was added HCl/dioxane (4 M, 10 mL) in one portion at 20° C. and the resulting mixture was stirred at 20° C. for 2 h. LCMS showed starting material was consumed completely and one peak with desired mass was detected. The reaction mixture was concentrated in vacuum to afford the titled compound (890 mg, crude, HCl salt) as a white solid. MS(M+H)+=384.2
- To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (0.5 g, 1.07 mmol) in DMF (5 mL) were added HATU (449.32 mg, 1.18 mmol) and DIPEA (277.69 mg, 2.15 mmol, 374.24 μL), the mixture was stirred at 20° C. for 10 min and a solution of benzyl (2-(4-((4-aminopiperidin-1-yl)methyl)phenoxy)ethyl)carbamate (541.37 mg, 1.29 mmol, HCl salt) in DMF (5 mL) with DIPEA (277.69 mg, 2.15 mmol, 374.24 μL) were added and the resulting mixture was stirred at 20° C. for 1 h. LCMS showed all starting material was consumed completely and one peak with desired mass was detected. The reaction mixture was diluted with H2O (20 mL) and extracted with EtOAc (20 mL×3). The organic layer was washed with brine (20 mL×3), dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=1/1 to 0/1 to Dichloromethane/Methanol=1/0 to 10/1) to afford the titled compound (612 mg, 714.46 μmol, 66.51% yield, 97% purity) as a white oil. MS(M+H)+=831.1
- To a mixture of benzyl (2-(4-((4-(4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzamido)piperidin-1-yl)methyl)phenoxy)ethyl)carbamate (612 mg, 736.56 μmol) in ACN (10 mL) was added TMSI (221.07 mg, 1.10 mmol, 150.39 μL) in one portion at 20° C. and the resulting mixture was stirred at 20° C. for 2 h. LCMS showed starting material was consumed completely and one peak with desired mass. To the reaction mixture was added TEA (223.59 mg, 2.21 mmol, 307.56 μL) and stirred at 20° C. for 1 h. The reaction mixture was concentrated in vacuo. The residue was purified by prep-HPLC (column: Phenomenex luna C18 150*40 mm*15 um; mobile phase: [water (0.225% FA)-ACN]; B %: 10%-40%, 10 min) and the eluent was lyophilized to afford the titled compound (393 mg, 547.12 μmol, 74.28% yield, 97% purity) as a white solid. MS(M+H)+=697.2
- To a mixture of 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (150 mg, 543.05 μmol) and N-(1-(4-(2-aminoethoxy)benzyl)piperidin-4-yl)-4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzamide (378.37 mg, 543.05 μmol) in DMSO (5 mL) was added TEA (164.85 mg, 1.63 mmol, 226.75 μL) in one portion and the resulting mixture was stirred at 80° C. for 16 h. LCMS showed all starting material was consumed completely and one peak with desired mass was detected. The reaction mixture was diluted with H2O (12 mL) and extracted with EtOAc (12 mL×3). The organic layer was washed with brine (12 mL×3), dried over Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (column: Phenomenex luna C18 150*40 mm*15 um; mobile phase: [water (0.225% FA)-ACN]; B %: 18%-48%, 10 min) and the eluent was lyophilized to afford the titled compound (30 mg, 29.59 μmol, 5.45% yield, 94% purity) as a yellow solid. MS(M+H)+=953.3
- 1H NMR (400 MHz, CD3OD) δ=8.41 (d, J=14.1 Hz, 1H), 8.22 (s, 1H), 7.59 (dd, J=7.2, 8.5 Hz, 1H), 7.35-7.28 (m, 3H), 7.20 (d, J=8.6 Hz, 1H), 7.09 (d, J=7.1 Hz, 1H), 6.97 (d, J=8.7 Hz, 2H), 5.07 (br dd, J=5.5, 12.5 Hz, 1H), 4.97-4.93 (m, 1H), 4.24 (t, J=5.1 Hz, 2H), 4.05 (br t, J=13.5 Hz, 2H), 4.00 (s, 3H), 3.79-3.64 (m, 4H), 3.42 (s, 3H), 3.12-3.01 (m, 2H), 2.89-2.70 (m, 2H), 2.54-2.29 (m, 2H), 2.22-1.96 (m, 6H), 1.90-1.64 (m, 9H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (112.4 mg, 92.44 μmol, 20.80% yield, 95% purity, TFA salt) as a yellow solid. MS(M+H)+=1042.1.
- 1H NMR (400 MHz, CD3OD) δ=8.32 (d, J=13.7 Hz, 1H), 8.24-8.22 (m, 1H), 7.55 (dd, J1=8.5 Hz, J2=7.2 Hz, 1H), 7.43-7.31 (m, 3H), 7.14-7.07 (m, 1H), 7.07-6.97 (m, 3H), 5.07-4.99 (m, 2H), 4.33-4.23 (m, 2H), 4.22-4.05 (m, 5H), 4.03-3.97 (m, 3H), 3.93-3.85 (m, 2H), 3.78-3.68 (m, 6H), 3.62-3.46 (m, 4H), 3.42 (s, 3H), 3.20-3.03 (m, 2H), 2.91-2.78 (m, 1H), 2.75-2.70 (m, 1H), 2.34-2.20 (m, 2H), 2.19-2.00 (m, 4H), 1.92-1.67 (m, 8H).
-
- To a mixture of ethyl 2-(4-bromophenyl)acetate (10 g, 41.14 mmol) and potassium; trifluoro (vinyl) boranuide (6.61 g, 49.36 mmol) in H2O (20 mL) and dioxane (100 mL) were added K2CO3 (17.06 g, 123.41 mmol) and Pd(dppf) Cl2 (1.50 g, 2.06 mmol) in one portion at 20° C. under N2. The suspension was degassed under vacuum and purged with N2 several times and the resulting mixture was stirred at 100° C. for 16 h. LCMS showed all starting material was consumed completely and one peak with desired mass was detected. TLC (SiO2, Petroleum ether:Ethyl acetate=10:1) indicated ethyl 2-(4-bromophenyl)acetate was consumed completely and two new spots were detected. The reaction mixture was diluted with H2O (100 mL) and extracted with EtOAc (100 mL×3). The organic layer dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=1/0 to 100/1) to afford the titled compound (5.3 g, 25.91 mmol, 62.99% yield, 93% purity) as a yellow oil. MS(M+H)+=191.5
- To a mixture of ethyl 2-(4-vinylphenyl)acetate (2.3 g, 12.09 mmol) in THF (20 mL) was added BH3·Me2S (10 M, 1.81 mL) drop-wise at 0° C. under N2 and the resulting mixture was stirred at 20° C. for 2 h. TLC (SiO2, Petroleum ether:Ethyl acetate=5:1) indicated starting material was consumed completely and one major new spot was detected. Then H2O (8.28 g, 459.61 mmol, 8.28 mL), NaOH (3 M, 4.60 mL) and H2O2 (9.77 g, 86.17 mmol, 8.28 mL, 30% purity) were added sequentially to this reaction at 0° C. and the resulting mixture was allowed to stir another 2 h at 20° C. TLC (SiO2, Petroleum ether:Ethyl acetate=5:1) indicated starting material was consumed completely and four new spots were detected. The reaction mixture was quenched with saturated Na2SO3 (50 mL) and extracted with EtOAc (50 mL×3). The organic layer was dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=10/1 to 5/1) to afford the titled compound (1.2 g, 4.84 mmol, 40.03% yield, 84% purity) as a white oil. MS(M+H)+=209.2
- To a mixture of ethyl 2-(4-(2-hydroxyethyl)phenyl)acetate (1.2 g, 4.84 mmol, 84% purity) in DCM (12 mL) were added TEA (1.47 g, 14.52 mmol, 2.02 mL) and TosCl (1.38 g, 7.26 mmol) in one portion at 20° C. and the resulting mixture was stirred at 20° C. for 16 h. LCMS showed ethyl 2-(4-(2-hydroxyethyl)phenyl)acetate was consumed completely and one peak with desired mass was detected. TLC (SiO2, Petroleum ether:Ethyl acetate=5:1) indicated ethyl 2-(4-(2-hydroxyethyl)phenyl)acetate was consumed completely and three new spots were detected. The reaction mixture was concentrated in vacuum. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=10/1 to 5/1) to afford ethyl 2-(4-(2-(tosyloxy)ethyl)phenyl)acetate (1.7 g, 4.60 mmol, 94.97% yield, 98% purity) as a white solid. MS(M+NH4)+=380.2
- To a mixture of ethyl 2-(4-(2-(tosyloxy)ethyl)phenyl)acetate (1.7 g, 4.69 mmol) and tert-butyl N-(4-piperidyl) carbamate (1.88 g, 9.38 mmol) in dioxane (10 mL) were added NaI (140.61 mg, 938.09 μmol) and DIPEA (1.82 g, 14.07 mmol, 2.45 mL) in one portion at 20° C. and the resulting mixture was stirred at 60° C. for 16 h. LCMS showed ethyl 2-(4-(2-(tosyloxy)ethyl)phenyl) acetate remained and one peak with desired mass was detected. TLC (SiO2, Petroleum ether:Ethyl acetate=1:3) indicated ethyl 2-(4-(2-(tosyloxy)ethyl)phenyl) acetate remained and four new spots were detected. The reaction mixture was concentrated in vacuum. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=2/1 to 1/3) to afford the titled compound (1.36 g, 3.27 mmol, 69.79% yield, 94% purity) as a white solid. MS(M+H)+=391.4
- To a mixture of ethyl 2-(4-(2-(4-((tert-butoxycarbonyl)amino)piperidin-1-yl)ethyl)phenyl)acetate (600 mg, 1.54 mmol) in EtOH (6 mL) and THF (6 mL) was added NaOH (2 M, 1.54 mL) in one portion at 20° C. and the resulting mixture was stirred at 20° C. for 1 h. LCMS showed starting material was consumed completely and one peak with desired mass was detected. HCl (12 N) was added to this reaction mixture to adjust the pH=7 at 0° C. The reaction mixture was concentrated in vacuum to afford the titled compound (710 mg, crude) as a white solid. MS(M−H)+=361.0
- To a mixture of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (400 mg, 1.46 mmol) and 2-(4-(2-(4-((tert-butoxycarbonyl)amino)piperidin-1-yl)ethyl) phenyl)acetic acid (689.79 mg, 1.90 mmol) in DMF (5 mL) were added T3P (2.79 g, 8.78 mmol, 50% purity EtOAc in solution, 2.61 mL) and Py (1.16 g, 14.64 mmol, 1.18 mL) in one portion at 20° C. and the resulting mixture was stirred at 80° C. for 16 h. LCMS showed all starting material was consumed completely and one peak with desired mass was detected. TLC (SiO2, Dichloromethane:Methanol=10:1) indicated all starting material was consumed completely and one major new spot was detected. The reaction mixture was diluted with H2O (15 mL) and extracted with EtOAc (15 mL×3). The organic layer was washed with brine (15 mL×3), dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=1/1 to 0/1 to Dichloromethane/Methanol=1/0 to 10/1) to afford the titled compound (618 mg, 930.47 μmol, 63.56% yield, 93% purity) as a yellow solid. MS(M+H)+=618.2
- To a mixture of tert-butyl (1-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-2-oxoethyl)phenethyl)piperidin-4-yl)carbamate (615 mg, 995.64 μmol) in dioxane (3 mL) was added HCl/dioxane (4 M, 9 mL) in one portion at 20° C. and the resulting mixture was stirred at 20° C. for 16 h. LCMS showed starting material was consumed completely and one peak with desired mass was detected. The reaction mixture was concentrated in vacuum to afford the titled compound (556 mg, crude, HCl) as a white solid. MS(M+H)+=518.2
- To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (250 mg, 537.14 μmol) in DMF (3 mL) were added HATU (224.66 mg, 590.86 μmol) and DIPEA (138.84 mg, 1.07 mmol, 187.12 μL). The mixture was stirred at 20° C. for 10 min and a solution of 24442-(4-aminopiperidin-1-yl)ethyl)phenyl)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)acetamide (357.12 mg, crude, HCl) in DMF (3 mL) and DIPEA (138.84 mg, 1.07 mmol, 187.12 μL, 2 eq) were added and the resulting mixture was stirred at 20° C. for 1 h. LCMS showed all starting material was consumed completely and one peak with desired mass was detected. The reaction mixture was diluted with H2O (15 mL) and extracted with EtOAc (15 mL×3). The organic layer was washed with brine (15 mL×3), dried over Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (column: Phenomenex luna C18 150*40 mm*15 um; mobile phase: [water (0.225% FA)-ACN]; B %: 20%-50%, 10 min) and then lyophilized to the titled compound (132.9 mg, 130.84 μmol, 24.36% yield, 95% purity) as a off-white solid. MS(M+H)+=965.2
- 1H NMR (400 MHz, DMSO-d6) δ=11.33-10.96 (m, 1H), 9.79 (s, 1H), 8.49 (d, J=8.4 Hz, 1H), 8.30 (s, 1H), 8.24 (d, J=13.6 Hz, 1H), 8.03 (s, 1H), 7.88 (dd, J=3.2, 7.2 Hz, 1H), 7.82 (t, J=7.9 Hz, 1H), 7.60 (d, J=7.2 Hz, 1H), 7.31-7.25 (m, 2H), 7.23-7.16 (m, 3H), 5.12 (dd, J=5.4, 12.8 Hz, 1H), 4.85-4.77 (m, 1H), 4.07 (t, J=13.9 Hz, 2H), 3.91 (s, 3H), 3.85-3.68 (m, 4H), 3.33 (s, 3H), 2.94-2.84 (m, 3H), 2.76-2.56 (m, 4H), 2.11-1.93 (m, 5H), 1.85-1.48 (m, 11H)
-
- To a solution of methyl 1H-imidazole-4-carboxylate (10 g, 79.29 mmol) in CH3CN (200 mL) were added K2CO3 (35 g, 253.25 mmol) and 3-bromopropoxy-tert-butyl-dimethyl-silane (25.78 g, 101.80 mmol). The mixture was stirred at 25° C. for 16 h. LCMS showed a main peak with desired mass. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=10:1-0:1) to afford the titled compound (8.2 g, 27.20 mmol, 34.30% yield, 99% purity) as a light yellow oil. MS (M+H)+=299.1
- To a solution of methyl 1-(3-((tert-butyldimethylsilyl)oxy)propyl)-1H-imidazole-4-carboxylate (6.5 g, 21.78 mmol) in dioxane (20 mL) was added HCl/dioxane (4 M, 86.67 mL) at 25° C. The mixture was stirred at 25° C. for 16 h. LCMS showed a main peak with the desired mass. The reaction mixture was concentrated under reduced pressure to afford the titled compound (4.0 g, crude) as a light yellow oil. MS (M+H)+=185.2
- To a solution of methyl 1-(3-hydroxypropyl)-1H-imidazole-4-carboxylate (4 g, 21.72 mmol) in DCM (50 mL) was added TEA (18.18 g, 179.61 mmol, 25 mL) and TosCl (13.33 g, 69.94 mmol) at 25° C. The mixture was stirred at 25° C. for 16 h. LCMS showed 26% peak with the desired mass. The reaction mixture was concentrated under reduced pressure to give a residue. Then H2O (40 mL) was added, the mixture was extracted with EtOAc (80 mL×3), the combined organic layers were washed with brine 180 ml (60 mL×3), dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, Petroleum ether:Ethyl acetate=5:1˜0:1) to afford the titled compound (4.5 g, 13.30 mmol, 61.24% yield) as a light yellow oil. MS (M+H)+=339.2
- To a solution of methyl 1-(3-(tosyloxy)propyl)-1H-imidazole-4-carboxylate (2 g, 5.91 mmol) in dioxane (40 mL) were added NaI (400.00 mg, 2.67 mmol), DIPEA (2.97 g, 22.96 mmol, 4.00 mL) and tert-butyl piperidin-4-ylcarbamate (2.00 g, 9.99 mmol) at 25° C. The mixture was stirred at 80° C. for 16 h. LCMS showed 56% peak with the desired mass. The reaction mixture was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Waters Xbridge BEH C18 250*50 mm*10 um; mobile phase: [water (10 mM NH4HCO3)-ACN]; B %: 10%-40%, 25 min, Column Temp: 30° C.) followed by lyophilization to afford the titled compound (1.5 g, 4.09 mmol, 69.25% yield) as a light yellow oil. MS (M+H)+=367.1.
- To a solution of methyl 1-(3-(4-((tert-butoxycarbonyl)amino)piperidin-1-yl)propyl)-1H-imidazole-4-carboxylate (1.5 g, 4.09 mmol) in THF (20 mL) was added LiAlH4 (300 mg, 7.90 mmol) at −20° C. The mixture was stirred at 20° C. for 3 hr. LCMS showed main peak with the mass [M+Li] was detected. The reaction mixture was quenched with H2O (2 mL) and NaOH solution (15%, 3 mL) at 0° C., then Na2SO4 (25 g) was added, the mixture was filtered and the filtrate was concentrated under reduced pressured to afford the titled compound (1.3 g, crude) as a light yellow oil. MS (M+Li)+=345.1.
- To a solution of tert-butyl (1-(3-(4-(hydroxymethyl)-1H-imidazol-1-yl)propyl)piperidin-4-yl)carbamate (1.3 g, 3.84 mmol) in THF (30 mL) were added DPPA (2.54 g, 9.23 mmol, 2 mL) and DBU (2.02 g, 13.27 mmol, 2 mL) at 0° C. The mixture was stirred at 25° C. for 16 h under N2 atmosphere. LCMS showed 32% peak with the desired mass. To the reaction mixture was added H2O (20 mL), the mixture was extracted with EtOAc (50 mL×2), the combined organic layers were washed with brine (30 mL×3), dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, Ethyl acetate:Methanol=1:0-3:1) to afford the titled compound (850 mg, 2.34 mmol, 60.88% yield) as a light yellow oil. MS (M+H)+=364.1
- To a solution of tert-butyl (1-(3-(4-(azidomethyl)-1H-imidazol-1-yl)propyl)piperidin-4-yl)carbamate (680 mg, 1.87 mmol, 1 eq) in THF (30 mL) was added Pd/C (200 mg, 10% purity) at 25° C. The mixture was stirred at 25° C. for 16 h under H2 atmosphere (15 Psi). LCMS showed 40% peak with the desired mass. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure to afford the titled compound (600 mg, crude) as a light yellow oil. MS (M+H)+=338.3
- To a solution of tert-butyl (1-(3-(4-(aminomethyl)-1H-imidazol-1-yl)propyl)piperidin-4-yl)carbamate (600 mg, 1.78 mmol) in DMSO (15 mL) were added TEA (727.00 mg, 7.18 mmol, 1 mL) and 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (400 mg, 1.45 mmol) at 25° C. The mixture was stirred at 100° C. for 16 h under N2 atmosphere. LCMS showed 33% peak with the desired mass. To the reaction mixture was added H2O (20 mL), the mixture was extracted with EtOAc (30 mL×2), the combined organic layers were washed with brine (30 mL×3), dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, DCM/MeOH=30/1˜10/1) to afford the titled compound (400 mg, 673.77 μmol, 37.90% yield) as a light yellow oil. MS (M+H)+=594.5
- To a solution of tert-butyl (1-(3-(4-(((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)methyl)-1H-imidazol-1-yl)propyl)piperidin-4-yl)carbamate (400 mg, 673.77 μmol) in dioxane (10 mL) was added HCl/dioxane (4 M, 10 mL) at 25° C. The mixture was stirred at 25° C. for 16 h under N2 atmosphere. LCMS showed 62% peak with the desired mass. The reaction mixture was concentrated under reduced pressure to afford the titled compound (350 mg, crude, 2HCl) as a light yellow solid. MS (M+H)+=494.4
- To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (200 mg, 429.71 μmol) in DMF (4 mL) were added HATU (400 mg, 1.05 mmol), DIPEA (445.20 mg, 3.44 mmol, 600 μL) and 4 #(1-(3-(4-aminopiperidin-1-yl)propyl)-1H-imidazol-4-yl)methyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (300 mg, 529.59 μmol, 2HCl) at 25° C. The mixture was stirred at 25° C. for 16 h under N2 atmosphere. LCMS showed 39% peak with the desired mass. To the reaction mixture was added H2O (10 mL), the mixture was extracted with EtOAc (30 mL×2), the combined organic layers were washed with brine (30 mL×3), dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure. The residue was purified by prep-HPLC (column: Waters Xbridge 150*25 mm*5 um; mobile phase: [water (10 mM NH4HCO3)-ACN]; B %: 42%-62%, 9 min, Column Temp: 30° C.) followed by lyophilization to afford the titled compound (84.7 mg, 83.71 μmol, 19.48% yield, 93% purity) as a light yellow solid. MS (M+H)+=941.7
- 1H NMR (400 MHz, DMSO-d6) δ 11.08 (br s, 1H), 8.31 (s, 1H), 8.25 (d, J=13.3 Hz, 1H), 8.04 (s, 1H), 7.87 (dd, J=3.1, 7.7 Hz, 1H), 7.61-7.50 (m, 2H), 7.23-7.14 (m, 2H), 7.09 (s, 1H), 7.04 (d, J=7.0 Hz, 1H), 6.89 (t, J=5.8 Hz, 1H), 5.05 (dd, J=5.5, 12.7 Hz, 1H), 4.86-4.77 (m, 1H), 4.40-4.33 (m, 2H), 4.08 (t, J=13.9 Hz, 2H), 3.97-3.93 (m, 2H), 3.92 (s, 3H), 3.80-3.59 (m, 1H), 3.34 (s, 3H), 2.95-2.83 (m, 1H), 2.81-2.73 (m, 2H), 2.62-2.54 (m, 2H), 2.22-2.14 (m, 2H), 2.06-1.87 (m, 6H), 1.83-1.72 (m, 5H), 1.64-1.47 (m, 6H)
-
- To a solution of 2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethyl 4-methylbenzenesulfonate (2 g, 3.88 mmol) in DMF (20 mL) was added NaN3 (450 mg, 6.92 mmol). The mixture was stirred at 70° C. for 16 h. LCMS showed main peak with the desired mass. The reaction mixture was poured into H2O (20 mL) and extracted with EA (30 mL×3). The combined organic layer was washed with brine (30 mL×3). The organic layer was dried over Na2SO4, filtrated and concentrated to afford the titled compound (1.40 g, crude) as a light yellow solid. MS(M+H)+=387.1
- 1H NMR (400 MHz, DMSO-d6) δ 11.15 (s, 1H), 7.64 (dd, J=7.2, 8.4 Hz, 1H), 7.21 (d, J=8.6 Hz, 1H), 7.10 (d, J=7.0 Hz, 1H), 6.68 (t, J=5.9 Hz, 1H), 5.15-5.05 (m, 1H), 3.74-3.66 (m, 4H), 3.55 (q, J=5.5 Hz, 2H), 3.49-3.43 (m, 2H), 2.99-2.89 (m, 1H), 2.69-2.57 (m, 2H), 2.12-2.04 (m, 1H).
- To a solution of tert-butyl (1-(prop-2-yn-1-yl)piperidin-4-yl)carbamate (900 mg, 3.78 mmol) in MeOH (20 mL) was added CuSO4 (750 mg, 4.70 mmol, 721.15 μL), sodium L-ascorbate (1 g, 5.05 mmol) and 4-((2-(2-azidoethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (1.2 g, 3.11 mmol) at 25° C. The mixture was stirred at 25° C. for 16 h. LCMS showed 90% peak with the desired mass. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure. The residue was purified by prep-HPLC (column: Phenomenex Synergi Max-RP 250*50 mm*10 um; mobile phase: [water (10 mM NH4HCO3)-ACN]; B %: 32%-62%, 14 min, Column Temp: 30° C.) followed by lyophilization to afford the titled compound (1.5 g, 2.40 mmol, 63.59% yield) as a light yellow solid. MS(M+H)+=625.5
- To a solution of tert-butyl (1-((1-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methyl)piperidin-4-yl)carbamate (500 mg, 800.40 μmol) in dioxane (10 mL) was added HCl/dioxane (4 M, 10 mL). The mixture was stirred at 25° C. for 16 h. LCMS showed 82% peak with the desired mass. The reaction mixture was concentrated to give a residue to afford the titled compound (450 mg, crude, 2HCl) as a light yellow solid.
- MS(M+H)+=525.4
- To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (200 mg, 429.71 μmol) in DMF (4 mL) were added HATU (400 mg, 1.05 mmol), DIPEA (445.20 mg, 3.44 mmol, 600 μL) and 4-((2-(2-(4-((4-aminopiperidin-1-yl)methyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (350 mg, 585.78 μmol, 2HCl). The mixture was stirred at 25° C. for 16 h. LCMS showed 46% peak with the desired mass. To the reaction mixture was added H2O (10 mL), the mixture was extracted with EtOAc (30 mL×2), the combined organic layers were washed with brine 90 mL (30 mL×3), dried over anhydrous Na2SO4, filtered and the filtrate was concentrated under reduced pressure. The residue was purified by prep-HPLC (column: 3_Phenomenex Luna C18 75*30 mm*3 um; mobile phase: [water (0.1% TFA)-ACN]; B %: 32%-52%, 7 min, Column Temp: 30° C.) followed by lyophilization to the titled compound (101.3 mg, 0.0886 mmol, 20.62% yield, 95% purity, TFA) as a light yellow solid. MS(M+H)+=972.7
- 1H NMR (400 MHz, DMSO-d6) δ 11.12 (s, 1H), 9.95-9.72 (m, 1H), 8.35-8.08 (m, 5H), 7.58 (t, J=7.8 Hz, 1H), 7.17-7.05 (m, 2H), 6.56 (s, 1H), 5.11-5.06 (m, 1H), 4.88-4.79 (m, 1H), 4.62 (t, J=4.9 Hz, 2H), 4.44-4.36 (m, 2H), 4.13-4.06 (m, 1H), 3.94-3.92 (m, 2H), 3.91 (s, 3H), 3.89-3.88 (m, 2H), 3.68-3.60 (m, 2H), 3.51-3.43 (m, 4H), 3.33 (s, 3H), 3.12-2.91 (m, 2H), 2.68-2.55 (m, 2H), 2.16-1.83 (m, 6H), 1.78-1.53 (m, 8H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (75.3 mg, 66.77 μmol, 15.54% yield, 94% purity, TFA) as a light yellow solid.
- MS(M+H)+=1060.8
- 1H NMR (400 Mhz, DMSO-d6) δ 11.10 (s, 1H), 9.91-9.71 (m, 1H), 8.32-8.09 (m, 5H), 7.62-7.53 (m, 1H), 7.16-7.04 (m, 2H), 6.60 (s, 1H), 5.06 (dd, J=5.2, 13.0 Hz, 1H), 4.89-4.79 (m, 1H), 4.62-4.55 (m, 2H), 4.48-4.39 (m, 2H), 4.09 (t, J=13.9 Hz, 1H), 3.94-3.92 (m, 2H), 3.91-3.89 (m, 3H), 3.86-3.82 (m, 2H), 3.64-3.61 (m, 2H), 3.56-3.44 (m, 12H), 3.34 (s, 3H), 3.14-2.90 (m, 2H), 2.67-2.53 (m, 2H), 2.11-1.91 (m, 6H), 1.78-1.55 (m, 8H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (42.5 mg, 36.85 μmol, 8.58% yield, 94% purity, TFA) as a white solid. MS(M+H)+=970.2
- 1H NMR (400 MHz, DMSO-d6) δ=11.15 (s, 1H), 9.93-9.67 (m, 2H), 8.39 (d, J=8.2 Hz, 1H), 8.30 (d, J=5.8 Hz, 1H), 8.28-8.17 (m, 2H), 8.11 (s, 1H), 7.84 (t, J=7.8 Hz, 1H), 7.64 (d, J=7.4 Hz, 1H), 7.23-7.15 (m, 1H), 5.13 (dd, J=5.2, 12.8 Hz, 1H), 4.85-4.79 (m, 1H), 4.52 (t, J=7.0 Hz, 2H), 4.46-4.39 (m, 2H), 4.13-4.09 (m, 1H), 4.08 (t, J=13.8 Hz, 2H), 4.02-3.93 (m, 2H), 3.91 (s, 3H), 3.33 (s, 3H), 3.30-3.03 (m, 4H), 2.65-2.53 (m, 4H), 2.22-2.12 (m, 2H), 2.10-2.00 (m, 2H), 2.00-1.90 (m, 2H), 1.80-1.68 (m, 4H), 1.66-1.56 (m, 4H)
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (7.5 mg, 7.46 μmol, 3.19% yield, 98% purity) as yellow solid. MS(M+H)+=985.3
- 1H NMR (400 MHz, CDCl3) δ=8.45-8.28 (m, 1H), 8.13-7.97 (m, 2H), 7.58-7.48 (m, 2H), 7.26-7.22 (m, 1H), 7.18 (d, J=7.3 Hz, 1H), 7.15-7.10 (m, 1H), 7.07 (d, J=7.3 Hz, 1H), 6.87-6.74 (m, 1H), 5.02-4.81 (m, 2H), 4.63-4.45 (m, 2H), 4.41-5.36 (m, 1H), 4.34-4.21 (m, 2H), 4.13-4.02 (m, 1H), 4.00-3.86 (m, 6H), 3.85-3.71 (m, 3H), 3.44-3.41 (m, 3H), 2.91-2.71 (m, 3H), 2.28-2.22 (m, 2H), 2.24-2.07 (m, 3H), 1.80-1.78 (m, 4H), 1.68-1.59 (m, 7H).
-
- A solution of 3-oxabicyclo[3.1.0]hexane-2,4-dione (5 g, 44.61 mmol) in NH3·H2O (50 mL) was stirred at 20° C. for 16 h in a 100 mL of sealed tube. TLC (SiO2, Petroleum ether: Ethyl acetate=1:2) indicated starting material was consumed completely and one new spot was detected. The reaction mixture was concentrated in vacuum to afford (1R, 2S)-2-carbamoylcyclopropanecarboxylic acid (6.2 g, crude) as an off-white solid.
- 1H NMR (400 MHz, DMSO-d6) δ=8.37 (br s, 1H), 6.82-6.38 (m, 2H), 1.71-1.63 (m, 1H), 1.59-1.50 (m, 1H), 1.20-1.10 (m, 1H), 1.10-1.00 (m, 1H)
- To a mixture of (1R, 2S)-2-carbamoylcyclopropanecarboxylic acid (6.2 g, 48.02 mmol) in THF (100 mL) was added BH3·Me2S (10 M, 48.02 mL) drop-wise at 20° C. under N2 and the resulting mixture was stirred at 60° C. for 16 h. The reaction mixture was quenched with HCl (1 N) and the reaction mixture was stirred at 60° C. for 4 h. NaOH (2 M, 72.03 mL) and CbzCl (12.29 g, 72.03 mmol, 10.24 mL) were added to this reaction mixture at 20° C. and the reaction mixture was stirred at 60° C. for 12 h. LCMS showed all starting material was consumed completely and peak with desired mass was detected. The reaction mixture was diluted with H2O (100 mL) and extracted with EtOAc (100 mL×3). The organic layer was dried over Na2SO4, filtered and concentrated. The crude product was purified by reversed-phase HPLC (method: FA) and then lyophilized to afford to the titled compound (5.4 g, 22.49 mmol, 46.84% yield, 98% purity) as a white oil. MS(M+Na)+=258.4
- To a mixture of benzyl (((1S,2R)-2-(hydroxymethyl)cyclopropyl)methyl)carbamate (2.7 g, 11.48 mmol) in DCM (30 mL) were added TEA (3.48 g, 34.43 mmol, 4.79 mL) and TosCl (3.28 g, 17.21 mmol) in one portion at 20° C. and the resulting mixture was stirred at 20° C. for 16 h. LCMS showed all starting material was consumed completely and one peak with desired mass was detected. The reaction mixture was concentrated in vacuum. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=5/1 to 0/1) to afford to the titled compound (2.4 g, 6.16 mmol, 53.70% yield) as a yellow oil. MS(M+Na)+=412.1
- To a mixture of ((1R, 2S)-2-((((benzyloxy)carbonyl)amino)methyl)cyclopropyl)methyl 4-methylbenzenesulfonate and tert-butyl N-(4-piperidyl)carbamate (1.60 g, 8.01 mmol) in dioxane (30 mL) were added DIPEA (2.39 g, 18.49 mmol, 3.22 mL) and NaI (184.74 mg, 1.23 mmol) in one portion at 20° C. and the resulting mixture was stirred at 80° C. for 16 h. LCMS showed ((1R, 2S)-2-((((benzyloxy)carbonyl)amino)methyl)cyclopropyl)methyl 4-methylbenzenesulfonate was consumed completely and one peak with desired mass was detected. The reaction mixture was concentrated in vacuum. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=1/1 to 0/1) to afford to the titled compound (1.4 g, 3.15 mmol, 51.15% yield, 94% purity) as a white oil. MS(M+H)+=418.3
- To a solution of tert-butyl N-[1-[[2-(benzyloxycarbonylaminomethyl)cyclopropyl]methyl]-4-piperidyl]carbamate (1.40 g, 3.35 mmol) in MeOH (15 mL) was added Pd/C (0.2 g, 10% purity) under N2. The suspension was degassed under vacuum and purged with H2 several times. The mixture was stirred under H2 (15 psi) at 20° C. for 16 h. LCMS showed starting material was consumed completely and one peak with desired mass was detected. The reaction mixture was diluted with MeOH (60 mL) and filtrated. The filtrate was concentrated in vacuum to afford to the titled compound (920 mg, crude) as a white oil. MS(M+H)+=284.3
- To a mixture of 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (0.8 g, 2.90 mmol) and tert-butyl (1-(((1R, 2S)-2-(aminomethyl)cyclopropyl)methyl) piperidin-4-yl)carbamate (902.90 mg, 3.19 mmol) in DMSO (5 mL) was added TEA (879.20 mg, 8.69 mmol, 1.21 mL) in one portion at 20° C. and the resulting mixture was stirred at 80° C. for 16 h. LCMS showed 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione was consumed completely and one peak with desired mass was detected. The reaction mixture was diluted with H2O (15 mL) and extracted with EtOAc (15 mL×3). The organic layer was washed with brine (15 mL×3), dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=10/1 to 1/4) to afford to the titled compound (850 mg, 1.56 mmol, 53.84% yield, 99% purity) as a green solid. MS(M+H)+=540.2
- To a mixture of tert-butyl (1-(((1R,2S)-2-(((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)methyl)cyclopropyl)methyl)piperidin-4-yl)carbamate (850 mg, 1.58 mmol) in dioxane (4 mL) was added HCl/dioxane (4 M, 8 mL, 20.32 eq) in one portion at 20° C. and the resulting mixture was stirred at 20° C. for 1 h. LCMS showed starting material was consumed completely and one peak with desired mass was detected. The reaction mixture was concentrated in vacuum to afford to the titled compound (760 mg, crude, HCl) as a green solid. MS(M+H)+=440.3
- To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (200 mg, 429.71 μmol) in DMF (4 mL) were added HATU (163.39 mg, 429.71 μmol) and DIPEA (111.08 mg, 859.43 μmol, 149.70 μL). The mixture was stirred at 20° C. for 10 min and a solution of 4-((((1S,2R)-2-((4-aminopiperidin-1-yl)methyl)cyclopropyl)methyl)amino)-2-(2, 6-dioxopiperidin-3-yl)isoindoline-1,3-dione (226.63 mg, crude, HCl) in DMF (4 mL) and DIPEA (111.08 mg, 859.43 μmol, 149.70 μL) was added drop-wise at 20° C. and the resulting mixture was stirred at 20° C. for 1 h. LCMS showed all starting material was consumed completely and one peak with desired mass was detected. The reaction mixture was diluted with H2O (12 mL) and extracted with EtOAc (12 mL×3). The organic layer was dried over Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (column: Phenomenex luna C18 150*40 mm*15 um; mobile phase: [water (0.1% TFA)-ACN]; B %: 30%-40%, 10 min) and re-purified by prep-HPLC (column: 3_Phenomenex Luna C18 75*30 mm*3 um; mobile phase: [water (0.1% TFA)-ACN]; B %: 34%-54%, 7 min) and then lyophilized to afford to the titled compound (104 mg, 100.79 μmol, 23.45% yield, 97% purity, TFA) as a yellow solid. MS(M+H)+=887.2
- 1H NMR (400 MHz, CD3OD) δ=8.33 (d, J=13.6 Hz, 1H), 8.21 (s, 1H), 7.64-7.57 (m, 1H), 7.38-7.34 (m, 1H), 7.16-7.08 (m, 2H), 5.12-5.06 (m, 1H), 5.04-4.91 (m, 2H), 4.25-4.14 (m, 1H), 4.09 (t, J=13.0 Hz, 2H), 4.00 (s, 3H), 3.79 (d, J=12.4 Hz, 1H), 3.60-3.45 (m, 2H), 3.40 (s, 3H), 3.29-3.12 (m, 4H), 2.94-2.82 (m, 1H), 2.79-2.66 (m, 2H), 2.38-2.19 (m, 2H), 2.17-2.05 (m, 3H), 1.99-1.67 (m, 8H), 1.64-1.53 (m, 1H), 1.36-1.26 (m, 1H), 1.17-1.11 (m, 1H), 0.59-0.51 (m, 1H)
-
- A solution of 2-(2-aminoethoxy) ethanol (7 g, 66.58 mmol, 6.67 mL) in ethyl formate (32.24 g, 435.15 mmol, 35.00 mL) was stirred at 90° C. for 12 h. LCMS showed that the reaction was completed. The mixture was combined with the pilot (0.5 g scale) and concentrated to afford to the titled compound (8 g, 60.08 mmol, 90.24% yield) as yellow oil.
- MS(M+H)+=134.1
- To the mixture of LAH (2.57 g, 67.60 mmol) in THF (100 mL) was added a solution of N-(2-(2-hydroxyethoxy) ethyl) formamide (6 g, 45.06 mmol) in THF (10 mL) and the resulting mixture was stirred at 20° C. for 3 h. TLC (Ethyl acetate/Methanol=10/1) showed that the reaction was completed. The mixture was quenched with water (2.5 mL), 2.5 mL 15% NaOH in water and water (7.5 mL) sequently. The mixture was stirred at 25° C. for 30 min, the mixture was filtered and the filtrate was concentrated under vacuum to afford to the titled compound (9.7 g, crude) as yellow oil.
- To the mixture of 2-(2-(methylamino) ethoxy) ethanol (9.7 g, 81.40 mmol) and K2CO3 (22.50 g, 162.80 mmol) in THF (40 mL) and H2O (20 mL) was added CbzCl (20.83 g, 122.10 mmol, 17.36 mL) and the resulting mixture was stirred at 20° C. for 12 h. LCMS showed that the reaction was completed. The mixture was combined with the pilot (1.3 g scale) and poured into water (100 mL) and extracted with EtOAc (50 mL×3), the combined organic layer was washed with brine (50 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column (Petroleum ether/Ethyl acetate=1/1) to the titled compound (7.6 g, 30.00 mmol, 36.86% yield) as yellow oil.
- To the mixture of benzyl (2-(2-hydroxyethoxy)ethyl)(methyl)carbamate (7.6 g, 30.00 mmol) and TEA (9.11 g, 90.01 mmol, 12.53 mL) in DCM (50 mL) was added TosCl (8.58 g, 45.01 mmol) and the resulting mixture was stirred at 20° C. for 12 h. LCMS showed that the reaction was completed. The mixture was concentrated under vacuum. The residue was purified by silica gel chromatography (Petroleum ether/Ethyl acetate=2/1) to the titled compound (7.6 g, 14.92 mmol, 49.73% yield, 80% purity) as yellow oil. MS(M+H)+=408.1
- To the mixture of 2-(2-(((benzyloxy)carbonyl)(methyl)amino)ethoxy)ethyl 4-methylbenzenesulfonate (4 g, 7.85 mmol, 80% purity) and tert-butyl piperidin-4-ylcarbamate (2.36 g, 11.78 mmol) in Dioxane (20 mL) were added NaI (117.71 mg, 785.31 μmol) and DIPEA (2.03 g, 15.71 mmol, 2.74 mL) and the resulting mixture was stirred at 80° C. for 12 h. LCMS showed that the reaction was completed. The mixture was concentrated under vacuum. The residue was purified by silica gel chromatography (Ethyl acetate) to afford the titled compound (1.8 g, 4.05 mmol, 51.57% yield, 98% purity) as yellow oil. MS(M+H)+=436.1
- To the solution of benzyl (2-(2-(4-((tert-butoxycarbonyl)amino)piperidin-1-yl)ethoxy)ethyl)(methyl)carbamate (1.8 g, 4.13 mmol) in MeOH (20 mL) was added Pd/C (0.2 g, 4.13 mmol, 10% purity) and the resulting mixture was stirred at 20° C. for 12 h under H2 (15 psi). LCMS showed that the reaction was completed. The mixture was filtered and concentrated to afford the titled compound (1.2 g, 3.98 mmol, 96.33% yield) as brown oil. MS(M+H)+=302.2
- To the solution of tert-butyl (1-(2-(2-(methylamino)ethoxy)ethyl)piperidin-4-yl)carbamate (1 g, 3.32 mmol) and benzyl (2-bromoethyl) carbamate (1.03 g, 3.98 mmol) in dioxane (4 mL) were added NaI (49.73 mg, 331.76 μmol) and DIPEA (857.55 mg, 6.64 mmol, 1.16 mL) and the resulting mixture was stirred at 80° C. for 12 h. LCMS showed that the reaction was completed. The mixture was combined with the pilot (0.2 g scale) and concentrated. The residue was purified by reserved phase column (method: FA, MeCN/water) to afford the titled compound (0.9 g, 1.77 mmol, 53.28% yield, 94% purity) as red oil. MS(M+H)+=479.4
- To the solution of tert-butyl N-[1-[2-[2-[2-(benzyloxycarbonylamino)ethyl-methylamino]ethoxy]ethyl]-4-piperidyl]carbamate (0.9 g, 1.88 mmol) in MeOH (10 mL) was added Pd/C (0.1 g, 10% purity) and the resulting mixture was stirred at 20° C. for 12 h under H2 (15 psi). LCMS showed that the reaction was completed. The mixture was filtered and concentrated to afford the titled compound (0.5 g, 1.45 mmol, 77.19% yield) as yellow oil. MS(M+H)+=345.2
- To the solution of 2-(2, 6-dioxo-3-piperidyl)-4-fluoro-isoindoline-1,3-dione (0.3 g, 1.09 mmol) and tert-butyl (1-(2-(2-((2-aminoethyl)(methyl)amino)ethoxy)ethyl)piperidin-4-yl)carbamate (340 mg, 986.96 μmol) in DMSO (5 mL) was added TEA (329.70 mg, 3.26 mmol, 453.51 μL) and the resulting mixture was stirred at 60° C. for 12 h. TLC (Ethyl acetate/Methanol=10/1) showed that the reaction was completed. The mixture was combined with the pilot (50 mg scale) and poured into water (30 mL) and extracted with EtOAc (20 mL×3), the combined organic layer was dried over Na2SO4, filtered and concentrated. The residue was purified by silica gel column (Ethyl acetate/Methanol=10/1) to afford the titled compound (0.12 g, 193.77 μmol, 17.84% yield, 97% purity) as yellow oil. MS(M+H)+=601.3
- To the mixture of tert-butyl (1-(2-(2-((2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)(methyl)amino)ethoxy)ethyl)piperidin-4-yl)carbamate (120 mg, 199.77 μmol) in dioxane (5 mL) was added HCl/dioxane (4 M, 5 mL) and the resulting mixture was stirred at 20° C. for 1 h. LCMS showed that the reaction was completed. The mixture was concentrated to afford the titled compound (110 mg, crude, HCl) as yellow oil.
- To the solution of 4-((2-((2-(2-(4-aminopiperidin-1-yl)ethoxy)ethyl)(methyl)amino)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (110 mg, 204.82 μmol, HCl) and 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (95.33 mg, 204.82 μmol) in DMF (3 mL) were HATU (155.76 mg, 409.65 μmol) and DIPEA (105.89 mg, 819.29 μmol, 142.71 μL) and the mixture was stirred at 20° C. for 1 h. LCMS showed that the reaction was completed. the mixture was poured into water (20 mL) and extracted with EtOAc (20 mL×3), the combined organic layer was washed with brine (50 mL), dried over Na2SO4, filtered and concentrated, the residue was purified by prep-HPLC (column: Unisil 3-100 C18 μLtra 150*50 mm*3 um; mobile phase: [water (0.225% FA)-ACN]; B %: 30%-50%, 10 min) and the eluant was lyophilized. The solid was dissolved in DMF, the mixture was adjusted pH=8 by DIPEA and the resulting mixture was re-purified by prep-HPLC (column: Waters Xbridge 150*25 mm*5 um; mobile phase: [water (10 mM NH4HCO3)-ACN]; B %: 43%-76%, 8 min) followed by prep-TLC (Ethyl acetate/Methanol=6/1) to afford the titled compound (10.7 mg, 10.61 μmol, 15.03% yield, 94% purity) as yellow solid.
- MS(M+H)+=948.3
- 1H NMR (400 MHz, DMSO-d6) δ=11.09 (s, 1H), 8.30 (s, 1H), 8.24 (d, J=13.2 Hz, 1H), 8.03 (s, 1H), 7.86-7.84 (m, 1H), 7.58-7.56 (m, 1H), 7.18 (d, J=7.2 Hz, 1H), 7.08 (d, J=8.8 Hz, 1H), 7.02 (d, J=6.8 Hz, 1H), 6.75-6.71 (m, 1H), 5.07-5.04 (m, 1H), 4.84-4.79 (m, 1H), 4.11-4.03 (m, 3H), 3.91 (s, 3H), 3.73-3.65 (m, 2H), 3.52-3.45 (m, 4H), 2.91-2.80 (m, 3H), 2.65-2.58 (m, 2H), 2.58-2.55 (m, 4H), 2.45-2.42 (m, 2H), 2.26 (s, 3H), 2.01-1.98 (m, 6H), 1.77-1.72 (m, 5H), 1.70-1.60 (m, 4H), 1.49-1.41 (m, 3H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (69 mg, 69.37 μmol, 18.18% yield, 94% purity) as a yellow solid. MS(M+H)+=935.4.
- 1H NMR (400 MHz, CDCl3) δ=8.29 (d, J=14.9 Hz, 1H), 8.00 (s, 1H), 7.74 (s, 1H), 7.54 (d, J=8.3 Hz, 1H), 7.48 (d, J=7.2 Hz, 1H), 6.97-6.91 (m, 1H), 6.71 (dd, J=2.1, 8.3 Hz, 1H), 6.68-6.60 (m, 1H), 5.33-5.24 (m, 1H), 4.88-4.72 (m, 2H), 4.04-3.92 (m, 1H), 3.90 (s, 3H), 3.87-3.80 (m, 2H), 3.67 (t, J=5.0 Hz, 2H), 3.62-3.53 (m, 6H), 3.37-3.30 (m, 5H), 2.91-2.61 (m, 5H), 2.56 (t, J=5.4 Hz, 2H), 2.27-2.11 (m, 2H), 2.08-1.95 (m, 5H), 1.77-1.63 (m, 5H), 1.55-1.47 (m, 3H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (45.6 mg, 36.89 μmol, 9.03% yield, 92% purity, TFA salt) as a brown solid. MS(M+H)+=1023.3.
- 1H NMR (400 MHz, CD3OD) δ=8.29 (d, J=13.8 Hz, 1H), 8.23-8.15 (m, 1H), 7.55-7.53 (m, 1H), 7.36 (d, J=6.7 Hz, 1H), 7.01 (d, J=1.9 Hz, 1H), 6.83 (dd, J1=8.4 Hz, J2=2.1 Hz, 1H), 5.05-5.00 (m, 2H), 4.09 (t, J=13.1 Hz, 3H), 4.01-3.95 (m, 3H), 3.83-3.79 (m, 2H), 3.74-3.62 (m, 16H), 3.53-3.46 (m, 1H), 3.44-3.35 (m, 7H), 3.19-3.13 (m, 1H), 2.92-2.81 (m, 1H), 2.75-2.70 (m, 1H), 2.35-2.21 (m, 2H), 2.18-2.02 (m, 4H), 1.98-1.77 (m, 4H), 1.78-1.67 (m, 4H).
-
- The mixture of 3-iodophthalic acid (25 g, 85.61 mmol) in Ac2O (100 mL) was stirred at 80° C. for 16 hours. LCMS showed the reaction was completed. The reaction mixture was concentrated in vacuum. The crude product was washed with petrol ether (40 mL×5) and dried in vacuum to afford the titled compound (22.4 g, crude) as white solid. MS(M+Na)+=296.2
- To a solution of 4-iodoisobenzofuran-1,3-dione (10 g, 36.49 mmol) in AcOH (100 mL) was added 3-aminopiperidine-2, 6-dione (6.61 g, 40.14 mmol, HCl), NaOAc (3.59 g, 43.79 mmol) in one portion and the mixture was stirred at 140° C. for 16 hours. TLC (EtOAc) indicated that the reaction was completed. The reaction mixture was filtered and the cake was washed with H2O (100 mL×3), the cake was dried in vacuum to afford the titled compound (13 g, crude) as black solid.
- 1H NMR (400 MHz, DMSO-d6) δ=11.2 (s, 1H), 8.27 (d, J=7.6, 1H), 7.92 (d, J=7.2, 1H), 7.58 (d, J=7.6, 1H), 5.18-5.14 (m, 1H), 2.96-2.83 (m, 1H), 2.63-2.53 (m, 2H), 2.09-2.05 (m, 1H).
- To a mixture of 2-(2,6-dioxopiperidin-3-yl)-4-iodoisoindoline-1,3-dione (2 g, 5.21 mmol) and 2-[2-[2-(2-prop-2-ynoxyethoxy) ethoxy]ethoxy]ethanol (1.81 g, 7.81 mmol) in DMF (20 mL) were added Pd(PPh3)2Cl2 (380.97 mg, 520.67 μmol), CuI (198.32 mg, 1.04 mmol) and TEA (5.27 g, 52.07 mmol, 7.25 mL) and the mixture was stirred at 60° C. for 0.5 h under microwave under N2. LCMS indicated that the reaction was completed. The reaction mixture was concentrated. The residue was purified by silica gel column (EtOAc) to afford the titled compound (2 g, 4.09 mmol, 78.64% yield) as yellow oil. MS(M+H)+=489.1
- To a mixture of 2-(2,6-dioxopiperidin-3-yl)-4-(1-hydroxy-3,6,9,12-tetraoxapentadec-14-yn-15-yl)isoindoline-1,3-dione (2 g, 4.09 mmol) and TEA (1.24 g, 12.28 mmol, 1.71 mL) in DCM (10 mL) was added TosCl (1.17 g, 6.14 mmol) and the mixture was stirred at 20° C. for 16 hours. LCMS indicated the reaction was completed. The reaction mixture was concentrated. The residue was purified by silica gel column (EtOAc) to afford the titled compound (1.8 g, 2.49 mmol, 60.88% yield, 89% purity) as yellow oil. MS (M+H)+=643.1
- To the solution of 15-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-3,6,9,12-tetraoxapentadec-14-yn-1-yl 4-methylbenzenesulfonate (1 g, 1.56 mmol) and tert-butyl piperidin-4-ylcarbamate (467.45 mg, 2.33 mmol) in dioxane (10 mL) were added NaI (23.32 mg, 155.60 μmol) and DIPEA (402.21 mg, 3.11 mmol, 542.06 μL) and the resulting mixture was stirred at 80° C. for 12 hours. TLC (Ethyl acetate/Methanol=10/1) showed that the reaction was completed. The mixture was concentrated and the residue was purified by silica gel column (Ethyl acetate/Methanol=10/1) to afford the titled compound (0.9 g, 1.29 mmol, 82.78% yield, 96% purity) as yellow oil.
- MS(M+H)+=671.2
- To the solution of tert-butyl (1-(15-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-3,6,9,12-tetraoxapentadec-14-yn-1-yl)piperidin-4-yl)carbamate (0.9 g, 1.34 mmol) in dioxane (10 mL) was added HCl/dioxane (4 M, 10 mL) and the resulting mixture was stirred at 25° C. for 2 h. LCMS showed that the reaction was completed. The mixture was concentrated under vacuum to afford 4-(1-(4-aminopiperidin-1-yl)-3,6,9,12-tetraoxapentadec-14-yn-15-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (0.8 g, 1.32 mmol, 98.21% yield, HCl) as yellow oil. MS(M+H)+=571.2
- To the solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (300 mg, 644.57 μmol), 4-(1-(4-aminopiperidin-1-yl)-3,6,9,12-tetraoxapentadec-14-yn-15-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (391.32 mg, 644.57 μmol, HCl) and HATU (490.17 mg, 1.29 mmol) in DMF (4 mL) was added DIPEA (249.91 mg, 1.93 mmol, 336.81 μL) and the resulting mixture was stirred at 25° C. for 12 hours. LCMS showed that the reaction was completed. The mixture was poured into water (20 mL) and extracted with EtOAc (20 mL×3), the combined organic layer was washed with brine (50 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (column: Phenomenex luna C18 150*40 mm*15 um; mobile phase: [water (0.225% FA)-ACN]; B %: 27%-57%, 10 min) and the eluant was lyophilized to afford the titled compound (229.4 mg, 218.57 μmol, 33.91% yield, 97% purity) as yellow solid. MS(M+H)+=1018.6
- 1H NMR (400 MHz, DMSO-d6) δ=11.15 (s, 1H), 9.38-9.09 (m, 1H), 8.30 (s, 1H), 8.28-8.08 (m, 3H), 7.94-7.83 (m, 3H), 7.26-7.14 (m, 1H), 5.16 (dd, J=5.3, 12.8 Hz, 1H), 4.83 (t, J=7.9 Hz, 1H), 4.55-4.47 (m, 2H), 4.10 (t, J=13.8 Hz, 2H), 4.04-3.96 (m, 1H), 3.94-3.89 (m, 3H), 3.80-3.70 (m, 4H), 3.64-3.53 (m, 12H), 3.34 (s, 3H), 3.27 (d, J=4.6 Hz, 2H), 3.12 (d, J=12.0 Hz, 1H), 2.95-2.85 (m, 1H), 2.65-2.54 (m, 2H), 2.10-2.04 (m, 2H), 1.98 (d, J=5.4 Hz, 3H), 1.87-1.70 (m, 4H), 1.57-1.47 (m, 4H).
- To the solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(15-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-3,6,9,12-tetraoxapentadec-14-yn-1-yl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide (70 mg, 68.76 μmol) in EtOAc (5 mL) was added Pd/C (20 mg, 10% purity) and the resulting mixture was stirred at 25° C. for 12 hours under H2 (15 psi). LCMS showed that the reaction was completed. The mixture was combined with the pilot (50 mg scale) and filtered and the filtrate was concentrated, the residue was purified by prep-HPLC (column: Phenomenex Synergi C18 150*25 mm*10 um; mobile phase: [water (0.225% FA)-ACN]; B %: 19%-49%, min) and the eluant was lyophilized to afford the titled compound (23 mg, 21.60 μmol, 31.42% yield, 96% purity, FA salt) as white solid. MS(M+H)+=1022.7
- 1H NMR (400 MHz, DMSO-d6) δ=11.12 (s, 1H), 8.30 (s, 1H), 8.24 (t, J=6.6 Hz, 2H), 8.03 (s, 1H), 7.87 (dd, J=3.3, 7.6 Hz, 1H), 7.80-7.73 (m, 2H), 7.72-7.69 (m, 1H), 7.19 (d, J=6.8 Hz, 1H), 5.18-5.04 (m, 1H), 4.87-4.76 (m, 1H), 4.08 (t, J=13.9 Hz, 2H), 3.91 (s, 3H), 3.79-3.67 (m, 1H), 3.53-3.48 (m, 18H), 3.34 (s, 3H), 3.10-3.03 (m, 2H), 2.95-2.80 (m, 4H), 2.65-2.53 (m, 2H), 2.48-2.45 (m, 2H), 2.11-2.03 (m, 2H), 1.99-1.93 (m, 2H), 1.89-1.82 (m, 2H), 1.80-1.71 (m, 4H), 1.61-1.52 (m, 4H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (36.2 mg, 36.35 μmol, 6.29% yield, 98% purity, FA salt) as white solid. MS(M+H)+=930.3.
- 1H NMR (400 MHz, CD3OD) δ=8.49 (br s, 1H), 8.40 (d, J=14.2 Hz, 1H), 8.21 (s, 1H), 7.86-7.74 (m, 3H), 7.30 (d, J=6.8 Hz, 1H), 5.15-5.11 (m, 1H), 4.98-4.96 (m, 1H), 4.66-5.47 (m, 2H), 4.55 (s, 2H), 4.08-3.99 (m, 5H), 3.97-3.92 (m, 1H), 3.91-3.74 (m, 5H), 3.51 (d, J=11.8 Hz, 2H), 3.41 (s, 3H), 3.25-3.16 (m, 2H), 3.07-2.94 (m, 2H), 2.94-2.83 (m, 1H), 2.81-2.64 (m, 2H), 2.18-2.09 (m, 4H), 1.90-1.77 (m, 4H), 1.76-1.65 (m, 4H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (118.1 mg, 121.39 umol, 42.33% yield, 96% purity) as white solid. MS(M+H)+=934.7.
- 1H NMR (400 MHz, DMSO-d6) δ=11.13 (s, 1H), 8.30 (s, 1H), 8.24 (d, J=13.2 Hz, 1H), 8.03 (s, 1H), 7.90-7.84 (m, 1H), 7.81-7.72 (m, 2H), 7.72-7.65 (m, 1H), 7.18 (d, J=6.8 Hz, 1H), 5.16-5.08 (m, 1H), 4.87-4.77 (m, 1H), 4.07 (t, J=13.8 Hz, 2H), 3.91 (s, 3H), 3.76-3.66 (m, 1H), 3.54-3.45 (m, 6H), 3.42 (t, J=6.4 Hz, 2H), 3.33 (s, 3H), 3.07 (t, J=7.6 Hz, 2H), 2.97-2.77 (m, 3H), 2.67-2.51 (m, 3H), 2.45 (t, J=5.8 Hz, 2H), 2.06-1.93 (m, 4H), 1.89-1.80 (m, 2H), 1.79-1.68 (m, 4H), 1.67-1.50 (m, 6H).
-
- To a solution of 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetic acid (6.95 g, 20.93 mmol) and 2-(2-aminoethoxy) ethanol (2.0 g, 19.02 mmol, 1.90 mL) in DMF (20 mL) were added EDCI (5.47 g, 28.53 mmol), HOBt (3.86 g, 28.53 mmol) and TEA (11.55 g, 114.14 mmol, 15.89 mL) and the mixture was stirred at 25° C. for 12 h. LCMS showed that the reaction was completed. The mixture was concentrated in vacuo. The residue was purified by reversed-phase HPLC (0.1% FA condition, MeCN, water) to afford 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)-N-(2-(2-hydroxyethoxy)ethyl)acetamide (5.6 g, 13.35 mmol, 70.19% yield) as gray solid. MS(M+H)+=420.0
- To a solution of 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)-N-(2-(2-hydroxyethoxy)ethyl)acetamide (2.5 g, 5.96 mmol) in DCM (20 mL) were added TEA (723.84 mg, 7.15 mmol, 995.65 μL) and TosCl (1.36 g, 7.15 mmol) and the mixture was stirred at 25° C. for 12 h. LCMS showed that the reaction was completed. The mixture was filtered and the filtrate was diluted with H2O (20 mL) and extracted with DCM (50 mL×3). The combined organic layers were washed with brine (15 mL), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (25 g SepaFlash® Silica Flash Column, Eluent of 20˜60% Ethyl acetate/Petroleum ether gradient @ 60 mL/min) to afford the titled compound (2.0 g, 4.77 mmol, 80.00% yield) as gray solid. MS(M+H)+=574.0
- To a solution of 2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)ethoxy)ethyl 4-methylbenzenesulfonate (350 mg, 610.21 μmol) and tert-butyl piperidin-4-ylcarbamate (183.32 mg, 915.32 μmol) in dioxane (5 mL) were added NaI (9.15 mg, 61.02 μmol) and DIPEA (78.87 mg, 610.21 μmol, 106.29 μL) and the resulting mixture was stirred at 60° C. for 24 h. LCMS showed that the reaction was completed. The reaction mixture was diluted with H2O (20 mL) and extracted with EtOAc (20 mL×3), the combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (12 g SepaFlash® Silica Flash Column, Eluent of 30˜100% Ethyl acetate/Petroleum ether gradient @ 60 mL/min) to afford the titled compound (166 mg, 275.91 μmol, 45.22% yield) as white solid.
- MS(M+H)+=602.2
- To a solution of tert-butyl (1-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)ethoxy)ethyl)piperidin-4-yl)carbamate (166 mg, 275.91 μmol) in dioxane (2 mL) was added HCl/dioxane (4 M, 3 mL) and the resulting mixture was stirred at 25° C. for 2 h. TLC (EA/MeOH=10:1) showed that the reaction was completed. The mixture was concentrated to afford the titled compound (150 mg, crude, HCl) as white solid.
- MS(M+H)+=502.2
- To the solution of N-(2-(2-(4-aminopiperidin-1-yl)ethoxy)ethyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide (150 mg, 278.81 umol, HCl) and 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (129.77 mg, 278.81 umol) in DMF (3 mL) were added HATU (212.03 mg, 557.63 umol) and DIPEA (108.10 mg, 836.44 umol, 145.69 μL) and the resulting mixture was stirred at 20° C. for 1 h. LCMS showed that the reaction was completed. The mixture was poured into water (20 mL) and extracted with EtOAc (20 mL×3), the combined organic layer was washed with brine (50 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (column: Unisil 3-100 C18 μLtra 150*50 mm*3 um; mobile phase: [water (0.225% FA)-ACN]; B %: 28%-48%, 10 min) and the eluant was lyophilized to afford the titled compound (114 mg, 118.93 umol, 42.66% yield, 99% purity, FA) as yellow solid. MS(M+H)+=949.2.
- 1H NMR (400 MHz, DMSO-d6) δ=11.13 (s, 1H), 9.19 (br s, 1H), 8.31 (s, 1H), 8.27 (d, J=13.2 Hz, 1H), 8.14 (s, 1H), 8.06 (s, 1H), 8.01 (t, J=5.5 Hz, 1H), 7.83 (dd, J=7.5, 8.4 Hz, 1H), 7.52 (d, J=7.2 Hz, 1H), 7.43 (d, J=8.6 Hz, 1H), 7.18 (s, 1H), 5.18-5.06 (m, 1H), 4.89-4.77 (m, 3H), 4.09 (t, J=13.9 Hz, 2H), 3.92 (s, 4H), 3.75 (s, 2H), 3.55 (t, J=5.4 Hz, 2H), 3.43-3.37 (m, 3H), 3.34 (s, 3H), 3.29-3.05 (m, 3H), 2.96-2.84 (m, 1H), 2.65-2.52 (m, 5H), 2.13-1.93 (m, 5H), 1.82-1.55 (m, 7H).
-
- To a solution of 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetic acid (1.89 g, 5.69 mmol) and 2-(2-(2-(2-aminoethoxy)ethoxy)ethoxy)ethanol (1 g, 5.17 mmol) in DMF (10 mL) were added EDCI (1.49 g, 7.76 mmol), HOBt (1.05 g, 7.76 mmol) and TEA (3.14 g, 31.05 mmol, 4.32 mL) and the resulting mixture was stirred at 25° C. for 16 h. LCMS showed that the reaction was completed. The mixture was purified by reversed-phase column (0.1% FA condition, MeCN/water) to afford the titled compound (1.63 g, 3.18 mmol, 61.45% yield, 99% purity) as white solid. MS(M+H)+=508.1
- To a solution of 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)-N-(2-(2-(2-(2-hydroxyethoxy)ethoxy)ethoxy)ethyl)acetamide (1.63 g, 3.21 mmol) in DCM (20 mL) were added TosCl (1.22 g, 6.42 mmol) and TEA (975.02 mg, 9.64 mmol, 1.34 mL) and the mixture was stirred at 25° C. for 40 h. LCMS showed that some of the starting material remained. To the reaction were added TosCl (1.22 g, 6.42 mmol) and TEA (975.02 mg, 9.64 mmol, 1.34 mL) and the resulting mixture was stirred at 25° C. for another 40 h. LCMS showed that the reaction was completed. The reaction mixture was concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, Ethyl acetate/MeOH=1/0 to 10/1) to afford the titled compound (1.56 g, 2.05 mmol, 63.86% yield, 87% purity) as white solid. MS(M+H)+=662.1
- To a solution of 1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)-2-oxo-6,9,12-trioxa-3-azatetradecan-14-yl 4-methylbenzenesulfonate (1.56 g, 2.36 mmol) and tert-butyl piperidin-4-ylcarbamate (708.28 mg, 3.54 mmol) in dioxane (15 mL) were added NaI (35.34 mg, 235.77 μmol) and DIPEA (304.71 mg, 2.36 mmol, 410.66 μL) and the mixture was stirred at 80° C. for 16 h. LCMS showed that the reaction was completed. The reaction mixture was poured into H2O (50 mL) and extracted with EtOAc (100 mL×3), the combined organic layer was washed with brine (100 mL×3), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, Ethyl acetate/MeOH=1/0 to 10/1) to afford the titled compound (1.15 g, 1.57 mmol, 66.47% yield, 94% purity) as red solid. MS(M+H)+=690.3
- To a solution of tert-butyl (1-(1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)-2-oxo-6,9,12-trioxa-3-azatetradecan-14-yl)piperidin-4-yl)carbamate (1.15 g, 1.67 mmol) in dioxane (10 mL) was added HCl/dioxane (4 M, 20.03 mL) and the mixture was stirred at 25° C. for 16 h. LCMS showed that the reaction was completed. The mixture was concentrated in vacuum to afford the titled compound (1.1 g, crude, HCl) as white solid. MS(M+H)+=590.2
- To the solution of N-(2-(2-(2-(2-(4-aminopiperidin-1-yl)ethoxy)ethoxy)ethoxy)ethyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide (250 mg, 399.30 HCl) and 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (185.84 mg, 399.30 μmol) in DMF (4 mL) were added HATU (303.65 mg, 798.60 μmol) and DIPEA (154.82 mg, 1.20 mmol, 208.65 μL) and the resulting mixture was stirred at 20° C. for 1 h. LCMS showed that the reaction was completed. The mixture was poured into water (20 mL) and extracted with EtOAc (20 mL×3), the combined organic layer was washed with brine (50 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (column: Unisil 3-100 C18 μLtra 150*50 mm*3 um; mobile phase: [water (0.225% FA)-ACN]; B %: 28%-48%, 10 min) and the eluant was lyophilized to afford the titled compound (170.3 mg, 162.57 μmol, 40.71% yield, 99% purity, FA) as yellow solid. MS(M+H)+=1037.2.
- 1H NMR (400 MHz, DMSO-d6) δ=11.13 (s, 1H), 9.53-9.03 (m, 1H), 8.31 (s, 1H), 8.26 (d, J=13.3 Hz, 1H), 8.14 (s, 1H), 8.05 (s, 1H), 7.99 (t, J=5.0 Hz, 1H), 7.81 (t, J=8.0 Hz, 1H), 7.51 (d, J=7.1 Hz, 1H), 7.40 (d, J=8.4 Hz, 1H), 7.19 (br d, J=6.1 Hz, 1H), 5.17-5.06 (m, 1H), 4.88-4.76 (m, 3H), 4.09 (t, J=13.8 Hz, 2H), 4.02-3.90 (m, 4H), 3.73 (s, 2H), 3.61-3.52 (m, 9H), 3.50-3.46 (m, 3H), 3.34 (s, 3H), 3.21-3.00 (m, 4H), 2.97-2.85 (m, 1H), 2.71-2.53 (m, 5H), 2.13-1.90 (m, 5H), 1.78-1.57 (m, 7H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (43.2 mg, 31.25 μmol, 9.70% yield, 96% purity, TFA) as a white solid. MS(M+H)+=1213.7
- 1H NMR (400 MHz, DMSO-d6) δ=11.11 (s, 1H), 9.52-9.29 (m, 1H), 8.30 (s, 1H), 8.28-8.24 (m, 1H), 8.23-8.19 (m, 1H), 8.15 (s, 1H), 8.00 (t, J=5.6 Hz, 1H), 7.81 (dd, J=7.3, 8.4 Hz, 1H), 7.50 (d, J=7.2 Hz, 1H), 7.40 (d, J=8.4 Hz, 1H), 7.25-7.16 (m, 1H), 5.11 (dd, J=5.4, 12.8 Hz, 1H), 4.86-4.78 (m, 3H), 4.13-4.05 (m, 4H), 3.91 (s, 3H), 3.77-3.74 (m, 2H), 3.61-3.58 (m, 2H), 3.57 (br d, J=1.7 Hz, 2H), 3.53-3.47 (m, 22H), 3.47-3.43 (m, 2H), 3.33 (s, 3H), 3.31 (br d, J=5.7 Hz, 2H), 3.29-3.25 (m, 2H), 3.21-3.03 (m, 2H), 2.94-2.85 (m, 1H), 2.64-2.54 (m, 2H), 2.07-2.03 (m, 2H), 1.99-1.95 (m, 2H), 1.86-1.69 (m, 4H), 1.68-1.57 (m, 4H)
-
- To a solution of 5-aminopentan-1-ol (10 g, 96.93 mmol) and NaHCO3 (24.43 g, 290.80 mmol, 11.31 mL) in THF (100 mL) and H2O (20 mL) was added CbzCl (21.50 g, 126.02 mmol, 17.91 mL) at 0° C. and the reaction mixture was stirred at 20° C. for 16 hr. LCMS showed one peak (60%) with desired mass. The reaction mixture was diluted with H2O (100 mL) and extracted with EtOAc (100 mL×2). The combined organic layer was dried over Na2SO4, filtered. The filtrate was concentrated in vacuo to afford the titled compound (22 g, crude) as a colorless oil.
- To a solution of benzyl (5-hydroxypentyl)carbamate (10 g, 42.14 mmol) in DCM (120 mL) were added TEA (8.53 g, 84.28 mmol, 11.73 mL) and TosCl (10.44 g, 54.78 mmol). The mixture was stirred at 20° C. for 16 hr. LCMS showed one peak (72%) with desired mass. The reaction mixture was diluted with H2O (60 mL) and separated the DCM layer. The organic layer was dried over Na2SO4, filtered. The filtrate was concentrated in vacuo. The residue was purified by column chromatography (SiO2, PE/EtOAc=10/13/1) to afford the titled compound (7.8 g, 17.53 mmol, 41.61% yield, 88% purity) as a colorless oil. MS(M+H)+=392.1
- To a solution of 5-(((benzyloxy)carbonyl)amino)pentyl 4-methylbenzenesulfonate (5 g, 12.77 mmol) in dioxane (60 mL) were added tert-butyl piperidin-4-ylcarbamate (3.33 g, 16.60 mmol), DIPEA (4.95 g, 38.32 mmol, 6.67 mL) and NaI (191.45 mg, 1.28 mmol). The reaction mixture was heated to 60° C. for 16 hr. LCMS showed the starting material remained. Additional 3 g of reactant was added and the reaction mixture was stirred at 60° C. for another 16 hr. The reaction mixture was diluted with H2O (100 mL) and extracted with EtOAc (100 mL×2). The combined organic layer was dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by reverse HPLC (FA) to afford the titled compound (5 g, 11.92 mmol, 93.31% yield) as a white solid. MS(M+H)+=420.2
- To a solution of tert-butyl N-[1-[5-(benzyloxycarbonylamino)pentyl]-4-piperidyl]carbamate (5 g, 11.92 mmol) in EtOH (60 mL) was added Pd/C (500 mg, 10% purity) under N2 atmosphere. The reaction mixture was stirred at 20° C. for 16 hr under H2 (15 psi). TLC (DCM/MeOH=10/1) showed the starting material was consumed. The reaction mixture was filtered and the filtrate was concentrated in vacuo to afford the titled compound (3.4 g, crude) as a colorless oil.
- To a solution of 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetic acid (500 mg, 1.50 mmol) and tert-butyl (1-(5-aminopentyl)piperidin-4-yl)carbamate (515.42 mg, 1.81 mmol) in DMF (8 mL) were added HATU (686.61 mg, 1.81 mmol) and DIPEA (583.46 mg, 4.51 mmol, 786.34 uL). The reaction mixture was stirred at 20° C. for 16 hr. LCMS showed one main peak with desired mass. The reaction mixture was diluted with H2O (50 mL) and extracted with EtOAc (50 mL×2). The combined organic layer was dried over Na2SO4, filtered and concentrated in vacuo to afford the titled compound (1 g, crude) as a brown oil. MS(M+H)+=600.2
- tert-butyl (1-(5-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido) pentyl)piperidin-4-yl)carbamate (1 g, 1.67 mmol) was dissolved in HCl/dioxane (4 M, 416.89 uL) and the reaction mixture was stirred at 15° C. for 1 hr. LCMS showed one main peak with desired mass. The reaction mixture was concentrated in vacuo to afford the titled compound (1 g, crude, HCl salt) as a brown oil. MS(M+H)+=500.4
- To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (250 mg, 537.14 umol) in DMF (4 mL) were added HATU (204.24 mg, 537.14 umol) and DIPEA (138.84 mg, 1.07 mmol, 187.12 μL). The mixture was stirred at 20° C. for 10 min and a solution of N-(5-(4-aminopiperidin-1-yl)pentyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide (575.84 mg, 1.07 mmol, HCl salt) in DMF (4 mL) with DIPEA (138.84 mg, 1.07 mmol, 187.12 μL) was added and the resulting mixture was stirred at 20° C. for 1 h. LCMS showed all starting material was consumed completely and one peak with desired mass was detected. The reaction mixture was diluted with H2O (15 mL) and extracted with EtOAc (15 mL×3). The organic layer was washed with brine (15 mL×3), dried over Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (column: Phenomenex luna C18 150*40 mm*15 um; mobile phase: [water (0.225% FA)-ACN]; B %: 18%-48%, 10 min) and the eluent was lyophilized to afford 4 the titled compound (82.2 mg, 78.12 μmol, 14.54% yield, 90% purity, FA salt) as a white solid. MS(M+H)+=946.7
- 1H NMR (400 MHz, CD3OD) δ=8.41 (d, J=14.0 Hz, 1H), 8.21 (s, 1H), 7.83 (dd, J=7.4, 8.4 Hz, 1H), 7.56 (d, J=7.0 Hz, 1H), 7.46 (d, J=8.5 Hz, 1H), 7.33 (d, J=6.6 Hz, 1H), 5.14 (dd, J=5.6, 12.4 Hz, 1H), 4.93 (br d, J=8.4 Hz, 1H), 4.78 (s, 2H), 4.18-4.00 (m, 3H), 3.99 (s, 3H), 3.52-3.43 (m, 2H), 3.40 (s, 3H), 3.39-3.35 (m, 2H), 3.03-2.67 (m, 7H), 2.23-2.06 (m, 5H), 1.91-1.63 (m, 12H), 1.49-1.39 (m, 2H).
-
- To a mixture of 3-bromopropanoic acid (5 g, 32.69 mmol, 3.38 mL) and phenylmethanol (4.59 g, 42.49 mmol, 4.42 mL) in hexane (100 mL) was added TsOH (281.42 mg, 1.63 mmol) in one portion at 20° C. and the resulting mixture was stirred at 90° C. for 16 h. TLC (SiO2, Petroleum ether:Ethyl acetate=5:1) indicated starting material was consumed completely and two new spots were detected. The reaction mixture was concentrated in vacuum. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=100/1 to 10/1) to afford the titled compound (7.8 g, 32.09 mmol, 98.17% yield) as a white oil.
- 1H NMR (400 MHz, CDCl3) δ=7.44-7.35 (m, 5H), 5.21 (s, 2H), 3.62 (t, J=6.8 Hz, 2H), 2.99 (t, J=6.8 Hz, 2H)
- To a mixture of benzyl 3-bromopropanoate (7.8 g, 32.09 mmol) and tert-butyl N-(4-piperidyl) carbamate (7.71 g, 38.50 mmol) in dioxane (80 mL) were added DIPEA (12.44 g, 96.26 mmol, 16.77 mL), NaI (961.90 mg, 6.42 mmol) in one portion at 20° C. and the resulting mixture was stirred at 80° C. for 16 h. LCMS showed starting material was consumed completely and desired mass was detected. The reaction mixture was concentrated in vacuum. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=10/1 to 1/2) to afford the titled compound (9.3 g, 25.66 mmol, 79.97% yield) as an orange solid. MS(M+H)+=363.4
- To a solution of benzyl 3-(4-((tert-butoxycarbonyl)amino)piperidin-1-yl)propanoate (9.3 g, 25.66 mmol) in MeOH (100 mL) was added Pd/C (1 g, 10% purity) under N2. The suspension was degassed under vacuum and purged with H2 several times. The mixture was stirred under H2 (15 psi) at 20° C. for 16 h. LCMS showed starting material was consumed completely and desired mass was detected. The reaction mixture was filtered and the filtrate was concentrated in vacuum to afford the titled compound (6.7 g, 24.60 mmol, 95.88% yield) as a white solid. MS(M+H)+=273.2
- To a mixture of heptane-1, 7-diamine (9 g, 69.11 mmol) in DCM (396 mL) was added MeOH (396 mL) at 5° C., then a solution of CbzCl (10.61 g, 62.20 mmol, 8.84 mL) in MeOH (396 mL) was added drop-wise at 5° C. and the resulting mixture was stirred at 20° C. for 16 h. LCMS showed all starting material was consumed completely and one peak with desired mass was detected. The reaction mixture was concentrated in vacuum. The crude product was purified by reversed-phase HPLC (method: 0.1% FA, MeCN/water) to afford the titled compound (4.1 g, 15.04 mmol, 21.77% yield, 97% purity) as a white solid. MS(M+H)+=265.4
- A mixture of 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetic acid (1 g, 3.01 mmol), benzyl(7-aminoheptyl)carbamate (1.03 g, 3.91 mmol), EDCI (865.43 mg, 4.51 mmol), HOBt (610.01 mg, 4.51 mmol) and TEA (913.63 mg, 9.03 mmol, 1.26 mL) in DMF (10 mL) a was stirred at 20° C. for 16 h. LCMS showed all starting material was consumed completely and one peak with desired mass was detected. The reaction mixture was diluted with H2O (20 mL) and extracted with EtOAc (20 mL×3). The organic layer was washed with brine (20 mL×3), dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=3/1 to 0/1) to afford the titled compound (1.7 g, 2.67 mmol, 88.84% yield, 91% purity) as a yellow oil. MS(M+H)+=579.2
- To a solution of benzyl (7-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)heptyl)carbamate (1.7 g, 2.94 mmol) in ACN (10 mL) was added TMSI (1.76 g, 8.81 mmol, 1.20 mL) at 20° C. and the resulting mixture was stirred at 20° C. for 2 h. LCMS showed starting material was consumed completely and one peak with desired mass was detected. TEA (891.90 mg, 8.81 mmol, 1.23 mL) was added to this reaction mixture at 20° C. and the resulting mixture was stirred at 20° C. for 2 h. The reaction mixture was concentrated in vacuum. The residue was purified by prep-HPLC (column: Phenomenex luna C18 150*40 mm*15 um; mobile phase: [water (0.1% TFA)-ACN]; B %: 6%-36%, 10 min) and then lyophilized to afford the titled compound (920 mg, 2.07 mmol, 70.45% yield) as a yellow solid. MS(M+H)+=445.2
- To a solution of 3-(4-((tert-butoxycarbonyl)amino)piperidin-1-yl)propanoic acid (500 mg, 1.84 mmol) and N-(7-aminoheptyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy) acetamide (816.04 mg, 1.84 mmol) in DMF (5 mL) were added EDCI (527.93 mg, 2.75 mmol), HOBt (372.12 mg, 2.75 mmol) and TEA (557.33 mg, 5.51 mmol, 766.62 μL) at 20° C. and The resulting mixture was stirred at 20° C. for 16 h. LCMS showed all starting material was consumed completely and one peak with desired mass was detected. The reaction mixture was diluted with H2O (15 m) and extracted with EtOAc (15 mL×3). The organic layer was washed with brine (15 mL×3), dried over Na2SO4, filtrated and concentrated. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=1/1 to 0/1 to Dichloromethane/Methanol=1/0 to 10/1) to afford the titled compound (1.1 g, 1.43 mmol, 78.02% yield, 91% purity) as a yellow oil. MS(M+H)+=699.2
- To a mixture of tert-butyl (1-(3-((7-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)heptyl)amino)-3-oxopropyl)piperidin-4-yl)carbamate (1.1 g, 1.57 mmol) in dioxane (10 mL) was added HCl/dioxane (4 M, 10 mL) in one portion at 20° C. and the resulting mixture was stirred at 20° C. for 1 h. LCMS showed starting material was consumed completely and one peak with desired mass was detected. The reaction mixture was concentrated in vacuum to afford the titled compound (1 g, crude, HCl) as a yellow solid. MS(M+H)+=599.2
- To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (200 mg, 429.71 μmol) in DMF (4 mL) were added HATU (179.73 mg, 472.69 μmol) and DIPEA (111.08 mg, 859.43 μmol, 149.70 μL). The mixture was stirred at 20° C. for 10 min and a solution of 3-(4-aminopiperidin-1-yl)-N-(7-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)heptyl)propanamide (327.52 mg, crude, HCl) in DMF (4 mL) and DIPEA (111.08 mg, 859.43 μmol, 149.70 μL) was added and the resulting mixture was stirred at 20° C. for 1 h. LCMS showed all starting material was consumed completely and one peak with desired mass was detected. The reaction mixture was diluted with H2O (12 mL) and extracted with EtOAc (12 mL×3). The organic layer was dried over Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (column: 3_Phenomenex Luna C18 75*30 mm*3 um; mobile phase: [water (0.1% TFA)-ACN]; B %: 34%-54%, 7 min) and then lyophilized to afford the titled compound (48.5 mg, 40.97 μmol, 9.53% yield, 98% purity, TFA) as a white solid. MS(M+H)+=1046.7
- 1H NMR (400 MHz, CD3OD) δ=8.34 (d, J=13.8 Hz, 1H), 8.21 (s, 1H), 7.85-7.77 (m, 1H), 7.54 (d, J=7.4 Hz, 1H), 7.43 (d, J=8.4 Hz, 1H), 7.35 (d, J=6.7 Hz, 1H), 5.14 (dd, J=5.6, 12.6 Hz, 1H), 5.02-4.94 (m, 1H), 4.75 (s, 2H), 4.25-4.14 (m, 1H), 4.08 (t, J=13.2 Hz, 2H), 3.99 (s, 3H), 3.79-3.62 (m, 2H), 3.56-3.47 (m, 1H), 3.46-3.41 (m, 2H), 3.40 (s, 3H), 3.24-3.12 (m, 4H), 2.96-2.84 (m, 1H), 2.80 (s, 1H), 2.76-2.70 (m, 3H), 2.38-2.21 (m, 2H), 2.19-2.04 (m, 4H), 1.99-1.86 (m, 2H), 1.85-1.78 (m, 2H), 1.76-1.65 (m, 4H), 1.62-1.48 (m, 4H), 1.44-1.28 (m, 6H)
-
- To a mixture of (3-(aminomethyl)phenyl)methanol (1 g, 7.29 mmol) in THF (10 mL) and H2O (5 mL) was added Na2CO3 (1.55 g, 14.58 mmol) at 20° C. Then CbzCl (1.37 g, 8.02 mmol, 1.14 mL) was added drop-wise at 20° C. and the resulting mixture was stirred at 20° C. for 16 h. LCMS showed (3-(aminomethyl)phenyl)methanol was consumed completely and one peak with desired mass was detected. The reaction mixture was diluted with H2O (20 mL) and extracted with EtOAc (20 mL×3). The organic layer was dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=10/1 to 2/1) to afford the titled compound (1.7 g, 5.89 mmol, 80.80% yield, 94% purity) as a white solid. MS(M+Na)+=294.3
- To a mixture of benzyl 3-(hydroxymethyl)benzylcarbamate (1.7 g, 6.27 mmol) in DCM (15 mL) was added SOCl2 (1.12 g, 9.40 mmol, 681.81 μL) in one portion at 20° C. and the resulting mixture was stirred at 20° C. for 2 h. TLC (SiO2, Petroleum ether:Ethyl acetate=2:1) indicated starting material was consumed completely and one new spot was detected. The reaction mixture was concentrated in vacuum to afford the titled compound (1.6 g, 5.52 mmol, 88.13% yield) as a white solid.
- To a mixture of benzyl 3-(chloromethyl)benzylcarbamate (1.6 g, 5.52 mmol) and tert-butyl piperidin-4-ylcarbamate (1.44 g, 7.18 mmol) in ACN (20 mL) was added K2CO3 (2.29 g, 16.57 mmol) in one portion at 20° C. and the resulting mixture was stirred at 20° C. for 4 h. LCMS showed all starting material was consumed completely and one peak with desired mass was detected. The reaction mixture was concentrated in vacuum. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=5/1 to 1/4) to afford the titled compound (2.4 g, 5.29 mmol, 95.82% yield) as a white solid. MS(M+H)+=454.3
- To a mixture of tert-butyl N-[1-[[3-(benzyloxycarbonylaminomethyl) phenyl]methyl]-4-piperidyl]carbamate (2.4 g, 5.29 mmol) in dioxane (10 mL) was added HCl/dioxane (4 M, 20 mL) in one portion at 20° C. and the resulting mixture was stirred at 20° C. for 1 h. LCMS showed starting material was consumed completely and one peak with desired mass was detected. The reaction mixture was concentrated in vacuum to afford the titled compound (2.1 g, crude, HCl) as a white solid. MS(M+H)+=354.4
- To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (0.7 g, 1.50 mmol) in DMF (5 mL) were added HATU (629.05 mg, 1.65 mmol) and DIPEA (388.76 mg, 3.01 mmol, 523.94 μL). The reaction mixture was stirred at 20° C. for 10 min and a solution of benzyl 3-((4-aminopiperidin-1-yl) methyl)benzylcarbamate (821.01 mg, 2.11 mmol, HCl) in DMF (5 mL) and DIPEA (388.76 mg, 3.01 mmol, 523.94 μL) was added and the resulting mixture was stirred at 20° C. for 1 h. LCMS showed all starting material was consumed completely and one peak with desired mass was detected. The reaction mixture was diluted with H2O (20 mL) and extracted with EtOAc (20 mL×3). The organic layer was washed with brine (20 mL×3), dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=3/1 to 1/2) to afford the titled compound (362 mg, 424.89 μmol, 28.25% yield, 94% purity) as a white oil. MS(M+H)+=801.4
- To a mixture of benzyl 3-((4-(4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzamido)piperidin-1-yl)methyl)benzylcarbamate (360 mg, 449.51 μmol) in ACN (2 mL) was added TMSI (179.89 mg, 899.03 μmol, 122.37 μL) in one portion at 20° C. and the resulting mixture was stirred at 20° C. for 1 h. LCMS showed starting material remained and one peak with desired mass was detected. TMSI (89.94 mg, 449.51 μmol, 61.19 μL) was added to this reaction mixture at 20° C. and the resulting mixture was stirred at 20° C. for 12 h. LCMS showed starting material was consumed completely and desired mass was detected. TEA (136.46 mg, 1.35 mmol, 187.70 μL) was added to this reaction mixture at 20° C. The reaction mixture was stirred at 20° C. for 2 h. The reaction mixture was concentrated in vacuum to afford the titled compound (330 mg, crude) as a orange solid. MS(M+H)+=667.3
- To a solution of 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetic acid (150 mg, 451.45 μmol) in DMF (2 mL) were added HATU (188.82 mg, 496.59 μmol) and DIPEA (175.04 mg, 1.35 mmol, 235.90 μL). The mixture was stirred at 20° C. for 10 min and a solution of N-(1-(3-(aminomethyl)benzyl)piperidin-4-yl)-4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzamide (316.05 mg, 474.02 μmol) in DMF (2 mL) was added and the resulting mixture was stirred at 20° C. for 1 h. LCMS showed all starting material was consumed completely and one peak with desired mass was detected. The reaction mixture was diluted with H2O (12 mL) and extracted with EtOAc (12 mL×3). The organic layer was dried over Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (column: 3-Phenomenex Luna C18 75*30 mm*3 um; mobile phase: [water (0.1% TFA)-ACN]; B %: 32%-52%, 7 min) and then lyophilized to afford two batches of products with 59% and 42% purity. They were re-purified by prep-HPLC (column: Waters Xbridge 150*25 mm*5 um; mobile phase: [water (10 mM NH4HCO3)-ACN]; B %: 46%-76%, 10 min) and combined the eluents to lyophilize to afford product with 75% purity by LCMS and HPLC. It was re-purified by prep-HPLC (column: 3_Phenomenex Luna C18 75*30 mm*3 um; mobile phase: [water (0.1% TFA)-ACN]; B %: 32%-52%, 7 min) and then lyophilized to afford 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(3-((2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)methyl)benzyl)piperidin-4-yl)-2-fluoro-5-methoxybenzamide (9.5 mg, 9.59 μmol, 2.12% yield, 99% purity, TFA) as a white solid. MS(M+H)+=981.2
- 1H NMR (400 MHz, CD3OD) δ=8.33 (br d, J=13.7 Hz, 1H), 8.20 (s, 1H), 7.85-7.78 (m, 1H), 7.56 (d, J=7.3 Hz, 1H), 7.51-7.40 (m, 5H), 7.33 (d, J=6.6 Hz, 1H), 5.12 (dd, J=5.4, 12.8 Hz, 1H), 4.98-4.93 (m, 2H), 4.57 (s, 2H), 4.44-4.32 (s, 2H), 4.28-4.13 (m, 1H), 4.07 (t, J=13.1 Hz, 2H), 3.98 (s, 3H), 3.55 (d, J=12.5 Hz, 2H), 3.40 (s, 3H), 3.16 (t, J=12.4 Hz, 2H), 2.93-2.82 (m, 1H), 2.78-2.62 (m, 2H), 2.24 (d, J=13.3 Hz, 2H), 2.17-2.03 (m, 4H), 1.91-1.79 (m, 4H), 1.77-1.64 (m, 4H)
-
- To a mixture of (5-bromo-3-pyridyl) methanol (7 g, 37.23 mmol) and phthalimide (5.48 g, 37.23 mmol), PPh3 (14.65 g, 55.84 mmol) in THF (50 mL) was added DEAD (9.73 g, 55.84 mmol, 10.15 mL) drop-wise at 0° C. under N2 and the resulting mixture was stirred at 20° C. for 12 h. LCMS showed all starting material was consumed completely and one peak with desired mass was detected. The reaction mixture was diluted with brine (150 mL) and extracted with EtOAc (150 mL×3). The organic layer was dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=10/1 to 4/1) to afford the titled compound (8.2 g, 25.86 mmol, 69.46% yield) as a white solid. MS(M+H)+=317.0
- To a mixture of 2-((5-bromopyridin-3-yl)methyl)isoindoline-1,3-dione (8.2 g, 25.86 mmol) in EtOH (80 mL) was added N2H4·H2O (15.23 g, 258.56 mmol, 14.78 mL, 85% purity) in one portion at 20° C. and the resulting mixture was stirred at 80° C. for 4 h. TLC (SiO2, Petroleum ether:Ethyl acetate=3:1) indicated starting material was consumed completely and one new spot was detected. The reaction mixture was diluted with EtOH (160 mL) and filtered. The filtrate was concentrated in vacuum. The residue was diluted with DCM (160 mL) and filtered. The filtrate was concentrated in vacuum to afford the titled compound (7.2 g, crude) as a yellow oil.
- To a mixture of (5-bromopyridin-3-yl)methanamine (7.2 g, 38.50 mmol) in THF (70 mL) and H2O (35 mL) was added K2CO3 (10.64 g, 76.99 mmol) at 20° C. Then CbzCl (7.22 g, 42.34 mmol, 6.02 mL) was added drop-wise at 20° C. and The resulting mixture was stirred at 20° C. for 16 h. LCMS showed all starting material was consumed completely and one peak with desired mass was detected. The reaction mixture was diluted with H2O (30 mL) and extracted with EtOAc (70 mL×3). The organic was dried over Na2SO4, filtrated and concentrated. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=10/1 to 3/1) to afford the titled compound (4.4 g, 12.33 mmol, 32.03% yield, 90% purity) as a yellow oil. MS(M+H)+=321.0
- To a solution of benzyl ((5-bromopyridin-3-yl)methyl)carbamate (4.4 g, 13.70 mmol) in MeOH (50 mL) were added Pd(dppf)Cl2 (501.22 mg, 685.00 μmol), TEA (4.16 g, 41.10 mmol, 5.72 mL, 3 eq). The suspension was degassed under vacuum and purged with CO several times. The mixture was stirred under CO (50 psi) at 80° C. for 16 h. LCMS showed starting material was consumed completely and one peak with desired mass was detected. The reaction mixture was diluted with MeOH (200 mL) and filtered. The filtrate was concentrated in vacuum. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=5/1 to 1/1) to afford the titled compound (3.42 g, 9.79 mmol, 71.49% yield, 86% purity) as a yellow oil. MS(M+H)+=301.1
- To a suspension of LiAlH4 (554.32 mg, 14.60 mmol) in THF (30 mL) was added a solution of methyl 5-((((benzyloxy)carbonyl)amino)methyl)nicotinate (3.4 g, 9.74 mmol, 86% purity) in THF (15 mL) drop-wise at 0° C. and the resulting mixture was stirred at 20° C. for 2 h. TLC (SiO2, Petroleum ether:Ethyl acetate=1:2) indicated starting material was consumed completely and one new spot was detected. The reaction mixture was quenched with H2O (1 mL), NaOH (15% aq, 1 mL) and H2O (3 mL). The reaction mixture was filtered. The filtrate was concentrated in vacuum to afford the titled compound (3 g, crude) as a yellow oil. MS(M+H)+=273.3
- To a mixture of benzyl ((5-(hydroxymethyl)pyridin-3-yl)methyl)carbamate (2.8 g, 10.28 mmol) in DCM (20 mL) was added SOCl2 (1.47 g, 12.34 mmol, 895.13 μL) in one portion at 20° C. and the resulting mixture was stirred at 20° C. for 2 h. LCMS showed starting material was consumed completely and one peak with desired mass was detected. The reaction mixture was concentrated in vacuum to afford the titled compound (3 g, crude) as a yellow solid. MS(M+H)+=291.3
- To a mixture of benzyl ((5-(chloromethyl)pyridin-3-yl)methyl)carbamate (2.7 g, 9.29 mmol) and tert-butyl N-(4-piperidyl) carbamate (2.23 g, 11.14 mmol) in ACN (30 mL) was added K2CO3 (3.85 g, 27.86 mmol) in one portion at 20° C. and the resulting mixture was stirred at 60° C. for 4 h. LCMS showed all starting material was consumed completely and one peak with desired mass was detected. The reaction mixture was filtered and the filtrate was concentrated in vacuum. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=1/1 to 0/1) to afford the titled compound (3.7 g, 7.49 mmol, 80.64% yield, 92% purity) as a off-white solid. MS(M+H)+=455.4
- To a solution of tert-butyl N-[1-[[5-(benzyloxycarbonylaminomethyl)-3-pyridyl]methyl]-4-piperidyl]carbamate (1 g, 2.20 mmol) in dioxane (5 mL) was added HCl/dioxane (4 M, 10 mL) at 20° C. and the resulting mixture was stirred at 20° C. for 1 h. LCMS showed starting material was consumed completely and one peak with desired mass was detected. The reaction mixture was concentrated in vacuum to afford the titled compound (910 mg, crude, HCl) as a orange solid. MS(M+H)+=355.3
- To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (525.24 mg, 1.13 mmol) in DMF (4 mL) were added HATU (472.01 mg, 1.24 mmol) and DIPEA (291.71 mg, 2.26 mmol, 393.14 μL). The mixture was stirred at 20° C. for 10 min and a solution of benzyl ((5-(4-aminopiperidin-1-yl)methyl)pyridin-3-yl)methyl)carbamate (400.00 mg, crude, HCl) in DMF (4 mL) and DIPEA (291.71 mg, 2.26 mmol, 393.14 μL) was added and the resulting mixture was stirred at 20° C. for 1 h. LCMS showed all starting material was consumed completely and one peak with desired mass was detected. The reaction mixture was diluted with H2O (12 mL) and extracted with EtOAc (12 mL×3). The organic layer was washed with brine (12 mL×3), dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=1/1 to 0/1 to Dichloromethane/Methanol=1/0 to 10/1) to afford the titled compound (426 mg, 531.27 μmol, 47.08% yield) as a off-white solid. MS(M+H)+=02.1
- To a mixture of benzyl ((5-((4-(4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzamido)piperidin-1-yl)methyl)pyridin-3-yl)methyl)carbamate (426 mg, 531.27 μmol) in ACN (10 mL) was added TMSI (159.45 mg, 796.90 μmol, 108.47 μL) in one portion at 20° C. and the resulting mixture was stirred at 20° C. for 2 h. LCMS showed starting material was consumed completely and one peak with desired mass was detected. TEA (161.28 mg, 1.59 mmol, 221.84 μL) was added to this reaction mixture at 20° C. and the resulting mixture was stirred at 20° C. for 1 h. The reaction mixture was concentrated in vacuum. The residue was purified by prep-HPLC (column: Phenomenex luna C18 150*40 mm*15 um; mobile phase: [water (0.225% FA)-ACN]; B %: 7%-37%, 10 min) and then lyophilized to afford the titled compound (212 mg, 307.97 μmol, 57.97% yield, 97% purity) as a white solid. MS(M+H)+=668.2
- To a mixture of 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetic acid (100 mg, 300.97 μmol) and N-(1-((5-(aminomethyl)pyridin-3-yl)methyl)piperidin-4-yl)-4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzamide (211.01 mg, 316.01 μmol) in DMF (4 mL) were added T3P (1.15 g, 1.81 mmol, 1.07 mL, 50% purity in EtOAc solution) and Py (238.06 mg, 3.01 mmol, 242.92 μL) in one portion at 20° C. and the resulting mixture was stirred at 80° C. for 16 h. LCMS showed all starting material was consumed completely and one peak with desired mass was detected. The reaction mixture was diluted with H2O (12 mL) and extracted with EtOAc (12 mL×3). The organic layer was washed with brine (12 mL×3), dried over Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (column: Phenomenex luna C18 150*40 mm*15 um; mobile phase: [water (0.225% FA)-ACN]; B %: 18%-48%, 10 min) and then lyophilized to afford product A (24 mg) with 89% purity by LCMS and HPLC and product B (72 mg). The product A was re-purified by prep-HPLC (column: 3_Phenomenex Luna C18 75*30 mm*3 um; mobile phase: [water (0.1% TFA)-ACN]; B %: 28%-48%, 7 min). The product B was re-purified by prep-HPLC (column: 3_Phenomenex Luna C18 75*30 mm*3 um; mobile phase: [water (0.1% TFA)-ACN]; B %: 30%-50%, 7 min). two batches of eluents were combined and lyophilized to afford the titled compound (64.4 mg, 64.27 μmol, 21.35% yield, 98% purity, TFA salt) as a white solid. MS(M+H)+=981.7
- 1H NMR (400 MHz, CD3OD) δ=8.71 (d, J=1.7 Hz, 1H), 8.64 (d, J=1.8 Hz, 1H), 8.27 (d, J=13.4 Hz, 1H), 8.21 (s, 1H), 8.03 (s, 1H), 7.86-7.78 (m, 1H), 7.56 (d, J=7.2 Hz, 1H), 7.46 (d, J=8.6 Hz, 1H), 7.34 (d, J=6.6 Hz, 1H), 5.13 (dd, J=5.4, 12.8 Hz, 1H), 5.05-4.90 (m, 2H), 4.81-4.74 (m, 1H), 4.63 (s, 2H), 4.44 (s, 2H), 4.25-4.04 (m, 3H), 3.98 (s, 3H), 3.69-3.45 (m, 2H), 3.40 (s, 3H), 3.26-3.11 (m, 2H), 2.93-2.83 (m, 1H), 2.80-2.67 (m, 2H), 2.31-2.18 (m, 2H), 2.17-2.06 (m, 3H), 1.98-1.66 (m, 8H)
-
- To a solution of (3-bromophenyl)methanamine (5 g, 26.87 mmol) in THF (50 mL) was added a solution of K2CO3 (7.43 g, 53.75 mmol) in H2O (25 mL) followed by CbzCl (5.50 g, 32.25 mmol, 4.58 mL) drop-wise at 25° C. and the resulting mixture was stirred at 25° C. for 12 h. LCMS showed starting material was consumed completely and one peak with desired mass was detected. TLC (SiO2, Petroleum ether:Ethyl acetate=5:1) indicated starting material was consumed completely and two new spots were detected. The reaction mixture was diluted with H2O (50 mL) and extracted with EtOAc (50 mL×3). The organic layer was dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=1/0 to 5/1) to afford the titled compound (6.8 g, 20.60 mmol, 76.66% yield, 97% purity) as a white solid. MS(M+H)+=320.0
- To a mixture of benzyl 3-bromobenzylcarbamate (6 g, 18.74 mmol) and hept-6-yn-1-ol (3.15 g, 28.11 mmol) in DMF (60 mL) were added CuI (713.78 mg, 3.75 mmol), TEA (5.69 g, 56.22 mmol, 7.82 mL) and Pd(PPh3)4 (1.08 g, 936.97 μmol) in one portion at 20° C. under N2 and the resulting mixture was stirred at 80° C. for 16 h. LCMS showed all starting material was consumed completely and one peak with desired mass was detected. TLC (SiO2, Petroleum ether:Ethyl acetate=1:1) indicated starting material was consumed completely and three new spots was detected. The reaction mixture was diluted with H2O (120 mL) and extracted with EtOAc (120 mL×3). The organic layer was washed with brine (120 mL×3), dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=10/1 to 1/1) to afford the titled compound (6.8 g, 16.06 mmol, 85.70% yield, 83% purity) as a yellow oil. MS(M+Na)+=374.4
- To a mixture of benzyl 3-(7-hydroxyhept-1-yn-1-yl)benzylcarbamate (6.8 g, 16.06 mmol, 83% purity) in DCM (70 mL) were added TEA (4.88 g, 48.18 mmol, 6.71 mL) and TosCl (4.59 g, 24.09 mmol) in one portion at 20° C. and the resulting mixture was stirred at 20° C. for 16 h. LCMS showed all starting material was consumed completely and desired mass was detected. TLC (SiO2, Petroleum ether:Ethyl acetate=2:1) indicated starting material was consumed completely and one major new spot was detected. The reaction mixture was concentrated in vacuum. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=10/1 to 2/1) to afford the titled compound (6.2 g, 12.02 mmol, 74.83% yield, 98% purity) as a yellow oil. MS(M+H)+=506.4
- To a mixture of 7-(3-((((benzyloxy)carbonyl)amino)methyl)phenyl)hept-6-yn-1-yl 4-methylbenzenesulfonate (3.1 g, 6.13 mmol) and tert-butyl piperidin-4-ylcarbamate (2.46 g, 12.26 mmol) in dioxane (40 mL) were added NaI (91.90 mg, 613.10 μmol) and DIPEA (2.38 g, 18.39 mmol, 3.20 mL) in one portion at 20° C. under N2 and the resulting mixture was stirred at 60° C. for 16 h. LCMS showed all starting material was consumed completely and one peak with desired mass was detected. TLC (SiO2, Petroleum ether:Ethyl acetate=1:2) indicated starting material was consumed completely and three new spots were detected. The reaction mixture was concentrated in vacuum. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=10/1 to 1/2) to afford the titled compound (2.4 g, 4.50 mmol, 73.35% yield) as a yellow oil. MS(M+H)+=534.3
- To a solution of tert-butyl N-[1-[7-[3-(benzyloxycarbonylaminomethyl) phenyl]hept-6-ynyl]-4-piperidyl]carbamate (2.4 g, 4.50 mmol) in MeOH (24 mL) was added Pd/C (1 g, 10% purity) under N2. The suspension was degassed under vacuum and purged with H2 several times. The mixture was stirred under H2 (15 psi) at 20° C. for 16 h. LCMS showed starting material was consumed completely and one peak with desired mass was detected. The reaction mixture was diluted with MeOH (80 mL) and filtered. The filtrate was concentrated in vacuum to afford the titled compound (1.3 g, crude) as a white oil. MS(M+H)+=404.5
- To a mixture of 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetic acid (800 mg, 2.41 mmol) and tert-butyl (1-(7-(3-(aminomethyl)phenyl)heptyl)piperidin-4-yl)carbamate (1.17 g, 2.89 mmol) in DMF (10 mL) were added HATU (915.49 mg, 2.41 mmol) and DIPEA (933.54 mg, 7.22 mmol, 1.26 mL) in one portion at 20° C. and the resulting mixture was stirred at 20° C. for 2 h. LCMS showed all starting material was consumed completely and one peak with desired mass was detected. TLC (SiO2, Petroleum ether:Ethyl acetate=1:3) indicated starting material was consumed completely and four new spots were detected. The reaction mixture was diluted with H2O (30 mL) and extracted with EtOAc (30 mL×3). The organic layer was washed with brine (30 mL×3), dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=5/1 to 0/1) to afford the titled compound (1.17 g, 1.63 mmol, 67.69% yield) as a yellow oil. MS(M+H)+=718.2
- To a mixture of tert-butyl (1-(7-(3-((2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy) acetamido)methyl)phenyl)heptyl)piperidin-4-yl)carbamate (1.17 g, 1.63 mmol) in dioxane (5 mL) was added HCl/dioxane (4 M, 10 mL) in one portion at 20° C. and the resulting mixture was stirred at 20° C. for 1 h. LCMS showed starting material was consumed completely and one peak with desired mass was detected. The reaction mixture was concentrated in vacuum to afford the titled compound (1.5 g, crude, HCl) as a yellow solid. MS(M+H)+=618.2
- To a mixture of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (250 mg, 537.14 μmol) and N-(3-(7-(4-aminopiperidin-1-yl)heptyl)benzyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide (421.68 mg, crude, HCl) in DMF (3 mL) were added HATU (224.66 mg, 590.86 μmol) and DIPEA (208.27 mg, 1.61 mmol, 280.68 μL) in one portion at 20° C. and the resulting mixture was stirred at 20° C. for 2 h. LCMS showed starting material was consumed completely and desired mass was detected. The reaction mixture was diluted with toluene (15 mL) and the reaction mixture was concentrated in vacuum. The residue was purified by prep-HPLC (column: Phenomenex luna C18 150*40 mm*15 um; mobile phase: [water (0.225% FA)-ACN]; B %: 30%-60%, 10 min) and then lyophilized to afford product (192 mg) with 59% purity. The product was re-purified by prep-HPLC (column: Shim-pack C18 150*25*10 um; mobile phase: [water (0.225% FA)-ACN]; B %: 31%-57%, 13 min) and then lyophilized to afford the titled compound (81.2 mg, 72.42 μmol, 69.25% yield, 95% purity) as a white solid. MS(M+H)+=1065.4
- 1H NMR (400 MHz, DMSO-d6) δ=11.11 (s, 1H), 8.50 (t, J=6.0 Hz, 1H), 8.30 (s, 1H), 8.26 (d, J=13.4 Hz, 1H), 8.13 (s, 1H), 8.06 (s, 1H), 7.81 (dd, J=7.4, 8.4 Hz, 1H), 7.51 (d, J=7.2 Hz, 1H), 7.41 (d, J=8.6 Hz, 1H), 7.27-7.14 (m, 2H), 7.12-7.01 (m, 3H), 5.11 (dd, J=5.4, 12.8 Hz, 1H), 4.87 (s, 2H), 4.85-4.76 (m, 1H), 4.34 (d, J=6.0 Hz, 2H), 4.14-4.03 (m, 2H), 4.02-3.95 (m, 1H), 3.92 (s, 3H), 3.33 (s, 3H), 3.00-2.81 (m, 4H), 2.69-2.51 (m, 7H), 2.09-1.88 (m, 5H), 1.84-1.67 (m, 4H), 1.67-1.48 (m, 8H), 1.35-1.21 (m, 6H)
-
- According to the above reaction scheme, in a manner similar to the other examples obtained the titled compound (161.2 mg, 137.59 μmol, 32.02% yield, 91% purity) as a white solid. MS(M+H)+=1065.6
- 1H NMR (400 MHz, DMSO-d6) δ=11.12 (br s, 1H), 8.58 (t, J=5.9 Hz, 1H), 8.34-8.28 (m, 3H), 8.25 (d, J=13.3 Hz, 1H), 8.20 (s, 1H), 8.03 (s, 1H), 7.88 (dd, J=3.5, 7.5 Hz, 1H), 7.80 (dd, J=7.4, 8.4 Hz, 1H), 7.53-7.46 (m, 2H), 7.40 (d, J=8.4 Hz, 1H), 7.20 (d, J=6.8 Hz, 1H), 5.11 (dd, J=5.4, 12.9 Hz, 1H), 4.88 (s, 2H), 4.86-4.77 (m, 1H), 4.37 (d, J=6.0 Hz, 2H), 4.08 (t, J=13.9 Hz, 2H), 3.92 (s, 3H), 3.34 (s, 3H), 2.97-2.79 (m, 4H), 2.58-2.54 (m, 3H), 2.28 (t, J=7.3 Hz, 2H), 2.06-1.94 (m, 5H), 1.83-1.70 (m, 4H), 1.66-1.50 (m, 8H), 1.46-1.37 (m, 2H), 1.32-1.20 (m, 6H)
-
- To a solution of benzyl 4-formylpiperidine-1-carboxylate (5 g, 20.22 mmol) in DCE (80 mL) were added tert-butyl piperidin-4-ylcarbamate (4.50 g, 22.47 mmol) and HOAc (1.21 g, 20.22 mmol, 1.16 mL). The mixture was stirred at 20° C. for 2 h. Then NaBH(OAc)3 (16.00 g, 75.49 mmol) was added to the mixture at 20° C., the mixture was stirred at 20° C. for 14 hr. LCMS showed the starting material was consumed and main peak with the desired mass. To the reaction mixture was added H2O (100 mL) at 0° C. and adjusted to pH=9 at 0° C. by saturated Na2CO3 solution, the aqueous phase was extracted with Ethyl acetate (200 mL×3), then the combined organic layers were washed with brine (250 mL×2), dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure to give a residue. The crude product was triturated with Petroleum ether:Ethyl acetate=5:1 (120 mL) at 20° C. for 30 min, then it was filtered and the cake was dried under reduced pressure to afford the titled compound (8 g, 18.54 mmol, 91.68% yield) as a white solid. MS (M+H)+=432.3
- To a solution of benzyl 4-((4-((tert-butoxycarbonyl)amino)piperidin-1-yl)methyl)piperidine-1-carboxylate (4 g, 9.27 mmol) in MeOH (100 mL) was added Pd/C (0.4 g, 10% purity) and Pd(OH)2/C (0.4 g, 20% purity), the mixture was stirred at 20° C. for 16 h under H2 atmosphere (15 Psi). LCMS showed the starting material was consumed and desired mass was detected. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure to afford the titled compound (2.6 g, crude) as a light yellow oil. MS (M+H)+=298.3
- To a solution of 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (800 mg, 2.90 mmol) in DMSO (3 mL) was added TEA (1.16 g, 11.50 mmol, 1.60 mL) and tert-butyl (1-(piperidin-4-ylmethyl)piperidin-4-yl)carbamate (1.0 g, 3.36 mmol). The mixture was stirred at 100° C. for 16 h under N2 atmosphere. LCMS showed the starting material was consumed and a main peak with desired mass. To the reaction mixture was added H2O (20 mL), the mixture was extracted with EtOAc (50 mL×2), the combined organic layers were washed with brine (40 mL×3), dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (Biotage; 10 g SepaFlash® Silica Flash Column, Eluent of 0˜10% Methanol:Ethyl acetate gradient, 50 mL/min) to the titled compound (1.5 g, 2.71 mmol, 93.55% yield) as a yellow oil. MS (M+H)+=554.5
- To a solution of tert-butyl (1-((1-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperidin-4-yl)methyl)piperidin-4-yl)carbamate (1.5 g, 2.71 mmol) in DCM (10 mL) was added HCl/dioxane (4 M, 10 mL) at 20° C. The mixture was stirred at 20° C. for 16 h under N2 atmosphere. LCMS showed the starting material was consumed and a main peak with the desired mass. The reaction mixture was concentrated under reduced pressure to afford the titled compound (1.4 g, crude, 2HCl) as a light yellow solid. MS (M+H)+=454.5
- To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (150 mg, 322.29 μmol) in DMF (4 mL) were added HATU (245.09 mg, 644.58 μmol), DIPEA (222.60 mg, 1.72 mmol, 300 μL) and 4-(4-(4-aminopiperidin-1-yl)methyl)piperidin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (200 mg, 379.90 μmol, 2HCl) at 25° C. The mixture was stirred at 25° C. for 2 h under N2 atmosphere. LCMS showed the starting material was consumed and a main peak with the desired mass. To the reaction mixture was added H2O (10 mL), the mixture was extracted with EtOAc (30 mL×2), the combined organic layers were washed with brine 90 mL (30 mL×3), dried over Na2SO4, filtered and the filtrate was concentrated under reduced pressure. The residue was purified by prep-HPLC (column: Waters Xbridge 150*25 mm*5 um; mobile phase: [water (10 mM NH4HCO3)-ACN]; B %: 48%-81%, 9 min; Column Temp: 30° C.) followed by lyophilization to afford the titled compound (123.3 mg, 127.28 μmol, 39.49% yield, 93% purity) as a light yellow solid. MS (M+H)+=901.6
- 1H NMR (400 MHz, DMSO-d6) δ 11.10 (s, 1H), 8.35-8.22 (m, 2H), 8.04 (s, 1H), 7.95-7.83 (m, 1H), 7.68 (t, J=7.8 Hz, 1H), 7.33 (t, J=7.3 Hz, 2H), 7.20 (d, J=6.6 Hz, 1H), 5.09 (dd, J=5.3, 12.9 Hz, 1H), 4.88-4.78 (m, 1H), 4.09 (t, J=13.9 Hz, 2H), 3.92 (s, 3H), 3.83-3.67 (m, 3H), 3.32 (s, 3H), 2.93-2.75 (m, 5H), 2.63-2.57 (m, 2H), 2.25-2.14 (m, 2H), 2.08-1.95 (m, 5H), 1.84-1.56 (m, 13H), 1.37-1.25 (m, 2H)
-
- A mixture of tert-butyl piperidin-4-ylcarbamate (10 g, 49.93 mmol), 1-bromo-2-chloroethane (10.74 g, 74.90 mmol, 6.21 mL) and K2CO3 (20.70 g, 149.79 mmol) in acetone (100 mL) was stirred at 15° C. for 16 h. LCMS showed reactant was consumed completely and 100% of the desired mass was detected. The reaction mixture was filtered and the filtrate was concentrated in vacuo. The residue was purified by flash silica gel chromatography (25 g SepaFlash® Silica Flash Column, Eluent of 20˜51% Ethyl acetate/Petroleum ether gradient @ 100 mL/min) to afford the titled compound (2 g, 7.61 mmol, 15.24% yield) as a white solid.
- 1H NMR (400 MHz, DMSO-d6) δ=6.75 (br d, J=7.5 Hz, 1H), 3.64 (t, J=6.8 Hz, 2H), 3.26-3.12 (m, 1H), 2.80 (br d, J=11.5 Hz, 2H), 2.59 (br t, J=6.8 Hz, 2H), 2.05-1.95 (m, 2H), 1.65 (br d, J=11.0 Hz, 2H), 1.41-1.29 (m, 11H).
- To a solution of 2-(2,6-dioxopiperidin-3-yl)-4-(piperazin-1-yl)isoindoline-1,3-dione (200 mg, 527.97 μmol, HCl salt) in DMF (3 mL) were added DIEA (204.71 mg, 1.58 mmol, 275.89 μL) and tert-butyl (1-(2-chloroethyl)piperidin-4-yl)carbamate (194.23 mg, 739.16 μmol), the mixture was stirred at 15° C. for 16 hours. LCMS showed 15% of reactant remained and 66% of desired mass was detected. The reaction mixture was diluted with H2O (50 mL) and extracted with EtOAc (50 mL×3). The combined organic layers were washed with brine (80 mL×5), dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash silica gel chromatography (12 g SepaFlash® Silica Flash Column, Eluent of 0˜18% MeOH/Ethyl acetate gradient @ 60 mL/min) to afford the titled compound (110 mg, 193.44 μmol, 36.64% yield) as a yellow solid. MS(M+H)+=569.6.
- To a solution of tert-butyl (1-(2-(4-(2-(2, 6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperazin-1-yl)ethyl)piperidin-4-yl)carbamate (110 mg, 193.44 μmol) in dioxane (5 mL) was added HCl/dioxane (4 M in dioxane, 10 mL), the mixture was stirred at 15° C. for 16 hours. LCMS showed reactant was consumed completely and desired mass was detected. The reaction mixture was concentrated in vacuo to afford the titled compound (160 mg, crude, HCl salt) as a yellow solid. MS(M+H)+=469.2.
- To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (90 mg, 193.37 μmol) in DMF (2 mL) were added HATU (110.29 mg, 290.06 μmol) and DIEA (99.97 mg, 773.49 μmol, 134.73 μL), the mixture was stirred at 15° C. for 15 minutes, then 4-(4-(2-(4-aminopiperidin-1-yl)ethyl)piperazin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (156.25 mg, 309.39 μmol, HCl salt) was added and the resulting mixture was stirred at 15° C. for 1 hour. LCMS showed reactant was consumed completely and 91% of desired mass was detected. The mixture was added CH3COOH to adjust pH<7. The resulting mixture was purified by prep-HPLC (column: Waters Xbridge 150*25 mm*5 um; mobile phase: [water (10 mM NH4HCO3)-ACN]; B %: 40%-70%, 8 min) followed by prep-HPLC (column: Phenomenex luna C18 150*25 mm*10 um; mobile phase: [water (0.225% FA)-ACN]; B %: 18%-38%, 10 min) to afford the titled compound (32.4 mg, 32.54 μmol, 16.83% yield, 92% purity) as a yellow solid. MS(M+H)+=916.3.
- 1H NMR (400 MHz, DMSO-d6) δ=11.09 (s, 1H), 8.30 (s, 1H), 8.24 (d, J=13.4 Hz, 1H), 8.03 (s, 1H), 7.89 (br dd, J1=3.3, J2=7.5 Hz, 1H), 7.70 (dd, J1=7.3, J2=8.3 Hz, 1H), 7.40-7.28 (m, 2H), 7.19 (d, J=6.6 Hz, 1H), 5.09 (dd, J1=5.5, J2=12.8 Hz, 1H), 4.90-4.76 (m, 1H), 4.08 (br t, J=13.9 Hz, 2H), 3.91 (s, 3H), 3.80-3.67 (m, 1H), 3.31-3.23 (m, 4H), 2.96-2.78 (m, 3H), 2.65-2.57 (m, 4H), 2.57-2.51 (m, 9H), 2.09-1.91 (m, 5H), 1.85-1.68 (m, 4H), 1.68-1.48 (m, 6H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (129.2 mg, 130.50 μmol, 40.49% yield, 91% purity) as a light yellow solid. MS (M+H)+=901.5
- 1H NMR (400 MHz, DMSO-d6) δ 11.07 (br s, 1H), 8.31-8.22 (m, 2H), 8.03 (s, 1H), 7.87 (dd, J=3.4, 7.5 Hz, 1H), 7.64 (d, J=8.5 Hz, 1H), 7.29 (d, J=1.6 Hz, 1H), 7.24-7.18 (m, 2H), 5.06 (dd, J=5.4, 12.9 Hz, 1H), 4.87-4.78 (m, 1H), 4.12-3.98 (m, 4H), 3.91 (s, 3H), 3.78-3.70 (m, 1H), 3.33 (s, 3H), 2.99-2.79 (m, 5H), 2.63-2.54 (m, 2H), 2.15-2.08 (m, 2H), 2.03-1.93 (m, 5H), 1.81-1.55 (m, 13H), 1.18-1.09 (m, 2H)
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (79.1 mg, 84.63 μmol, 39.39% yield, 98% purity) as yellow solid. MS(M+H)+=917.0
- 1H NMR (400 MHz, DMSO-d6) δ 11.09 (s, 1H), 8.30 (s, 1H), 8.24 (d, J=13.3 Hz, 1H), 8.04 (d, J=1.3 Hz, 1H), 7.90 (dd, J=7.8, 3.4 Hz, 1H), 7.68 (d, J=8.5 Hz, 1H), 7.34 (d, J=2.2 Hz, 1H), 7.25 (dd, J=8.7, 2.3 Hz, 1H), 7.19 (d, J=6.7 Hz, 1H), 5.07 (dd, J=12.9, 5.3 Hz, 1H), 4.91-4.74 (m, 1H), 4.08 (t, J=13.9 Hz, 2H), 3.91 (s, 3H), 3.80-3.67 (m, 1H), 3.50-3.37 (m, 4H), 3.31 (s, 3H), 2.97-2.78 (m, 3H), 2.65-2.51 (m, 6H), 2.47-2.44 (m, 4H), 2.08-1.92 (m, 5H), 1.83-1.68 (m, 4H), 1.66-1.49 (m, 6H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (78.3 mg, 83.78 μmol, 25.99% yield, 98% purity) as a light yellow solid. MS(M+H)+=916.6
- 1H NMR (400 MHz, DMSO-d6) δ 11.07 (br s, 1H), 8.34-8.23 (m, 2H), 8.04 (s, 1H), 7.96 (dd, J=3.0, 7.7 Hz, 1H), 7.73 (dd, J=7.3, 8.2 Hz, 1H), 7.38 (dd, J=7.8, 12.0 Hz, 2H), 7.21 (d, J=6.7 Hz, 1H), 5.11 (dd, J=5.4, 12.9 Hz, 1H), 4.87-4.75 (m, 1H), 4.08 (t, J=13.9 Hz, 2H), 4.02-3.97 (m, 1H), 3.92 (s, 3H), 3.65 (d, J=12.7 Hz, 2H), 3.40-3.37 (m, 2H), 3.32-3.30 (m, 5H), 2.96-2.84 (m, 3H), 2.64-2.52 (m, 6H), 2.06-1.90 (m, 3H), 1.86-1.79 (m, 2H), 1.75-1.50 (m, 8H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (81.8 mg, 86.20 μmol, 33.43% yield, 98% purity) as a yellow solid. MS (M+H)+=930.1
- 1H NMR (400 MHz, DMSO-d6) δ=11.08 (s, 1H), 8.31-8.22 (m, 2H), 8.07-7.93 (m, 2H), 7.70 (dd, J=7.2, 8.2 Hz, 1H), 7.39-7.31 (m, 2H), 7.19 (d, J=6.8 Hz, 1H), 5.14-5.04 (m, 1H), 4.87-4.76 (m, 1H), 4.35-4.24 (m, 1H), 4.12-4.01 (m, 4H), 3.91 (s, 3H), 3.33 (s, 3H), 3.19-3.10 (m, 2H), 2.95-2.68 (m, 3H), 2.65-2.53 (m, 10H), 2.04-1.81 (m, 5H), 1.72-1.50 (m, 7H), 1.46-1.32 (m, 1H)
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (62.2 mg, 64.57 μmol, 25.05% yield, 98% purity) as a yellow solid. MS (M+H)+=943.9
- 1H NMR (400 MHz, DMSO-d6) δ=11.08 (s, 1H), 8.34-8.23 (m, 2H), 8.06-7.93 (m, 2H), 7.73-7.67 (m, 1H), 7.35 (t, J=7.0 Hz, 2H), 7.20 (d, J=6.6 Hz, 1H), 5.09 (dd, J=5.4, 12.6 Hz, 1H), 4.88-4.76 (m, 1H), 4.36-4.26 (m, 1H), 4.11-4.04 (m, 2H), 3.91 (s, 3H), 3.33 (s, 3H), 3.27-3.06 (m, 5H), 2.89-2.82 (m, 1H), 2.78-2.70 (m, 1H), 2.69-2.65 (m, 1H), 2.65-2.51 (m, 10H), 2.07-1.78 (m, 6H), 1.76-1.68 (m, 2H), 1.68-1.56 (m, 4H), 1.53-1.45 (m, 1H), 1.42-1.32 (m, 1H)
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (39.9 mg, 42.69 μmol, 13.25% yield, 98% purity) as a light yellow solid. MS(M+H)+=916.6
- 1H NMR (400 MHz, DMSO-d6) δ 11.06 (br s, 1H), 8.32-8.24 (m, 2H), 8.04 (s, 1H), 7.98 (dd, J=3.0, 7.5 Hz, 1H), 7.71 (d, J=8.5 Hz, 1H), 7.36 (d, J=1.8 Hz, 1H), 7.26 (dd, J=2.0, 8.7 Hz, 1H), 7.21 (d, J=6.8 Hz, 1H), 5.08 (dd, J=5.3, 12.9 Hz, 1H), 4.83 (t, J=8.0 Hz, 1H), 4.08 (t, J=13.9 Hz, 2H), 4.02-3.97 (m, 1H), 3.92 (s, 3H), 3.65 (d, J=13.1 Hz, 2H), 3.53-3.45 (m, 4H), 3.32-3.29 (m, 3H), 2.97-2.85 (m, 3H), 2.65-2.51 (m, 6H), 2.04-1.91 (m, 3H), 1.83 (d, J=10.4 Hz, 2H), 1.76-1.52 (m, 8H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (51.8 mg, 54.59 μmol, 25.41% yield, 98% purity) as a yellow solid. MS(M+H)+=930.7.
- 1H NMR (400 MHz, DMSO-d6) δ=11.06 (br s, 1H), 8.45-8.16 (m, 2H), 8.13-7.91 (m, 2H), 7.68 (d, J=8.6 Hz, 1H), 7.35 (d, J=1.7 Hz, 1H), 7.25 (dd, J1=1.9, J2=8.7 Hz, 1H), 7.19 (d, J=6.7 Hz, 1H), 5.07 (dd, J1=5.4, J2=12.8 Hz, 1H), 4.81 (br t, J=7.9 Hz, 1H), 4.29 (br d, J=11.7 Hz, 1H), 4.16-3.97 (m, 4H), 3.91 (s, 3H), 3.52-3.35 (m, 8H), 3.20-3.06 (m, 2H), 2.94-2.82 (m, 1H), 2.81-2.71 (m, 1H), 2.63-2.53 (m, 6H), 2.10-1.91 (m, 3H), 1.91-1.75 (m, 2H), 1.71-1.60 (m, 2H), 1.67-1.47 (m, 5H), 1.46-1.30 (m, 1H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (29.8 mg, 30.94 μmol, 28.80% yield, 98% purity) as a yellow solid. MS(M+H)+=944.8.
- 1H NMR (400 MHz, DMSO-d6) δ=11.07 (s, 1H), 8.30 (s, 1H), 8.24 (d, J=13.3 Hz, 1H), 8.04 (s, 1H), 7.97 (br dd, J1=2.7, J2=7.2 Hz, 1H), 7.67 (d, J=8.4 Hz, 1H), 7.34 (s, 1H), 7.31-7.23 (m, 1H), 7.20 (d, J=6.7 Hz, 1H), 5.07 (dd, J1=5.4, J2=12.8 Hz, 1H), 4.82 (br t, J=8.1 Hz, 1H), 4.31 (br d, J=12.6 Hz, 1H), 4.14-3.99 (m, 3H), 3.98-3.84 (m, 4H), 3.48-3.38 (m, 7H), 3.15 (br t, J=12.5 Hz, 1H), 2.94-2.81 (m, 1H), 2.74 (br t, J=11.4 Hz, 1H), 2.63-2.54 (m, 10H), 2.09-1.92 (m, 3H), 1.91-1.78 (m, 2H), 1.72 (br d, J=1.2 Hz, 2H), 1.68-1.54 (m, 4H), 1.53-1.43 (m, 1H), 1.43-1.29 (m, 1H).
-
- To a solution of 2-(2-(2-hydroxyethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (4.0 g, 13.14 mmol) and tert-butyl N-(4-piperidyl)carbamate (3.95 g, 19.71 mmol) in dioxane (20 mL) were added NaI (197.00 mg, 1.31 mmol) and DIPEA (1.70 g, 13.14 mmol, 2.29 mL) and the resulting mixture was stirred at 60° C. for 12 h. LCMS showed that the reaction was completed. The mixture was diluted with H2O (100 mL) and extracted with EtOAc (300 mL×3), the combined organic layers were washed with Brine (100 mL×1), dried over Na2SO4, filtered and concentrated under reduced pressure to afford the titled compound (5.55 g, crude) as yellow solid. MS(M+H)+=333.4
- To a solution of tert-butyl (1-(2-(2-(2-hydroxyethoxy)ethoxy)ethyl)piperidin-4-yl)carbamate (5.55 g, 16.70 mmol) in DCM (30 mL) were added TEA (5.07 g, 50.09 mmol, 6.97 mL) followed by TosCl (6.37 g, 33.39 mmol) and the mixture was stirred at 15° C. for 16 h. LCMS showed that the reaction was completed. The mixture was concentrated in vacuo. The residue was purified by column chromatography (SiO2, EtOAc/MeOH=10/1) to afford the titled compound (4.27 g, 8.77 mmol, 52.56% yield) as brown oil. MS (M+H)+=487.2
- To a solution of 2-(2-(2-(4-((tert-butoxycarbonyl)amino)piperidin-1-yl)ethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (4.27 g, 8.77 mmol) and 3-(4-amino-1-oxo-isoindolin-2-yl) piperidine-2, 6-dione (2.73 g, 10.53 mmol) in DMF (30 mL) was added DIEA (1.13 g, 8.77 mmol, 1.53 mL) and the mixture was stirred at 110° C. for 16 h. LCMS showed that the reaction was completed. The reaction mixture was diluted with H2O (30 mL) and extracted with EtOAc (500 mL×3), the combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by reversed-phase HPLC (0.1% FA condition, MeCN/water) to afford the titled compound (200 mg, 0.322 mmol, 3.68% yield, FA) as brown solid. MS(M+H)+=574.3
- To the mixture of tert-butyl (1-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethyl)piperidin-4-yl)carbamate (200 mg, 348.63 μmol) in dioxane (2 mL) was added HCl/dioxane (4 M, 2 mL) and the resulting mixture was stirred at 25° C. for 0.5 h. LCMS showed that the reaction was completed. The mixture was concentrated to afford the titled compound (178 mg, crude, HCl salt) as yellow oil. MS(M+H)+=474.2
- To the mixture of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (160 mg, 343.77 μmol), 3-(4-((2-(2-(2-(4-aminopiperidin-1-yl)ethoxy)ethoxy)ethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (175.33 mg, 343.77 μmol, HCl salt) and HATU (261.42 mg, 687.54 μmol) in DMF (4 mL) was added DIPEA (133.29 mg, 1.03 mmol, 179.64 μL) and the resulting mixture was stirred at 20° C. for 12 h. LCMS showed that the reaction was completed. The mixture was poured into water (50 mL) and extracted with EtOAc (50 mL×3), the combined organic layer was washed with brine (100 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (column: Phenomenex luna C18 150*40 mm*15 um; mobile phase: [water (0.225% FA)-ACN]; B %: 18%-48%, 10 min) and the eluant was lyophilized to afford the titled compound (44.3 mg, 44.73 μmol, 13.01% yield, 93% purity) as black brown solid. MS (M+H)+=921.7.
- 1H NMR (400 MHz, DMSO-d6) δ 11.02 (s, 1H), 8.30 (s, 1H), 8.25 (d, J=13.3 Hz, 1H), 8.16 (s, 1H), 8.05 (s, 1H), 7.94 (dd, J=7.8, 3.3 Hz, 1H), 7.29 (t, J=7.8 Hz, 1H), 7.19 (d, J=6.7 Hz, 1H), 6.95 (d, J=7.4 Hz, 1H), 6.81 (d, J=8.1 Hz, 1H), 5.61 (t, J=5.7 Hz, 1H), 5.12 (dd, J=13.3, 5.1 Hz, 1H), 4.91-4.74 (m, 1H), 4.23 (d, J=17.2 Hz, 1H), 4.17-4.02 (m, 3H), 3.91 (s, 3H), 3.82-3.73 (m, 1H), 3.62-3.58 (m, 2H), 3.58-3.51 (m, 7H), 3.32 (s, 3H), 3.00-2.85 (m, 3H), 2.66-2.54 (m, 3H), 2.38-2.16 (m, 3H), 2.08-1.90 (m, 3H), 1.87-1.77 (m, 2H), 1.76-1.69 (m, 2H), 1.68-1.53 (m, 6H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (41.3 mg, 34.20 μmol, 6.20% yield, 93% purity, TFA salt) as a light brown solid. MS(M+H)+=1009.1
- 1H NMR (400 MHz, CD3OD) δ=8.30-8.13 (m, 2H), 7.42-7.23 (m, 2H), 7.13-7.00 (m, 1H), 6.86 (d, J=8.0 Hz, 1H), 5.21-5.10 (m, 1H), 5.05-4.97 (m, 1H), 4.38-4.22 (m, 2H), 4.21-4.05 (m, 3H), 4.01-3.94 (m, 3H), 3.85-3.54 (m, 18H), 3.48-3.35 (m, 6H), 3.28-3.25 (m, 1H), 3.12-3.06 (m, 1H), 2.98-2.85 (m, 1H), 2.83-2.74 (m, 1H), 2.5-2.38 (m, 1H), 2.33-2.14 (m, 3H), 2.13-2.00 (m, 3H), 1.98-1.65 (m, 8H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (17.7 mg, 18.14 μmol, 8.44% yield, 94% purity). MS(M+H)+=917.8.
- 1H NMR (400 MHz, DMSO-d6) δ=11.01 (br s, 1H), 8.30 (s, 1H), 8.25 (d, J=13.3 Hz, 1H), 8.04 (s, 1H), 7.88 (br dd, J=3.3, 7.6 Hz, 1H), 7.28 (t, J=7.7 Hz, 1H), 7.19 (d, J=6.6 Hz, 1H), 6.93 (d, J=7.4 Hz, 1H), 6.74 (d, J=7.9 Hz, 1H), 5.56 (br t, J=5.2 Hz, 1H), 5.12 (dd, J=5.0, 13.3 Hz, 1H), 4.89-4.75 (m, 1H), 4.27-4.11 (m, 2H), 4.11-4.02 (m, 2H), 3.92 (s, 3H), 3.79-3.67 (m, 1H), 3.33-3.29 (m, 3H), 3.15-3.08 (m, 2H), 2.98-2.88 (m, 1H), 2.81 (br d, J=11.4 Hz, 2H), 2.65-2.59 (m, 1H), 2.35-2.28 (m, 1H), 2.24 (br t, J=7.4 Hz, 2H), 2.08-1.89 (m, 5H), 1.90-1.65 (m, 4H), 1.68-1.48 (m, 8H), 1.45-1.22 (m, 10H).
-
- To a solution of 3-(5-fluoro-4-oxobenzo[d][1,2,3]triazin-3(4H)-yl)piperidine-2,6-dione (1 g, 3.62 mmol) and TEA (1.10 g, 10.86 mmol, 1.51 mL) in dioxane (10 mL) was added 2-[2-[2-[2-(2-aminoethoxy) ethoxy]ethoxy]ethoxy]ethanol (944.97 mg, 3.98 mmol) at 25° C. and the resulting mixture was stirred at 110° C. for 14 h. LCMS showed main peak with the desired mass. The mixture was concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (Silica Flash Column, Eluent of 0-15% Ethyl acetate/Methanol @ 30 mL/min) to afford the titled compound (1.6 g, 3.05 mmol, 84.18% yield, 94% purity) as a yellow oil. MS(M+H)+=494.2
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (25.8 mg, 24.21 μmol, 11.27% yield, 96% purity) as a yellow solid. MS(M+H)+=1023.3
- 1H NMR (400 MHz, DMSO-d6) δ=11.20 (br s, 1H), 8.32 (t, J=5.4 Hz, 1H), 8.29 (s, 1H), 8.23 (d, J=13.6 Hz, 1H), 8.05 (s, 1H), 7.96-7.86 (m, 1H), 7.79 (t, J=8.0 Hz, 1H), 7.19 (dd, J=7.2, 18.8 Hz, 2H), 7.00 (d, J=8.8 Hz, 1H), 5.86 (dd, J=4.8, 11.6 Hz, 1H), 4.97-4.69 (m, 1H), 4.08 (br t, J=14.0 Hz, 2H), 3.90 (s, 3H), 3.66 (br t, J=5.2 Hz, 3H), 3.59-3.53 (m, 4H), 3.50-3.46 (m, 7H), 3.46-3.44 (m, 3H), 3.34-3.31 (m, 4H), 3.01-2.88 (m, 1H), 2.83 (br d, J=11.6 Hz, 2H), 2.71-2.61 (m, 2H), 2.43 (t, J=5.8 Hz, 2H), 2.29-2.17 (m, 1H), 2.05-1.90 (m, 4H), 1.82-1.42 (m, 11H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (49.1 mg, 51.68 μmol, 24.05% yield, 98% purity) as a yellow solid. MS(M+H)+=931.8.
- 1H NMR (400 MHz, DMSO-d6) δ=11.18 (s, 1H), 8.30 (s, 1H), 8.27-8.16 (m, 2H), 8.03 (s, 1H), 7.86 (dd, J1=7.8 Hz, J2=3.4 Hz, 1H), 7.79 (t, J=8.2 Hz, 1H), 7.19 (dd, J1=8.3 Hz, J2=7.4 Hz, 2H), 6.96 (d, J=8.5 Hz, 1H), 5.86 (dd, =11.9 Hz, J2=5.2 Hz, 1H), 4.90-4.73 (m, 1H), 4.07 (t, J=13.9 Hz, 2H), 3.91 (s, 3H), 3.78-3.65 (m, 1H), 3.33 (s, 3H), 3.25-3.20 (m, 2H), 2.99-2.88 (m, 1H), 2.80 (d, J=11.1 Hz, 2H), 2.70-2.61 (m, 2H), 2.28-2.18 (m, 3H), 2.01-1.88 (m, 4H), 1.82-1.68 (m, 4H), 1.66-1.44 (m, 8H), 1.43-1.23 (m, 10H).
-
- To a solution of 2-(2-hydroxyethoxy)ethyl 4-methylbenzenesulfonate (500 mg, 1.92 mmol) and Rh(OAc)2 (42 mg, 190.05 μmol) in DCM (10 mL) was added ethyl 2-diazoacetate (327.00 mg, 2.87 mmol, 300 μL) and the mixture was stirred at 20° C. for 14 h. LCMS showed the desired mass was detected and the starting material remained. Additional ethyl 2-diazoacetate (218.00 mg, 1.91 mmol, 200 μL) was added and the mixture was stirred at 30° C. for another 3 h. TLC (Petroleum ether:Ethyl acetate=1:1) showed the starting material was consumed and the new spot was detected. The mixture was concentrated under reduce pressure. The residue was purified by flash silica gel chromatography (5 g SepaFlash® Silica Flash Column, Eluent of 10˜30% Ethyl acetate/Petroleum ether gradient @ 50 mL/min) to afford the titled compound (460 mg, 1.33 mmol, 69.14% yield) as a yellow oil. MS(M+H)+=347.3
- To a solution of ethyl 2-(2-(2-(tosyloxy)ethoxy)ethoxy)acetate (460 mg, 1.33 mmol) and tert-butyl piperidin-4-ylcarbamate (240 mg, 1.20 mmol) in dioxane (10 mL) were added NaI (39.87 mg, 266.00 μmol) and K2CO3 (551.44 mg, 3.99 mmol) and the mixture was stirred at 80° C. for 14 h. LCMS showed the desired mass was detected. The mixture was filtered and the filter cake was washed with EtOAc (30 mL). The filtrate was concentrated under reduce pressure. The residue was purified by flash silica gel chromatography (5 g SepaFlash® Silica Flash Column, Eluent of 20˜90% MeOH/Ethyl acetate gradient @ 50 mL/min) to afford the titled compound (370 mg, 938.66 μmol, 70.58% yield, 95% purity) as yellow oil. MS(M+H)+=375.5.
- To a solution of ethyl 2-(2-(2-(4-((tert-butoxycarbonyl)amino)piperidin-1-yl)ethoxy)ethoxy)acetate (370 mg, 988.06 μmol) in THF (3 mL) was added a solution of LiOH. H2O (49.76 mg, 1.19 mmol) in H2O (1.5 mL) and the mixture was stirred at 40° C. for 14 h. LCMS showed the desired mass was detected. The mixture was concentrated under reduce pressure to afford the titled compound (350 mg, crude) as yellow solid.
- To a solution of 2-(2-(2-(4-((tert-butoxycarbonyl)amino)piperidin-1-yl)ethoxy)ethoxy)acetic acid (300 mg, 851.42 μmol) in DMF (3 mL) were added HATU (647.47 mg, 1.70 mmol) and DIPEA (222.60 mg, 1.72 mmol, 300.00 μL) and the mixture was stirred at 20° C. for 15 min. Then a solution of (2S,4R)-1-(((S)-2-amino-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (360 mg, 770.84 HCl salt) and DIPEA (222.60 mg, 1.72 mmol, 300.00 μL) in DMF (3 mL) was added and the mixture was stirred at 20° C. for 14 h. LCMS showed the starting material remained and trace of the desired mass was detected. Additional HATU (647.47 mg, 1.70 mmol) was added and the mixture was stirred at 40° C. for another 14 h. LCMS showed desired mass was detected. The mixture was diluted with H2O (10 mL) and extracted with EtOAc (10 mL×3). The combined organic layer was washed with H2O (10 mL) and brine (10 mL×2), dried over Na2SO4 and filtered. The filtrate was concentrated under reduce pressure. The residue was purified by flash silica gel chromatography (5 g SepaFlash® Silica Flash Column, Eluent of 50˜100% Ethyl acetate/Petroleum ether to 0-50% MeOH/EtOAc gradient @ 50 mL/min) and then re-purified by prep-HPLC (column: Waters Xbridge C18 150*50 mm*10 um; mobile phase: [water (10 mM NH4HCO3)-ACN]; B %: 26%-56%, min) the titled compound (80 mg, 100.14 μmol, 11.76% yield, 95% purity) as a yellow solid. MS(M+H)+=759.8.
- To a solution of tert-butyl (1-(2-(2-(2-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)ethoxy)ethyl)piperidin-4-yl)carbamate (80 mg, 105.41 μmol) in dioxane (2 mL) was added HCl/dioxane (4 M, 2 mL) and the mixture was stirred at 20° C. for 1 h. LCMS showed the desired mass was detected after work-up. The reaction was concentrated under reduce pressure to afford the titled compound (70 mg, HCl salt) as a yellow solid. MS(M+H)+=659.7.
- To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (45 mg, 96.69 μmol) in DMF (1 mL) were added HATU (55 mg, 144.65 μmol) and DIPEA (22.26 mg, 172.23 μmol, 30 μL), after stirring at 20° C. for 15 min. Then a solution of (2S,4R)-1-((S)-2-(2-(2-(2-(4-aminopiperidin-1-yl)ethoxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (70 mg, 95.66 μmol, HCl salt) in DMF (1 mL) was added and the mixture was stirred at 20° C. for 1 h. LCMS showed the desired mass was detected. The mixture was diluted with H2O (10 mL) and extracted with EtOAc (10 mL×3). The combined organic layer was washed with H2O (10 mL) and brine (10 mL×2), dried over Na2SO4 and filtered. The filtrate was concentrated under reduced pressure. The crude was purified by prep-HPLC (column: Waters Xbridge 150*25 mm*5 um; mobile phase: [water (10 mM NH4HCO3)-ACN]; B %: 43%-73%, 10 min) and the eluent was lyophilized to afford the titled compound (23.8 mg, 20.44 μmol, 21.37% yield, 95% purity) as a white solid. MS(M+H)+=1106.6.
- 1H NMR (400 MHz, DMSO-d6) δ=8.98 (s, 1H), 8.62-8.57 (m, 1H), 8.30 (s, 1H), 8.24 (d, J=13.3 Hz, 1H), 8.03 (s, 1H), 7.88-7.82 (m, 1H), 7.45-7.38 (m, 5H), 7.19 (d, J=6.6 Hz, 1H), 5.17-5.14 (m, 1H), 4.86-4.79 (m, 1H), 4.57 (br d, J=9.7 Hz, 1H), 4.47-4.41 (m, 1H), 4.39-4.34 (m, 1H), 4.29-4.23 (m, 1H), 4.08 (br t, J=13.9 Hz, 3H), 3.98 (s, 2H), 3.94-3.89 (s, 4H), 3.71-3.65 (m, 2H), 3.64-3.59 (m, 4H), 3.58-3.54 (m, 2H), 3.30 (br s, 3H), 2.86-2.80 (m, 2H), 2.53-2.52 (m, 2H), 2.44 (s, 3H), 2.09-1.90 (m, 6H), 1.79-1.69 (m, 4H), 1.65-1.49 (m, 6H), 0.95 (s, 9H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (51.9 mg, 41.06 μmol, 27.41% yield, 91% purity) as white solid. MS(M+H)+=1150.7
- 1H NMR (400 MHz, DMSO-d6) δ=8.97 (s, 1H), 8.59 (t, J=6.0 Hz, 1H), 8.29 (s, 1H), 8.23 (d, J=13.3 Hz, 1H), 8.02 (s, 1H), 7.86 (br s, 1H), 7.44-7.35 (m, 5H), 7.18 (d, J=6.8 Hz, 1H), 5.15 (d, J=3.4 Hz, 1H), 4.85-4.77 (m, 1H), 4.56 (d, J=9.7 Hz, 1H), 4.47-4.32 (m, 3H), 4.28-4.19 (m, 1H), 4.07 (br t, J=13.8 Hz, 2H), 3.96 (s, 2H), 3.90 (s, 3H), 3.69-3.43 (m, 15H), 2.82 (br s, 2H), 2.43 (s, 3H), 2.10-1.85 (m, 7H), 1.82-1.44 (m, 12H), 0.96-0.91 (m, 9H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (14.1 mg, 11.33 μmol, 4.40% yield, 96% purity) as a white solid.
- MS(M+H)+=1194.6
- 1H NMR (400 MHz, DMSO-d6) δ=8.98 (s, 1H), 8.59 (br t, J=6.0 Hz, 1H), 8.30 (s, 1H), 8.24 (d, J=13.3 Hz, 1H), 8.02 (s, 1H), 7.86 (br dd, J=3.4, 7.6 Hz, 1H), 7.46-7.36 (m, 5H), 7.19 (d, J=6.7 Hz, 1H), 5.17 (br s, 1H), 4.82 (br t, J=8.2 Hz, 1H), 4.56 (d, J=9.7 Hz, 1H), 4.47-4.32 (m, 3H), 4.26 (m, 1H), 4.07 (br t, J=13.9 Hz, 2H), 3.97 (s, 2H), 3.91 (s, 3H), 3.66-3.57 (m, 6H), 3.56-3.52 (m, 4H), 3.50-3.45 (m, 6H), 3.33 (br s, 3H), 2.83 (br d, J=11.4 Hz, 2H), 2.44 (s, 3H), 2.11-1.99 (m, 4H), 1.98-1.86 (m, 3H), 1.82-1.67 (m, 5H), 1.67-1.48 (m, 7H), 0.97-0.91 (s, 9H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (31.7 mg, 25.34 μmol, 9.83% yield, 99% purity) as a white solid.
- MS(M+H)+=1238.9
- 1H NMR (400 MHz, DMSO-d6) δ 8.98 (s, 1H), 8.59 (t, J=6.1 Hz, 1H), 8.30 (s, 1H), 8.24 (d, J=13.3 Hz, 1H), 8.02 (s, 1H), 7.87 (dd, J=3.3, 7.8 Hz, 1H), 7.43-7.37 (m, 5H), 7.19 (d, J=6.6 Hz, 1H), 5.16-5.14 (m, 1H), 4.84-4.76 (m, 1H), 4.57-4.55 (m, 1H), 4.47-4.33 (m, 3H), 4.28-4.21 (m, 1H), 4.07 (t, J=13.9 Hz, 2H), 3.96 (s, 2H), 3.91 (s, 3H), 3.71-3.51 (m, 13H), 3.50-3.46 (m, 10H), 3.33 (s, 3H), 2.85-2.82 (m, 2H), 2.44 (s, 3H), 2.08-1.91 (m, 6H), 1.76-1.52 (m, 10H), 0.94 (s, 9H)
-
- To a solution of tert-butyl (1-(8-hydroxyoctyl)piperidin-4-yl)carbamate (5.5 g, 16.74 mmol) and Rh(OAc)2 (37.00 mg, 167.43 μmol) in DCM (50 mL) was added solution of ethyl 2-diazoacetate (2.48 g, 21.77 mmol, 2.28 mL) in DCM (10 mL) drop-wise at 0° C. The mixture was stirred at 25° C. for 12 hr. LCMS showed most of the starting material remained. Another portion of Rh (OAc)2 (185.01 mg, 837.17 μmol) was added to the reaction mixture at 25° C. The resulting mixture was stirred at 40° C. for another 6 hrs. LCMS showed 76% of desired mass. The mixture solution was concentrated under reduced pressure. The crude product was purified by silica gel column chromatography (1000 mesh silica gel, eluted with petroleum ether:ethyl acetate=10/1 to 0/1) to give ethyl 2-((8-(4-((tert-butoxycarbonyl)amino)piperidin-1-yl)octyl)oxy)acetate (4.5 g, crude) as yellow oil, which was used for the next step directly. MS(M+H)+=415.2
- A mixture of ethyl 2-((8-(4-((tert-butoxycarbonyl)amino)piperidin-1-yl)octyl)oxy)acetate (4.5 g, 10.85 mmol), LiOH (519.89 mg, 21.71 mmol) in THF (30 mL) and H2O (30 mL) was stirred at 45° C. for 12 hr. LCMS showed the starting material was consumed completely. The reaction solution was concentrated to remove the organic phase. The residual aqueous solution was washed with EtOAc (50 mL×3). The 1M HCl aqueous solution was added to the suspension to adjust pH to 6. The aqueous layer was extracted with EtOAc (50 mL×4). The combined organic layers were dried over Na2SO4 and concentrated. The crude product was purified by reversed-phase HPLC (0.1% NH3·H2O condition, MeCN/H2O) afford 2-((8-(4-((tert-butoxy carbonyl)amino)piperidin-1-yl)octyl)oxy)acetic acid (1.8 g, 4.66 mmol, 42.90% yield, 100% purity) as white solid which was used for the next step directly. MS (M−H)+=385.4
- To a solution of 2-((8-(4-((tert-butoxycarbonyl)amino)piperidin-1-yl)octyl)oxy)acetic acid (300 mg, 776.15 μmol) in DMF (5 mL) was added HATU (442.67 mg, 1.16 mmol) and DIPEA (300.93 mg, 2.33 mmol, 405.56 μL). The mixture was stirred at 25° C. for 10 min. To mixture was added (2S,4R)-1-((S)-2-amino-3,3-di methylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl) benzyl)pyrrolidine-2-carboxamide (289.98 mg, 620.92 μmol, 0.8 eq, HCl). The mixture was stirred at 25° C. for 12 h. LCMS showed 63% peak with desired mass. The solution was diluted with ethyl acetate (30 mL) and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (20 g SepaFlash® Silica Flash Column, Eluent of 0˜100% Ethyl acetate/Petroleum ether gradient @ 100 mL/min; Eluent of 0-50% Ethyl acetate/Methanol gradient @ 100 mL/min) to afford the titled compound (0.5 g, crude) was obtained as brown oil which was used for the next step directly. MS(M+H)+=799.4
- To a solution of tert-butyl (1-(8-(2-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl) carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)octyl)piperidin-4-yl)carbamate (0.5 g, 625.73 μmol) in dioxane (2 mL) was added HCl/dioxane (4 M, 10 mL, 63.93 eq) at 25° C. The resulting mixture was stirred at 25° C. for 0.5 hr. LCMS showed the starting material was consumed completely and a main peak with desired mass. The mixture solution was concentrated under reduced pressure to afford the titled compound (380 mg, crude, HCl) as brown solid, which was used for the next step directly. MS(M+H)+=699.4
- To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (70 mg, 150.40 μmol) in DMF (5 mL) were added HATU (85.78 mg, 225.60 μmol) and DIPEA (58.31 mg, 451.20 μmol, 78.59 μL). The mixture was stirred at 25° C. for 10 min. To mixture was added (2S,4R)-1-((S)-2-(2-((8-(4-aminopiperidin-1-yl)octyl)oxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (110.61 mg, 150.40 μmol, HCl). The mixture was stirred at 25° C. for 12 h. LCMS showed a main peak with desired mass. The mixture solution was concentrated under reduced pressure. The crude product was purified prep-HPLC (column: Waters Xbridge 150*25 mm*5 um; mobile phase: [water (10 mM NH4HCO3)-ACN]; B %: 58%-88%, 10 min) and lyophilized to afford the titled compound (22.9 mg, 19.18 μmol, 12.75% yield, 96% purity) as white solid. MS(M+H)+=1146.4
- 1H NMR (400 MHz, DMSO-d6) δ=8.98 (s, 1H), 8.62 (t, J=5.9 Hz, 1H), 8.34-8.17 (m, 2H), 8.03 (s, 1H), 7.86 (dd, J=3.4, 7.7 Hz, 1H), 7.44-7.36 (m, 4H), 7.34 (d, J=9.6 Hz, 1H), 7.19 (d, J=6.8 Hz, 1H), 5.29-5.07 (m, 1H), 4.88-4.70 (m, 1H), 4.55 (d, J=9.6 Hz, 1H), 4.48-4.32 (m, 3H), 4.30-4.18 (m, 1H), 4.07 (t, J=13.9 Hz, 2H), 3.94-3.87 (m, 5H), 3.77-3.55 (m, 3H), 3.50-3.45 (m, 2H), 2.77 (d, J=11.0 Hz, 2H), 2.46-2.42 (m, 4H), 2.19 (t, J=7.3 Hz, 2H), 2.11-2.02 (m, 1H), 2.00-1.80 (m, 5H), 1.82-1.69 (m, 4H), 1.66-1.43 (m, 9H), 1.40-1.31 (m, 4H), 1.30-1.15 (m, 7H), 0.94 (s, 9H).
-
- To a solution of 2,2′-oxydiethanol (20 g, 188.47 mmol, 17.86 mL) in DCM (200 mL) were added TosCl (35.93 g, 188.47 mmol), KI (6.26 g, 37.69 mmol) and silver oxide (65.51 g, 282.71 mmol). The mixture was stirred at 20° C. for 14 h. LCMS showed the desired mass was detected. The mixture was filtered and the filter cake was washed with EtOAc (100 mL). The filtrate was concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (120 g SepaFlash® Silica Flash Column, Eluent of 0˜100% Ethyl acetate/Petroleum ether to 0-50% MeOH/EtOAc gradient @ 80 mL/min) to afford (27.1 g, 104.11 mmol, 55.24% yield) as a yellow oil. MS(M+H)+=261.1.
- To a solution of (2S,4R)-1-((S)-2-(1-fluorocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(2-hydroxy-4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (500 mg, 938.74 μmol) and 2-(2-hydroxyethoxy)ethyl 4-methylbenzenesulfonate (293 mg, 1.13 mmol) in DMF (10 mL) were added NaI (70.35 mg, 469.37 μmol) and K2CO3 (389.23 mg, 2.82 mmol). The reaction mixture was stirred at 100° C. for 14 h. LCMS showed the desired mass was detected. The mixture was diluted with H2O (10 mL) and extracted with EtOAc (10 mL×3). The combined organic layer was washed with H2O (10 mL) and brine (10 mL×2), dried over Na2SO4 and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (5 g SepaFlash® Silica Flash Column, Eluent of 50˜100% Ethyl acetate/Petroleum ether to 0-20% MeOH/EtOAc gradient @ 50 mL/min) to afford the titled compound (460 mg, 741.06 μmol, 78.94% yield) as a yellow oil. MS(M+H)+=621.4.
- To a solution of (2S,4R)-1-(((S)-2-(1-fluorocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(2-(2-(2-hydroxy ethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (510 mg, 821.61 μmol) in DCM (8 mL) were added TEA (501.63 mg, 4.96 mmol, 690 μL) and a solution of TosCl (469.91 mg, 2.46 mmol) in DCM (2 mL). The mixture was stirred at 20° C. for 14 h. TLC (Ethyl acetate:Methanol=10:1) showed the desired spot was detected. The mixture was concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (5 g SepaFlash® Silica Flash Column, Eluent of 20˜100% Ethyl acetate/Petroleum ether gradient @ 50 mL/min) to afford (0.3 g, 387.14 μmol, 47.12% yield) as a white solid. MS(M+H)+=775.6.
- To a solution of 2-(2-(2-(((2S,4R)-1-((S)-2-(1-fluorocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)ethoxy)ethyl 4-methylbenzenesulfonate (300 mg, 387.14 μmol) and tert-butyl piperidin-4-ylcarbamate (74 mg, 369.49 μmol) in dioxane (6 mL) were added NaI (5.80 mg, 38.71 μmol) and K2CO3 (160.51 mg, 1.16 mmol) and the mixture was stirred at 80° C. for 14 h. LCMS showed the desired mass was detected. The mixture was concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (5 g SepaFlash® Silica Flash Column, Eluent of 0˜100% MeOH/Ethyl acetate gradient @ 50 mL/min) to afford the titled compound (280 mg, 348.70 μmol, 90.07% yield) as a yellow solid. MS(M+H)+=803.8.
- To a solution of tert-butyl (1-(2-(2-(2-(((2S,4R)-1-((S)-2-(1-fluorocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)ethoxy)ethyl)piperidin-4-yl)carbamate (280 mg, 348.70 μmol) in dioxane (4 mL) was added HCl/dioxane (4 M, 4 mL) and the mixture was stirred at 20° C. for 1 h. LCMS showed the desired mass was detected after work-up. The reaction mixture was concentrated under reduced pressure to afford the titled compound (260 mg, crude, HCl salt) as a yellow solid. MS(M+H)+=703.7.
- To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (60 mg, 128.91 μmol) in DMF (1 mL) were added HATU (74 mg, 194.62 μmol) and DIPEA (37.10 mg, 287.06 μmol, 50 μL) and the mixture was stirred at 20° C. for 15 min. Then a solution of (2S,4R)—N-(2-(2-(2-(4-aminopiperidin-1-yl)ethoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((S)-2-(1-fluorocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide (120 mg, 137.00 μmol, HCl salt) and DIPEA (44.52 mg, 344.47 μmol, 60 μL) in DMF (1 mL) was added and the mixture was stirred at 20° C. for 1 h. LCMS showed the desired mass was detected. The mixture was diluted with H2O (10 mL) and extracted with EtOAc (10 mL×3). The combined organic layer was washed with H2O (10 mL) and brine (10 mL×2), dried over Na2SO4 and filtered. The filtrate was concentrated under reduced pressure. The crude was purified by prep-HPLC (column: Waters Xbridge 150*25 mm*5 um; mobile phase: [water (10 mM NH4HCO3)-ACN]; B %: 49%-79%, 10 min) and the eluent was lyophilized to afford the titled compound (32.0 mg, 26.43 μmol, 20.50% yield, 95% purity) as a white solid. MS(M+H)+=1150.5
- 1H NMR (400 MHz, DMSO-d6) δ=8.98 (s, 1H), 8.49 (br t, J=5.9 Hz, 1H), 8.30 (s, 1H), 8.24 (d, J=13.3 Hz, 1H), 8.03 (s, 1H), 7.85-7.80 (m, 1H), 7.41 (d, J=7.7 Hz, 1H), 7.31-7.26 (m, 1H), 7.19 (d, J=6.6 Hz, 1H), 7.05 (s, 1H), 6.96 (br d, J=8.1 Hz, 1H), 5.17-5.14 (m, 1H), 4.85-4.78 (m, 1H), 4.59 (br d, J=9.2 Hz, 1H), 4.51 (br t, J=8.2 Hz, 1H), 4.36-4.28 (m, 2H), 4.23-4.16 (m, 3H), 4.07 (br t, J=13.9 Hz, 2H), 3.91 (s, 3H), 3.77 (br d, J=3.3 Hz, 2H), 3.73-3.69 (m, 1H), 3.63-3.58 (m, 4H), 3.33-3.33 (m, 3H), 2.89-2.82 (m, 2H), 2.53-2.52 (m, 2H), 2.46 (s, 3H), 2.11-2.02 (m, 4H), 2.00-1.89 (m, 4H), 1.76-1.71 (m, 2H), 1.64-1.57 (m, 4H), 1.55-1.49 (m, 2H), 1.40-1.32 (m, 2H), 1.24-1.19 (m, 2H), 0.95 (s, 9H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (49.5 mg, 37.72 μmol, 29.26% yield, 91% purity) as white solid. MS(M+H)+=1193.6
- 1H NMR (400 MHz, DMSO-d6) δ=8.97 (s, 1H), 8.49 (br t, J=6.0 Hz, 1H), 8.30 (s, 1H), 8.24 (d, J=13.4 Hz, 1H), 8.03 (s, 1H), 7.85 (dd, J=3.2, 7.6 Hz, 1H), 7.41 (d, J=7.6 Hz, 1H), 7.29 (dd, J=2.8, 9.0 Hz, 1H), 7.18 (d, J=6.8 Hz, 1H), 7.04 (d, J=1.4 Hz, 1H), 6.97 (s, 1H), 5.17 (d, J=3.6 Hz, 1H), 4.91-4.77 (m, 1H), 4.59 (d, J=8.8 Hz, 1H), 4.51 (t, J=8.2 Hz, 1H), 4.39-4.27 (m, 2H), 4.25-4.15 (m, 3H), 4.07 (br t, J=14.0 Hz, 2H), 3.91 (s, 3H), 3.84-3.77 (m, 2H), 3.77-3.56 (m, 6H), 3.56-3.41 (m, 6H), 2.92-2.78 (m, 2H), 2.42-2.51 (m, 4H), 2.07 (br d, J=8.8 Hz, 3H), 1.95 (br d, J=4.0 Hz, 3H), 1.81-1.69 (m, 4H), 1.67-1.45 (m, 7H), 1.43-1.30 (m, 2H), 1.21 (br dd, J=3.6, 8.8 Hz, 2H), 0.95 (s, 9H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (15.5 mg, 11.26 μmol, 6.55% yield, 90% purity) as white solid. MS(M+H)+=1238.7
- 1H NMR (400 MHz, DMSO-d6) δ 8.98 (s, 1H), 8.51 (t, J=5.9 Hz, 1H), 8.30 (s, 1H), 8.24 (d, J=13.3 Hz, 1H), 8.04 (s, 1H), 7.93-7.83 (m, 1H), 7.41 (d, J=7.8 Hz, 1H), 7.34-7.23 (m, 1H), 7.18 (d, J=6.7 Hz, 1H), 7.04 (d, J=1.7 Hz, 1H), 6.99-6.92 (m, 1H), 5.19 (s, 1H), 4.90-4.75 (m, 1H), 4.65-4.43 (m, 2H), 4.42-4.25 (m, 2H), 4.25-4.12 (m, 3H), 4.08 (t, J=13.9 Hz, 2H), 3.94-3.87 (m, 4H), 3.79 (t, J=4.6 Hz, 2H), 3.75-3.65 (m, 2H), 3.65-3.60 (m, 3H), 3.59-3.53 (m, 3H), 3.53-3.45 (m, 7H), 2.82 (d, J=10.9 Hz, 2H), 2.47-2.41 (m, 5H), 2.12-1.99 (m, 3H), 1.98-1.88 (m, 3H), 1.80-1.69 (m, 4H), 1.66-1.57 (m, 4H), 1.56-1.46 (m, 2H), 1.42-1.31 (m, 2H), 1.25-1.22 (m, 1H), 1.22-1.19 (m, 1H), 0.95 (s, 9H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (16 mg, 11.73 μmol, 10.65% yield, 94% purity) as yellow solid. MS(M+H)+=1283.2
- 1H NMR (400 MHz, DMSO-d6) δ=8.97 (s, 1H), 8.50-8.45 (m, 1H), 8.30 (s, 1H), 8.24 (d, J=13.3 Hz, 1H), 8.02 (s, 1H), 7.88-7.83 (m, 1H), 7.40 (d, J=7.7 Hz, 1H), 7.31-7.25 (m, 1H), 7.18 (d, J=6.7 Hz, 1H), 7.05-7.02 (m, 1H), 6.98-6.94 (m, 1H), 5.16 (d, J=3.5 Hz, 1H), 4.86-4.76 (m, 1H), 4.59 (br d, J=9.0 Hz, 1H), 4.51 (t, J=8.3 Hz, 1H), 4.39-4.27 (m, 2H), 4.24-4.15 (m, 3H), 4.07 (br t, J=13.9 Hz, 2H), 3.91 (s, 3H), 3.82-3.76 (m, 2H), 3.75-3.68 (m, 1H), 3.65-3.59 (m, 3H), 3.57-3.53 (m, 2H), 3.52-3.46 (m, 11H), 3.30 (s, 3H), 2.86-2.80 (m, 2H), 2.47-2.44 (m, 5H), 2.11-1.89 (m, 8H), 1.81-1.69 (m, 3H), 1.67-1.47 (m, 5H), 1.42-1.31 (m, 2H), 1.26-1.18 (m, 2H), 0.95 (s, 9H).
-
- To a solution of (2S,4R)-1-(((S)-2-(1-fluorocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(2-hydroxy-4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (0.5 g, 938.74 μmol) and 8-(4-((tert-butoxycarbonyl)amino)piperidin-1-yl)octyl 4-methylbenzenesulfonate (589.04 mg, 1.22 mmol) in MeCN (2 mL) were added K2CO3 (259.48 mg, 1.88 mmol) and NaI (70.36 mg, 469.37 μmol) and the resulting mixture was heated to 60° C. for 16 hours. LCMS showed 33% of reactant remained. Additional 8-(4-((tert-butoxycarbonyl)amino)piperidin-1-yl)octyl 4-methylbenzenesulfonate (543.74 mg, 1.12 mmol) was added and the resulting mixture was stirred at 60° C. for another 24 hrs. LCMS showed the starting material was consumed completely and a main peak with desired mass. The mixture was diluted with ethyl acetate (30 mL) and filtered. The filtrate was concentrated. The residue was purified by flash silica gel chromatography (25 g SepaFlash® Silica Flash Column, Eluent of 0˜100% Ethyl acetate/Petroleum ether gradient @ 50 mL/min; Eluent of 0-20% Methanol/Ethyl acetate @ 100 mL/min) to afford the titled compound (0.6 g, crude) as a yellow oil, which was used for the next step directly. MSM+H)+=843.7
- To a solution of tert-butyl (1-(8-(2-((2S,4R)-1-(((S)-2-(1-fluorocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamido)methyl)-5-(4-methylthiazol-5-yl)phenoxy)octyl)piperidin-4-yl)carbamate (0.6 g, 711.66 μmol) in dioxane (5 mL) was added HCl/dioxane (4 M, 15 mL) at 0° C. The mixture was stirred at 25° C. for 0.5 hr. TLC (Ethyl acetate:Methanol=10:1; Rf=0) showed the starting material was consumed completely and new spot was formed. The reaction mixture was concentrated under reduced pressure to afford the titled compound (0.9 g, crude, HCl salt) as a yellow solid, which was used for the next step directly. MS(M+H)+=743.7
- To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (60 mg, 128.91 μmol) in DMF (2 mL) were added HATU (122.54 mg, 322.27 μmol) and DIPEA (33.32 mg, 257.82 μmol, 44.91 μL), the mixture was stirred at 20° C. for 10 min. Then a solution of (2S,4R)—N-(2-((8-(4-aminopiperidin-1-yl)octyl)oxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((S)-2-(1-fluorocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide (120.57 mg, 154.69 μmol, HCl salt) in DMF (2 mL) and DIPEA (33.32 mg, 257.82 μmol, 44.91 μL) were added and the resulting mixture was stirred at 25° C. for 12 h. LCMS showed the starting material was consumed completely and a main peak with desired mass. The mixture solution was concentrated under reduced pressure. The crude product was purified prep-HPLC (column: Waters Xbridge 150*25 mm*5 um; mobile phase: [water (10 mM NH4HCO3)-ACN]; B %: 62%-92%, 10 min) and the eluent was lyophilized to afford the titled compound (58.4 mg, 47.10 μmol, 36.53% yield, 96% purity) as a white solid. MS(M+H)+=1190.9
- 1H NMR (400 MHz, DMSO-d6) δ=8.97 (s, 1H), 8.48 (t, J=5.8 Hz, 1H), 8.33-8.18 (m, 2H), 8.03 (s, 1H), 7.85 (dd, J=3.4, 7.6 Hz, 1H), 7.40 (d, J=7.6 Hz, 1H), 7.29 (dd, J=2.8, 9.2 Hz, 1H), 7.19 (d, J=6.8 Hz, 1H), 7.03-6.90 (m, 2H), 5.17 (br s, 1H), 4.89-4.74 (m, 1H), 4.59 (d, J=8.8 Hz, 1H), 4.51 (t, J=8.2 Hz, 1H), 4.40-4.14 (m, 3H), 4.13-3.99 (m, 4H), 3.91 (s, 3H), 3.79-3.68 (m, 1H), 3.68-3.42 (m, 2H), 2.80 (br d, J=11.0 Hz, 2H), 2.53-2.51 (m, 1H), 2.45 (s, 3H), 2.23 (br t, J=7.2 Hz, 2H), 2.14-2.04 (m, 1H), 2.01-1.88 (m, 5H), 1.84-1.49 (m, 13H), 1.48-1.18 (m, 15H), 0.95 (s, 9H).
-
- To a solution of ethanol (499.02 mg, 10.83 mmol, 633.27 μL) in THF (10 mL) was added NaH (787.71 mg, 19.69 mmol, 60% purity in mineral oil) at 0° C., the mixture was stirred at 0° C. for 15 minutes. To this mixture was added a solution of 2, 5-difluoro-4-nitrobenzoic acid (2 g, 9.85 mmol) in THF (10 mL) slowly at 0° C., the resulting mixture was stirred at 15° C. for 3 hours. TLC (SiO2, Petroleum ether/Ethyl acetate=1/1) indicated the starting material was consumed completely, and one major new spot with lower polarity was detected. The reaction mixture was quenched by addition H2O (50 mL), and adjusted to pH=5 HCl by a solution (1M) of HCl. The resulting mixture was extracted with EtOAc (80 mL×3). The combined organic layers were washed with brine (100 mL×2), dried over Na2SO4, filtered and concentrated in vacuo to afford the titled compound (2.4 g, 9.74 mmol, 98.91% yield, 93% purity) as a gray solid, which was used for the next step directly.
- A solution of 5-ethoxy-2-fluoro-4-nitrobenzoic acid (2.4 g, 9.74 mmol, 93% purity) in toluene (30 mL) was added a solution of TMSCHN2 (2 M, 7.30 mL) in toluene (6 mL) and MeOH (6 mL) slowly, the mixture was stirred at 15° C. for 2 hours. TLC (SiO2, Petroleum ether/Ethyl acetate=2/1) indicated trace of the starting material remained and one major new spot with lower polarity was detected. The reaction mixture was quenched by addition H2O (80 mL), then extracted with EtOAc (100 mL×3). The combined organic layers were washed with brine (150 mL×2), dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash silica gel chromatography (25 g SepaFlash® Silica Flash Column, Eluent of 12˜50% Ethyl acetate/Petroleum ether gradient @ 65 mL/min) to afford the titled compound (1.1 g, 4.52 mmol, 46.44% yield) as a brown solid.
- To a solution of methyl 5-ethoxy-2-fluoro-4-nitrobenzoate (1.1 g, 4.52 mmol) in MeOH (20 mL) was added Pd/C (600 mg, 10% purity) under N2 atmosphere, the mixture was degassed and purged with H2 for 3 times, the mixture was stirred at 15° C. for 16 hours under H2 atmosphere (15 psi). LCMS showed reactant was consumed completely and 80% of desired mass was detected. The reaction mixture was filtered and the filtrate was concentrated in vacuo to afford the titled compound (940 mg, 3.53 mmol, 77.98% yield, 80% purity) as a brown solid, which was used for the next step directly. MS(M+H)+=214.2.
- A mixture of 2-chloro-9-cyclopentyl-7,7-difluoro-5-methyl-8, 9-dihydro-5H-pyrimido[4, 5-b][1, 4]diazepin-6(7H)-one (300 mg, 947.17 μmol), methyl 4-amino-5-ethoxy-2-fluorobenzoate (378.64 mg, 1.42 mmol, 80% purity) and TsOH (326.21 mg, 1.89 mmol) in 1, 4-dioxane (8 mL) was stirred at 100° C. for 12 hours. LCMS showed 13% of reactant remained and 39% of desired mass was detected. To this mixture was added methyl 4-amino-5-ethoxy-2-fluoro-benzoate (126.21 mg, 473.59 μmol, 80% purity) followed by TsOH (163.10 mg, 947.17 μmol), the resulting mixture was stirred at 100° C. for 12 hours. LCMS showed reactant was consumed completely and 37% of desired mass was detected. The reaction mixture was concentrated in vacuo. The residue was purified by prep-HPLC (column: Waters Xbridge 150*25 mm*5 um; mobile phase: [water (10 mM NH4HCO3)-ACN]; B %: 60%-90%, 10 min), the eluent was freeze-dried to afford the titled compound (80 mg, 162.11 μmol, 17.12% yield) as a brown solid. MS(M+H)+=494.3.
- To a solution of methyl 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6, 7, 8, 9-tetrahydro-5H-pyrimido[4, 5-b][1, 4]diazepin-2-yl)amino)-5-ethoxy-2-fluorobenzoate (80 mg, 162.11 μmol) in THF (2 mL) and MeOH (2 mL) was added NaOH (2 M in H2O, 2 mL), the mixture was stirred at 25° C. for 16 hours. LCMS showed reactant was consumed completely and 90% of desired mass was detected. The reaction mixture was quenched by addition with HCl solution (1 M) to adjust pH=5. The resulting mixture was concentrated in vacuo to afford the titled compound (310 mg, 646.57 μmol, 398.84% yield,) as a brown solid, which was used for the next step directly. MS(M+H)+=480.1.
- To a solution of 4-((2-(2-(2-(4-aminopiperidin-1-yl)ethoxy)ethoxy)ethyl)amino)-2-(2, 6-dioxopiperidin-3-yl)isoindoline-1,3-dione (65 mg, 115.97 μmol, 2HCl salt), 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6, 7, 8, 9-tetrahydro-5H-pyrimido[4, 5-b][1, 4]diazepin-2-yl)amino)-5-ethoxy-2-fluorobenzoic acid (233.54 mg, 487.09 μmol) and HATU (66.15 mg, 173.96 μmol) in DMF (2 mL) was added DIEA (89.93 mg, 695.85 μmol, 121.20 μL), the mixture was stirred at 15° C. for 2 hours. LCMS showed 17% of reactant remained and 33% of desired mass was detected. To this mixture was added 4-[2-[2-[2-(4-amino-1-piperidyl)ethoxy]ethoxy]ethylamino]-2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione (13.00 mg, 23.19 μmol, 2HCl salt), the resulting mixture was stirred at 15° C. for 2 hours. The reaction mixture was combined with another batch (20 mg). The reaction mixture was filtered and the filtrate was purified by prep-HPLC (column: Waters Xbridge 150*25 mm*5 um; mobile phase: [water (10 mM NH4HCO3)-ACN]; B %: 36%-69%, 10 min) followed by prep-HPLC (column: Phenomenex luna C18 150*40 mm*15 um; mobile phase: [water (0.225% FA)-ACN]; B %: 18%-48%, 10 min), the eluent was freeze-dried to afford the titled compound (29.2 mg, 29.54 μmol, 25.47% yield, 96% purity) as a yellow solid. MS(M+H)+=949.6.
- 1H NMR (400 MHz, CDCl3) δ=8.35 (d, J=15.0 Hz, 1H), 8.07 (s, 1H), 7.85 (s, 1H), 7.64-7.41 (m, 2H), 7.11 (d, J=7.1 Hz, 1H), 6.92 (d, J=8.6 Hz, 1H), 6.76-6.60 (m, 1H), 6.53 (s, 1H), 5.03-4.69 (m, 2H), 4.20 (q, J=6.8 Hz, 2H), 4.03 (m, 1H), 3.92 (t, J=13.3 Hz, 2H), 3.75-3.71 (m, 2H), 3.70-3.59 (m, 6H), 3.47 (m, 2H), 3.42 (s, 3H), 3.06-2.84 (m, 3H), 2.83-2.69 (m, 2H), 2.66-2.61 (m, 2H), 2.30-2.23 (m, 2H), 2.20-2.07 (m, 3H), 2.07-2.00 (m, 2H), 1.92-1.74 (m, 5H), 1.69-1.55 (m, 4H), 1.54-1.45 (m, 3H).
-
- Step 1-5 are Described in the Above Reaction Scheme.
- To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido [4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-isopropoxybenzoic acid (306.93 mg, 621.98 μmol), 4-((2-(2-(2-(4-aminopiperidin-1-yl)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (83 mg, 148.09 μmol, 2HCl salt) and HATU (84.46 mg, 222.14 μmol) in DMF (3 mL) was added DIEA (95.70 mg, 740.45 μmol, 128.97 μL), the mixture was stirred at 15° C. for 2 hours. LCMS showed reactant was consumed completely and 82% of desired mass was detected. The reaction mixture was filtered and the filtrate was purified by prep-HPLC (column: Waters Xbridge BEH C18 150*25 mm*5 um; mobile phase: [water (10 mM NH4HCO3)-ACN]; B %: 53%-83%, 10 min) to afford the titled compound (38.4 mg, 38.28 μmol, 25.85% yield, 96% purity) as a yellow solid. MS(M+H)+=963.6.
- 1H NMR (400 MHz, CDCl3) δ=8.35 (d, J=15.3 Hz, 1H), 8.07 (s, 1H), 7.86 (s, 1H), 7.58 (d, J=7.3 Hz, 1H), 7.50 (dd, J1=8.3 Hz, J2=7.3 Hz, 1H), 7.11 (d, J=7.0 Hz, 1H), 6.92 (d, J=8.6 Hz, 1H), 6.69 (dd, J=7.6, 14.9 Hz, 1H), 6.53 (t, J=5.4 Hz, 1H), 4.98-4.79 (m, 2H), 4.73-4.71 (m, 1H), 4.11-3.99 (m, 1H), 3.92 (t, J=13.4 Hz, 2H), 3.78-3.61 (m, 8H), 3.48-3.47 (m, 2H), 3.42 (s, 3H), 3.04-2.91 (m, 2H), 2.90-2.83 (m, 1H), 2.84-2.77 (m, 1H), 2.77-2.71 (m, 1H), 2.69-2.56 (m, 2H), 2.27 (t, J=10.8 Hz, 2H), 2.19-2.09 (m, 3H), 2.06-2.03 (m, 2H), 1.88-1.69 (m, 9H), 1.40 (d, J=6.1 Hz, 6H).
-
- Step 1-5 are Described in the Above Reaction Scheme.
- To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-5-cyclopropoxy-2-fluorobenzoic acid (180 mg, 366.25 umol) in DMF (4 mL) were added HATU (181.04 mg, 476.13 umol) and DIPEA (236.68 mg, 1.83 mmol, 318.97 uL), after stirring for 20 min, 4-((2-(2-(2-(4-aminopiperidin-1-yl)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (211.11 mg, 402.88 umol, HCl salt) was added and the resulting mixture was stirred at 15° C. for 3 hr. LCMS showed one peak (78%) with desired mass. The reaction mixture was diluted with H2O (50 mL) and extracted with EtOAc (40 mL×2). The combined organic layer was dried over Na2SO4, filtered. The filtrate was concentrated in vacuo. The residue was purified by prep-HPLC (column: Phenomenex luna C18 150*40 mm*15 um; mobile phase: [water (0.225% FA)-ACN]; B %: 18%-48%, 10 min) followed by prep-HPLC (column: Phenomenex Gemini-NX C18 75*30 mm*3 um; mobile phase: [water (10 mM NH4HCO3)-ACN]; B %: 38%-68%, 8 min) to afford the titled compound (60 mg, 60.56 umol, 16.54% yield, 95% purity) as a yellow solid. MS(M+H)+=961.6
- 1H NMR (400 MHz, MeOD) δ=8.41-8.33 (m, 1H), 8.19 (s, 1H), 7.66 (d, J=7.0 Hz, 1H), 7.55 (dd, J=7.2, 8.5 Hz, 1H), 7.10 (d, J=8.6 Hz, 1H), 7.05 (d, J=7.1 Hz, 1H), 5.05 (dd, J=5.5, 12.5 Hz, 1H), 4.95-4.92 (m, 1H), 4.08-3.87 (m, 4H), 3.76-3.63 (m, 8H), 3.53-3.47 (m, 2H), 3.40 (s, 3H), 3.02 (br d, J=10.0 Hz, 2H), 2.91-2.81 (m, 1H), 2.78-2.69 (m, 2H), 2.68-2.60 (m, 2H), 2.37-2.22 (m, 2H), 2.15-2.05 (m, 3H), 1.94 (br d, J=12.2 Hz, 2H), 1.85-1.63 (m, 8H), 0.94-0.88 (m, 2H), 0.87-0.79 (m, 2H).
-
- Step 1-5 are Described in the Above Reaction Scheme.
- To a solution of 5-cyclobutoxy-4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluorobenzoic acid (268.00 mg, 530.18 umol) in DMF (4 mL) were added HATU (262.07 mg, 689.23 umol) and DIPEA (342.60 mg, 2.65 mmol, 461.73 uL), after stirring for 20 min, 4-((2-(2-(2-(4-aminopiperidin-1-yl)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (305.60 mg, 583.20 umol, HCl salt) was added and the resulting mixture was stirred at 15° C. for 3 hr. LCMS showed one peak (87%) with desired mass. The reaction mixture was diluted with H2O (50 mL) and extracted with EtOAc (40 mL×2). The combined organic layer was dried over Na2SO4, filtered. The filtrate was concentrated in vacuo. The residue was purified by prep-HPLC (column: Phenomenex luna C18 150*40 mm*15 um; mobile phase: [water (0.225% FA)-ACN]; B %: 25%-55%, 10 min) followed by prep-HPLC (column: Phenomenex Gemini-NX C18 75*30 mm*3 um; mobile phase: [water (10 mM NH4HCO3)-ACN]; B %: 42%-72%, 8 min) to afford the titled compound (69.1 mg, 69.45 umol, 13.10% yield, 98% purity) as a yellow solid.
- MS(M+H)+=975.5
- 1H NMR (400 MHz, CD3OD) δ=8.40 (d, J=14.1 Hz, 1H), 8.22 (s, 1H), 7.57 (dd, J=7.1, 8.6 Hz, 1H), 7.21 (d, J=6.8 Hz, 1H), 7.12 (d, J=8.6 Hz, 1H), 7.06 (d, J=7.1 Hz, 1H), 5.06 (dd, J=5.5, 12.5 Hz, 1H), 4.99-4.82 (m, 1H), 4.07 (t, J=13.4 Hz, 2H), 3.96-3.85 (m, 1H), 3.75 (t, J=5.2 Hz, 2H), 3.72-3.61 (m, 6H), 3.57-3.49 (m, 2H), 3.43 (s, 3H), 3.00 (br d, J=12.6 Hz, 2H), 2.93-2.82 (m, 1H), 2.80-2.70 (m, 2H), 2.66-2.52 (m, 4H), 2.33-2.20 (m, 4H), 2.18-2.07 (m, 3H), 2.00-1.52 (m, 13H).
-
- Step 1-5 are Described in the Above Reaction Scheme.
- To a solution of 5-(sec-butoxy)-4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluorobenzoic acid (180 mg, 354.68 umol) in DMF (8 mL) were added HATU (175.32 mg, 461.08 umol) and DIPEA (229.19 mg, 1.77 mmol, 308.88 uL), after stirring for 20 min, 4-((2-(2-(2-(4-aminopiperidin-1-yl)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (204.44 mg, 390.14 umol, HCl salt) was added and the resulting mixture was stirred at 15° C. for 3 hr. LCMS showed one peak (67%) with desired mass. The reaction mixture was diluted with H2O (50 mL) and extracted with EtOAc (40 mL×2). The combined organic layer was dried over Na2SO4, filtered. The filtrate was concentrated in vacuo. The residue was purified by prep-HPLC (column: Phenomenex luna C18 150*40 mm*15 um; mobile phase: [water (0.225% FA)-ACN]; B %: 25%-55%, 10 min) to obtain 172.5 mg of product with 92% purity, which was treated with basic ion exchange resin and lyophilized to afford 5-(sec-butoxy)-4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-(1-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethyl)piperidin-4-yl)-2-fluorobenzamide (134.9 mg, 125.64 umol, 35.42% yield, 91% purity) as a yellow solid. MS(M+H)+=977.6
- 1H NMR (400 MHz, CD3OD) δ=8.41 (d, J=14.1 Hz, 1H), 8.22 (s, 1H), 7.57 (dd, J=7.1, 8.6 Hz, 1H), 7.36 (d, J=6.8 Hz, 1H), 7.12 (d, J=8.7 Hz, 1H), 7.09-7.04 (m, 1H), 5.07 (dd, J=5.5, 12.5 Hz, 1H), 4.99-4.92 (m, 1H), 4.57-4.48 (m, 1H), 4.07 (t, J=13.4 Hz, 2H), 3.99-3.89 (m, 1H), 3.76 (t, J=5.2 Hz, 2H), 3.73-3.63 (m, 6H), 3.58-3.50 (m, 2H), 3.42 (s, 3H), 3.07 (br d, J=11.1 Hz, 2H), 2.94-2.82 (m, 1H), 2.80-2.65 (m, 4H), 2.43-2.30 (m, 2H), 2.18-2.07 (m, 3H), 1.97 (br d, J=11.1 Hz, 2H), 1.91-1.62 (m, 10H), 1.39 (d, J=6.0 Hz, 3H), 1.06 (t, J=7.5 Hz, 3H).
-
- Step 1-5 are Described in the Above Reaction Scheme.
- To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-5-(cyclopentyloxy)-2-fluorobenzoic acid (108.00 mg, 207.89 umol) in DMF (8 mL) were added HATU (102.76 mg, 270.25 umol) and DIPEA (134.34 mg, 1.04 mmol, 181.05 uL), after stirring for 20 min, 4-((2-(2-(2-(4-aminopiperidin-1-yl)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (119.83 mg, 228.67 umol, HCl salt) was added and the resulting mixture was stirred at 15° C. for 3 hr. LCMS showed one peak (84%) with desired mass. The reaction mixture was diluted with H2O (50 mL) and extracted with EtOAc (40 mL×2). The combined organic layer was dried over Na2SO4, filtered. The filtrate was concentrated in vacuo. The residue was purified by prep-HPLC (column: Phenomenex luna C18 150*40 mm*15 um; mobile phase: [water (0.225% FA)-ACN]; B %: 22%-52%, 10 min). The product was treated with basic ion exchange resin and lyophilized to afford (64.7 mg, 59.53 umol, 28.64% yield, 91% purity) as a yellow solid. MS(M+H)+=990.4
- 1H NMR (400 MHz, CD3OD) δ=8.40 (d, J=14.1 Hz, 1H), 8.22 (s, 1H), 7.57 (dd, J=7.2, 8.5 Hz, 1H), 7.35 (d, J=6.8 Hz, 1H), 7.12 (d, J=8.6 Hz, 1H), 7.07 (d, J=7.1 Hz, 1H), 5.07 (dd, J=5.4, 12.5 Hz, 1H), 5.02-4.93 (m, 2H), 4.07 (t, J=13.4 Hz, 2H), 4.01-3.90 (m, 1H), 3.79-3.64 (m, 8H), 3.59-3.48 (m, 3H), 3.42 (s, 3H), 3.18-3.06 (m, 2H), 2.94-2.82 (m, 1H), 2.81-2.67 (m, 3H), 2.55-2.34 (m, 2H), 2.17-1.64 (m, 21H).
-
- A mixture of methyl 4-amino-3-methoxybenzoate (514.85 mg, 2.84 mmol), 2-chloro-9-cyclopentyl-7,7-difluoro-5-methyl-8,9-dihydro-5H-pyrimido[4,5-b][1,4]diazepin-6(7H)-one (300 mg, 947.17 μmol) and TosOH (148.01 mg, 2.84 mmol) in 1,4-dioxane (10 mL) was stirred at 100° C. for 16 hours. LCMS showed 39% of methyl 4-amino-3-methoxybenzoate remained and 55% of desired mass was detected. The reaction mixture was diluted with H2O (30 mL) and the resulting mixture was added NaHCO3 solution to adjust pH=8, and extracted with EtOAc (50 mL×3). The combined organic layers were washed with brine (50 mL×3), dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash silica gel chromatography (12 g SepaFlash® Silica Flash Column, Eluent of 0-20% Ethyl acetate/Petroleum ether gradient @ 65 mL/min) to afford the titled compound (1 g, 1.76 mmol, 185.32% yield, 81% purity) as a yellow solid. MS(M+H)+=462.3.
- To a solution of methyl 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-3-methoxybenzoate (900 mg, 1.54 mmol, 79% purity) in THF (8 mL) and MeOH (8 mL) was added NaOH (2 M in H2O, 8 mL), the mixture was stirred at 25° C. for 12 hours. LCMS showed the starting material was consumed completely and 63% of desired mass was detected. The reaction mixture was acidified with HCl solution (1 M) to adjust pH=5, and then diluted with H2O (30 mL) and extracted with EtOAc (40 mL×3). The combined organic layers were washed with brine (50 mL×2), dried over Na2SO4, filtered and concentrated in vacuo to afford the titled compound (160 mg, 318.26 μmol, 20.66% yield, 89% purity) as a white solid.
- To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-3-methoxybenzoic acid (383.19 mg, 856.42 μmol) in DMF (6 mL) were added HATU (305.29 mg, 802.90 μmol) and DIEA (276.72 mg, 2.14 mmol, 372.93 μL), the mixture was stirred at 15° C. for 15 minutes, then 4-((2-(2-(2-(4-aminopiperidin-1-yl)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (300 mg, 535.27 μmol, 2HCl) was added and the resulting mixture was stirred at 15° C. for 2 hours. LCMS showed reactant was consumed completely and 68% of desired mass was detected. The reaction mixture was purified by prep-HPLP (column: Waters Xbridge 150*25 mm*5 um; mobile phase: [water (10 mM NH4HCO3)-ACN]; B %: 33%-63%, 9 min) followed by prep-HPLC (column: Phenomenex luna C18 150*40 mm*15 um; mobile phase: [water (0.225% FA)-ACN]; B %: 15%-45%, 10 min) twice and freeze dried to afford the titled compound (71 mg, 75.88 μmol, 14.18% yield, 98% purity) as a yellow solid. MS(M+H)+=917.5.
- 1H NMR (400 MHz, CDCl3) δ=8.46 (d, J=8.4 Hz, 1H), 8.06 (s, 1H), 7.75 (s, 1H), 7.50 (dd, J=8.3 Hz, 7.3 Hz, 1H), 7.44 (d, J=1.6 Hz, 1H), 7.24 (d, J=1.6 Hz, 1H), 7.11 (d, J=7.0 Hz, 1H), 6.92 (d, J=8.7 Hz, 1H), 6.55 (t, J=5.7 Hz, 1H), 6.06 (d, J=8.3 Hz, 1H), 4.98-4.76 (m, 2H), 4.05-3.96 (m, 4H), 3.90 (t, J=13.5 Hz, 2H), 3.74 (t, J=5.3 Hz, 2H), 3.70-3.63 (m, 6H), 3.50-3.45 (m, 2H), 3.41 (s, 3H), 3.09-2.93 (m, 2H), 2.90-2.75 (m, 2H), 2.74-2.60 (m, 3H), 2.31-2.21 (m, 2H), 2.16-2.07 (m, 3H), 2.06-2.00 (m, 2H), 1.88-1.50 (m, 9H).
-
- Step 1-5 are Described in the Above Reaction Scheme.
- To a solution of 4-((2-(2-(2-(4-aminopiperidin-1-yl)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (200 mg, 356.84 μmol, 2HCl salt), 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-(2-hydroxyethoxy)benzoic acid (210.47 mg, 356.84 μmol, 84% purity) and HATU (203.52 mg, 535.27 μmol) in DMF (5 mL) was added DIEA (161.42 mg, 1.25 mmol, 217.55 μL), the mixture was stirred at 15° C. for 3 hours. LCMS showed starting material was consumed completely and 68% of desired mass was detected. The reaction mixture was purified by prep-HPLC (column: Phenomenex Gemini-NX C18 75*30 mm*3 um; mobile phase: [water (10 mM NH4HCO3)-ACN]; B %: 28%-58%, 8 min) twice followed by prep-HPLC (column: Phenomenex luna C18 150*40 mm*15 um; mobile phase: [water (0.225% FA)-ACN]; B %: 20%-50%, 10 min) and lyophilized to afford the titled compound (40.7 mg, 40.49 μmol, 11.35% yield, 96% purity) as a yellow solid. MS(M+H)+=965.7.
- 1H NMR (400 MHz, CDCl3) δ=8.30 (d, J=15.1 Hz, 1H), 8.23 (s, 1H), 8.09 (s, 1H), 7.56 (d, J=7.2 Hz, 1H), 7.52-7.43 (m, 1H), 7.10 (d, J=7.2 Hz, 1H), 6.92 (d, J=8.5 Hz, 1H), 6.67-6.61 (m, 1H), 6.51 (t, J=5.5 Hz, 1H), 5.00-4.81 (m, 2H), 4.20 (t, J=4.1 Hz, 2H), 4.06-3.96 (m, 3H), 3.91 (t, J=13.1 Hz, 2H), 3.73 3.71 (t, J=5.3 Hz, 2H), 3.69-3.60 (m, 6H), 3.50-3.44 (m, 2H), 3.39 (s, 3H), 2.98-2.84 (m, 3H), 2.83-2.72 (m, 2H), 2.62 (t, J=5.7 Hz, 2H), 2.31-1.97 (m, 9H), 1.83-1.71 (m, 4H), 1.62-1.59 (m, 4H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (57.5 mg, 59.50 μmol, 11.12% yield, 98% purity) as a yellow solid. MS(M+H)+=947.7.
- 1H NMR (400 MHz, CDCl3) δ=8.35 (d, J=8.4 Hz, 1H), 8.15 (s, 1H), 8.04 (s, 1H), 7.46 (dd, J=8.3 Hz, 7.4 Hz, 1H), 7.40 (d, J=1.5 Hz, 1H), 7.30 (dd, J=8.5 Hz, 1.5 Hz, 1H), 7.07 (d, J=7.0 Hz, 1H), 6.91 (d, J=8.7 Hz, 1H), 6.52 (t, J=5.5 Hz, 1H), 6.43 (d, J=7.9 Hz, 1H), 4.94-4.78 (m, 2H), 4.18 (d, J=3.0 Hz, 2H), 4.01-3.92 (m, 3H), 3.87 (t, J=13.3 Hz, 2H), 3.72 (t, J=5.3 Hz, 2H), 3.63 (dt, J=11.2 Hz, 5.1 Hz, 6H), 3.47 (q, J=5.4 Hz, 2H), 3.36 (s, 3H), 2.95 (d, J=9.3 Hz, 2H), 2.89-2.51 (m, 6H), 2.17 (t, J=11.9 Hz, 2H), 2.11-2.01 (m, 3H), 2.00-1.92 (m, 2H), 1.78-1.52 (m, 8H).
-
- To the suspension of Pd/C (0.2 g, 10% purity) in MeOH (20 mL) was added 4-fluoro-2-nitro-1-(trifluoromethoxy) benzene (2 g, 8.89 mmol) and the resulting mixture was stirred at 20° C. for 12 h under H2 (15 psi). LCMS showed that reactant was consumed and 100% desired mass. The mixture was filtered and concentrated to afford the titled compound (1.4 g, 7.18 mmol, 80.76% yield) as yellow oil. MS(M+H)+=195.9
- To the solution of 5-fluoro-2-(trifluoromethoxy)aniline (0.8 g, 4.10 mmol) in DMF (10 mL) was added NB S (875.72 mg, 4.92 mmol) and the resulting mixture was stirred at 25° C. for 12 h. TLC (Petroleum ether:Ethyl acetate=5/1) showed that most of starting material was consumed and new spot formed. The mixture was poured into water (50 mL) and extracted by EtOAc (50 mL×3), the combined organic layer was washed with brine (50 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by gel silica column (Petroleum ether:Ethyl acetate=10/1) to afford the titled compound (1.4 g, crude) as yellow oil. MS (M+H)+=274.1
- To the solution of 4-bromo-5-fluoro-2-(trifluoromethoxy)aniline (1 g, crude) in DMF (10 mL) were added DCC (1.51 g, 7.30 mmol, 1.48 mL), HCOOH (1.23 g, 25.55 mmol), Pd (OAc)2 (81.93 mg, 364.95 μmol), Xantphos (211.17 mg, 364.95 μmol), TEA (738.58 mg, 7.30 mmol, 1.02 mL) and the resulting mixture was stirred at 80° C. for 12 h. LCMS showed that reactant3 was consumed and desired mass was detected. The mixture was poured into saturated aq. Na2CO3 (50 mL) and extracted by EtOAc (50 mL×2), the combined organic layer was discarded, the aqueous layer was adjusted pH=4 by con. HCl then extracted by EtOAc (50 mL×3), the combined organic layer was washed by brine (100 mL), dried over Na2SO4, filtered and concentrated to afford the titled compound (540 mg, 2.26 mmol, 61.88% yield) as yellow solid. MS(M+H)+=240.1
- To a solution of 4-amino-2-fluoro-5-(trifluoromethoxy)benzoic acid (200 mg, 836.39 umol) in DCM (3 mL) and MeOH (3 mL) was added TMSCHN2 (2 M, 1.2 mL) at 0° C. The mixture was stirred at 25° C. for 1 h. TLC (Petroleum ether:Ethyl acetate=2:1) showed the starting material was consumed and a new spot was detected. The reaction mixture was concentrated under reduced pressure to afford the titled compound (200 mg, crude) as a light yellow solid. MS(M+H)+=253.8
- To a solution of 2-chloro-9-cyclopentyl-7,7-difluoro-5-methyl-5,7,8,9-tetrahydro-6H-pyrimido[4,5-b][1,4]diazepin-6-one (340 mg, 1.07 mmol) in dioxane (20 mL) were added Cs2CO3 (1.2 g, 3.68 mmol), BINAP (1.02 g, 1.64 mmol), Pd(OAc)2 (100 mg, 445.41 μmol) and methyl 4-amino-2-fluoro-5-(trifluoromethoxy)benzoate (298.92 mg, 1.18 mmol). The mixture was stirred at 100° C. for 16 h under N2 atmosphere. LCMS showed 17% peak with the desired mass was detected. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=10:1-2:1) to afford the titled compound (300 mg, 562.41 μmol, 52.39% yield) as a white solid. MS(M+H)+=534.0
- 1H NMR (400 MHz, DMSO-d6) δ 9.44 (s, 1H), 8.41-8.30 (m, 2H), 7.80 (dd, J=1.3, 7.0 Hz, 1H), 4.81 (quin, J=8.3 Hz, 1H), 4.08 (t, J=13.8 Hz, 2H), 3.84 (s, 3H), 3.34 (s, 3H), 1.98-1.85 (m, 2H), 1.74-1.68 (m, 2H), 1.66-1.47 (m, 4H).
- To a solution of methyl 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-(trifluoromethoxy)benzoate (200 mg, 374.94 μmol) in THF (5 mL) and MeOH (5 mL) was added LiOH·H2O (157.34 mg, 3.75 mmol). The mixture was stirred at 20° C. for 2 h. LCMS showed main peak with the desired mass [M+H+H2O] was detected. The reaction mixture was concentrated under reduced pressure to give a residue. To the residue was added H2O (10 mL), the mixture was extracted with EtOAc 30 mL (10 mL×3), the aqueous phase was adjust to pH=7 slowly with HCl (1M) at 0° C., then freeze dried to afford the titled compound (190 mg, crude) as a light yellow solid. MS(M+H+H2O)+=538.4.
- To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-(trifluoromethoxy)benzoic acid (80 mg, 154.03 μmol) in DMF (4 mL) were added HATU (151.71 mg, 399.00 μmol), DIPEA (150.09 mg, 1.16 mmol, 202.28 μL) and 4-((2-(2-(2-(4-aminopiperidin-1-yl)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (110 mg, 196.26 μmol, 2HCl) at 20° C. The mixture was stirred at 20° C. for 12 h. LCMS showed 60% peak with the desired mass was detected. To the reaction mixture was added H2O (15 mL), the mixture was extracted with EtOAc (30 mL×2), the combined organic layers were washed with brine (30 mL×3), dried over anhydrous Na2SO4, filtered and the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (column: Unisil 3-100 C18 uLtra 150*50 mm*3 um; mobile phase: [water (0.225% FA)-ACN]; B %: 35%-55%, 10 min, Column Temp: 30° C.) followed by prep-HPLC (column: Unisil 3-100 C18 uLtra 150*50 mm*3 um; mobile phase: [water (0.225% FA)-ACN]; B %: 35%-55%, 10 min, Column Temp: 30° C.) followed by re-purified by prep-HPLC (column: Unisil 3-100 C18 uLtra 150*50 mm*3 um; mobile phase: [water (0.225% FA)-ACN]; B %: 30%-50%, 10 min, Column Temp: 30° C.) and lyophilized to afford the titled compound (29.0 mg, 12.28 μmol, 7.97% yield, 92% purity, FA) as a light yellow solid. MS (M+H)+=989.5.
- 1H NMR (400 MHz, DMSO-d6) δ 11.08 (s, 1H), 9.16 (s, 1H), 8.32 (s, 1H), 8.29 (s, 1H), 8.22 (d, J=13.1 Hz, 1H), 8.06 (d, J=6.0 Hz, 1H), 7.61-7.51 (m, 2H), 7.15 (d, J=8.6 Hz, 1H), 7.03 (d, J=6.9 Hz, 1H), 6.60 (t, J=5.6 Hz, 1H), 5.09-5.00 (m, 1H), 4.78 (t, J=8.2 Hz, 1H), 4.09-4.05 (m, 2H), 3.64-3.60 (m, 2H), 3.58-3.55 (m, 2H), 3.53-3.46 (m, 8H), 3.33 (s, 3H), 2.91-2.78 (m, 3H), 2.43-2.39 (m, 2H), 2.09-1.99 (m, 3H), 1.95-1.87 (m, 2H), 1.79-1.63 (m, 5H), 1.62-1.44 (m, 6H).
-
- To a solution of chloromethylbenzene (55.00 g, 434.50 mmol, 50 mL) and propan-2-amine (128.42 g, 2.17 mol, 186.65 mL) in MeCN (1000 mL) was added K2CO3 (180.16 g, 1.30 mol) and the mixture was stirred at 80° C. for 16 h. TLC indicated the reaction was completed. The reaction mixture was filtered. The filtrate was concentrated in vacuo to afford the titled compound (56.5 g, 378.60 mmol, 87.14% yield) as yellow oil.
- 1H NMR (400 MHz, CDCl3) δ=7.44-7.19 (m, 5H), 3.68 (s, 2H), 2.80-2.50 (m, 1H), 1.75 (s, 1H), 1.03-0.98 (m, 6H).
- To a solution of N-benzylpropan-2-amine (36.72 g, 246.06 mmol, 40.53 mL) in EtOH (150 mL) was added benzotriazol-1-ylmethanol (36.7 g, 246.06 mmol) and the mixture was stirred at 25° C. for 12 h. TLC indicated the reaction was completed. The reaction mixture was concentrated in vacuo. The residue was diluted with H2O (200 mL) and extracted with EtOAc (300 mL×2), the combined organic layer was dried over Na2SO4, filtered. The filtrate was concentrated in vacuo to afford the titled compound (77 g, crude) as yellow oil.
- To a suspension of Zn (23.32 g, 356.68 mmol) in THF (500 mL) was added TMSCl (29.06 g, 267.51 mmol, 33.95 mL) drop wise. After stirring 20 minutes, the ethyl 2-bromo-2, 2-difluoro-acetate (54.30 g, 267.51 mmol, 34.37 mL) was added slowly at 0° C. and the mixture was stirred 20 minutes at 0° C. and cooled to −10° C. N-(benzotriazol-1-ylmethyl)-N-benzyl-propan-2-amine (50 g, 178.34 mmol) in THF (250 mL) was added at −10° C. After 20 minutes was warmed to 25° C. and stirred at 25° C. for 12 h. LCMS showed that the reaction was completed. The reaction mixture was filtered and the filtrate was concentrated in vacuo to afford the titled compound (100 g, crude) as yellow oil. MS(M+H)+=286.2
- To a solution of ethyl 3-(benzyl(isopropyl)amino)-2,2-difluoropropanoate (100 g, 350.47 mmol) in EtOH (700 mL) were added Pd/C (10 g, 10% purity) and HCl (12 M, 14.60 mL) and the resulting mixture was stirred at 20° C. for 12 h under H2 (15 psi). LCMS showed that the reaction was completed. The reaction mixture was filtered and the filtrate was concentrated in vacuo to afford the titled compound (68 g, crude) as yellow oil.
- To a solution of
ethyl 2,2-difluoro-3-(isopropylamino)propanoate (68 g, 348.35 mmol) in acetone (500 mL) were added K2CO3 (57.80 g, 418.22 mmol) and 2, 4-dichloro-5-nitro-pyrimidine (33.79 g, 174.17 mmol) and the mixture was stirred at 25° C. for 16 h. TLC indicated that the reaction was completed. The reaction mixture filtered and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=1/0 to 5/1) to afford the titled compound (11 g, 24.33 mmol, 6.98% yield, 78% purity) as yellow solid. MS(M+H)+=353.1 - To a solution of ethyl 3-((2-chloro-5-nitropyrimidin-4-yl)(isopropyl)amino)-2,2-difluoropropanoate (10 g, 28.35 mmol) in AcOH (100 mL) was added Fe (9.50 g, 170.11 mmol) and HCl (12 M, 14.18 mL) and the mixture was stirred at 85° C. for 5 h. LCMS showed that the reaction was completed. The mixture was combined with the pilot (2 g scale) and filtered, concentrated, the residue was diluted with NaHCO3 (sat, aq. 300 mL) and the resulting mixture was extracted with EtOAc (300 mL×3), the combined organic layer was washed with brine (500 mL×2), dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=1/0 to 5/1) to afford the titled compound (5.1 g, 18.06 mmol, 63.72% yield, 98% purity) as gray solid. MS(M+H)+=277.1
- 1H NMR (400 MHz, DMSO-d6) δ=11.0 (s, 1H), 8.09 (s, 1H), 4.93-4.86 (m, 1H), 4.05-3.95 (m, 2H), 1.19-1.17 (m, 6H).
- To the mixture of 2-chloro-7,7-difluoro-9-isopropyl-8,9-dihydro-5H-pyrimido[4,5-b][1,4]diazepin-6(7H)-one (5.1 g, 18.43 mmol) and K2CO3 (5.10 g, 36.87 mmol) in DMF (50 mL) was added MeI (2.88 g, 20.28 mmol, 1.26 mL) and the resulting mixture was stirred at 20° C. for 12 h. LCMS showed that the reaction was completed. The mixture was poured into water (200 mL) and extracted with EtOAc (100 mL×3), the combined organic layer was washed with brine (300 mL), dried over Na2SO4, filtered and concentrated to afford the titled compound (4.5 g, 15.02 mmol, 81.46% yield, 97% purity) as yellow solid. MS(M+H)+=291.1
- To a solution of 2-chloro-7,7-difluoro-9-isopropyl-5-methyl-8,9-dihydro-5H-pyrimido[4,5-b][1,4]diazepin-6(7H)-one (1 g, 3.44 mmol) and methyl 4-amino-2-fluoro-5-methoxy-benzoate (1.03 g, 5.16 mmol) in dioxane (20 mL) was added TsOH (1.78 g, 10.32 mmol) and the mixture was stirred at 100° C. for 16 h. LCMS showed that the reaction was completed. The mixture was poured into water (100 mL) and extracted with EtOAc (100 mL×3), the combined organic layer was washed with brine (300 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=1/0 to 2/1) to afford the titled compound (1.5 g, 3.24 mmol, 94.25% yield, 98% purity) as white solid. MS(M+H)+=454.2
- To a solution of methyl 4-((7,7-difluoro-9-isopropyl-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoate (1.5 g, 3.31 mmol) in THF (6 mL) and MeOH (6 mL) was added NaOH (2 M, 6.00 mL, in water) and the mixture was stirred at 25° C. for 12 h. LCMS showed that the reaction was completed. The organic solvent was concentrated and the residue was adjusted pH=6 by 1 M HCl, the suspensions was filtered and collected filter cake to afford the titled compound (590 mg, 1.34 mmol, 40.59% yield, 100% purity) as white solid. MS(M+H)+=440.1
- To a mixture of 2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (600 mg, 1.07 mmol) and tert-butyl piperidin-4-ylcarbamate (429.48 mg, 2.14 mmol) in dioxane (10 mL) were added DIPEA (415.73 mg, 3.22 mmol, 560.28 μL) and NaI (16.07 mg, 107.22 μmol) and the mixture was heated to 80° C. for 16 h. TLC (EtOAc/MeOH=10/1) showed that the reaction was completed. The reaction mixture was diluted with H2O (30 mL) and extracted with EtOAc (30 mL×2), the combined organic layer was dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by column chromatography (SiO2, EtOAc EtOAc/MeOH=10/1) to afford the titled compound (590 mg, 973.86 umol, 90.83% yield, 97% purity) as yellow solid.
- MS(M+H)+=588.3
- To a solution of tert-butyl (1-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethyl)piperidin-4-yl)carbamate (590 mg, 1.00 mmol) in dioxane (10 mL) was added HCl/dioxane (4 M, 10 mL) and the reaction mixture was stirred at 25° C. for 3 h. LCMS showed that the reaction was completed. The reaction mixture was concentrated in vacuo to afford the titled compound (0.7 g, 1.44 mmol, 143.01% yield) as yellow solid. MS(M+H)+=488.2
- To the solution of 4-((2-(2-(2-(4-aminopiperidin-1-yl)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (0.2 g, 381.67 μmol, HCl) and 4-((7,7-difluoro-9-isopropyl-5-methyl-6-oxo-6, 7,8, 9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (167.70 mg, 381.67 μmol) in DMF (3 mL) were added HATU (290.25 mg, 763.35 μmol) and DIPEA (147.99 mg, 1.15 mmol, 199.44 μL) and the resulting mixture was stirred at 20° C. for 1 h. LCMS showed that the reaction was completed. The mixture was poured into water (20 mL) and extracted with EtOAc (20 mL×3), the combined organic layer was washed with brine (50 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (column: Phenomenex Gemini-NX C18 75*30 mm*3 um; mobile phase: [water (0.225% FA)-ACN]; B %: 18%-48%, 7 min) and the eluent was lyophilized. The solid was poured into sat, aq. NaHCO3 (20 mL) and extracted with EtOAc (20 mL×3), the combined organic layer was washed by brine (50 mL), dried over Na2SO4, filtered and concentrated to afford the titled compound (86.4 mg, 90.30 μmol, 74.62% yield, 95% purity) as yellow solid. MS(M+H)+=909.5.
- 1H NMR (400 MHz, DMSO-d6) δ=11.14 (s, 1H), 8.31-8.25 (m, 2H), 8.02 (s, 1H), 7.95-7.86 (m, 1H), 7.63-7.57 (m, 1H), 7.21-7.14 (m, 2H), 7.05 (d, J=8.0 Hz, 1H), 6.61 (t, J=5.7 Hz, 1H), 5.14-5.07 (m, 1H), 5.01-4.92 (m, 1H), 4.07 (t, J=13.4 Hz, 2H), 3.92 (s, 3H), 3.82-3.71 (m, 1H), 3.66-3.62 (m, 2H), 3.60-3.58 (m, 2H), 3.57-3.50 (m, 6H), 3.02-2.85 (m, 3H), 2.70-2.60 (m, 4H), 2.52-2.45 (m, 3H), 2.14-2.05 (m, 3H), 1.84-1.77 (m, 2H), 1.67-1.52 (m, 2H), 1.32 (d, J=6.6 Hz, 6H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (16.5 mg, 16.22 μmol, 7.13% yield, 98% purity) as a yellow solid. MS(M+H)+=997.7
- 1H NMR (400 MHz, DMSO-d6) δ=11.10 (s, 1H), 8.26 (br t, J=6.0 Hz, 2H), 7.99-7.78 (m, 2H), 7.58 (dd, J=7.2, 8.4 Hz, 1H), 7.22-7.11 (m, 2H), 7.03 (d, J=7.0 Hz, 1H), 6.67-6.55 (m, 1H), 5.05 (dd, J=5.6, 12.8 Hz, 1H), 4.96-4.82 (m, 1H), 4.06 (br t, J=13.6 Hz, 2H), 3.91 (s, 3H), 3.76-3.67 (m, 1H), 3.64-3.59 (m, 2H), 3.59-3.53 (m, 4H), 3.53-3.43 (m, 12H), 3.31-3.28 (m, 2H), 2.97-2.77 (m, 3H), 2.62-2.51 (m, 3H), 2.48-2.39 (m, 2H), 2.14-1.89 (m, 3H), 1.86-1.68 (m, 2H), 1.62-1.45 (m, 2H), 1.26 (s, 3H), 1.25 (s, 3H).
-
- Step 1-5 are Described in the Above Reaction Scheme.
- To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)benzoic acid (130 mg, 311.45 μmol) in DMF (2 mL) was added HATU (130.26 mg, 342.59 μmol) and DIPEA (80.50 mg, 622.89 μmol, 108.50 μL). The mixture was stirred at 20° C. for 10 min and a solution of 4-((4-(4-aminopiperidin-1-yl)-4-oxobutyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (163.74 mg, 342.59 μmol, HCl) in DMF (2 mL) and DIPEA (80.50 mg, 622.89 μmol, 108.50 μL) was added drop-wise at the reaction mixture and the resulting mixture was stirred at 20° C. for 1 h. LCMS showed starting material was consumed completely and desired mass was detected. The reaction mixture was diluted with H2O (12 mL) and extracted with EtOAc (12 mL×3). The organic layer was washed with brine (12 mL×3), dried over Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (column: Unisil 3-100 C18 μLtra 150*50 mm*3 um; mobile phase: [water (0.225% FA)-ACN]; B %: 32%-62%, 10 min) followed by lyophilization to afford the titled compound (185.8 mg, 214.33 μmol, 68.82% yield, 97% purity) as a yellow solid. MS (M+H)+=840.9
- 1H NMR (400 MHz, DMSO-d6) δ=11.09 (s, 1H), 9.67 (s, 1H), 8.27 (s, 1H), 8.06 (d, J=7.7 Hz, 1H), 7.81-7.74 (m, 4H), 7.60 (dd, J=7.3, 8.4 Hz, 1H), 7.19 (d, J=8.7 Hz, 1H), 7.02 (d, J=7.0 Hz, 1H), 6.68 (t, J=6.1 Hz, 1H), 5.05 (dd, J=5.4, 12.8 Hz, 1H), 4.83-4.73 (m, 1H), 4.39 (d, J=12.2 Hz, 1H), 4.08-4.00 (m, 2H), 3.88 (d, J=13.4 Hz, 1H), 3.33 (s, 3H), 3.11 (t, J=11.8 Hz, 1H), 2.94-2.83 (m, 1H), 2.73-2.66 (m, 1H), 2.62-2.51 (m, 4H), 2.45-2.40 (m, 3H), 2.07-1.96 (m, 3H), 1.88-1.78 (m, 4H), 1.75-1.69 (m, 2H), 1.67-1.57 (m, 4H), 1.47-1.35 (m, 2H)
-
- To a mixture of 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (8 g, 28.96 mmol) in DMSO (50 mL) were added TEA (8.79 g, 86.89 mmol, 12.09 mL) and 2-(2-aminoethoxy) ethanol (3.96 g, 37.65 mmol, 3.77 mL) in one portion at 20° C. and the mixture was stirred at 80° C. for 16 h. LC-MS showed that the reaction was completed. The reaction mixture was partitioned between H2O (300 mL) and EtOAc (600 mL). The organic phase was separated, washed with brine (100 mL×3), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=1/0 to 0/1) to afford the titled compound (10.4 g, 27.92 mmol, 96.39% yield, 97% purity) as a green solid. MS(M+H)+=362.1
- To a solution of 2-(2,6-dioxopiperidin-3-yl)-4-((2-(2-hydroxyethoxy)ethyl)amino)isoindoline-1,3-dione (10.4 g, 28.78 mmol) in DCM (100 mL) were added TEA (4.37 g, 43.17 mmol, 6.01 mL) and TosCl (6.58 g, 34.54 mmol) and the mixture was stirred at 20° C. for 16 h. LCMS showed that the reaction was completed. The mixture was concentrated under vacuum. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=1/0 to 1/3) to afford the titled compound (4.65 g, 8.57 mmol, 29.77% yield, 95% purity) as a yellow solid. MS (M+H)+=516.1
- To a mixture of benzyl piperazine-1-carboxylate (5 g, 22.70 mmol, 4.39 mL) and tert-butyl N-(4-oxocyclohexyl) carbamate (5.81 g, 27.24 mmol, 5.81 mL), AcOH (2.04 g, 34.05 mmol, 1.95 mL) in ACN (200 mL) was added NaBH(OAc)3 (19.24 g, 90.80 mmol) slowly at 20° C. under N2 and the mixture was stirred at 20° C. for 16 h. LCMS showed that the reaction was completed, the reaction mixture was diluted with saturated NaHCO3 (aq.) to adjust the pH>10 and extracted with EtOAc (200 mL×3), the organic layer was dried over Na2SO4, filtrated and concentrated. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=3/1 to 1/1) to afford the titled compound (9.1 g, 18.96 mmol, 83.53% yield, 87% purity) as white solid. 2.0 g of benzyl 4-(4-((tert-butoxycarbonyl)amino)cyclohexyl)piperazine-1-carboxylate was purified by prep-HPLC (column: Waters Xbridge BEH C18 250*50 mm*10 um; mobile phase: [water (0.05% ammonia hydroxide v/v)-ACN]; B %: 40%-65%, 20 min) to afford the titled compound (412 mg, 986.73 umol, 20.60% yield) as white solid. MS(M+H)+=418.4
- To a solution of benzyl 4-((1r,4r)-4-((tert-butoxycarbonyl)amino)cyclohexyl)piperazine-1-carboxylate (200 mg, 479.00 μmol) in EtOAc (30 mL) was added Pd/C (100 mg, 10% purity) under N2 atmosphere and the resulting mixture was stirred under H2 (15 psi) at 20° C. for 16 h. TLC indicated the reaction was completed. The reaction mixture was filtered and the filtrate was concentrated in vacuum to afford the titled compound (120 mg, crude) as white solid.
- To a solution of 2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethyl 4-methylbenzenesulfonate (167.91 mg, 325.71 μmol) and tert-butyl ((1r,4r)-4-(piperazin-1-yl)cyclohexyl)carbamate (120 mg, 423.42 μmol) in dioxane (5 mL) were added DIPEA (126.29 mg, 977.12 μmol, 170.20 μL) and NaI (4.88 mg, 32.57 μmol) and the mixture was stirred at 80° C. for 16 h. LCMS showed that the reaction was completed. The reaction mixture was combined with pilot reaction (0.2 g scale) and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=1/0 to 0/1) to afford the titled compound (620 mg, crude) as white solid. MS(M+H)+=627.4
- To a solution of tert-butyl ((1r,4r)-4-(4-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethyl)piperazin-1-yl)cyclohexyl)carbamate (620 mg, 989.24 μmol) in dioxane (6 mL) was added HCl/dioxane (4 M, 12 mL, 48.52 eq) and the mixture was stirred at 20° C. for 6 h. LCMS showed that the reaction was completed. The mixture was concentrated in vacuum to afford the titled compound (520 mg, 987.42 μmol, 99.82% yield, 100% purity, HCl) as a white solid. MS(M+H)+=527.2
- To the mixture of 4-((2-(2-(4-((1r,4r)-4-aminocyclohexyl)piperazin-1-yl)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (0.2 g, 355.18 μmol HCl) and 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (165.31 mg, 355.18 μmol) in DMF (4 mL) were HATU (270.10 mg, 710.37 μmol) and DIPEA (137.72 mg, 1.07 mmol, 185.60 μL) and the resulting mixture was stirred at 20° C. for 12 h. LCMS showed that the reaction was completed. The mixture was poured into water (20 mL) and extracted with EtOAc (20 mL×3), the combined organic layer was washed with brine (50 mL), dried over Na2SO4, filtered and concentrated, the residue was purified by prep-HPLC (column: Unisil 3-100 C18 μLtra 150*50 mm*3 um; mobile phase: [water (0.225% FA)-ACN]; B %: 30%-50%, 10 min) and the eluant was lyophilized to afford the titled compound (151.3 mg, 152.23 μmol, 42.86% yield, 98% purity, FA salt) as yellow solid. MS(M+H)+=974.2.
- 1H NMR (400 MHz, DMSO-d6) δ=11.12 (s, 1H), 9.34-8.85 (m, 1H), 8.31 (s, 1H), 8.26 (d, J=13.3 Hz, 1H), 8.06 (s, 1H), 7.95 (s, 1H), 7.61 (dd, J=7.3, 8.3 Hz, 1H), 7.22-7.15 (m, 2H), 7.08 (d, J=7.0 Hz, 1H), 6.61 (s, 1H), 5.15-5.03 (m, 1H), 4.91-4.70 (m, 1H), 4.09 (br t, J=13.9 Hz, 2H), 3.92 (s, 3H), 3.79-3.34 (m, 14H), 3.21-2.80 (m, 4H), 2.66-2.52 (m, 5H), 2.44-2.35 (m, 1H), 2.14-1.91 (m, 6H), 1.81-1.49 (m, 8H), 1.47-1.19 (m, 3H).
-
- Step 1-2 are Described in the Above Reaction Scheme.
- To the suspensions of 4-((2-(2-(2-(3-aminopiperidin-1-yl)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (230 mg, 471.75 μmol) and 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (219.56 mg, 471.75 μmol) in DMF (4 mL) were added HATU (358.75 mg, 943.50 μmol) and DIPEA (182.91 mg, 1.42 mmol, 246.51 μL) and the resulting mixture was stirred at 20° C. for 1 h. LCMS showed that the reaction was completed, the mixture was poured into water (20 mL) and extracted with EtOAc (20 mL×3), the combined organic layer was washed with brine (50 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (column: Unisil 3-100 C18 μLtra 150*50 mm*3 um; mobile phase: [water (0.225% FA)-ACN]; B %: 33%-53%, 10 min) and the eluant was lyophilized to afford the titled compound (156 mg, 161.85 μmol, 34.31% yield, 97% purity, FA) as yellow solid. MS(M+H)+=935.3
- 1H NMR (400 MHz, CD3OD) δ=8.37-8.27 (m, 1H), 8.22 (d, J=3.2 Hz, 1H), 7.48-7.39 (m, 1H), 7.34 (d, J=6.8 Hz, 1H), 7.02-6.88 (m, 2H), 5.12-5.04 (m, 1H), 4.96-4.92 (m, 1H), 4.41-4.32 (m, 1H), 4.06 (t, J=13.4 Hz, 2H), 3.97 (s, 3H), 3.95-3.84 (m, 2H), 3.81-3.68 (m, 7H), 3.53-3.42 (m, 6H), 3.41-3.34 (m, 2H), 3.09-2.83 (m, 3H), 2.79-2.64 (m, 2H), 2.19-2.01 (m, 5H), 1.98-1.89 (m, 1H), 1.86-1.67 (m, 7H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (56.8 mg, 61.84 μmol, 19.79% yield, 97% purity, FA) as yellow solid. Ms(M+H)+=891.3
- 1H NMR (400 MHz, MeOD) δ=8.39 (dd, J=3.6, 14.2 Hz, 1H), 8.23 (s, 1H), 7.57-7.49 (m, 1H), 7.31 (dd, J=6.8, 10.2 Hz, 1H), 7.09 (d, J=6.8 Hz, 1H), 6.99 (t, J=7.8 Hz, 1H), 5.08-5.02 (m, 1H), 4.99-4.93 (m, 1H), 4.37-4.28 (m, 1H), 4.06 (t, J=13.4 Hz, 2H), 3.97 (s, 3H), 3.92-3.82 (m, 2H), 3.84-3.78 (m, 2H), 3.74-3.64 (m, 1H), 3.61-3.55 (m, 2H), 3.51-3.37 (m, 6H), 3.16-2.98 (m, 2H), 2.90-2.80 (m, 1H), 2.78-2.62 (m, 2H), 2.16-2.02 (m, 5H), 1.98-1.64 (m, 8H).
-
- Step 1-2 are Described in the Above Reaction Scheme.
- To the suspensions of 4-((2-(2-(3-aminopyrrolidin-1-yl)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (166.09 mg, 386.74 μmol, HCl) and 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (180 mg, 386.74 μmol) in DMF (3 mL) were added HATU (294.10 mg, 773.49 μmol) and DIPEA (149.95 mg, 1.16 mmol, 202.09 μL) and the resulting mixture was stirred at 20° C. for 1 h. LCMS showed that the reaction was completed. The mixture was poured into water (20 mL) and extracted with EtOAc (20 mL×3), the combined organic layer was washed with brine (50 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (column: Unisil 3-100 C18 μLtra 150*50 mm*3 um; mobile phase: [water (0.225% FA)-ACN]; B %: 35%-55%, 10 min) and the eluant was lyophilized to afford the titled compound (97.8 mg, 109.30 μmol, 28.26% yield, 98% purity) as yellow solid. MS(M+H)+=877.0.
- 1H NMR (400 MHz, CD3OD) δ=8.42-8.34 (m, 1H), 8.23 (d, J=1.8 Hz, 1H), 7.61-7.46 (m, 1H), 7.35 (dd, J=3.2, 6.8 Hz, 1H), 7.11 (dd, J=6.8, 8.4 Hz, 1H), 6.98 (t, J=6.8 Hz, 1H), 5.04-4.93 (m, 4H), 4.66-4.60 (m, 2H), 4.06 (t, J=13.4 Hz, 2H), 3.94 (s, 3H), 3.90-3.82 (m, 4H), 3.58-3.52 (m, 2H), 3.43 (s, 3H), 3.13-2.96 (m, 3H), 2.88-2.66 (m, 4H), 2.51-2.37 (m, 1H), 2.15-2.05 (m, 3H), 1.97-1.87 (m, 1H), 1.86-1.67 (m, 5H)
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (40.9 mg, 39.97 μmol, 12.40% yield, 90% purity) as a yellow solid. MS(M+H)+=921.6.
- 1H NMR (400 MHz, CDCl3) δ=8.34 (d, J=14.9 Hz, 1H), 8.07 (d, J=1.7 Hz, 1H), 7.82 (d, J=1.7 Hz, 1H), 7.55 (dd, J=7.2 Hz, J2=4.0 Hz, 1H), 7.47 (dd, J=8.3 Hz,
J 2=7.3 Hz, 1H), 7.09 (d, J=7.0 Hz, 2H), 6.90 (d, J=8.4 Hz, 1H), 6.55-6.46 (m, 1H), 4.92-4.82 (m, 2H), 4.74-4.62 (m, 1H), 3.97-3.92 (m, 4H), 3.93-3.85 (m, 2H), 3.72 (t, J=5.4 Hz, 2H), 3.69-3.62 (m, 6H), 3.48-3.42 (m, 2H), 3.42 (s, 3H), 3.02-2.93 (m, 1H), 2.88-2.79 (m, 3H), 2.77-2.67 (m, 3H), 2.49-2.34 (m, 2H), 2.15-2.08 (m, 3H), 1.71-1.52 (m, 7H). -
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (61.4 mg, 57.81 μmol, 17.29% yield, 95% purity, FA) as yellow solid. MS(M+H)+=1009.3.
- 1H NMR (400 MHz, MeOD) δ=8.35-8.24 (m, 1H), 8.20 (s, 1H), 7.50 (dd, J=7.2, 8.5 Hz, 1H), 7.46-7.34 (m, 1H), 7.08-6.94 (m, 2H), 5.08-4.90 (m, 3H), 4.74-4.56 (m, 1H), 4.15-4.05 (m, 2H), 4.07-3.94 (m, 4H), 3.89-3.76 (m, 3H), 3.72-3.59 (m, 13H), 3.55-3.36 (m, 8H), 3.27-3.16 (m, 1H), 2.92-2.79 (m, 1H), 2.78-2.39 (m, 3H), 2.26-2.16 (m, 1H), 2.15-2.01 (m, 3H), 1.88-1.77 (m, 2H), 1.74-1.51 (m, 4H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (41.5 mg, 45.54 μmol, 10.56% yield, 96% purity) as yellow solid. MS (M+H)+=875.2.
- 1H NMR (400 MHz, CD3OD) δ=8.42 (d, J=14.4 Hz, 1H), 8.21 (s, 1H), 7.57-7.53 (m, 1H), 7.44-7.33 (m, 1H), 7.08-7.03 (m, 2H), 5.06-5.02 (m, 1H), 4.95-4.92 (m, 2H), 4.70-4.60 (m, 3H), 4.11-3.95 (m, 5H), 3.80-3.71 (m, 1H), 3.40-3.37 (m, 5H), 3.26-3.24 (m, 2H), 2.85-2.75 (m, 1H), 2.71-2.50 (m, 3H), 2.32-2.16 (m, 1H), 2.11-2.08 (m, 3H), 1.78-1.71 (m, 10H) 1.60-1.50 (m, 2H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (67.9 mg, 70.88 μmol, 34.02% yield, 93% purity) as yellow solid. MS(M+H)+=891.0
- 1H NMR (400 MHz, DMSO-d6) δ=11.10 (s, 1H), 8.30 (s, 1H), 8.27 (d, J=13.6 Hz, 1H), 8.05-8.02 (m, 2H), 7.57 (t, J=7.8 Hz, 1H), 7.24 (d, J=6.8 Hz, 1H), 7.09 (d, J=8.8 Hz, 1H), 7.01 (d, J=7.0 Hz, 1H), 6.67 (t, J=5.6 Hz, 1H), 5.09-4.98 (m, 1H), 4.89-4.74 (m, 1H), 4.37-4.30 (m, 1H), 4.09 (t, J=13.8 Hz, 2H), 3.91 (s, 3H), 3.57-3.45 (m, 4H), 3.47-3.39 (m, 8H), 2.94-2.76 (m, 2H), 2.71-2.55 (m, 5H), 2.19-2.06 (m, 1H), 2.05-1.90 (m, 3H), 1.85-1.79 (m, 2H), 1.75-1.70 (m, 3H), 1.69-1.52 (m, 3H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (98.4 mg, 106.56 μmol, 17.55% yield, 98% purity) as a yellow solid. MS(M+H)+=905.7.
- 1H NMR (400 MHz, DMSO-d6) δ=11.09 (s, 1H), 8.36-8.16 (m, 2H), 8.11-7.93 (m, 2H), 7.57 (dd, J1=7.3 Hz, J2=8.4 Hz, 1H), 7.20 (d, J=6.7 Hz, 1H), 7.08 (d, J=8.7 Hz, 1H), 7.01 (d, J=7.0 Hz, 1H), 6.66 (t, J=5.6 Hz, 1H), 5.04 (dd, J1=12.9 Hz, J2=5.4 Hz, 1H), 4.90-4.71 (m, 1H), 4.43-4.28 (m, 1H), 4.07 (t, J=13.9 Hz, 2H), 3.91 (s, 3H), 3.51-3.35 (m, 9H), 2.94-2.82 (m, 1H), 2.72 (dd, J1=9.1 Hz, J2=7.3 Hz, 1H), 2.65-2.53 (m, 3H), 2.48-2.37 (m, 5H), 2.18-2.09 (m, 1H), 2.05-1.91 (m, 3H), 1.85-1.77 (m, 2H), 1.73-1.67 (m, 4H), 1.66-1.56 (m, 4H).
-
- A mixture of 2-((2-(2, 6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)acetic acid (500 mg, 1.36 mmol, HCl salt), 2-(2-aminoethoxy)ethanol (214.42 mg, 2.04 mmol, 204.21 μL), EDCI (390.97 mg, 2.04 mmol), HOBt (275.58 mg, 2.04 mmol) and TEA (412.75 mg, 4.08 mmol, 567.74 μL) in DCM (5 mL) was stirred at 15° C. for 16 hours. LCMS showed 4% of reactant remained and 79% of desired mass was detected. The reaction mixture was concentrated in vacuo. The residue was purified by flash silica gel chromatography (12 g SepaFlash® Silica Flash Column, Eluent of 0-9% MeOH/Ethyl acetate gradient @ 60 mL/min) to afford the titled compound (400 mg, crude) as a green solid. MS(M+H)+=419.1.
- To a solution of 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-N-(2-(2-hydroxyethoxy)ethyl)acetamide (400 mg, 956.02 μmol) in DCM (15 mL) were added TosCl (328.07 mg, 1.72 mmol) and TEA (290.22 mg, 2.87 mmol, 399.20 μL) and the mixture was stirred at 15° C. for 16 hours. LCMS showed 15% of reactant remained and 35% of desired mass was detected. Additional TosCl (273.39 mg, 1.43 mmol) and TEA (193.48 mg, 1.91 mmol, 266.13 μL) were added and the resulting mixture was stirred at 15° C. for further 3 hours. LCMS showed 8% of reactant remained and 38% of desired mass was detected. The reaction mixture was concentrated in vacuo. The residue was purified by flash silica gel chromatography (20 g SepaFlash® Silica Flash Column, Eluent of 25˜85% Ethyl acetate/Petroleum ether gradient @ 100 mL/min) to afford the titled compound (410 mg, 716.05 μmol, 74.90% yield, N/A purity) as a yellow oil. MS(M+H)+=573.0.
- A mixture of 2-(2-(2-((2-(2, 6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)acetamido) ethoxy)ethyl 4-methylbenzenesulfonate (410 mg, 716.05 μmol), (5)-tert-butyl pyrrolidin-3-ylcarbamate (266.73 mg, 1.43 mmol), NaI (10.73 mg, 71.60 μmol) and DIEA (277.63 mg, 2.15 mmol, 374.17 μL) in DMF (6 mL) was stirred at 60° C. for 16 hours. LCMS showed reactant was consumed completely and 83% of desired mass was detected. The reaction mixture was diluted with H2O (50 mL) and extracted with brine (50 mL×3). The combined organic layers were washed with brine (80 mL×5), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (12 g SepaFlash® Silica Flash Column, Eluent of 0-5% MeOH/Ethyl acetate gradient @ 60 mL/min) to afford the titled compound (160 mg, 272.74 μmol, 38.09% yield) as a yellow solid. MS(M+H)+=587.2.
- To a solution of tert-butyl ((3S)-1-(2-(2-(2-((2-(2, 6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl) amino)acetamido)ethoxy)ethyl)pyrrolidin-3-yl)carbamate (160 mg, 272.74 μmol) in dioxane (5 mL) was added HCl/dioxane (4 M, 10 mL), the mixture was stirred at 15° C. for 2 hours. LCMS showed reactant was consumed completely and 100% of desired mass was detected. The reaction mixture was concentrated in vacuo to afford the titled compound (220 mg, crude, HCl) as a yellow solid, which was used for the next step directly. MS(M+H)+=487.2.
- To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8, 9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (120 mg, 257.83 μmol) in DMF (3 mL) were added HATU (147.05 mg, 386.74 μmol) and DIEA (133.29 mg, 1.03 mmol, 179.64 μL) and the resulting mixture was stirred at 15° C. for 15 minutes, then N-(2-(2-((S)-3-aminopyrrolidin-1-yl)ethoxy)ethyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)acetamide (215.74 mg, 412.53 μmol, HCl salt) and the resulting mixture was stirred at 15° C. for 12 hours. LCMS showed reactant was consumed completely and 79% of desired mass was detected. To the mixture was added CH3COOH to adjust pH<7. The resulting mixture was purified by prep-HPLC (column: Waters Xbridge 150*25 mm*5 um; mobile phase: [water (10 mM NH4HCO3)-ACN]; B %: 37%-67%, 10 min) followed by prep-HPLC (column: Phenomenex luna C18 150*25 mm*10 um; mobile phase: [water (0.225% FA)-ACN]; B %: 15%-55%, 13 min) to afford the titled compound (58.2 mg, 60.45 μmol, 23.44% yield, 97% purity) as a yellow solid. MS(M+H)+=934.2.
- 1H NMR (400 MHz, DMSO-d6) δ=11.09 (s, 1H), 8.29 (s, 1H), 8.23 (d, J=13.4 Hz, 1H), 8.14 (t, J=5.5 Hz, 1H), 8.09-7.94 (m, 2H), 7.57 (dd, J1=7.5, J2=8.2 Hz, 1H), 7.19 (d, J=6.7 Hz, 1H), 7.05 (d, J=7.0 Hz, 1H), 6.93 (t, J=5.5 Hz, 1H), 6.84 (d, J=8.6 Hz, 1H), 5.07 (dd, J1=5.4, J2=12.9 Hz, 1H), 4.89-4.74 (m, 1H), 4.39-4.27 (m, 1H), 4.07 (t, J=13.9 Hz, 2H), 4.01-3.78 (m, 5H), 3.48 (t, J=5.9 Hz, 2H), 3.45-3.39 (m, 2H), 3.33 (s, 3H), 3.30-3.25 (m, 2H), 2.95-2.83 (m, 1H), 2.79 (dd, J1=7.3, J2=9.3 Hz, 1H), 2.69-2.60 (m, 2H), 2.59-2.52 (m, 4H), 2.45-2.40 (m, 1H), 2.17-2.08 (m, 1H), 2.07-1.90 (m, 3H), 1.78-1.52 (m, 7H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (40.8 mg, 43.38 μmol, 13.61% yield, 97.6% purity) as a yellow solid. MS(M+H)+=918.2
- 1H NMR (400 MHz, DMSO-d6) δ=11.09 (s, 1H), 8.34-8.20 (m, 3H), 8.16-8.07 (m, 1H), 8.04 (s, 1H), 7.63-7.47 (m, 1H), 7.25-7.15 (m, 1H), 7.11-7.03 (m, 1H), 6.94 (t, J=5.5 Hz, 1H), 6.89-6.82 (m, 1H), 5.11-5.03 (m, 1H), 4.87-4.76 (m, 1H), 4.52-4.35 (m, 1H), 4.07 (t, J=13.9 Hz, 2H), 3.91 (d, J=2.0 Hz, 5H), 3.75-3.45 (m, 3H), 3.33-3.21 (m, 5H), 2.94-2.83 (m, 1H), 2.63-2.54 (m, 2H), 2.45-2.37 (m, 2H), 2.26-1.84 (m, 6H), 1.72 (d, J=0.9 Hz, 2H), 1.51-1.68 (m, 4H)
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (71 mg, 76.89 μmol, 22.37% yield, 98% purity) as a yellow solid. MS(M+H)+=905.0
- 1H NMR (400 MHz, DMSO-d6) δ=11.08 (br s, 1H), 8.30 (s, 1H), 8.28-8.19 (m, 2H), 8.03 (s, 1H), 7.62-7.53 (m, 1H), 7.22-7.16 (m, 1H), 7.13 (dd, J=6.8, 8.4 Hz, 1H), 7.02 (t, J=6.8 Hz, 1H), 6.62-6.54 (m, 1H), 5.10-5.02 (m, 1H), 4.87-4.77 (m, 1H), 4.53-4.36 (m, 1H), 4.07 (t, J=13.8 Hz, 2H), 3.91 (d, J=2.1 Hz, 3H), 3.72-3.65 (m, 2H), 3.64-3.56 (m, 3H), 3.54-3.36 (m, 6H), 3.34-3.32 (m, 3H), 3.27-3.21 (m, 1H), 2.96-2.80 (m, 1H), 2.62-2.53 (m, 2H), 2.10-1.86 (m, 5H), 1.74-1.57 (m, 6H)
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (53.2 mg, 55.20 μmol, 21.41% yield, 97% purity) as a yellow solid. MS(M+H)+=935.5
- 1H NMR (400 MHz, DMSO-d6) δ=11.07 (br s, 1H), 8.35-8.17 (m, 3H), 8.03 (br s, 1H), 7.62-7.51 (m, 1H), 7.25-7.08 (m, 2H), 7.06-6.97 (m, 1H), 6.60 (q, J=5.6 Hz, 1H), 5.04 (br dd, J=5.1, 12.5 Hz, 1H), 4.89-4.75 (m, 1H), 4.55-4.31 (m, 1H), 4.16-4.00 (m, 4H), 3.91 (d, J=4.0 Hz, 3H), 3.75-3.56 (m, 7H), 3.55-3.36 (m, 5H), 2.96-2.79 (m, 1H), 2.65-2.51 (m, 5H), 2.19-1.86 (m, 5H), 1.78-1.52 (m, 6H).
-
- the titled compound (70.7 mg, 67.04 μmol, 31.20% yield, 97% purity) as a yellow solid. MS(M+H)+=1023.4.
- 1H NMR (400 MHz, DMSO-d6) δ=11.09 (s, 1H), 8.35-8.18 (m, 3H), 8.09 (s, 1H), 7.62-7.53 (m, 1H), 7.20 (d, J=6.7 Hz, 1H), 7.14 (dd, J1=3.7, J2=8.6 Hz, 1H), 7.04 (dd, J1=1.8, J2=6.8 Hz, 1H), 6.60 (br s, 1H), 5.06 (br dd, J1=5.3, J2=13.0 Hz, 1H), 4.88-4.78 (m, 1H), 4.50-4.39 (m, 1H), 4.13-4.04 (m, 4H), 3.92 (s, 3H), 3.75-3.70 (m, 1H), 3.62 (br d, J=4.8 Hz, 2H), 3.57-3.50 (m, 12H), 3.49-3.44 (m, 4H), 3.34 (br s, 3H), 2.91-2.87 (m, 1H), 2.59-2.51 (m, 2H), 2.21-2.13 (m, 1H), 2.08-1.88 (m, 5H), 1.78-1.69 (m, 2H), 1.68-1.55 (m, 4H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (76 mg, 79.52 μmol, 19.00% yield, 93% purity) as yellow solid. MS(M+H)+=889.3
- 1H NMR (400 MHz, DMSO-d6) δ=11.08 (s, 1H), 8.33-8.21 (m, 3H), 8.04 (s, 1H), 7.64-7.51 (m, 1H), 7.19 (d, J=6.6 Hz, 1H), 7.10 (dd, J=3.3, 8.6 Hz, 1H), 7.01 (dd, J=2.6, 7.0 Hz, 1H), 6.62-6.50 (m, 1H), 5.13-4.97 (m, 1H), 4.89-4.73 (m, 1H), 4.56-4.32 (m, 1H), 4.07 (t, J=13.8 Hz, 2H), 3.91 (s, 3H), 3.87-3.73 (m, 1H), 3.64-3.53 (m, 1H), 3.52-3.42 (m, 1H), 3.38-3.36 (m, 1H), 3.29-3.23 (m, 5H), 2.94-2.82 (m, 1H), 2.62-2.51 (m, 2H), 2.35-2.24 (m, 2H), 2.18-1.89 (m, 5H), 1.76-1.56 (m, 10H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (143.1 mg, 152.15 μmol, 37.43% yield, 96% purity) as yellow solid. MS(M+H)+=903.6
- 1H NMR (400 MHz, DMSO-d6) δ 11.10 (s, 1H), 8.35-8.20 (m, 3H), 8.05 (s, 1H), 7.61-7.53 (m, 1H), 7.19 (d, J=6.6 Hz, 1H), 7.08 (dd, J=8.7, 5.9 Hz, 1H), 7.01 (dd, J=7.1, 4.5 Hz, 1H), 6.58-6.50 (m, 1H), 5.10-4.99 (m, 1H), 4.89-4.76 (m, 1H), 4.52-4.32 (m, 0H), 4.07 (t, J=13.8 Hz, 2H), 3.91 (d, J=1.4 Hz, 3H), 3.80-3.53 (m, 1H), 3.53-3.40 (m, 1H), 3.31 (s, 3H), 3.29-3.28 (m, 1H), 2.96-2.82 (m, 0H), 2.71-2.52 (m, 1H), 2.29-2.18 (m, 2H), 2.11-1.85 (m, 4H), 1.78-1.68 (m, 2H), 1.67-1.49 (m, 8H), 1.41-1.30 (m, 2H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (64 mg, 68.76 μmol, 26.67% yield, 97% purity) as a yellow solid. MS(M+H)+=903.1
- 1H NMR (400 MHz, DMSO-d6) δ=11.09 (s, 1H), 8.32-8.20 (m, 3H), 8.04 (s, 1H), 7.63-7.50 (m, 1H), 7.19 (d, J=6.8 Hz, 1H), 7.08 (dd, J=5.8, 8.6 Hz, 1H), 7.01 (dd, J=4.4, 7.0 Hz, 1H), 6.53 (q, J=5.8 Hz, 1H), 5.08-5.01 (m, 1H), 4.86-4.76 (m, 1H), 4.52-4.35 (m, 1H), 4.07 (t, J=13.8 Hz, 2H), 3.91 (s, 3H), 3.79-3.36 (m, 3H), 3.31-3.22 (m, 3H), 2.94-2.82 (m, 1H), 2.63-2.51 (m, 4H), 2.30-1.77 (m, 8H), 1.76-1.68 (m, 2H), 1.65-1.50 (m, 8H), 1.43-1.31 (m, 2H)
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (39.1 mg, 40.71 μmol, 12.63% yield, 94% purity) as a light yellow solid. MS(M+H)+=903.7
- 1H NMR (400 MHz, DMSO-d6) δ 11.07 (br s, 1H), 8.31-8.23 (m, 3H), 8.04 (s, 1H), 7.61-7.54 (m, 1H), 7.20 (d, J=6.6 Hz, 1H), 7.09 (dd, J=5.8, 8.6 Hz, 1H), 7.01 (dd, J=4.4, 7.0 Hz, 1H), 6.58-6.50 (m, 1H), 5.03 (dd, J=5.1, 13.0 Hz, 1H), 4.87-4.76 (m, 1H), 4.52-4.36 (m, 1H), 4.08 (t, J=13.9 Hz, 2H), 3.92 (s, 3H), 3.77-3.51 (m, 2H), 3.49-3.41 (m, 1H), 3.34 (s, 3H), 2.93-2.78 (m, 1H), 2.65-2.55 (m, 4H), 2.29-1.91 (m, 8H), 1.80-1.70 (m, 2H), 1.69-1.54 (m, 8H), 1.42-1.33 (m, 2H)
-
- Step 1-4 are Described in the Above Reaction Scheme.
- To a solution of 4-[(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-8H-pyrimido[4, 5-b][1, 4]diazepin-2-yl) amino]-2-fluoro-5-methoxy-benzoic acid (177.99 mg, 382.42 μmol) in DMF (3 mL) were added HATU (290.82 mg, 764.85 μmol) and DIPEA (197.70 mg, 1.53 mmol, 266.44 μL), the mixture was stirred at 25° C. for 10 min. Then 2-((S)-3-aminopyrrolidin-1-yl)-N-(2-(2-((2-(2, 6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethyl)acetamide (200 mg, 382.42 μmol, HCl salt) was added and the resulting mixture was stirred at 25° C. for another 1 h. LCMS showed a peak (55%) with desired mass. The mixture was purified by prep-HPLC (column: Waters Xbridge 150*25 mm*5 um; mobile phase: [water (10 mM NH4HCO3)-ACN]; B %: 38%-68%, 10 min) and prep-HPLC (column: Waters Xbridge 150*25 mm*5 um; mobile phase: [water (10 mM NH4HCO3)-ACN]; B %: 40%-70%, 10 min) to afford the titled compound (15.8 mg, 15.72 μmol, 36.70% yield, 92.920% purity) as yellow solid. MS(M+H)+=934.3
- 1H NMR (400 MHz, DMSO-d6) δ=11.17-10.96 (m, 1H), 8.29 (s, 1H), 8.22 (d, J=13.4 Hz, 1H), 8.14 (br d, J=4.3 Hz, 1H), 8.00 (s, 1H), 7.81 (t, J=5.9 Hz, 1H), 7.58-7.48 (m, 1H), 7.19 (d, J=6.6 Hz, 1H), 7.10 (d, J=8.4 Hz, 1H), 7.00 (d, J=7.1 Hz, 1H), 6.62-6.50 (m, 1H), 5.09-4.96 (m, 1H), 4.85-4.77 (m, 1H), 4.52-4.33 (m, 1H), 4.12-4.03 (m, 2H), 3.90 (s, 3H), 3.61-3.56 (m, 2H), 3.50-3.41 (m, 4H), 3.30 (s, 3H), 3.12-2.99 (m, 2H), 2.94-2.68 (m, 4H), 2.47-2.43 (m, 5H), 2.22-2.11 (m, 1H), 2.04-1.93 (m, 3H), 1.71 (br d, J=6.8 Hz, 3H), 1.65-1.54 (m, 4H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (48 mg, 52.57 μmol, 27.83% yield, 99% purity) as yellow solid MS(M+H)+=904.9
- 1H NMR (400 MHz, DMSO-d6) δ=11.14 (br s, 1H), 8.33 (d, J=3.9 Hz, 1H), 8.29-8.22 (m, 2H), 8.13-8.00 (m, 2H), 7.60 (t, J=7.8 Hz, 1H), 7.24 (dd, J=0.9, 6.7 Hz, 1H), 7.10 (dd, J=2.3, 8.6 Hz, 1H), 7.02 (dd, J=3.9, 7.0 Hz, 1H), 6.79-6.71 (m, 1H), 5.15-5.05 (m, 1H), 4.91-4.76 (m, 1H), 4.55-4.44 (m, 1H), 4.13 (t, J=14.0 Hz, 2H), 3.96 (s, 3H), 3.39-3.37 (m, 3H), 3.34-3.26 (m, 3H), 3.25-3.16 (m, 2H), 3.10-3.03 (m, 1H), 3.00-2.90 (m, 1H), 2.88-2.80 (m, 2H), 2.69-2.62 (m, 3H), 2.30-2.21 (m, 1H), 2.10-1.99 (m, 3H), 1.83-1.62 (m, 10H).
-
- To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido [4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (300 mg, 644.57 μmol) and tert-butyl 3-aminoazetidine-1-carboxylate (111.01 mg, 644.57 μmol) in DMF (3 mL) were added HATU (490.17 mg, 1.29 mmol) and DIPEA (333.22 mg, 2.58 mmol, 449.08 μL) and the resulting mixture was stirred at 20° C. for 1 h. LCMS showed that 76% desired mass was detected. The reaction mixture was diluted with H2O (20 mL) and extracted with EtOAc (50 mL×3). The combined organic layers were washed with brine (80 mL), dried over Na2SO4, filtered. The filtrate was concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (Biotage, 20 g SepaFlash® Silica Flash Column, Eluent of 30˜100% Ethyl acetate/Petroleum ether gradient @ 60 mL/min) to afford the titled compound (360 mg, 580.99 μmol, 90.14% yield) as a colorless oil. MS(M+H)+=620.5
- To a solution of tert-butyl 3-(4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzamido)azetidine-1-carboxylate (180 mg, 290.49 μmol) in DCM (2 mL) was added TFA (1.54 g, 13.51 mmol, 1 mL) and the resulting mixture was stirred at 20° C. for 1 h. LCMS showed a peak (97%) with desired mass. The mixture was concentrated. The residue were dissolved in dioxane (2 mL) and basic resin (200 mg) was added, the suspension was stirred for 1 h at 20° C., then filtered. The filtrate was used for next step directly. MS(M+H)+=520.3
- To the solution of N-(azetidin-3-yl)-4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzamide (150 mg, 288.73 umol) and 2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy) ethoxy)ethyl 4-methylbenzenesulfonate (161.57 mg, 288.73 umol) in dioxane (3 mL) were added NaI (4.33 mg, 28.87 umol) and DIPEA (111.95 mg, 866.19 umol, 150.87 uL) and the resulting mixture was stirred at 60° C. for 12 hr. TLC (Petroleum ether:Ethyl acetate=10:1) showed that most of reactant was consumed and new spots were formed. The mixture was poured into water (20 mL) and extracted with EtOAc (20 mL×3). The combined organic layer was washed with brine (50 mL), dried over Na2SO4, filtered. The filtrate was concentrated. The residue was purified by pre-HPLC (column: Waters Xbridge C18 150*50 mm*10 um; mobile phase: [water (10 mM NH4HCO3)-ACN]; B %: 35%-65%, min) to afford the titled compound (7.8 mg, 7.81 umol, 3.54% yield, 90.8% purity) as a yellow solid. MS (M+H)+=907.2
- 1H NMR (400 MHz, DMSO-d6) δ=11.23-10.96 (m, 1H), 8.41-8.36 (m, 1H), 8.32-8.23 (m, 2H), 8.13-7.95 (m, 1H), 7.60-7.55 (m, 1H), 7.21-7.13 (m, 2H), 7.03 (d, J=7.0 Hz, 1H), 6.66-6.56 (m, 1H), 5.08-5.02 (m, 1H), 4.87-4.79 (m, 1H), 4.45-4.38 (m, 1H), 4.11-4.04 (m, 2H), 3.91 (s, 3H), 3.66-3.59 (m, 3H), 3.57-3.46 (m, 10H), 3.38-3.37 (m, 2H), 3.34-3.33 (m, 3H), 3.02-2.95 (m, 2H), 2.92-2.83 (m, 1H), 2.09-1.83 (m, 4H), 1.74-1.57 (m, 6H).
-
- To a solution of 2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethyl 4-methylbenzenesulfonate (400 mg, 775.89 μmol) and tert-butyl (pyrrolidin-2-ylmethyl) carbamate (155.39 mg, 775.89 μmol) in dioxane (5 mL) were added NaI (11.63 mg, 77.59 μmol) and DIEA (200.56 mg, 1.55 mmol, 270.29 μL), the mixture was heated at 80° C. for 12 h. LCMS showed the desired mass was detected. The mixture was concentrated in vacuo. The residue was purified by flash silica gel chromatography (Biotage, 12 g SepaFlash® Silica Flash Column, Eluent of 30˜100% Ethyl acetate/Petroleum ether gradient @ 60 mL/min) to afford the titled compound (337 mg, 607.53 μmol, 78.30% yield, 98% purity) as yellow solid. MS (M+H)+=544.2
- To a solution of tert-butyl ((1-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino) ethoxy)ethyl)pyrrolidin-2-yl)methyl)carbamate (337 mg, 619.93 μmol) in dioxane (4 mL) was added HCl/dioxane (4 M, 2 mL) and the mixture was stirred at 25° C. for 30 min. LCMS showed the desired mass detected. The mixture was concentrated in vacuo to afford the titled compound (450 mg, crude, HCl salt) as a yellow solid. Ms(M+H)+=444.1
- To a solution of 4-((2-(2-(2-(aminomethyl)pyrrolidin-1-yl)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (150 mg, 312.53 μmol, HCl salt) and 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (121.22 mg, 260.44 μmol) in DMF (5 mL) were added HATU (198.05 mg, 520.88 μmol) and DIEA (100.98 mg, 781.32 μmol, 136.09 μL), the mixture was stirred at 25° C. for 12 h. LCMS showed the desired mass was detected. The reaction mixture was concentrated in vacuo. The residue was purified by prep-HPLC (column: Phenomenex luna C18 150*40 mm*15 um; mobile phase: [water (0.225% FA)-ACN]; B %: 20%-50%, 10 min) to afford the titled compound (128.4 mg, 138.93 μmol, 53.35% yield, 96.4% purity) as a yellow solid. MS (M+H)+=891.3
- 1H NMR (400 MHz, DMSO-d6) δ=11.09 (s, 1H), 8.29 (s, 1H), 8.25 (d, J=13.9 Hz, 1H), 8.16-8.03 (m, 2H), 7.54 (t, J=7.8 Hz, 1H), 7.29 (d, J=6.8 Hz, 1H), 7.15-7.10 (m, 1H), 7.02-6.98 (m, 1H), 6.64-6.56 (m, 1H), 5.06-5.00 (m, 1H), 4.84-4.76 (m, 1H), 4.08 (t, J=13.8 Hz, 2H), 3.89 (d, J=1.3 Hz, 3H), 3.81-3.61 (m, 6H), 3.58-3.47 (m, 6H), 3.34 (s, 3H), 2.95-2.81 (m, 2H), 2.57 (d, J=18.7 Hz, 2H), 2.06-1.92 (m, 5H), 1.74-1.72 (m, 4H), 1.67-1.59 (m, 4H).
-
- To a solution of 2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethyl 4-methylbenzenesulfonate (400 mg, 775.89 μmol) and tert-butyl (piperidin-3-ylmethyl)carbamate (332.55 mg, 1.55 mmol) in dioxane (5 mL) were added NaI (11.63 mg, 77.59 μmol) and DIPEA (200.56 mg, 1.55 mmol, 270.29 μL), the mixture was heated at 80° C. for 12 h. LCMS showed the desired mass was detected. The mixture was concentrated in vacuo. The residue was purified by flash silica gel chromatography (Biotage, 12 g SepaFlash® Silica Flash Column, Eluent of 10˜20% EtOAc/MeOH gradient @ 60 mL/min) to afford the titled compound (613 mg, crude) as a yellow solid. MS(M+H)+=558.2
- A solution of tert-butyl ((1-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino) ethoxy)ethyl)piperidin-3-yl)methyl)carbamate (613 mg, 1.10 mmol) and HCl/dioxane (4 M, 4 mL) in dioxane (2 mL) was stirred at 25° C. for 12 h. LCMS showed the desired mass was detected. The mixture was concentrated in vacuo to afford the titled compound (540 mg, crude, HCl salt) as a yellow solid. MS(M+H)+=458.1
- To a solution of 4-((2-(2-(3-(aminomethyl) piperidin-1-yl)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl) isoindoline-1,3-dione (150 mg, 303.65 μmol, HCl salt) and 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (117.77 mg, 253.05 μmol) in DMF (3 mL) were added HATU (192.43 mg, 506.09 μmol) and DIEA (98.11 mg, 759.14 μmol, 132.22 μL), the mixture was stirred at 25° C. for 12 h. LCMS showed the desired mass was detected. The mixture was concentrated in vacuo. The residue was purified by prep-HPLC (column: Shim-pack C18 150*25*10 um; mobile phase: [water (0.225% FA)-ACN]; B %: 27%-51%, 12 min). Compound 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-N-((1-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethyl)piperidin-3-yl)methyl)-2-fluoro-5-methoxybenzamide (82.6 mg, 88.54 μmol, 34.99% yield, 97% purity) was obtained as a yellow solid. MS(M+H)+=905.3
- 1H NMR (400 MHz, DMSO-d6) δ=11.09 (s, 1H), 8.29 (s, 1H), 8.23 (d, J=13.6 Hz, 1H), 8.17-8.09 (m, 1H), 8.03 (s, 1H), 7.55 (t, J=7.6 Hz, 1H), 7.24 (d, J=6.8 Hz, 1H), 7.10 (d, J=8.5 Hz, 1H), 7.01 (d, J=6.9 Hz, 1H), 6.58 (t, J=6.0 Hz, 1H), 5.12-4.98 (m, 1H), 4.86-4.75 (m, 1H), 4.13-4.03 (m, 2H), 3.90 (s, 3H), 3.80-3.69 (m, 2H), 3.63 (t, J=4.5 Hz, 2H), 3.50-3.35 (m, 12H), 2.98-2.81 (m, 2H), 2.63-2.54 (m, 3H), 2.08-1.87 (m, 4H), 1.85-1.48 (m, 9H).
-
- To a solution of 2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethyl 4-methylbenzenesulfonate (400 mg, 775.89 μmol), tert-butyl (piperidin-2-ylmethyl)carbamate (166.28 mg, 775.89 μmol) in dioxane (5 mL) were added NaI (11.63 mg, 77.59 μmol) and DIPEA (200.56 mg, 1.55 mmol, 270.29 μL), the mixture was heated at 80° C. for 12 h. LCMS showed reactant remained, additional tert-butyl (piperidin-2-ylmethyl)carbamate (332.56 mg, 1.55 mmol) was added and the resulting mixture was heated at 80° C. for another 12 h. LCMS showed the desired mass was detected. The mixture was concentrated in vacuo. The residue was purified by flash silica gel chromatography (Biotage, 12 g SepaFlash® Silica Flash Column, Eluent of EtOAc/MeOH=10:1 gradient @ 60 mL/min) to afford the titled compound (268 mg, 478.68 μmol, 61.69% yield, 99.6% purity) as a yellow solid. MS(M+H)+=558.1
- A solution of tert-butyl ((1-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino) ethoxy) ethyl)piperidin-2-yl)methyl)carbamate (268 mg, 480.60 μmol) and HCl/dioxane (4 M, 2 mL) in dioxane (2 mL) was stirred at 25° C. for 12 h. LCMS showed the desired mass was detected. The mixture was concentrated in vacuo to afford the titled compound (235 mg, crude, HCl salt) as a yellow solid. MS (M+H)+=458.2
- To a solution of 4-((2-(2-(2-(aminomethyl)piperidin-1-yl)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (150 mg, 303.65 μmol, HCl salt) and 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (117.77 mg, 253.05 μmol) in DMF (3 mL) were added HATU (192.43 mg, 506.09 μmol) and DIEA (98.11 mg, 759.14 μmol, 132.23 μL), the mixture was stirred at 25° C. for 12 h. LCMS showed the desired mass was detected. The mixture was concentrated in vacuo. The residue was purified by prep-HPLC (column: Unisil 3-100 C18 μLtra 150*50 mm*3 um; mobile phase: [water (0.225% FA)-ACN]; B %: 30%-50%, 10 min) and the eluent was freeze dried. The residue was diluted with H2O (3 mL), then basified with NaHCO3 (2 mL), then extracted with EtOAc (15 mL×2). The combined organic layer was dried over Na2SO4, filtered. The filtrate was concentrated under reduced pressure to afford the titled compound (90.9 mg, 98.34 μmol, 90.81% yield, 97.9% purity) as a yellow solid. Ms (M+H)+=905.4
- 1H NMR (400 MHz, DMSO-d6) δ=11.21-11.01 (m, 1H), 8.29 (s, 1H), 8.24-8.13 (m, 1H), 8.01 (s, 1H), 7.73 (s, 1H), 7.52-7.42 (m, 1H), 7.25 (d, J=7.0 Hz, 1H), 7.08-7.02 (m, 1H), 7.01-6.89 (m, 1H), 6.63-6.48 (m, 1H), 5.07-4.99 (m, 1H), 4.84-4.75 (m, 1H), 4.12-4.03 (m, 2H), 3.88 (s, 3H), 3.61-3.56 (m, 3H), 3.54-3.48 (m, 2H), 3.30-3.50 (m, 4H), 2.96-2.80 (m, 4H), 2.31-2.25 (m, 1H), 2.05-1.89 (m, 4H), 1.75-1.43 (m, 11H), 1.40-1.18 (m, 5H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (10.1 mg, 10.06 umol, 6.54% yield, 93.1% purity) as a white solid. MS(M+H)+=935.3
- 1H NMR (400 MHz, DMSO-d6) δ=11.13 (s, 1H), 9.74-9.45 (m, 1H), 8.32-8.25 (m, 2H), 8.08 (s, 1H), 8.00 (s, 1H), 7.79 (s, 1H), 7.53-7.46 (m, 1H), 7.43-7.36 (m, 1H), 7.25 (d, J=2.4 Hz, 1H), 5.15-5.09 (m, 1H), 4.88-4.76 (m, 3H), 4.67-4.54 (m, 1H), 4.09 (t, J=13.9 Hz, 2H), 3.91 (s, 3H), 3.72 (s, 2H), 3.56 (d, J=5.4 Hz, 2H), 3.50-3.30 (m, 3H), 2.95-2.86 (m, 1H), 2.65-2.53 (m, 10H), 2.14-1.89 (m, 5H), 1.77-1.70 (m, 2H), 1.68-1.58 (m, 4H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (13.2 mg, 13.69 μmol, 9.42% yield, 96% purity) as a yellow solid. MS(M+H)+=926.4
- 1H NMR (400 MHz, CDCl3) δ=8.48 (d, J=8.5 Hz, 1H), 8.37 (br d, J=10.4 Hz, 1H), 8.06 (s, 1H), 7.77 (s, 1H), 7.64 (dd, J=7.4, 8.3 Hz, 1H), 7.50-7.41 (m, 2H), 7.29 (br d, J=1.8 Hz, 1H), 7.18 (d, J=8.3 Hz, 1H), 6.14 (br d, J=8.0 Hz, 1H), 4.97 (dd, J=5.3, 12.2 Hz, 1H), 4.82 (quin, J=8.4 Hz, 1H), 4.62 (br d, J=13.8 Hz, 1H), 4.33-4.15 (m, 1H), 3.99 (s, 3H), 3.94-3.86 (m, 3H), 3.55 (br s, 4H), 3.41 (s, 3H), 3.26-3.18 (m, 2H), 3.14 (br s, 3H), 2.97-2.86 (m, 2H), 2.84-2.77 (m, 3H), 2.26-1.97 (m, 6H), 1.87-1.30 (m, 10H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (16.8 mg, 17.06 μmol, 11.87% yield, 97% purity) as a yellow solid. MS(M+H)+=896.1
- 1H NMR (400 MHz, CDCl3) δ=9.45 (br d, J=7.0 Hz, 1H), 8.06 (s, 1H), 7.77-7.71 (m, 2H), 7.70-7.64 (m, 3H), 7.60 (dd, J=7.3, 8.3 Hz, 1H), 7.41 (d, J=7.0 Hz, 1H), 7.17 (d, J=8.4 Hz, 1H), 6.14 (br dd, J=7.8, 16.3 Hz, 1H), 4.97 (dd, J=5.4, 12.3 Hz, 1H), 4.83 (quin, J=8.3 Hz, 1H), 4.63 (br d, J=13.0 Hz, 1H), 4.29-4.15 (m, 1H), 3.89 (br t, J=13.3 Hz, 3H), 3.40 (s, 3H), 3.37 (br d, J=4.6 Hz, 3H), 3.21 (br t, J=12.4 Hz, 1H), 2.93-2.80 (m, 4H), 2.72 (br s, 4H), 2.64-2.55 (m, 2H), 2.27-1.95 (m, 6H), 1.80-1.39 (m, 10H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (22.8 mg, 23.90 μmol, 11.12% yield, 96% purity) as a light yellow solid. MS(M+H)+=916.6
- 1H NMR (400 MHz, DMSO-d6) δ 11.08 (br s, 1H), 8.32-8.23 (m, 3H), 8.05 (s, 1H), 7.72-7.64 (m, 1H), 7.37-7.27 (m, 2H), 7.21 (d, J=6.7 Hz, 1H), 5.11-5.08 (m, 1H), 4.86-4.78 (mz, 1H), 4.53-4.39 (m, 1H), 4.08 (t, J=13.9 Hz, 2H), 3.91 (d, J=7.3 Hz, 3H), 3.85-3.60 (m, 2H), 3.57-3.43 (m, 2H), 3.32 (s, 3H), 3.28-3.26 (m, 2H), 3.21-3.15 (m, 2H), 2.93-2.82 (m, 1H), 2.70-2.59 (m, 6H), 2.23-2.03 (m, 2H), 2.02-1.82 (m, 4H), 1.79-1.54 (m, 7H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (70.4 mg, 69.65 μmol, 21.61% yield, 92% purity) as a light yellow solid. MS(M+H)+=930.6
- 1H NMR (400 MHz, DMSO-d6) δ 11.08 (br s, 1H), 8.32-8.22 (m, 3H), 8.04 (s, 1H), 7.72-7.64 (m, 1H), 7.37-7.27 (m, 2H), 7.21 (d, J=6.7 Hz, 1H), 5.16-5.05 (m, 1H), 4.87-4.78 (m, 1H), 4.54-4.40 (m, 1H), 4.08 (t, J=13.9 Hz, 2H), 3.92 (d, J=2.9 Hz, 3H), 3.83-3.56 (m, 2H), 3.55-3.40 (m, 2H), 3.34 (s, 3H), 3.29-3.27 (m, 4H), 2.94-2.82 (m, 1H), 2.64-2.56 (m, 8H), 2.25-2.03 (m, 2H), 2.03-1.84 (m, 4H), 1.78-1.41 (m, 7H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (94.1 mg, 95.42 μmol, 33.02% yield, 94.3% purity) as yellow solid. MS(M+H)+=930.2
- 1H NMR (400 MHz, DMSO-d6) δ=11.08 (s, 1H), 8.31-8.22 (m, 3H), 8.04 (s, 1H), 7.72-7.64 (m, 1H), 7.37-7.26 (m, 2H), 7.20 (d, J=6.6 Hz, 1H), 5.13-5.05 (m, 1H), 4.86-4.75 (m, 1H), 4.55-4.37 (m, 1H), 4.07 (t, J=14.0 Hz, 2H), 3.91 (d, J=2.8 Hz, 3H), 3.53-3.35 (m, 2H), 3.33 (s, 3H), 3.28 (d, J=5.1 Hz, 2H), 2.94-2.81 (m, 1H), 2.65-2.55 (m, 8H), 2.69-2.52 (m, 4H), 2.50-2.32 (m, 2H), 2.25-2.14 (m, 1H), 2.04-1.92 (m, 4H), 1.76-1.69 (m, 2H), 1.66-1.57 (m, 4H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (37.2 mg, 37.44 μmol, 11.62% yield, 95% purity) as a light yellow solid. MS(M+H)+=944.8
- 1H NMR (400 MHz, DMSO-d6) δ 11.08 (br s, 1H), 8.34-8.23 (m, 3H), 8.04 (s, 1H), 7.74-7.65 (m, 1H), 7.38-7.29 (m, 2H), 7.20 (d, J=6.5 Hz, 1H), 5.07 (dd, J=5.5, 12.6 Hz, 1H), 4.89-4.76 (m, 1H), 4.52-4.36 (m, 1H), 4.08 (t, J=13.9 Hz, 2H), 3.92 (s, 3H), 3.83-3.53 (m, 2H), 3.52-3.38 (m, 2H), 3.34 (s, 3H), 3.29 (s, 3H), 2.92-2.81 (m, 1H), 2.65-2.55 (m, 4H), 2.40-2.25 (m, 5H), 2.21-2.09 (m, 1H), 2.08-1.82 (m, 5H), 1.81-1.54 (m, 9H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (13.2 mg, 13.50 umol, 5.91% yield, 98% purity) as yellow solid. MS (M+H)+=958.4
- 1H NMR (400 MHz, DMSO-d6) δ=11.07 (s, 1H), 8.30-8.21 (m, 3H), 8.05 (s, 1H), 7.81-7.72 (m, 1H), 7.48-7.38 (m, 2H), 7.22-7.17 (m, 1H), 5.01-5.11 (m, 1H), 4.87-4.7 (m, 1H), 4.36 4.51 m, 1H), 4.07 (br t, J=13.8 Hz, 2H), 3.91 (s, 3H), 3.8-3.7 (m, 1H), 3.67-3.52 (m, 2H), 3.55-3.41 (m, 2H), 3.45-3.33 (m, 12H), 2.95-2.81 (m, 1H), 2.68-2.50 (m, 2H), 2.37-2.28 (m, 2H), 2.13-1.88 (m, 5H), 1.74-1.48 (m, 10H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (58.0 mg, 61.42 μmol, 19.06% yield, 97% purity) as a light yellow solid. MS(M+H)+=916.6
- 1H NMR (400 MHz, DMSO-d6) δ 11.07 (br s, 1H), 8.32-8.19 (m, 3H), 8.04 (d, J=11.7 Hz, 1H), 7.76-7.61 (m, 1H), 7.38-7.29 (m, 1H), 7.28-7.13 (m, 2H), 5.09-5.05 (m, 1H), 4.87-4.74 (m, 1H), 4.54-4.39 (m, 1H), 4.08 (t, J=13.9 Hz, 2H), 3.95-3.87 (m, 3H), 3.85-3.60 (m, 2H), 3.60-3.43 (m, 4H), 3.41 (s, 3H), 3.24-3.13 (m, 2H), 2.94-2.83 (m, 1H), 2.66-2.54 (m, 7H), 2.23-1.75 (m, 6H), 1.74-1.54 (m, 6H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (77.2 mg, 82.19 μmol, 25.45% yield, 99% purity) as a light yellow solid. MS (M+H)+=930.7
- 1H NMR (400 MHz, DMSO-d6) δ 11.08 (s, 1H), 8.32-8.20 (m, 3H), 8.05-8.00 (m, 1H), 7.65 (dd, J=8.5, 14.8 Hz, 1H), 7.35-7.19 (m, 3H), 5.11-5.03 (m, 1H), 4.86-4.76 (m, 1H), 4.51-4.38 (m, 1H), 4.08 (t, J=13.8 Hz, 2H), 3.91 (d, J=5.9 Hz, 3H), 3.82-3.57 (m, 2H), 3.54-3.44 (m, 2H), 3.41-3.37 (m, 3H), 2.94-2.85 (m, 1H), 2.65-2.52 (m, 8H), 2.49-2.39 (m, 4H), 2.22-2.03 (m, 2H), 2.02-1.87 (m, 4H), 1.81-1.53 (m, 7H)
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (21.5 mg, 20.86 μmol, 29.53% yield, 90.24% purity) as yellow solid. MS(M+H)+=930.4
- 1H NMR (400 MHz, DMSO-d6) δ=11.07 (s, 1H), 8.32-8.18 (m, 3H), 8.11-7.95 (m, 1H), 7.73-7.58 (m, 1H), 7.37-7.15 (m, 3H), 5.11-5.02 (m, 1H), 4.89-4.72 (m, 1H), 4.52-4.37 (m, 1H), 4.14-4.01 (m, 2H), 3.94-3.86 (m, 3H), 3.83-3.70 (m, 1H), 3.67-3.48 (m, 3H), 3.46-3.35 (m, 3H), 3.33 (s, 3H), 2.93-2.83 (m, 1H), 2.64-2.53 (m, 11H), 2.24-1.92 (m, 5H), 1.76-1.68 (m, 2H), 1.66-1.52 (m, 4H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (51.0 mg, 52.95 μmol, 16.43% yield, 98% purity) as a light yellow solid. MS(M+H)+=944.7
- 1H NMR (400 MHz, DMSO-d6) δ 11.08 (s, 1H), 8.33-8.23 (m, 3H), 8.04 (s, 1H), 7.66 (dd, J=4.3, 8.5 Hz, 1H), 7.36-7.30 (m, 1H), 7.26-7.18 (m, 2H), 5.07 (dd, J=5.4, 13.0 Hz, 1H), 4.82 (t, J=7.7 Hz, 1H), 4.53-4.39 (m, 1H), 4.08 (t, J=13.9 Hz, 2H), 3.93-3.91 (m, 3H), 3.82-3.57 (m, 2H), 3.52-3.45 (m, 5H), 3.34 (s, 3H), 2.94-2.83 (m, 1H), 2.71-2.57 (m, 4H), 2.39-2.23 (m, 5H), 2.21-1.89 (m, 6H), 1.79-1.58 (m, 9H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (13.2 mg, 13.50 umol, 5.91% yield, 98% purity) as a yellow solid. MS(M+H)+=958.4
- 1H NMR (400 MHz, DMSO-d6) δ 11.07 (s, 1H), 8.36-8.19 (m, 3H), 8.03 (d, J=7.3 Hz, 1H), 7.70-7.60 (m, 1H), 7.38-7.14 (m, 3H), 5.06 (d, J=12.7 Hz, 1H), 4.87-4.76 (m, 1H), 4.44 (dd, J=33.7, 7.1 Hz, 1H), 4.07 (t, J=13.9 Hz, 2H), 3.91 (d, J=5.2 Hz, 3H), 3.82-3.45 (m, 3H), 3.46-3.35 (m, 6H), 2.95-2.80 (m, 1H), 2.69-2.53 (m, 4H), 2.47-2.41 (m, 3H), 2.38-2.21 (m, 5H), 2.20-1.86 (m, 5H), 1.79-1.69 (m, 2H), 1.67-1.57 (m, 4H), 1.57-1.42 (m, 4H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (94.1 mg, 95.28 μmol, 36.96% yield, 97% purity) as a yellow solid. MS(M+H)+=958.0
- 1H NMR (400 MHz, DMSO-d6) δ=11.09 (s, 1H), 8.34-8.23 (m, 3H), 8.05 (s, 1H), 7.76-7.68 (m, 1H), 7.42-7.33 (m, 2H), 7.21 (dd, J=3.2, 6.6 Hz, 1H), 5.11 (dd, J=5.4, 12.8 Hz, 1H), 4.87-4.77 (m, 1H), 4.54-4.37 (m, 1H), 4.07 (t, J=13.8 Hz, 2H), 3.92 (s, 3H), 3.89-3.77 (m, 1H), 3.71-3.51 (m, 6H), 3.51-3.40 (m, 3H), 3.33 (br s, 3H), 3.27-3.24 (m, 3H), 2.93-2.83 (m, 1H), 2.63-2.59 (m, 2H), 2.59-2.53 (m, 2H), 2.52-2.50 (m, 1H), 2.14-1.87 (m, 5H), 1.77-1.68 (m, 2H), 1.68-1.57 (m, 4H)
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (20.9 mg, 21.12 μmol, 13.59% yield, 95% purity) as a yellow solid. MS(M+H)+=940.1.
- 1H NMR (400 MHz, DMSO-d6) δ=11.02 (br s, 1H), 8.48-8.35 (m, 1H), 8.33-8.23 (m, 2H), 7.98 (d, J=2.4 Hz, 1H), 7.72 (t, J=7.6 Hz, 1H), 7.56-7.46 (m, 2H), 7.37 (dd, J=7.8, 16.4 Hz, 2H), 5.11 (dd, J=5.5, 12.8 Hz, 1H), 4.77 (quin, J=7.9 Hz, 1H), 4.58-4.38 (m, 1H), 4.04 (br t, J=14.0 Hz, 2H), 3.94 (s, 3H), 3.84 (br dd, J=6.9, 10.3 Hz, 1H), 3.77-3.58 (m, 5H), 3.58-3.48 (m, 1H), 3.37-3.46 (m, 1H), 3.34-3.37 (m, 5H), 3.22-3.28 (m, 2H), 2.95-2.82 (m, 1H), 2.65-2.52 (m, 6H), 2.27-2.08 (m, 1H), 2.07-1.87 (m, 4H), 1.78-1.66 (m, 2H), 1.66-1.52 (m, 4H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (32.2 mg, 32.38 μmol, 65.47% yield, 91.5% purity) as a yellow solid. MS(M+H)+=910.0
- 1H NMR (400 MHz, DMSO-d6) δ=11.08 (s, 1H), 9.68 (d, J=1.5 Hz, 1H), 8.38-8.28 (m, 1H), 8.27 (s, 1H), 7.79 (d, J=3.5 Hz, 4H), 7.72 (t, J=7.9 Hz, 1H), 7.42-7.33 (m, 2H), 5.13-5.09 (m, 1H), 4.84-4.74 (m, 1H), 4.53-4.38 (m, 1H), 4.04 (br t, J=14.1 Hz, 2H), 3.88-3.75 (m, 1H), 3.73-3.39 (m, 8H), 3.33 (br s, 3H), 3.29 (s, 1H), 3.26 (br d, J=4.8 Hz, 1H), 2.93-2.83 (m, 1H), 2.79-2.70 (m, 1H), 2.61 (br d, J=5.0 Hz, 3H), 2.56 (br d, J=7.3 Hz, 1H), 2.27-2.14 (m, 1H), 2.13-1.86 (m, 6H), 1.76-1.68 (m, 2H), 1.65-1.56 (m, 4H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (63.3 mg, 63.82 μmol, 24.75% yield, 98% purity) as a yellow solid. MS(M+H)+=972.0
- 1H NMR (400 MHz, DMSO-d6) δ=11.10 (br s, 1H), 8.35-8.23 (m, 3H), 8.04 (s, 1H), 7.75-7.68 (m, 1H), 7.41-7.32 (m, 2H), 7.19 (d, J=6.4 Hz, 1H), 5.11 (dd, J=5.4, 12.8 Hz, 1H), 4.86-4.77 (m, 1H), 4.53-4.36 (m, 1H), 4.12-4.03 (m, 2H), 3.91 (s, 3H), 3.69-3.60 (m, 4H), 3.59-3.42 (m, 4H), 3.33 (s, 3H), 3.25-3.17 (m, 3H), 2.92-2.83 (m, 1H), 2.62-2.54 (m, 2H), 2.42-2.37 (m, 2H), 2.29 (q, J=7.6 Hz, 2H), 2.22-1.87 (m, 6H), 1.79-1.68 (m, 4H), 1.66-1.54 (m, 4H)
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (31.9 mg, 30.64 μmol, 12.96% yield, 92% purity) as a yellow solid. MS(M+H)+=958.3.
- 1H NMR (400 MHz, DMSO-d6) δ 11.03 (s, 1H), 8.37-8.19 (m, 3H), 8.04 (s, 1H), 7.70 (d, J=8.5 Hz, 1H), 7.34 (d, J=2.3 Hz, 1H), 7.30-7.15 (m, 2H), 5.06 (dd, J=12.8, 5.4 Hz, 1H), 4.92-4.75 (m, 1H), 4.45 (dd, J=37.6, 6.3 Hz, 1H), 4.07 (t, J=13.8 Hz, 2H), 3.92 (s, 3H), 3.85-3.50 (m, 8H), 3.50-3.35 (m, 5H), 3.29-3.17 (m, 2H), 2.94-2.80 (m, 1H), 2.70-2.53 (m, 6H), 2.26-2.06 (m, 1H), 2.05-1.87 (m, J=7.0, 6.2 Hz, 4H), 1.80-1.68 (m, 2H), 1.68-1.53 (m, 4H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (24.9 mg, 25.17 μmol, 14.08% yield, 97% purity) as a yellow solid. MS(M+H)+=940.1.
- 1H NMR (400 MHz, DMSO-d6) δ=11.35-10.65 (m, 1H), 8.50-8.35 (m, 1H), 8.34-8.23 (m, 2H), 7.98 (d, J=2.9 Hz, 1H), 7.70 (d, J=8.5 Hz, 1H), 7.59-7.45 (m, 2H), 7.34 (d, J=1.8 Hz, 1H), 7.29-7.19 (m, 1H), 5.07 (dd, J=5.4, 12.9 Hz, 1H), 4.84-4.70 (m, 1H), 4.57-4.38 (m, 1H), 4.04 (t, J=14.1 Hz, 2H), 3.94 (s, 3H), 3.88-3.80 (m, 1H), 3.71-3.58 (m, 5H), 3.58-3.49 (m, 3H), 3.48-3.44 (m, 2H), 3.43-3.37 (m, 1H), 3.36-3.32 (m, 3H), 2.93-2.81 (m, 1H), 2.65-2.53 (m, 6H), 2.27-2.08 (m, 1H), 2.06-1.87 (m, 4H), 1.77-1.67 (m, 2H), 1.66-1.53 (m, 4H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (15.4 mg, 16.42 μmol, 8.57% yield, 94% purity) as a yellow solid. MS(M+H)+=911.0.
- 1H NMR (400 MHz, DMSO-d6) δ=11.08 (br s, 1H), 9.70 (d, J=2.5 Hz, 1H), 8.40-8.29 (m, 1H), 8.27 (s, 1H), 7.79 (d, J=3.6 Hz, 4H), 7.70 (d, J=8.5 Hz, 1H), 7.35 (d, J=1.9 Hz, 1H), 7.24 (dd, J=1.8, 8.6 Hz, 1H), 5.08 (dd, J=5.3, 12.9 Hz, 1H), 4.85-4.73 (m, 1H), 4.54-4.35 (m, 1H), 4.04 (t, J=14.1 Hz, 2H), 3.85-3.64 (m, 3H), 3.63-3.52 (m, 5H), 3.51-3.41 (m, 3H), 3.41-3.33 (m, 3H), 3.30-3.22 (m, 1H), 2.95-2.83 (m, 1H), 2.64-2.56 (m, 3H), 2.56-2.52 (m, 3H), 2.24-2.08 (m, 1H), 2.04-1.91 (m, 4H), 1.76-1.68 (m, 2H), 1.65-1.54 (m, 4H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (45.3 mg, 45.67 μmol, 21.26% yield, 98% purity) as a yellow solid. MS(M+H)+=972.8.
- 1H NMR (400 MHz, DMSO-d6) δ=11.07 (br s, 1H), 8.36-8.20 (m, 3H), 8.03 (s, 1H), 7.68 (dd, J1=3.2, J2=8.5 Hz, 1H), 7.33 (br s, 1H), 7.28-7.21 (m, 1H), 7.19 (dd, J1=1.6, J2=6.6 Hz, 1H), 5.07 (dd, J1=5.4, J2=13.1 Hz, 1H), 4.90-4.72 (m, 1H), 4.54-4.35 (m, 1H), 4.07 (br t, J=13.9 Hz, 2H), 3.91 (s, 3H), 3.76-3.55 (m, 6H), 3.54-3.38 (m, 9H), 2.94-2.82 (m, 1H), 2.70-2.56 (m, 2H), 2.44-2.37 (m, 2H), 2.34-2.26 (m, 2H), 2.19-2.05 (m, 1H), 2.05-1.89 (m, 4H), 1.80-1.68 (m, 4H), 1.68-1.54 (m, 4H).
-
- A mixture of 2-(2, 6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (1.6 g, 5.79 mmol), 6-(tert-butoxycarbonyl)-6-aza-2-azoniaspiro[3.3]heptane oxalate (3.10 g, 6.37 mmol) and DIEA (2.25 g, 17.38 mmol, 3.03 mL) in DMSO (15 mL) was stirred at 80° C. for 40 hours. LCMS showed 30% of reactant remained and 51% of desired mass was detected. The reaction mixture was diluted with H2O (100 mL) and extracted with EtOAc (80 mL×3). The combined organic layers were washed with brine (100 mL×5), dried over Na2SO4, filtered. The filtrate was concentrated in vacuo. The residue was purified by flash silica gel chromatography (12 g SepaFlash® Silica Flash Column, Eluent of 33˜45% Ethyl acetate/Petroleum ether gradient @ 60 mL/min) to afford the titled compound (1.36 g, 2.99 mmol, 51.66% yield) as a yellow solid. MS(M+H)+=455.1.
- To a solution of tert-butyl 6-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-2, 6-diazaspiro[3.3]heptane-2-carboxylate (300 mg, 660.10 μmol) in DCM (3 mL) was added TFA (3.31 g, 29.04 mmol, 2.15 mL) at 0° C., the mixture was stirred at 15° C. for 0.5 hours. LCMS showed the starting material was consumed completely. To the mixture was added TEA at 0° C. to adjust pH>7, the resulting mixture was used for the next step directly. MS(M+H)+=355.1.
- To a solution of 2-(2, 6-dioxopiperidin-3-yl)-4-(2, 6-diazaspiro[3.3]heptan-2-yl)isoindoline-1,3-dione (230 mg, 649.06 (S)-4-(3-((tert-butoxycarbonyl)amino)pyrrolidin-1-yl)-4-oxobutanoic acid (223.01 mg, 778.87 μmol), EDCI (248.85 mg, 1.30 mmol) and HOBt (175.41 mg, 1.30 mmol) in DCM (4 mL) was added TEA (262.71 mg, 2.60 mmol, 361.36 μL) and the resulting mixture was stirred at 15° C. for 16 hours. LCMS showed reactant was consumed completely and 75% of desired mass was detected. To the mixture was added CH3COOH at 0° C. to adjust pH<7, most of the solvent was blown away with N2, the residue was diluted with DMF and purified by prep-HPLC (column: Phenomenex Synergi C18 150*25 mm*10 um; mobile phase: [water (0.225% FA)-ACN]; B %: 25%-55%, 10 min) and the eluent was freeze-dried to afford the titled compound (200 mg, 321.20 μmol, 49.49% yield) as a yellow solid. MS(M+H)+=623.2.
- To a solution of tert-butyl ((3S)-1-(4-(6-(2-(2, 6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)-2,6-diazaspiro[3.3]heptan-2-yl)-4-oxobutanoyl)pyrrolidin-3-yl)carbamate (200 mg, 321.20 μmol) in DCM (2 mL) was added TFA (1.61 g, 14.13 mmol, 1.05 mL) at 0° C., the mixture was stirred at 15° C. for 0.5 hours. LCMS showed the starting material was consumed completely and 89% of desired mass was detected. To the mixture was added TEA at 0° C. to adjust pH>7, most of the solvent was blown away with N2, the residue was diluted with DMF and purified by prep-HPLC (column: Waters Xbridge 150*25 mm*5 um; mobile phase: [water (10 mM NH4HCO3)-ACN]; B %: 11%-41%, 10 min), the eluent was freeze-dried to afford the titled compound (110 mg, 210.51 μmol, 65.54% yield) as a yellow solid. MS(M+H)+=523.0.
- To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido [4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (85 mg, 182.63 μmol) in DMF (1 mL) were added HATU (83.33 mg, 219.15 μmol) and DIEA (59.01 mg, 456.57 μmol, 79.53 μL), the mixture was stirred at 15° C. for 15 minutes, then to the mixture was added 4-(6-(4-((S)-3-aminopyrrolidin-1-yl)-4-oxobutanoyl)-2,6-diazaspiro[3.3]heptan-2-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (104.98 mg, 200.89 μmol) and the resulting mixture was stirred at 15° C. for 1 hour. LCMS showed reactant was consumed completely and 78% of desired mass was detected. The reaction mixture was purified by prep-HPLC (column: Waters Xbridge 150*25 mm*5 um; mobile phase: [water (10 mM NH4HCO3)-ACN]; B %: 35%-65%, 10 min), the eluent was freeze-dried to afford the titled compound (71.8 mg, 72.54 μmol, 39.72% yield, 98% purity) as a yellow solid. MS(M+H)+=970.4.
- 1H NMR (400 MHz, DMSO-d6) δ=11.21-10.75 (m, 1H), 8.32-8.24 (m, 3H), 8.04 (s, 1H), 7.57 (t, J=7.8 Hz, 1H), 7.20 (dd, J=2.5, 6.3 Hz, 1H), 7.13 (d, J=7.0 Hz, 1H), 6.79 (d, J=8.5 Hz, 1H), 5.05 (dd, J=5.3, 12.6 Hz, 1H), 4.91-4.72 (m, 1H), 4.54-4.40 (m, 1H), 4.34 (m, 5H), 4.14-3.98 (m, 4H), 3.92 (s, 3H), 3.76 (m, 1H), 3.54 (m, 1H), 3.47-3.37 (m, 1H), 3.31 (m, 3H), 3.31-3.22 (m, 1H), 2.96-2.79 (m, 1H), 2.64-2.51 (m, 3H), 2.48-2.40 (m, 2H), 2.30-2.21 (m, 2H), 2.21-2.08 (m, 1H), 2.06-1.87 (m, 4H), 1.73 (m, 2H), 1.68-1.52 (m, 4H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (47.1 mg, 47.39 μmol, 36.76% yield, 99% purity) as a yellow solid. MS(M+H)+=984.0.
- 1H NMR (400 MHz, DMSO-d6) δ=11.02 (br s, 1H), 8.38-8.14 (m, 3H), 8.03 (s, 1H), 7.56 (ddd, J=2.6, 7.0, 8.5 Hz, 1H), 7.20 (dd, J=1.0, 6.6 Hz, 1H), 7.13 (dd, J=1.3, 6.9 Hz, 1H), 6.77 (dd, J=4.3, 8.4 Hz, 1H), 5.05 (dd, J=5.4, 12.7 Hz, 1H), 4.81 (quin, J=7.9 Hz, 1H), 4.52-4.38 (m, 1H), 4.26-4.37 (m, 4H), 4.27 (br d, J=3.4 Hz, 2H), 4.14-3.98 (m, 4H), 3.91 (s, 3H), 3.72 (dd, J=6.6, 10.3 Hz, 1H), 3.64-3.52 (m, 1H), 3.51-3.42 (m, 1H), 3.34-3.40 (m, 2H), 3.26-3.32 (m, 2H), 2.93-2.80 (m, 1H), 2.63-2.51 (m, 2H), 2.21-2.29 (m, 2H), 2.20-2.04 (m, 3H), 2.03-1.87 (m, 4H), 1.67-1.78 (m, 4H), 1.66-1.53 (m, 4H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (40.6 mg, 42.76 μmol, 24.23% yield, 97% purity) as yellow solid. MS(M+H)+=921.5
- 1H NMR (400 MHz, DMSO-d6) δ=11.01 (br s, 1H), 8.32-8.24 (m, 4H), 8.05 (s, 1H), 7.31-7.25 (m, 1H), 7.22-7.17 (m, 1H), 6.97-6.91 (m, 1H), 6.83-6.77 (m, 1H), 5.64-5.57 (m, 1H), 5.16-5.05 (m, 1H), 4.86-4.76 (m, 1H), 4.51-4.36 (m, 1H), 4.27-4.20 (m, 1H), 4.17-4.11 (m, 1H), 4.11-4.03 (m, 4H), 3.91 (d, J=3.8 Hz, 3H), 3.75-3.68 (m, 1H), 3.65-3.54 (m, 6H), 3.53-3.41 (m, 4H), 3.33-3.27 (m, 2H), 2.99-2.86 (m, 1H), 2.61 (br d, J=17.4 Hz, 1H), 2.31-2.24 (m, 1H), 2.19-2.10 (m, 1H), 2.08-1.85 (m, 5H), 1.78-1.54 (m, 6H).
-
- To a mixture of 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (1 g, 3.62 mmol) in DMSO (5 mL) were added TEA (1.10 g, 10.86 mmol, 1.51 mL) and tert-butyl (2-(2-aminoethoxy)ethyl)carbamate (887.41 mg, 4.34 mmol) in one portion at 20° C. and the resulting mixture was stirred at 80° C. for 16 h. LCMS showed starting material was consumed completely and desired mass was detected. The reaction mixture was diluted with H2O (20 mL) and extracted with EtOAC (20 mL×3). The organic layer was washed with brine (20 mL×3), dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=5/1 to 1/1) to afford the titled compound (687 mg, 1.46 mmol, 40.39% yield, 98% purity) as a green oil. MS(M-100+H)+=361.3
- To a mixture of tert-butyl (2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethyl)carbamate (680 mg, 1.48 mmol) in dioxane (5 mL) was added HCl/dioxane (4 M, 10 mL) in one portion at 20° C. and the resulting mixture was stirred at 20° C. for 1 h. LCMS showed starting material was consumed completely and desired mass was detected. The reaction mixture was concentrated in vacuum to afford the titled compound (590 mg, crude, HCl) as a yellow solid. MS(M+H)+=361.3
- To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (150 mg, 322.29 μmol) in DMF (2 mL) was added HATU (134.80 mg, 354.51 μmol) and DIPEA (83.31 mg, 644.57 μmol, 112.27 μL). The mixture was stirred at 20° C. for 10 min and a solution of 4-((2-(2-aminoethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (166.26 mg, 418.97 μmol, HCl) in DMF (2 mL) and DIPEA (83.31 mg, 644.57 μmol, 112.27 μL) was added drop-wise and the resulting mixture was stirred at 20° C. for 1 h. LCMS showed starting material was consumed completely and desired mass was detected. The reaction mixture was diluted with H2O (10 mL) and extracted with EtOAc (10 mL×3). The organic layer was dried over Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (column: 3_Phenomenex Luna C18 75*30 mm*3 um; mobile phase: [water (0.1% TFA)-ACN]; B %: 46%-66%, 7 min) and then lyophilized to afford the titled compound (95.9 mg, 101.96 μmol, 31.64% yield, 98% purity, TFA) as a yellow solid. MS(M+H)+=808.1
- 1H NMR (400 MHz, CD3OD) δ=8.22-8.17 (m, 2H), 7.51 (dd, J=7.2, 8.6 Hz, 1H), 7.42 (d, J=6.7 Hz, 1H), 7.09 (d, J=8.6 Hz, 1H), 7.00 (d, J=7.2 Hz, 1H), 5.06-4.98 (m, 1H), 4.98-4.92 (m, 1H), 4.13 (t, J=12.8 Hz, 2H), 3.98 (s, 3H), 3.79-3.75 (m, 2H), 3.74-3.70 (m, 2H), 3.65-3.59 (m, 2H), 3.54-3.49 (m, 2H), 3.42 (s, 3H), 2.78-2.50 (m, 3H), 2.08-1.93 (m, 3H), 1.85-1.66 (m, 6H)
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (167.6 mg, 190.85 μmol, 44.41% yield, 97% purity) as a yellow solid. MS(M+H)+=852.6
- 1H NMR (400 MHz, MeOD) δ=8.23 (d, J=14.6 Hz, 1H), 8.19 (s, 1H), 7.39-7.33 (m, 2H), 6.90 (dd, J=7.8, 11.8 Hz, 2H), 4.98 (dd, J=5.5, 12.7 Hz, 1H), 4.84-4.79 (m, 1H), 4.04 (t, J=13.4 Hz, 2H), 3.95 (s, 3H), 3.77-3.70 (m, 8H), 3.64-3.60 (m, 2H), 3.42-3.39 (m, 5H), 2.89-2.78 (m, 1H), 2.75-2.60 (m, 2H), 2.13-2.03 (m, 3H), 1.86-1.76 (m, 2H), 1.74-1.61 (m, 4H)
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (80.8 mg, 88.39 umol, 21.43% yield, 98% purity) was obtained as a yellow solid. MS(M+H)+=896.7.
- 1H NMR (400 MHz, DMSO-d6) δ=11.10 (s, 1H), 8.29 (s, 1H), 8.25 (d, J=13.8 Hz, 1H), 8.04 (s, 1H), 7.88-7.99 (m, 1H), 7.55 (dd, J1=8.3 Hz, J2=7.3 Hz, 1H), 7.28 (d, J=6.8 Hz, 1H), 7.10 (d, J=8.7 Hz, 1H), 7.01 (d, J=7.0 Hz, 1H), 6.58 (t, J=5.7 Hz, 1H), 5.05 (dd, J1=12.9 Hz, J2=5.4 Hz, 1H), 4.88-4.73 (m, 1H), 4.07 (t, J=13.9 Hz, 2H), 3.90 (s, 3H), 3.65-3.48 (m, 12H), 3.48-3.39 (m, 7H), 2.93-2.79 (m, 1H), 2.62-2.52 (m, 2H), 2.06-1.86 (m, 3H), 1.78-1.51 (m, 6H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (122.3 mg, 141.36 μmol, 61.76% yield, 98% purity) as yellow solid. MS(M+H)+=848.6.
- 1H NMR (400 MHz, DMSO-d6) δ 11.08 (s, 1H), 8.34-8.18 (m, 2H), 8.07-7.95 (m, 2H), 7.57 (dd, J=8.6, 7.0 Hz, 1H), 7.23 (d, J=6.7 Hz, 1H), 7.08 (d, J=8.6 Hz, 1H), 7.01 (d, J=7.0 Hz, 1H), 6.52 (t, J=5.9 Hz, 1H), 5.04 (dd, J=12.9, 5.4 Hz, 1H), 4.81 (t, J=8.0 Hz, 1H), 4.07 (t, J=13.9 Hz, 2H), 3.90 (s, 3H), 3.29-3.16 (m, 6H), 2.95-2.81 (m, 1H), 2.62-2.52 (m, 3H), 2.08-1.90 (m, 3H), 1.77-1.46 (m, 10H), 1.41-1.26 (m, 8H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (50.4 mg, 57.65 μmol, 26.83% yield, 94% purity) as a yellow solid. MS(M+H)+=822.6.
- 1H NMR (400 MHz, DMSO-d6) δ=11.08 (s, 1H), 8.29 (s, 1H), 8.22 (d, J=13.8 Hz, 1H), 8.04 (s, 1H), 7.96 (q, J=5.4 Hz, 1H), 7.54 (dd, J1=7.2, J2=8.4 Hz, 1H), 7.28 (d, J=6.9 Hz, 1H), 7.07 (d, J=8.6 Hz, 1H), 6.98 (d, J=7.0 Hz, 1H), 6.69 (t, J=5.9 Hz, 1H), 5.03 (dd, J1=5.4, J2=12.9 Hz, 1H), 4.88-4.70 (m, 1H), 4.07 (t, J=13.9 Hz, 2H), 3.89 (s, 3H), 3.59-3.51 (m, 4H), 3.50-3.47 (m, 2H), 3.42-3.33 (m, 5H), 2.93-2.80 (m, 1H), 2.60-2.52 (m, 2H), 2.05-1.88 (m, 3H), 1.82 (br t, J=6.1 Hz, 2H), 1.75-1.50 (m, 6H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (27.6 mg, 27.89 μmol, 12.98% yield, 99% purity, TFA) as a yellow solid. MS(M+H)+=866.3
- 1H NMR (400 MHz, CD3OD) δ=8.20 (s, 1H), 8.11 (d, J=13.8 Hz, 1H), 7.45-7.39 (m, 2H), 6.95 (t, J=7.4 Hz, 2H), 5.01 (dd, J=5.4, 12.8 Hz, 1H), 4.98-4.90 (m, 1H), 4.15 (t, J=12.6 Hz, 2H), 3.97 (s, 3H), 3.65-3.59 (m, 10H), 3.45-3.42 (m, 2H), 3.41 (s, 3H), 2.89-2.80 (m, 1H), 2.76-2.62 (m, 2H), 2.15-2.02 (m, 3H), 1.90-1.81 (m, 4H), 1.77-1.68 (m, 4H)
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (74.7 mg, 72.15 μmol, 16.79% yield, 96% purity, TFA) as a yellow solid. MS(M+H)+=880.0
- 1H NMR (400 MHz, CD3OD) δ=8.21-8.14 (m, 2H), 7.52-7.40 (m, 2H), 7.04-6.96 (m, 2H), 5.02 (br dd, J=5.6, 12.4 Hz, 1H), 4.99-4.95 (m, 1H), 4.13 (t, J=12.6 Hz, 2H), 3.98 (s, 3H), 3.65-3.61 (m, 2H), 3.61-3.55 (m, 6H), 3.51 (t, J=6.6 Hz, 2H), 3.44-3.41 (m, 2H), 3.40 (s, 3H), 2.89-2.63 (m, 3H), 2.13-2.02 (m, 3H), 1.89-1.66 (m, 10H)
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (66.7 mg, 64.93 μmol, 15.11% yield, 95% purity) as a light yellow solid. MS(M+H)=862.6.
- 1H NMR (400 MHz, CD3OD) δ 8.63 (d, J=8.4 Hz, 1H), 8.25-8.14 (m, 2H), 7.79-7.69 (m, 1H), 7.54 (d, J=7.3 Hz, 1H), 7.38 (d, J=6.7 Hz, 1H), 5.17-5.09 (m, 1H), 5.05-4.98 (m, 1H), 4.13 (t, J=12.7 Hz, 2H), 3.98 (s, 3H), 3.43-3.40 (m, 2H), 2.91-2.81 (m, 1H), 2.78-2.66 (m, 2H), 2.50 (t, J=7.4 Hz, 2H), 2.15-2.03 (m, 3H), 1.84-1.60 (m, 10H), 1.52-1.38 (m, 6H)
-
- A mixture of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6, 7, 8, 9-tetrahydro-5H-pyrimido[4, 5-b][1, 4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (100 mg, 214.86 tert-butyl 6-amino-2-azaspiro[3.3]heptane-2-carboxylate (54.73 mg, 257.83 μmol), EDCI (61.78 mg, 322.29 μmol), HOBt (43.55 mg, 322.29 μmol) and TEA (65.22 mg, 644.57 μmol, 89.72 μL) in DCM (2 mL) was stirred at 15° C. for 12 hours. LCMS showed reactant was consumed completely and 87% of desired mass was detected. The reaction mixture was combined with another batch (30 mg scale) and concentrated in vacuo. The residue was purified by flash silica gel chromatography (4 g SepaFlash® Silica Flash Column, Eluent of 25˜41% Ethyl acetate/Petroleum ether gradient @ 60 mL/min) to afford the titled compound (190 mg, 288.01 μmol, 134.05% yield) as a brown solid. MS(M+H)+=660.6.
- To a solution of tert-butyl 6-(4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6, 7, 8, 9-tetrahydro-5H-pyrimido[4, 5-b][1, 4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzamido)-2-azaspiro [3.3]heptane-2-carboxylate (160 mg, 242.54 μmol) in DCM (2 mL) was added TFA (1.23 g, 10.80 mmol, 800 μL) at 0° C. and the mixture was stirred at 15° C. for 0.5 hours. LCMS showed the starting material was consumed completely and 93% of desired mass was detected. To the reaction mixture was added TEA to adjust pH>7, the resulting mixture was used for the next step directly. MS(M+H)+=560.5.
- A mixture of 2-(2, 6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (300 mg, 1.09 mmol), tert-butyl 3-aminopropanoate (205.01 mg, 1.41 mmol) and DIEA (421.11 mg, 3.26 mmol, 567.53 μL) in DMSO (6 mL) was stirred at 80° C. for 12 hours. LCMS showed trace of the starting material remained and 50% of desired mass was detected. The reaction mixture was combined with another batch (30 mg scale), the combined mixture was diluted with H2O (100 mL) and extracted with EtOAc (50 mL×5). The combined organic layers were washed with brine (80 mL×5), dried over Na2SO4, filtered. The filtrate was concentrated in vacuo. The residue was purified by flash silica gel chromatography (12 g SepaFlash® Silica Flash Column, Eluent of 18˜45% Ethyl acetate/Petroleum ether gradient @ 100 mL/min) to afford the titled compound (240 mg, 597.89 μmol, 55.05% yield) as a yellow oil. MS(M+H)+=402.4.
- To a solution of tert-butyl 3-((2-(2, 6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)propanoate (240 mg, 597.89 μmol) in dioxane (5 mL) was added HCl/dioxane (4 M, 10 mL), the mixture was stirred at 15° C. for 12 hours. LCMS showed trace starting material remained and 84% of desired mass was detected. The reaction mixture was concentrated in vacuo to afford the titled compound (170 mg, crude) as a yellow solid, which was used for the next step directly. MS(M+H)+=345.9.
- To the above mixture from
step 2 in DCM (2 mL) were added 3-((2-(2, 6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)propanoic acid (100 mg, 289.60 μmol), EDCI (83.27 mg, 434.40 μmol), HOBt (58.70 mg, 434.40 μmol) and TEA (146.52 mg, 1.45 mmol, 201.54 μL) and the resulting mixture was stirred at 15° C. for 16 hours. LCMS showed 44% of desired mass was detected. The reaction mixture was concentrated in vacuo to remove most of the solvent, to the residue was added CH3COOH to adjust pH<7. The resulting mixture was diluted with DMF, the mixture was purified by prep-HPLC (column: Waters Xbridge 150*25 mm*5 um; mobile phase: [water (10 mM NH4HCO3)-ACN]; B %: 41%-71%, 10 min) followed by prep-HPLC (column: Phenomenex Synergi C18 150*25 mm*10 um; mobile phase: [water (0.225% FA)-ACN]; B %: 43%-73%, 10 min), the eluent was freeze-dried to afford the titled compound (28.9 mg, 30.96 μmol, 10.69% yield, 95% purity) as a yellow solid. MS(M+H)+=887.7. - 1H NMR (400 MHz, DMSO-d6) δ=11.11-11.03 (m, 1H), 8.30 (s, 1H), 8.25 (br d, J=13.3 Hz, 2H), 8.04 (s, 1H), 7.63-7.55 (m, 1H), 7.20 (d, J=6.4 Hz, 1H), 7.14 (dd, J=3.1, 8.8 Hz, 1H), 7.04 (dd, J=1.9, 7.0 Hz, 1H), 6.79-6.68 (m, 1H), 5.05 (dd, J=5.0, 12.7 Hz, 1H), 4.88-4.76 (m, 1H), 4.32-4.23 (m, 1H), 4.17 (s, 1H), 4.13-4.02 (m, 3H), 3.91 (s, 4H), 3.79 (s, 1H), 3.51 (q, J=6.0 Hz, 2H), 3.34-3.33 (m, 3H), 2.94-2.82 (m, 1H), 2.63-2.55 (m, 2H), 2.48-2.42 (m, 2H), 2.36 (q, J=6.8 Hz, 2H), 2.28-2.19 (m, 2H), 2.06-1.91 (m, 3H), 1.73 (m, 2H), 1.68-1.55 (m, 4H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (75.4 mg, 82.02 umol, 22.67% yield, 98% purity) as a yellow solid. MS(M+H)+=901.0.
- 1H NMR (400 MHz, DMSO-d6) δ=11.04-11.00 (m, 1H), 8.30 (s, 1H), 8.27-8.23 (m, 2H), 8.04 (s, 1H), 7.58 (t, J=7.8 Hz, 1H), 7.20 (d, J=6.5 Hz, 1H), 7.15 (dd, J=2.1, 8.6 Hz, 1H), 7.02 (dd, J=1.6, 7.0 Hz, 1H), 6.69-6.56 (m, 1H), 5.05 (ddd, J=2.9, 5.3, 12.8 Hz, 1H), 4.82 (quin, J=8.0 Hz, 1H), 4.28 (m, 1H), 4.20-3.98 (m, 4H), 3.91 (s, 4H), 3.78 (s, 1H), 3.33 (s, 3H), 3.30 (m, 2H), 2.95-2.80 (m, 1H), 2.63-2.52 (m, 2H), 2.47 (m, 2H), 2.30-2.18 (m, 2H), 2.11 (q, J=6.7 Hz, 2H), 2.06-2.00 (m, 1H), 1.96 (m, 2H), 1.82-1.69 (m, 4H), 1.68-1.55 (m, 4H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (38.3 mg, 41.02 μmol, 30.63% yield, 98% purity) as a yellow solid. MS(M+H)+=915.1.
- 1H NMR (400 MHz, DMSO-d6) δ=11.11-11.00 (m, 1H), 8.30 (s, 1H), 8.25 (br d, J=13.4 Hz, 2H), 8.04 (s, 1H), 7.62-7.51 (m, 1H), 7.20 (d, J=6.6 Hz, 1H), 7.10 (dd, J=3.1, 8.6 Hz, 1H), 7.02 (dd, J=1.6, 6.9 Hz, 1H), 6.57 (q, J=5.1 Hz, 1H), 5.10-5.00 (m, 1H), 4.82 (quin, J=8.0 Hz, 1H), 4.28 (m, 1H), 4.17 (s, 1H), 4.13-3.99 (m, 3H), 3.94-3.82 (m, 4H), 3.77 (s, 1H), 3.33 (br s, 3H), 3.30 (m, 2H), 2.96-2.81 (m, 1H), 2.63-2.51 (m, 4H), 2.25 (br t, J=9.6 Hz, 2H), 2.10-1.91 (m, 5H), 1.79-1.68 (m, 2H), 1.68-1.50 (m, 8H).
-
- To the solution of 3-aminopiperidine-2, 6-dione (16.55 g, 100.54 mmol, HCl) and 4-hydroxyisobenzofuran-1,3-dione (15 g, 91.40 mmol) in AcOH (300 mL) was added KOAc (27.81 g, 283.34 mmol) and the resulting mixture was stirred at 120° C. for 24 h. LCMS showed that the reaction was completed. The mixture was combined with the pilot (10 g scale) and filtered, the cake was washed with H2O (300 mL) and dried in vacuum to afford the titled compound (36.59 g, crude) as a black solid. MS(M+H)+=275.1
- To a solution of 2-(2,6-dioxopiperidin-3-yl)-4-hydroxyisoindoline-1,3-dione (10 g, 36.47 mmol) in DMF (200 mL) were added K2CO3 (7.56 g, 54.70 mmol) and tert-butyl 2-bromoacetate (7.11 g, 36.47 mmol, 5.39 mL) and the mixture was stirred at 20° C. for 2 h. LCMS showed that the reaction was completed. The mixture poured into H2O (450 mL) and extracted with EtOAc (450 mL×3), the combined organic layer was washed with brine (1000 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=1/0 to 0/1) to afford the titled compound (12 g, 30.90 mmol, 84.73% yield) as white solid. MS(M+H)+=389.1
- To a solution of tert-butyl 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetate (12 g, 30.90 mmol) in dioxane (50 mL) was added HCl/dioxane (4 M, 50 mL) and the mixture was stirred at 20° C. for 6 h. LCMS showed that the reaction was completed. The reaction mixture was concentrated in vacuum to afford the titled compound (10.27 g, crude) as white solid. MS (M+H)+=333.1
- To a solution of 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetic acid (1 g, 3.01 mmol) and tert-butyl N-(5-aminopentyl) carbamate (608.83 mg, 3.01 mmol, 626.37 μL) in DMF (10 mL) were added T3P (11.49 g, 18.06 mmol, 10.74 mL, 50% purity) and Py (2.38 g, 30.10 mmol, 2.43 mL) at 20° C. and the mixture was stirred at 80° C. for 16 h. LCMS showed that the reaction was completed. The reaction mixture was poured into H2O (80 mL) and extracted with EtOAc (30 mL×3), the organic phase was washed with brine (30 mL×3), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=1/0 to 0/1) to afford the titled compound (1.33 g, 2.50 mmol, 82.99% yield, 97% purity) as a yellow oil. MS(M+H)+=517.2
- To a solution of tert-butyl (5-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)pentyl)carbamate (1.33 g, 2.57 mmol) in dioxane (20 mL) was added HCl/dioxane (4 M, 20 mL) and the mixture was stirred at 20° C. for 16 h. LCMS showed that the reaction was completed. The reaction mixture was concentrated in vacuum to afford the titled compound (1.29 g, HCl) as white solid. MS(M+H)+=417.1
- to the solution of N-(5-aminopentyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide (0.2 g, 441.61 μmol, HCl) and 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (205.54 mg, 441.61 μmol) in DMF (4 mL) were added HATU (335.83 mg, 883.22 μmol) and DIPEA (171.23 mg, 1.32 mmol, 230.76 μL) and the resulting mixture was stirred at 20° C. for 1 h. LCMS showed that the reaction was completed. The mixture was poured into water (20 mL) and extracted with EtOAc (20 mL×3), the combined organic layer was washed with brine (50 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (column: Phenomenex luna C18 150*25 mm*10 um; mobile phase: [water (0.225% FA)-ACN]; B %: 41%-71%, 10 min) and the eluant was lyophilized, the solid was re-purified by prep-HPLC (column: 3_Phenomenex Luna C18 75*30 mm*3 um; mobile phase: [water (0.1% TFA)-ACN]; B %: 40%-60%, 7 min) and the eluant was lyophilized to afford the titled compound (94.8 mg, 94.04 μmol, 21.29% yield, 97% purity, TFA) as white solid. MS(M+H)+=864.2.
- 1H NMR (400 MHz, DMSO-d6) δ=11.13 (s, 1H), 8.34-8.26 (m, 2H), 8.19 (d, J=13.3 Hz, 1H), 8.06 (d, J=4.5 Hz, 1H), 7.96 (t, J=5.6 Hz, 1H), 7.86-7.77 (m, 1H), 7.49 (d, J=7.3 Hz, 1H), 7.40 (d, J=8.4 Hz, 1H), 7.25 (d, J=6.7 Hz, 1H), 5.18-5.09 (m, 1H), 4.84 (t, J=8.2 Hz, 1H), 4.77 (s, 2H), 4.12 (t, J=13.6 Hz, 2H), 3.94-3.90 (m, 3H), 3.34 (s, 3H), 3.28-3.22 (m, 2H), 3.20-3.13 (m, 2H), 2.97-2.85 (m, 1H), 2.66-2.55 (m, 2H), 2.09-1.93 (m, 3H), 1.75-1.46 (m, 10H), 1.38-1.25 (m, 2H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (31.1 mg, 35.05 μmol, 4.05% yield, 96% purity) as a yellow solid. MS(M+H)+=852.3.
- 1H NMR (400 MHz, DMSO-d6) δ=11.31-10.73 (m, 1H), 8.33-8.14 (m, 2H), 8.04 (s, 1H), 7.96 (q, J=5.6 Hz, 1H), 7.52 (d, J=8.4 Hz, 1H), 7.28 (d, J=6.9 Hz, 1H), 7.13 (t, J=5.4 Hz, 1H), 6.98 (d, J=1.8 Hz, 1H), 6.86 (dd, J1=8.4 Hz, J2=2.0 Hz, 1H), 5.02 (dd, J1=12.9 Hz, J2=5.4 Hz, 1H), 4.90-4.70 (m, 1H), 4.07 (t, J=13.8 Hz, 2H), 3.90 (s, 3H), 3.67-3.48 (m, 8H), 3.47-3.32 (m, 7H), 2.94-2.80 (m, 1H), 2.61-2.53 (m, 1H), 2.49-2.40 (m, 1H), 2.04-1.86 (m, 3H), 1.79-1.68 (m, 2H), 1.66-1.54 (m, 4H).
-
- To a mixture of 6-chlorohex-1-yne (5 g, 42.89 mmol, 5.20 mL) was added
potassium 1,3-dioxoisoindolin-2-ide (15.89 g, 85.77 mmol) in DMF (50 mL) at 20° C. and the resulting mixture was stirred at 85° C. for 16 h. LCMS showed all starting material was consumed completely and one peak with desired mass was detected. TLC (SiO2, Petroleum ether:Ethyl acetate=2:1) indicated 6-chlorohex-1-yne was consumed completely and two new spots were detected. The reaction mixture was diluted with H2O (100 mL) and extracted with EtOAc (100 mL×3). The organic layer was washed with brine (100 mL×3), dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=8/1 to 2/1) to afford the titled compound (8.3 g, 35.43 mmol, 82.61% yield, 97% purity) as a white solid. MS(M+H)+=228.4 - 1H NMR (400 MHz, CDCl3) δ=7.87-7.81 (m, 2H), 7.75-7.67 (m, 2H), 3.71 (t, J=7.1 Hz, 2H), 2.29-2.21 (m, 2H), 1.94 (t, J=2.7 Hz, 1H), 1.87-1.76 (m, 2H), 1.63-1.52 (m, 2H)
- To a mixture of 2-(hex-5-yn-1-yl)isoindoline-1,3-dione (8.3 g, 36.52 mmol) in EtOH (90 mL) was added N2H4·H2O (21.51 g, 365.20 mmol, 20.88 mL, 85% purity) in one portion at 20° C. and the resulting mixture was stirred at 80° C. for 4 h. TLC (SiO2, Petroleum ether:Ethyl acetate=2:1) indicated starting material was consumed completely and one new spot was detected. The reaction mixture was diluted with EtOH (200 mL) and filtered. The filtrate was concentrated in vacuum. The residue was diluted with DCM (150 mL) and filtrated. The filtrate was concentrated in vacuum to afford the titled compound (4.7 g, crude) as colorless oil.
- To a mixture of hex-5-yn-1-amine (4.7 g, 48.37 mmol) in THF (50 mL) and H2O (50 mL) was added NaHCO3 (8.13 g, 96.75 mmol, 3.76 mL) followed by (Boc)2O (13.72 g, 62.89 mmol, 14.45 mL) drop-wise at 0° C. and the resulting mixture was stirred at 20° C. for 16 h. TLC (SiO2, Petroleum ether:Ethyl acetate=3:1) indicated hex-5-yn-1-amine was consumed completely and two new spots were detected. The reaction mixture was diluted with H2O (100 mL) and extracted with EtOAc (100 mL×3). The organic layer was dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=10/1 to 3/1) to afford the titled compound (1.8 g, 9.12 mmol, 18.86% yield) as a colorless oil.
- To a mixture of methyl 3-bromo-2-methyl-benzoate (10 g, 43.65 mmol) in CHCl3 (100 mL) were added NB S (8.55 g, 48.02 mmol) and BPO (528.72 mg, 2.18 mmol) in one portion at 20° C. and the resulting mixture was stirred at 85° C. for 16 h. LCMS showed no peak with desired mass was detected. TLC (SiO2, Petroleum ether:Ethyl acetate=5:1) indicated a little of 3-bromo-2-methyl-benzoate remained and one new spot was detected. The reaction mixture was quenched with saturated Na2SO3 (100 mL) and extracted with DCM (100 mL×3). The organic layer was dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=1/1 to 200/1) to afford the titled compound (9.4 g, 30.52 mmol, 69.92% yield) as an orange oil.
- 1H NMR (400 MHz, CDCl3) δ=7.86 (d, J=7.7 Hz, 1H), 7.74 (d, J=7.5 Hz, 1H), 7.21 (t, J=7.9 Hz, 1H), 5.12 (s, 2H), 3.94 (s, 3H)
- To a mixture of methyl 3-bromo-2-(bromomethyl) benzoate (9.4 g, 30.52 mmol) and 3-aminopiperidine-2, 6-dione; hydrochloride (6.03 g, 36.63 mmol) in ACN (100 mL) was added DIPEA (19.72 g, 152.61 mmol, 26.58 mL) in one portion at 20° C. and the resulting mixture was stirred at 90° C. for 16 h. TLC (SiO2, Petroleum ether:Ethyl acetate=5:1) indicated methyl 3-bromo-2-(bromomethyl) benzoate was consumed completely and one new spot was detected. The reaction mixture was diluted with ACN (200 mL) and filtrated. The filter cake was washed with methyl tert-butyl ether (20 mL×4). The filter cake was dried in vacuum to afford the titled compound (7.6 g, 23.52 mmol, 77.05% yield) as a purple solid.
- 1H NMR (400 MHz, DMSO-d6) δ=11.02 (s, 1H), 7.87 (dd, J=0.6, 7.9 Hz, 1H), 7.79-7.75 (m, 1H), 7.54-7.48 (m, 1H), 5.15 (dd, J=5.0, 13.3 Hz, 1H), 4.46-4.38 (m, 1H), 4.30-4.22 (m, 1H), 2.98-2.85 (m, 1H), 2.65-2.54 (m, 1H), 2.49-2.38 (m, 1H), 2.06-1.97 (m, 1H)
- To a mixture of 3-(4-bromo-1-oxoisoindolin-2-yl)piperidine-2,6-dione (2 g, 6.19 mmol) and tert-butyl hex-5-yn-1-ylcarbamate (1.47 g, 7.43 mmol) in DMF (20 mL) were added CuI (235.75 mg, 1.24 mmol), TEA (6.26 g, 61.89 mmol, 8.61 mL), Pd(PPh3)2Cl2 (217.21 mg, 309.46 μmol) in one portion at 20° C. under N2 and the resulting mixture was stirred at 80° C. for 16 h. LCMS showed 15% of 3-(4-bromo-1-oxoisoindolin-2-yl)piperidine-2,6-dione remained and 80% peak with desired mass was detected. TLC (SiO2, Petroleum ether:Ethyl acetate=1:2) indicated 3-(4-bromo-1-oxoisoindolin-2-yl)piperidine-2,6-dione remained and three new spots were detected. The reaction mixture was diluted with H2O (60 mL) and extracted with EtOAc (60 mL×3). The organic layer was washed with brine (60 mL×3), dried over Na2SO4, filtered and concentrated. The residue was purified by column chromatography (SiO2, Petroleum ether/Ethyl acetate=5/1 to 1/2) and re-purified by reversed-phase HPLC (method: FA, MeCN/water) and then lyophilized to afford the titled compound (819 mg, 1.66 mmol, 26.80% yield, 89% purity) as a white solid. MS(M-100+H)+=340.4
- To a solution of tert-butyl (6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)hex-5-yn-1-yl)carbamate (810 mg, 1.64 mmol, 89% purity) in EtOAc (8 mL) and THF (2 mL) was added Pd/C (0.4 mg, 164.03 μmol, 10% purity) under N2. The suspension was degassed under vacuum and purged with H2 several times. The mixture was stirred under H2 (15 psi) at 20° C. for 16 h. LCMS showed starting material was consumed completely and one peak with desired mass was detected. The reaction mixture was diluted with THF (20 mL) and filtered. The filtrate was concentrated in vacuum to afford the titled compound (449 mg, 1.01 mmol, 61.72% yield) as a white solid. MS (M-100+H)+=344.3
- To a mixture of tert-butyl (6-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)hexyl)carbamate (449 mg, 1.01 mmol) in dioxane (5 mL) was added HCl/dioxane (4 M, 5 mL) in one portion at 20° C. and the resulting mixture was stirred at 20° C. for 1 h. TLC (SiO2, Petroleum ether:Ethyl acetate=1:2) indicated starting material was consumed completely and one new spot was detected. The reaction mixture was concentrated in vacuum to afford the titled compound (398 mg, crude, HCl) as a white solid.
- To a solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (150 mg, 322.29 μmol) in DMF (2 mL) were added HATU (122.54 mg, 322.29 μmol) and DIPEA (83.31 mg, 644.57 μmol, 112.27 μL). The mixture was stirred at 20° C. for 20 min and a solution of 3-(4-(6-aminohexyl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (183.65 mg, 483.43 μmol, HCl) in DMF (2 mL) and DIPEA (83.31 mg, 644.57 μmol, 112.27 μL) were added and the resulting mixture was stirred at 20° C. for 2 h. LCMS showed all starting material was consumed completely and one peak with desired mass was detected. The reaction mixture was diluted with H2O (15 mL) and extracted with EtOAc (15 mL×3). The organic layer was washed with brine (15 mL×3), dried over Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (column: Phenomenex luna C18 150*25 mm*10 um; mobile phase: [water (0.225% FA)-ACN]; B %: 45%-75%, 11 min) and then lyophilized to afford the titled compound (104 mg, 130.19 μmol, 40.40% yield, 99% purity) as a white solid. MS(M+H)+=791.6
- 1H NMR (400 MHz, DMSO-d6) δ=10.98 (br s, 1H), 8.32-8.27 (m, 1H), 8.24 (d, J=13.4 Hz, 1H), 8.07-7.98 (m, 2H), 7.59-7.53 (m, 1H), 7.48-7.41 (m, 2H), 7.23 (d, J=6.8 Hz, 1H), 5.12 (dd, J=5.1, 13.2 Hz, 1H), 4.87-4.76 (m, 1H), 4.50-4.42 (m, 1H), 4.35-4.26 (m, 1H), 4.07 (t, J=13.9 Hz, 2H), 3.90 (s, 3H), 3.33 (s, 3H), 3.27-3.21 (m, 2H), 2.97-2.86 (m, 1H), 2.67-2.56 (m, 3H), 2.46-2.36 (m, 1H), 2.05-1.90 (m, 3H), 1.74-1.48 (m, 10H), 1.42-1.32 (m, 4H)
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (37.1 mg, 46.80 μmol, 55.59% yield, 98% purity) as a light yellow solid. MS(M+H)+=777.6
- 1H NMR (400 MHz, CD3OD) δ 8.42 (d, J=14.3 Hz, 1H), 8.23 (s, 1H), 7.67-7.61 (m, 1H), 7.51-7.44 (m, 2H), 7.36 (d, J=6.8 Hz, 1H), 5.19 (d, J=5.4 Hz, 1H), 5.16 (d, J=5.3 Hz, 1H), 4.62-4.45 (m, 2H), 4.06 (t, J=13.6 Hz, 2H), 4.01-3.98 (m, 3H), 3.43 (s, 3H), 3.42-3.36 (m, 2H), 3.09-2.83 (m, 2H), 2.78-2.74 (m, 2H), 2.55-2.37 (m, 1H), 2.26-2.07 (m, 3H), 1.87-1.67 (m, 10H), 1.55-1.46 (m, 2H)
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (67.9 mg, 77.61 μmol, 59.43% yield, 92% purity) as a light yellow solid.
- MS(M+H)+=805.6
- 1H NMR (400 MHz, DMSO-d6) δ 10.98 (br s, 1H), 8.30 (s, 1H), 8.24 (d, J=13.4 Hz, 1H), 8.07-8.00 (m, 2H), 7.59-7.54 (m, 1H), 7.47-7.43 (m, 2H), 7.24 (d, J=6.8 Hz, 1H), 5.13 (dd, J=5.1, 13.3 Hz, 1H), 4.86-4.77 (m, 1H), 4.49-4.43 (m, 1H), 4.34-4.28 (m, 1H), 4.08 (t, J=13.9 Hz, 2H), 3.91 (s, 3H), 3.37-3.36 (m, 3H), 3.26-3.21 (m, 2H), 2.97-2.87 (m, 1H), 2.67-2.63 (m, 2H), 2.48-2.38 (m, 2H), 2.05-1.93 (m, 3H), 1.73-1.50 (m, 10H), 1.37-1.29 (m, 6H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (65.0 mg, 77.93 μmol, 17.18% yield, 99% purity) as a yellow solid. MS(M+H)+=826.6.
- 1H NMR (400 MHz, DMSO-d6) δ=11.09 (s, 1H), 8.36-8.13 (m, 2H), 8.08-7.74 (m, 2H), 7.53 (dd, J1=8.4 Hz, J2=7.3 Hz, 1H), 7.26 (d, J=6.8 Hz, 1H), 7.10 (d, J=8.7 Hz, 1H), 6.99 (d, J=7.1 Hz, 1H), 6.59 (t, J=5.6 Hz, 1H), 5.04 (dd, J1=12.9, J2=5.3 Hz, 1H), 4.94-4.81 (m, 1H), 4.05 (t, J=13.4 Hz, 2H), 3.90 (s, 3H), 3.66-3.60 (m, 2H), 3.60-3.51 (m, 6H), 3.49-3.38 (m, 7H), 2.94-2.81 (m, 1H), 2.63-2.52 (m, 2H), 2.07-1.95 (m, 1H), 1.24 (d, J=6.7 Hz, 6H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (38.6 mg, 45.37 μmol, 12.69% yield, 98% purity) as a yellow solid. MS(M+H)+=834.6.
- 1H NMR (400 MHz, DMSO-d6) δ=11.06 (s, 1H), 8.43 (t, J=5.4 Hz, 1H), 8.35-8.21 (m, 2H), 7.95 (s, 1H), 7.62-7.42 (m, 3H), 7.10 (d, J=8.7 Hz, 1H), 7.01 (d, J=7.1 Hz, 1H), 6.59 (t, J=5.7 Hz, 1H), 5.05 (dd, J1=12.8 Hz, J2=5.4 Hz, 1H), 4.85-4.68 (m, 1H), 4.04 (t, J=14.1 Hz, 2H), 3.92 (s, 3H), 3.64-3.50 (m, 8H), 3.45-3.39 (m, 4H), 3.33 (s, 3H), 2.94-2.81 (m, 1H), 2.63-2.54 (m, 2H), 2.06-1.85 (m, 3H), 1.78-1.66 (m, 2H), 1.65-1.49 (m, 4H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (29.7 mg, 33.43 μmol, 18.69% yield, 97% purity) as a yellow solid. MS(M+H)+=862.1
- 1H NMR (400 MHz, DMSO-d6) δ=11.07 (br s, 1H), 8.33 (t, J=5.6 Hz, 1H), 8.29-8.23 (m, 2H), 7.95 (s, 1H), 7.60-7.54 (m, 1H), 7.51-7.43 (m, 2H), 7.13 (d, J=8.5 Hz, 1H), 7.03 (d, J=7.0 Hz, 1H), 6.60 (t, J=5.6 Hz, 1H), 5.06 (dd, J=5.4, 12.9 Hz, 1H), 4.82-4.70 (m, 1H), 4.04 (t, J=14.0 Hz, 2H), 3.92 (s, 3H), 3.60-3.54 (m, 2H), 3.49 (t, J=6.4 Hz, 2H), 3.45-3.38 (m, 6H), 3.33 (s, 3H), 3.30-3.27 (m, 2H), 2.94-2.82 (m, 1H), 2.62-2.58 (m, 1H), 2.57-2.54 (m, 1H), 2.06-1.98 (m, 1H), 1.98-1.89 (m, 2H), 1.79-1.68 (m, 6H), 1.65-1.55 (m, 4H)
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (20.7 mg, 23.64 μmol, 12.33% yield, 95% purity) as a yellow solid. MS(M+H)+=832.1
- 1H NMR (400 MHz, DMSO-d6) δ=11.07 (s, 1H), 9.66 (s, 1H), 8.26 (s, 1H), 8.23 (t, J=5.6 Hz, 1H), 7.80-7.73 (m, 4H), 7.60-7.54 (m, 1H), 7.13 (d, J=8.6 Hz, 1H), 7.03 (d, J=7.0 Hz, 1H), 6.60 (t, J=5.6 Hz, 1H), 5.06 (dd, J=5.4, 12.9 Hz, 1H), 4.78 (t, J=8.1 Hz, 1H), 4.08-4.00 (m, 2H), 3.59-3.55 (m, 2H), 3.50-3.47 (m, 2H), 3.46-3.43 (m, 2H), 3.43-3.38 (m, 4H), 3.33 (s, 3H), 3.29-3.25 (m, 2H), 2.90-2.81 (m, 1H), 2.64-2.55 (m, 1H), 2.56-2.54 (m, 1H), 2.08-1.99 (m, 2H), 1.96-1.92 (m, 1H), 1.78-1.68 (m, 6H), 1.68-1.50 (m, 4H)
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (26 mg, 29.74 umol, 16.64% yield, 97% purity) as a white solid. MS(M+H)+=848.1
- 1H NMR (400 MHz, CDCl3) δ=8.94 (br s, 1H), 8.46 (d, J=8.3 Hz, 1H), 8.07 (s, 1H), 7.84 (s, 1H), 7.43 (d, J=1.7 Hz, 1H), 7.37-7.32 (m, 1H), 7.30 (dd, J=1.7, 8.4 Hz, 1H), 7.28-7.26 (m, 2H), 6.83 (t, J=5.0 Hz, 1H), 6.78 (d, J=7.8 Hz, 1H), 5.22 (dd, J=5.3, 13.1 Hz, 1H), 4.87-4.77 (m, 1H), 4.33 (d, J=15.5 Hz, 1H), 4.12 (d, J=15.5 Hz, 1H), 3.95 (s, 3H), 3.89 (t, J=13.4 Hz, 2H), 3.64 (t, J=5.0 Hz, 2H), 3.61-3.51 (m, 8H), 3.43-3.31 (m, 5H), 2.92-2.75 (m, 2H), 2.34-2.21 (m, 1H), 2.21-2.13 (m, 1H), 2.10-2.02 (m, 2H), 1.89 (m, 4H), 1.78-1.73 (m, 2H), 1.72-1.66 (m, 2H), 1.62-1.55 (m, 2H)
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (26.4 mg, 21.02 μmol, 12.23% yield, 92% purity) as a yellow solid. MS(M+H)+=1155.4.
- 1H NMR (400 MHz, DMSO-d6) δ=11.35-10.83 (m, 1H), 8.30 (s, 1H), 8.24 (d, J=13.3 Hz, 1H), 8.03 (s, 1H), 7.87 (dd, J=3.5, 7.6 Hz, 1H), 7.58 (dd, J=7.3, 8.4 Hz, 1H), 7.18 (d, J=6.7 Hz, 1H), 7.14 (d, J=8.7 Hz, 1H), 7.03 (d, J=7.1 Hz, 1H), 6.60 (t, J=5.6 Hz, 1H), 5.05 (dd, J=5.4, 13.0 Hz, 1H), 4.88-4.76 (m, 1H), 4.07 (br t, J=13.9 Hz, 2H), 3.91 (s, 3H), 3.75-3.69 (m, 1H), 3.63-3.60 (m, 2H), 3.58-3.51 (m, 6H), 3.51-3.48 (m, 19H), 3.48-3.44 (m, 4H), 2.90-2.81 (m, 3H), 2.63-2.52 (m, 4H), 2.47-2.43 (m, 2H), 2.09-2.00 (m, 3H), 1.99-1.92 (m, 2H), 1.81-1.69 (m, 4H), 1.66-1.50 (m, 6H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (119.3 mg, 119.80 μmol, 33.29% yield, 96.2% purity) as a yellow solid. MS(M+H)+=958.3.
- 1H NMR (400 MHz, CD3CN) δ=8.92-8.91 (m, 1H), 8.41-8.34 (m, 1H), 8.11 (s, 1H), 7.80-7.74 (m, 1H), 7.64-7.54 (m, 1H), 7.37 (t, J=7.5 Hz, 1H), 7.32-7.16 (m, 2H), 7.03-6.91 (m, 1H), 5.00-4.93 (m, 1H), 4.91-4.84 (m, 1H), 4.64-4.49 (m, 1H), 4.02-3.89 (m, 6H), 3.84-3.76 (m, 1H), 3.67-3.36 (m, 4H), 3.35-3.20 (m, 8H), 2.74-2.66 (m, 2H), 2.60-2.49 (m, 3H), 2.41-2.34 (m, 2H), 2.31-2.22 (m, 2H), 2.07-2.00 (m, 4H), 1.81-1.73 (m, 2H), 1.69-1.57 (m, 6H), 1.56-1.49 (m, 2H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (44.2 mg, 47.98 μmol, 21.47% yield, 99% purity) as a yellow solid. MS(M+H)+=912.3
- 1H NMR (400 MHz, DMSO-d6) δ=11.11-11.03 (m, 1H), 8.41 (dd, J=6.5, 19.3 Hz, 1H), 8.31-8.21 (m, 2H), 7.97 (d, J=7.7 Hz, 1H), 7.66 (dd, J=8.6, 11.9 Hz, 1H), 7.49 (dd, J=1.8, 5.6 Hz, 2H), 7.32 (dd, J=1.9, 16.2 Hz, 1H), 7.28-7.18 (m, 1H), 5.06 (ddd, J=2.9, 5.3, 13.0 Hz, 1H), 4.82-4.68 (m, 1H), 4.56-4.35 (m, 1H), 4.04 (br t, J=14.1 Hz, 2H), 3.93 (d, J=5.0 Hz, 3H), 3.82 (dd, J=6.6, 10.2 Hz, 1H), 3.69-3.61 (m, 1H), 3.61-3.49 (m, 2H), 3.44-3.33 (m, 7H), 2.93-2.82 (m, 1H), 2.60 (br t, J=6.3 Hz, 8H), 2.47-2.42 (m, 2H), 2.24-2.08 (m, 1H), 2.05-1.88 (m, 4H), 1.81-1.65 (m, 2H), 1.65-1.53 (m, 4H).
-
- According to the above reaction scheme, in a manner similar to the other examples, obtained the titled compound (17.5 mg, 17.39 μmol, 16.19% yield, 95% purity) as a yellow solid. MS(M+H)+=956.3
- 1H NMR (400 MHz, DMSO-d6) δ=11.05-11.03 (m, 1H), 8.30-8.23 (m, 3H), 8.03 (s, 1H), 7.58-7.51 (m, 1H), 7.20 (d, J=6.4 Hz, 1H), 7.13-7.08 (m, 1H), 6.76 (t, J=8.4 Hz, 1H), 5.08-4.99 (m, 1H), 4.87-4.76 (m, 1H), 4.51-4.37 (m, 1H), 4.26-4.21 (m, 3H), 4.07 (br t, J=14.0 Hz, 2H), 3.92-3.90 (m, 2H), 3.79-3.70 (m, 1H), 3.62-3.53 (m, 1H), 3.52-3.42 (m, 2H), 3.38-3.34 (m, 2H), 3.33-3.32 (m, 3H), 3.27-3.20 (m, 4H), 2.92-2.81 (m, 1H), 2.61-2.54 (m, 2H), 2.47-2.42 (m, 1H), 2.36-2.29 (m, 2H), 2.26-2.17 (m, 2H), 2.03-1.86 (m, 4H), 1.76-1.56 (m, 6H), 1.53-1.43 (m, 2H).
-
-
-
- Step 1-11 are Described in the Above Reaction Scheme.
- To the solution of 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxybenzoic acid (200 mg, 429.71 umol) and HATU (326.78 mg, 859.43 umol) in DMF (5 mL) was added DIPEA (166.61 mg, 1.29 mmol, 224.55 uL), the mixture was stirred at 25° C. for 10 min, 1-(2-(2-(2-(phenylamino)ethoxy)ethoxy)ethyl)piperidin-4-amine (184.00 mg, 483.76 umol, 2HCl salt) was added and the resulting mixture was stirred at 25° C. for 1 h. LCMS showed that the reaction was completed. The mixture was poured into water (20 mL) and extracted with EtOAc (20 mL×3). The combined organic layer was washed with brine (50 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (column: Waters Xbridge C18 150*50 mm*10 um; mobile phase: [water (10 mM NH4HCO3)-ACN]; B %: 45%-75%, 11.5 min) to 4-((9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4]diazepin-2-yl)amino)-2-fluoro-5-methoxy-N-(1-(2-(2-(2-(phenylamino)ethoxy)ethoxy)ethyl)piperidin-4-yl)benzamide (106.2 mg, 139.29 umol, 32.41% yield, 99% purity) as off-white solid.
- MS (M+H)+=755.5
- 1H NMR (400 MHz, CDCl3) δ=8.37 (d, J=15.0 Hz, 1H), 8.07 (s, 1H), 7.82 (s, 1H), 7.57 (d, J=7.2 Hz, 1H), 7.22-7.14 (m, 2H), 6.75-6.56 (m, 5H), 4.86 (q, J=8.5 Hz, 1H), 4.04 (br s, 1H), 3.97 (s, 3H), 3.92 (t, J=13.2 Hz, 2H), 3.72 (t, J=5.2 Hz, 2H), 3.68-3.58 (m, 6H), 3.42 (s, 3H), 3.31 (t, J=5.2 Hz, 2H), 2.91 (br s, 2H), 2.64 (br s, 2H), 2.29 (br s, 2H), 2.17-2.02 (m, 4H), 1.84-1.68 (m, 4H), 1.65-1.52 (br s, 4H).
- 1. Culture of HeLa Cell Line
- The HeLa cell line was purchased from Korea Cell Line Bank (KCLB), Seoul, Korea. The passage in cell culture was maintained at P115 to P125.
- For cell counting, cell counter (Thermo Fisher Scientific Inc., Catalog #AMQAX1000) and 0.4% trypan blue solution were used.
- For cell culture, DMEM (Gibco, Cat. No. 1195-65; Lot. No. 2085318), FBS (Gibco, Cat. No. 16000-044; Lot. No. 2097593), Penicillin/Streptomycin (PS) (Gibco, Cat. No. 15140-122; Lot. No. 2058855), 100 mm2 cell culture dish (SPL, Cat. No. 20100), 150 mm2 cell culture dish (SPL, Cat. No. 20150), 12-well culture plate (SPL, Cat. No. 30012), PBS pH 7.4 (Gibco, Cat. No. 10010-023; Lot. No. 2085080), TrypLE™ Express (Gibco, Cat. No. 12605-010; Lot No. 2070638), Counting Chamber (Hematocytometer) (Hirschmann, Cat. No. 8100204), and 0.4% Trypan Blue Solution (DYNEBIO, Cat. No. CBT3710; Lot. No. 20190723) were used.
- 2. Treatment of Compounds of the Present Invention
- 2×105 cells were seeded for each well of a 12-well plate (SPL), and the cells were cultured in the culture medium in a total volume of 2 ml.
- The compounds of Examples were completely dissolved in DMSO and used in the experiment, and thymidine was completely dissolved in DW and used in the experiment. For thymidine block, the products were treated with 2 mM of thymidine (Sigma-Aldrich Cat. No. T9250-5G) and then incubated for 24 hours.
- For release and chemical treatment, the medium was suctioned and washed 3 times with 1×PBS. Complete media was added, followed by incubation for 4 hours in a CO2 incubator. Each compound was diluted three folds from the highest concentration of 3 μM to the lowest concentration in 10 points and then incubated for 6 hours again.
- 3. Western Blotting
- For SDS-PAGE and Western blotting, 1×RIPA lysis buffer (Rockland, Cat. No. MB-030-0050; Lot no. 39751), 100× Protease Inhibitor Cocktail (Quartett, Cat. No. PPI1015; Lot no. PCO50038424), Pierce™ BCA protein assay kit (ThermoScientific, Cat. No. 23225; Lot no. UC276876), albumin standard (ThermoScientific, Cat. No. 23209; Lot no. UB269561), 4-15% Mini-PROTEAN TGX stain-free gel (Bio-rad, Cat. No. 4568085; Lot no. L007041B), 10× Tris/Glycine/SDS buffer (Bio-rad, Cat. No. 1610732; Lot no. 10000044375B); 10×TBS (Bio-rad, Cat. No. 1706435; Lot no. 1000045140B), 10% Tween 20 (Cat. No. 1610781; Lot no. L004152B), Color protein standard broad range (NEB, Cat. No. P7719S; Lot no. 10040349), 4× Laemmli sample buffer (Bio-rad, Cat. No. 1610747; Lot no. L004133B), β-mercaptoethanol (Sigma-Aldrich, Cat. No. M3148; Lot no. 60-24-2), SuperBlock™ T20 (TBS) blocking buffer (ThermoScientific, Cat. No. 37536; Lot no. UC282578), 1M sodium azide solution (Sigma-Aldrich, Cat. No. 08591-1 mL-F; Lot no. BCBV4989), α-Rabbit pAb to Ms IgG (abcam, Cat. No. ab97046; Lot no. GR3252115-1), α-Goat pAb to Rb IgG (CST, Cat. No. 7074S; Lot no. 28), α-GAPDH (abcam, Cat. No. ab8245; Lot no. GR3275542-2), α-Plk1 (CST, Cat. No. 208G4), α-BRD4 (CST, Cat. No. 13440S), ECL™ Prime western blotting reagents (GE Healthcare, Cat. No. RPN2232; Lot no. 17001655), Ponceau S solution (Sigma-Aldrich, Cat. No. P7170; Lot no. SLBV4112), Difco™ Skim milk (BD, Cat. No. 232100; Lot no. 8346795), and
iBlot® 2 NC Regular stacks (Invitrogen, Cat. No. IB323001; Lot no. 2NR110619-02) were used. - For cell harvesting, the cells were first separated from the plate using trypsin and then washed with the medium and PBS. Specifically, the medium was suctioned off and washed with 1 mL of PBS, and PBS was suctioned off. The cells were treated with 0.5 mL TrypLE™ Express at 37° C. for 7 minutes to separate the cells, and then 0.5 mL of complete medium was added to collect 1 mL of cell culture solution. Then, 1 mL of the cell collection solution was centrifuged at 8,000 rpm for 120 seconds, and the supernatant was removed. After washing with 0.2 mL of PBS, the PBS was removed.
- For cell lysis, a lysis buffer was added and cell debris was removed to obtain a cell lysate. Specifically, the cells were treated with 70 μL of 1×RIPA buffer containing a protease inhibitor and incubated for 30 minutes on ice. Then, the cells were centrifuged at 4° C. and 15,000 rpm for 10 minutes to obtain a cell lysate.
- Then, a standard curve was obtained using the BCA assay, and the protein mass in the lysate was quantified by substituting the curve equation. The mixture was incubated at 37° C. for 30 minutes using 20 μL of standard or sample solution, and 200 μL of BCA or Bradford solution, and measured at 562 nm absorbance. Samples were prepared by adding 4× sample buffer so that the quantity of protein added to each well was 15 μg.
- Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was performed by setting a running time of 100 minutes at 120 Von a 4-15% Mini-PROTEAN TGX stain-free gel (15 well). Transferring was performed on
iBlot® 2 NC Mini stacks at P0 mode of the dry blotting system. After staining using Ponceau S solution, blocking was performed for 1 hour with a blocking buffer (Thermo). After washing with 1×TBS containing 0.05% Tween 20, the product was reacted at 4° C. for 16 hours with anti-Plk1(CST) antibody (1:500), anti-BRD4 (Cell signaling) antibody (1:1000) or anti-GAPDH(abcam) antibody (1:10,000) in 1×TBS-T as a primary antibody. After washing three times for 10 minutes with 1×TBS containing 0.05% Tween20, the product was reacted at room temperature for 1 hour with anti-mouse antibody (abcam) (1:10000) or anti-rabbit antibody (CST) (1:5000) in 1×TBS-T as a secondary antibody. Then, after washing three times for 10 minutes with 1×TBS containing 0.05% Tween 20, the product was detected with an ECL working solution (1:1). To analyze the results, an image analyzer (GE) was used to obtain final blot data. The ratio of PLK1 to GAPDH for each sample was calculated using the ImageQuant TL (ver.8.2.0) program. Each calculated value was entered into each cell of the Graphpad Prism 9 program, and the graph was automatically calculated to confirm the Dmax value corresponding to the protein degradation ability (A: Dmax is 80% or more; B: Dmax is 80% or less and 60% or more; C: less than 60%). If the grade of Dmax is A or B, DC50 value was also measured (Grade A: DC50 is 50 nM or less; B: 500 nM or less; C: more than 500 nM). - 4. PLK1 Degradability of the Compounds of the Present Invention
- As a result of the experiment, Dmax and DC50 values for the compounds of the compounds of the present invention were measured as shown in the following table.
-
TABLE 2 No. Dmax DC50 No. Dmax DC50 1 A A 2 A A 3 A A 4 A A 5 A A 6 C — 7 C — 8 C 9 B B 10 B B 11 B B 12 B C 13 B B 14 C 15 B C 16 C 17 C 18 B B 19 B B 20 C 21 A A 22 B B 23 A A 24 A A 25 A A 26 C 27 B B 28 B B 29 A A 30 A A 31 C 32 A A 33 A A 34 A A 35 A A 36 A A 37 B B 38 B B 39 A A 40 B B 41 A A 42 B C 43 A A 44 A A 45 A A 46 C 47 C 48 B B 49 B B 50 A A 51 A A 52 A A 53 A A 54 B B 55 B B 56 B B 57 B B 58 C 59 C 60 A A 61 B A 62 B A 63 A A 64 A A 65 A A 66 B B 67 B B 68 B B 69 A A 70 B B 71 A A 72 B B 73 A A 74 A A 75 A A 76 B B 77 B B 78 A A 79 A A 80 C 81 C 82 C 83 C 84 B B 85 C 86 C 87 C 88 C 89 B B 90 B B 91 B B 92 A A 93 A A 94 B C 95 B C 96 A A 97 C 98 B B 99 B B 100 B B 101 A A 102 A A 103 A A 104 A A 105 B B 106 B B 107 A A 108 A A 109 B B 110 A A 111 A A 112 B B 113 C 114 A A 115 A A 116 A A 117 A A 118 A A 119 A A 120 A A 121 A A 122 A A 123 A A 124 B B 125 A A 126 B B 127 B B 128 A A 129 A A 130 A A 131 A A 132 A A 133 A A 134 A A 135 A A 136 A A 137 A A 138 A A 139 A A 140 A A 141 A A 142 B B 143 B B 144 A A 145 B C 146 C 147 B B 148 A A 149 B B 150 A A 151 B B 152 A A 153 A A 154 C 155 B B 156 A A 157 A A 158 B B 159 A A 160 A A 161 A A 162 A A 163 B B 164 B B 165 C 166 B B 167 B B 168 A A 169 A A 170 A A 171 A A 172 A A 173 A A 174 A A 175 A A - In particular, it was confirmed that
Compounds Comparative Compound 3 in which an aniline group was connected by a linker (FIG. 1 ). - 5. Selective PLK1 Degradability of the Compounds of the Present Invention
- In addition to excellent PLK1 degradability compared to
Comparative Compounds 1 and 2 (PLK1 inhibitors from BI), it was also confirmed thatCompounds 2 to 4 of the present invention did not exhibit protein degradability of Brd4, a target protein other than PLK1 (FIG. 2 ). This demonstrates that the compounds of the present invention have excellent selective PLK1 degradability. - The contents of all references, patents, pending patent applications and published patents, cited throughout this application are hereby expressly incorporated by reference.
- Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the disclosure described herein. Such equivalents are intended to be encompassed by the following claims. It is understood that the detailed examples and embodiments described herein are given by way of example for illustrative purposes only, and are in no way considered to be limiting to the disclosure. Various modifications or changes in light thereof will be suggested to persons skilled in the art and are included within the spirit and purview of this application and are considered within the scope of the appended claims. For example, the relative quantities of the ingredients may be varied to optimize the desired effects, additional ingredients may be added, and/or similar ingredients may be substituted for one or more of the ingredients described. Additional advantageous features and functionalities associated with the systems, methods, and processes of the present disclosure will be apparent from the appended claims. Moreover, those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the disclosure described herein. Such equivalents are intended to be encompassed by the following claims.
Claims (15)
1. A compound represented by Formula I, a stereoisomer thereof or a pharmaceutically acceptable salt thereof:
ULM-Linker-PTM [Formula I]
ULM-Linker-PTM [Formula I]
in the Formula I above,
ULM is CRBN or a VHL E3 ubiquitin ligase binding moiety;
PTM is a PLK1 binding moiety represented by Formula II:
{in the Formula II above,
R1 is hydrogen, C1-5 alkyl, or C3-6 cycloalkyl;
R1A is hydrogen or C1-3 alkyl;
R2 is hydrogen, halogen, C1-6 alkyl or —OR2A;
R2A is C1-4 alkyl or C3-6 cycloalkyl, optionally substituted by one or more halogen or hydroxy;
R3 is hydrogen, halogen, —NO2, —CN, —OH, C1-4 alkyl or —O(C1-4 alkyl);
R4 is selected from a single bond,
2. The compound of claim 1 , wherein ULM is CRBN E3 ubiquitin ligase binding moiety represented by Formula A-1:
—CO—, —COO—, —NHCO— or —CONH—;
X2 is —CH2—, —CH(C1-4 alkyl)-, —NH—, —N(C1-4 alkyl)-, —O—, —CO—, —CH2—CH2—, —NH—CH2—, —NH—CH(C1-4 alkyl)-, —N═CH—, —N═C(C1-4 alkyl)- or —N═N—;
X3 is hydrogen or C1-4alkyl;
X4 is hydrogen, halogen, C1-6 alkyl, CN, NH2, NO2, OH, COH, COOH or CF3; and
4. The compound of claim 1 , wherein ULM is VHL E3 ubiquitin ligase binding moiety represented by Formula B-1:
is 5- to 6-membered cycloalkyl, phenyl, 5- to 6-membered heterocycloalkyl, or 5- to 6-membered heteroaryl, wherein the heterocycloalkyl or the heteroaryl contains one to three heteroatoms, each heteroatom independently selected from N, O, or S;
Y1 is hydrogen or C1-4 alkyl;
Y2 is C1-4alkyl, hydroxy(C1-4alkyl), —(C0-2alkyl)-COH, C3-8cycloalkyl, or phenyl;
5. The compound of claim 4 , wherein ULM is a VHL E3 ubiquitin ligase binding moiety selected from Formula B-2-1 or Formula B-2-2:
is a 5-membered heteroaryl ring selected from oxazole, isoxazole, thiazole, isothiazole, imidazole, pyrazole, triazole, oxadiazole, pyrrole, pyrrolidine, furan, dihydrofuran, or tetrahydrofuran;
Y1 is hydrogen or C1-3 alkyl;
Y4 is C1-4 alkyl or C3-5 cycloalkyl, optionally substituted by hydrogen or halogen; and
6. The compound of claim 1 , wherein Formula II is represented by Formula III:
7. The compound of claim 1 , wherein the Linker is represented by Formula L:
wherein:
LULM, LPTM and LINT are independently selected from null, a single bond, —CH2—, —NH—, —O—, —S—, —SO—, —SO2—, —CO—, —CH2CH2—,
optionally substituted by one or more C1-6 alkyl, C3-8 cycloalkyl, halogen, hydroxy, amino, nitro, cyano or haloalkyl {wherein
8. The compound of claim 7 , wherein:
LULM is
LU1 is selected from a single bond, —CH2—, —CH2CH2—, —CH═CH—, —C≡C—, —NH—, —NCH3—, —CO—, —NHCO—, or —O—;
LU2 is selected from a single bond, —CH2—, —NH—, —O—, —CO—, or —CONH—; and
9. The compound of claim 7 , wherein:
LPTM is
LP1 is selected from a single bond, —O—, —S—, —NH—, —N(C1-4alkyl)-, —CH2—, —CH(C1-4alkyl)-, —CH2NH—, or —CH2CH2—;
LP2 is selected from a single bond, —CO—, —COCH2—, —NHCO—, —NHCOCH2—, —HET-, or —HET-CH2— {wherein HET is 5- to 6-membered heterocyclyl or heteroaryl containing one or more N, S, or O atoms}; and
10. The compound of claim 7 , wherein:
is
is null or a ring selected from 3- to 10-membered cycloalkyl, 4- to 10-membered heterocycloalkyl, 6- to 10-membered aryl, or 5- to 10-membered heteroaryl.
LINT1 and LINT2 are each independently selected from —CH2—, —NH—, —NCH3—, —O—, —S—, —SO—, —SO2—, —CO—, —CH2CH2O—, —OCH2CH2—, —CH2CH2S—, —SCH2CH2—, —COO—, —CONH—, or —NHCO—; and
q and r are each independently an integer from 1 to 10.
11. The compound of claim 1 , wherein the compound is selected from one of Compound 1 to Compound 175.
12. The compound of claim 1 , wherein the compound is a bifunctional compound that induces PLK1 protein degradation.
13. The compound of claim 12 , wherein the compound induces selective PLK1 protein degradation.
14. A method for preventing or treating a PLK1 related disease comprising administering a compound according to claim 1 , a stereoisomer thereof, or a pharmaceutically acceptable salt thereof to a subject in need thereof.
15. The method of claim 14 , wherein the PLK1 related disease is a disease selected from a cancer, a benign tumor, or a neurological disease.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/229,353 US20230372498A1 (en) | 2020-03-27 | 2023-08-02 | Plk1 selective degradation inducing compound |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2020-0037875 | 2020-03-27 | ||
KR20200037875 | 2020-03-27 | ||
US17/428,467 US11833208B2 (en) | 2020-03-27 | 2021-03-27 | PLK1 selective degradation inducing compound |
PCT/KR2021/003807 WO2021194318A1 (en) | 2020-03-27 | 2021-03-27 | Plk1 selective degradation inducing compound |
US18/229,353 US20230372498A1 (en) | 2020-03-27 | 2023-08-02 | Plk1 selective degradation inducing compound |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/003807 Continuation WO2021194318A1 (en) | 2020-03-27 | 2021-03-27 | Plk1 selective degradation inducing compound |
US17/428,467 Continuation US11833208B2 (en) | 2020-03-27 | 2021-03-27 | PLK1 selective degradation inducing compound |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230372498A1 true US20230372498A1 (en) | 2023-11-23 |
Family
ID=77892014
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/914,565 Pending US20230159515A1 (en) | 2020-03-27 | 2021-03-27 | Benzimidazole thiophene derivative compounds inducing selective degradation of plk1 |
US17/428,467 Active 2041-05-29 US11833208B2 (en) | 2020-03-27 | 2021-03-27 | PLK1 selective degradation inducing compound |
US17/914,574 Pending US20230203006A1 (en) | 2020-03-27 | 2021-03-27 | Vanillin derivative compounds inducing selective degradation of plk1 |
US17/914,545 Pending US20230158158A1 (en) | 2020-03-27 | 2021-03-27 | Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1 |
US18/229,353 Pending US20230372498A1 (en) | 2020-03-27 | 2023-08-02 | Plk1 selective degradation inducing compound |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/914,565 Pending US20230159515A1 (en) | 2020-03-27 | 2021-03-27 | Benzimidazole thiophene derivative compounds inducing selective degradation of plk1 |
US17/428,467 Active 2041-05-29 US11833208B2 (en) | 2020-03-27 | 2021-03-27 | PLK1 selective degradation inducing compound |
US17/914,574 Pending US20230203006A1 (en) | 2020-03-27 | 2021-03-27 | Vanillin derivative compounds inducing selective degradation of plk1 |
US17/914,545 Pending US20230158158A1 (en) | 2020-03-27 | 2021-03-27 | Pyrazolo quinazoline derivative compounds inducing selective degradation of plk1 |
Country Status (6)
Country | Link |
---|---|
US (5) | US20230159515A1 (en) |
EP (1) | EP3911654A4 (en) |
JP (2) | JP7440940B2 (en) |
KR (8) | KR20210122164A (en) |
CN (1) | CN113784969A (en) |
WO (4) | WO2021194321A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3150316A1 (en) * | 2019-09-27 | 2021-04-01 | Dana-Farber Cancer Institute, Inc. | Erk5 degraders as therapeutics in cancer and inflammatory diseases |
JP2024529298A (en) | 2021-07-09 | 2024-08-06 | プレキシウム インコーポレイテッド | Aryl compounds and pharmaceutical compositions that modulate IKZF2 - Patent application |
TW202321219A (en) | 2021-08-11 | 2023-06-01 | 大陸商四川海思科製藥有限公司 | Heterocyclic derivative, and composition and pharmaceutical use thereof |
CN114380682A (en) * | 2021-10-27 | 2022-04-22 | 上海毕得医药科技股份有限公司 | Synthesis method of 2, 3-difluoro-4-methoxyphenylacetic acid |
WO2023104178A1 (en) * | 2021-12-10 | 2023-06-15 | 山东绿叶制药有限公司 | Protein kinase inhibitor, preparation method therefor, and application thereof |
WO2023104195A1 (en) * | 2021-12-10 | 2023-06-15 | 正大天晴药业集团股份有限公司 | Preparation method for isothiazolo[5,4-d]pyrimidine irak4 inhibitor |
CN115490675A (en) * | 2022-09-19 | 2022-12-20 | 安阳师范学院 | Tetronic acid derivative and preparation method and application thereof |
WO2024117789A1 (en) * | 2022-11-29 | 2024-06-06 | Uppthera, Inc. | Plk1 degradation inducing compounds with increased rigidity |
WO2024153110A1 (en) * | 2023-01-17 | 2024-07-25 | 北京哲源科技有限责任公司 | Stereoisomer and deuterated derivative of pyrazoloquinazoline compound and use |
WO2024162828A1 (en) * | 2023-02-02 | 2024-08-08 | Uppthera, Inc. | Novel plk1 degradation inducing compound |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20070518A1 (en) * | 2005-09-06 | 2007-06-12 | Smithkline Beecham Corp | BENZIMIDAZOLE THIOPHENE COMPOUNDS AS PLK INHIBITING AGENTS |
EA017769B1 (en) * | 2006-12-21 | 2013-03-29 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Substituted pyrazoloquinazoline derivatives, process for their preparation and their use as kinase inhibitors |
EP2139892B1 (en) * | 2007-03-22 | 2011-09-14 | Takeda Pharmaceutical Company Limited | Substituted pyrimidodiazepines useful as plk1 inhibitors |
EP2205241B1 (en) | 2007-09-25 | 2014-05-21 | Takeda Pharmaceutical Company Limited | Polo-like kinase inhibitors |
JP2011527667A (en) | 2008-06-18 | 2011-11-04 | 武田薬品工業株式会社 | Halo-substituted pyrimidodiazepine |
AR076784A1 (en) | 2009-05-26 | 2011-07-06 | Nerviano Medical Sciences Srl | THERAPEUTIC COMBINATION UNDERSTANDING A PLK1 INHIBITOR AND AN ANTINEOPLASTIC AGENT |
RU2666530C2 (en) | 2012-01-12 | 2018-09-11 | Йейл Юниверсити | Compounds and methods for enhanced degradation of target proteins and other polypeptides by an e3 ubiquitin ligase |
EP3302482A4 (en) | 2015-06-05 | 2018-12-19 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
AU2016349781A1 (en) * | 2015-11-02 | 2018-05-10 | Yale University | Proteolysis targeting chimera compounds and methods of preparing and using same |
US20170281784A1 (en) | 2016-04-05 | 2017-10-05 | Arvinas, Inc. | Protein-protein interaction inducing technology |
CN106543185B (en) | 2016-11-10 | 2017-12-15 | 吉林大学 | A kind of compound for targetting ubiquitination degraded PLK1 and BRD4 albumen and its application |
CA3050309A1 (en) * | 2017-01-31 | 2018-08-09 | Arvinas Operations, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
CN106977584B (en) * | 2017-04-19 | 2019-12-06 | 吉林大学 | Compound for targeted ubiquitination degradation of PLK1 and BRD4 proteins and application thereof |
EP3725771A4 (en) | 2017-12-13 | 2021-10-13 | Shanghaitech University | Alk protein degradation agent and anti-tumor application thereof |
KR102127289B1 (en) * | 2018-09-18 | 2020-06-26 | 고려대학교 산학협력단 | Polo-like kinase(PLK) selective fluorescent probe compound for targeting tumor cells and a PLK detection fluorescence sensor comprising the same |
CN111018857B (en) | 2018-10-09 | 2023-06-02 | 嘉兴优博生物技术有限公司 | Targeted protease degradation platform (TED) |
CN109879877B (en) | 2019-03-04 | 2021-08-10 | 吉林大学 | Compound capable of degrading PLK1 and BRD4 proteins and application thereof |
KR102604803B1 (en) * | 2021-08-10 | 2023-11-22 | (주) 업테라 | Novel PLK1 degradation-inducing compound |
-
2021
- 2021-03-27 KR KR1020210040037D patent/KR20210122164A/en unknown
- 2021-03-27 WO PCT/KR2021/003810 patent/WO2021194321A1/en active Application Filing
- 2021-03-27 KR KR1020210040036D patent/KR20210122163A/en unknown
- 2021-03-27 US US17/914,565 patent/US20230159515A1/en active Pending
- 2021-03-27 JP JP2021578216A patent/JP7440940B2/en active Active
- 2021-03-27 KR KR1020210040038A patent/KR102313753B1/en active IP Right Grant
- 2021-03-27 KR KR1020210040038D patent/KR20210122165A/en unknown
- 2021-03-27 KR KR1020210040036A patent/KR102313752B1/en active IP Right Grant
- 2021-03-27 WO PCT/KR2021/003808 patent/WO2021194319A1/en active Application Filing
- 2021-03-27 US US17/428,467 patent/US11833208B2/en active Active
- 2021-03-27 KR KR1020210040035A patent/KR102337029B1/en active IP Right Grant
- 2021-03-27 CN CN202180002576.XA patent/CN113784969A/en active Pending
- 2021-03-27 KR KR1020210040037A patent/KR102319264B1/en active IP Right Grant
- 2021-03-27 WO PCT/KR2021/003809 patent/WO2021194320A1/en active Application Filing
- 2021-03-27 WO PCT/KR2021/003807 patent/WO2021194318A1/en unknown
- 2021-03-27 US US17/914,574 patent/US20230203006A1/en active Pending
- 2021-03-27 EP EP21749059.8A patent/EP3911654A4/en active Pending
- 2021-03-27 US US17/914,545 patent/US20230158158A1/en active Pending
- 2021-12-02 KR KR1020210171223A patent/KR102529222B1/en active IP Right Grant
-
2023
- 2023-08-02 US US18/229,353 patent/US20230372498A1/en active Pending
- 2023-10-13 JP JP2023177565A patent/JP2023171659A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3911654A4 (en) | 2022-05-11 |
JP2023171659A (en) | 2023-12-01 |
KR20210122163A (en) | 2021-10-08 |
US20230158158A1 (en) | 2023-05-25 |
KR20210122165A (en) | 2021-10-08 |
KR20210150341A (en) | 2021-12-10 |
KR102337029B1 (en) | 2021-12-09 |
EP3911654A1 (en) | 2021-11-24 |
CN113784969A (en) | 2021-12-10 |
US20230159515A1 (en) | 2023-05-25 |
WO2021194320A1 (en) | 2021-09-30 |
WO2021194319A1 (en) | 2021-09-30 |
US20230203006A1 (en) | 2023-06-29 |
JP7440940B2 (en) | 2024-02-29 |
US11833208B2 (en) | 2023-12-05 |
KR102313752B1 (en) | 2021-10-19 |
WO2021194318A1 (en) | 2021-09-30 |
JP2022539579A (en) | 2022-09-12 |
KR102319264B1 (en) | 2021-11-01 |
WO2021194321A1 (en) | 2021-09-30 |
KR20210122164A (en) | 2021-10-08 |
US20230104076A1 (en) | 2023-04-06 |
KR20210122162A (en) | 2021-10-08 |
KR102313753B1 (en) | 2021-10-19 |
KR102529222B1 (en) | 2023-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11833208B2 (en) | PLK1 selective degradation inducing compound | |
AU2021202065B2 (en) | Hepatitis B core protein modulators | |
US11427548B2 (en) | Compounds and methods for the targeted degradation of androgen receptor | |
US20220402907A1 (en) | Modulators of proteolysis and associated methods of use | |
US20230219966A1 (en) | Novel plk1 degradation inducing compound | |
US11685727B2 (en) | Compounds active towards nuclear receptors | |
JP2023509495A (en) | RORγt INHIBITOR, PRODUCTION METHOD AND USE THEREOF | |
US20230382923A1 (en) | Fused tetracyclic quinazoline derivatives as inhibitors of erbb2 | |
US11629152B2 (en) | Compound with anticancer activity | |
US20230322758A1 (en) | Compounds as glp-1r agonists | |
US20230078961A1 (en) | HMG-CoA Reductase Degradation Inducing Compound | |
US11274092B2 (en) | Potassium channel inhibitors | |
US20240101579A1 (en) | Boronic acid compounds | |
JP2023509496A (en) | RORγt INHIBITOR, PRODUCTION METHOD AND USE THEREOF | |
CN117794936A (en) | Novel PLK1 degradation inducing compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: UPPTHERA INC., KOREA, REPUBLIC OF Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHOI, SI WOO;RYU, SOO HEE;RYU, JI HOON;AND OTHERS;REEL/FRAME:064684/0522 Effective date: 20211027 |